



National Comprehensive  
Cancer Network®


NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

# Esophageal and Esophagogastric Junction Cancers

## NCCN Evidence Blocks™

Version 4.2025 — August 22, 2025  
NCCN.org

NCCN recognizes the importance of clinical trials and encourages participation when applicable and available.  
Trials should be designed to maximize inclusiveness and broad representative enrollment.



Continue



**\*Jaffer A. Ajani, MD/Chair †**  
The University of Texas  
MD Anderson Cancer Center

**\*Thomas A. D'Amico, MD/Vice Chair ¶**  
Duke Cancer Institute

**David J. Bentrem, MD, MS ¶**  
Robert H. Lurie Comprehensive  
Cancer Center of Northwestern  
University

**Sakti Chakrabarti, MD †**  
Case Comprehensive Cancer  
Center/University Hospitals  
Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer  
Institute

**Carlos U. Corvera, MD ¶**  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**Prajan Das, MD, MS, MPH §**  
The University of Texas  
MD Anderson Cancer Center

**Peter C. Enzinger, MD †**  
Dana-Farber/Brigham and  
Women's Cancer Center

**Thomas Enzler, MD, PhD † ‡**  
University of Michigan  
Rogel Cancer Center

**Hans Gerdes, MD † ‡**  
Memorial Sloan Kettering  
Cancer Center

**Michael K. Gibson, MD, PhD † ‡ † ‡**  
Vanderbilt-Ingram Cancer Center

**Patrick Grierson, MD, PhD †**  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

**Garima Gupta, MD †**  
O'Neal Comprehensive  
Cancer Center at UAB

**Wayne L. Hofstetter, MD ¶**  
The University of Texas  
MD Anderson Cancer Center

**David H. Ilson, MD, PhD † ‡**  
Memorial Sloan Kettering  
Cancer Center

**Shadia Jalal, MD †**  
Indiana University  
Melvin and Bren Simon  
Comprehensive Cancer Center

**Sunnie Kim, MD †**  
University of Colorado  
Cancer Center

**Lawrence R. Kleinberg, MD §**  
Johns Hopkins Kimmel Cancer  
Center

**Samuel Klempner, MD †**  
Mass General Cancer Center

**Moshim Kukar, MD ¶**  
Roswell Park Comprehensive  
Cancer Center

**Jill Lacy, MD †**  
Yale Cancer Center/  
Smilow Cancer Hospital

**Vincent Lam, MD †**  
Johns Hopkins Kimmel Cancer  
Center

**Byrne Lee, MD ¶**  
Stanford Cancer Institute

**Frank Licciardi ¥**  
Patient Advocate

**Shane Lloyd, MD §**  
Huntsman Cancer Institute  
at the University of Utah

**Quan P. Ly, MD ¶**  
Fred & Pamela Buffett  
Cancer Center

**Karen Matsukuma MD, PhD ≠**  
UC Davis  
Comprehensive Cancer Center

**Michael McNamara, MD †**  
Case Comprehensive Cancer  
Center/University Hospitals  
Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer  
Institute

**Ryan P. Merkow, MD, MS ¶**  
The UChicago Medicine  
Comprehensive Cancer Center

**Aaron M. Miller, MD, PhD †**  
UC San Diego  
Moores Cancer Center

**Sarbajit Mukherjee, MD, MS † ‡**  
Roswell Park Comprehensive  
Cancer Center

**Mary F. Mulcahy, MD † ‡**  
Robert H. Lurie Comprehensive  
Cancer Center of Northwestern  
University

**Kyle A. Perry, MD ¶**  
The Ohio State University  
Comprehensive Cancer Center -  
James Cancer Hospital and  
Solove Research Institute

**Jose M. Pimiento, MD ¶**  
Moffitt Cancer Center

**Deepti M. Reddi, MD ≠**  
Fred Hutchinson Cancer Center

**Scott Reznik, MD ¶**  
UT Southwestern Simmons  
Comprehensive Cancer Center

**Robert E. Roses, MD ¶**  
Abramson Cancer Center  
at the University of Pennsylvania

**Vivian E. Strong, MD ¶**  
Memorial Sloan Kettering  
Cancer Center

**Stacey Su, MD ¶**  
Fox Chase Cancer Center

**Nataliya Uboha, MD, PhD †**  
University of Wisconsin  
Carbone Cancer Center

**Zev A. Wainberg, MD †**  
UCLA Jonsson  
Comprehensive Cancer Center

**Christopher G. Willett, MD §**  
Duke Cancer Institute

**Yanghee Woo, MD ¶**  
City of Hope National Medical  
Center

**Harry H. Yoon, MD †**  
Mayo Clinic  
Comprehensive Cancer Center

#### NCCN

**Nicole R. McMillian, MS**  
**MaryElizabeth Stein, PhD**

**Continue**

- ▣ Gastroenterology
- △ Genetics
- ‡ Hematology/Hematology oncology
- ‡ Internal medicine
- † Medical oncology
- ≠ Pathology
- ¥ Patient advocacy
- § Radiotherapy/Radiation oncology
- ¶ Surgery/Surgical oncology
- \* Discussion Writing Committee Member



[NCCN Esophageal and Esophagogastric Junction Cancers Panel Members](#)

[NCCN Evidence Blocks Definitions \(EB-1\)](#)

[Workup and Histologic Classification \(ESOPH-1\)](#)

#### **Squamous Cell Carcinoma**

[Locoregional Disease \(ESOPH-2\)](#)

[Primary Treatment Options for Patients Who Are Medically Fit \(ESOPH-3\) and \(ESOPH-4\)](#)

[Response Assessment \(ESOPH-5\)](#)

[Surgical Outcomes/Clinical Pathologic Findings for Patients Who Have Not Received Preoperative Chemoradiation](#)

[\(ESOPH-6\)](#)

[Surgical Outcomes/Clinical Pathologic Findings for Patients Who Have Received Preoperative Chemoradiation \(ESOPH-7\)](#)

[Management of Disease for Non-Surgical Candidates \(ESOPH-8\)](#)

[Follow-up/Surveillance and Recurrence \(ESOPH-9\)](#)

[Palliative Management \(ESOPH-10\)](#)

#### **Adenocarcinoma**

[Locoregional Disease \(ESOPH-11\)](#)

[Primary Treatment Options for Patients Who Are Medically Fit \(ESOPH-12\) and \(ESOPH-13\)](#)

[Response Assessment \(ESOPH-14, ESOPH-15, ESOPH-16\)](#)

[Surgical Outcomes/Clinical Pathologic Findings for Patients Who Have Not Received Preoperative Therapy \(ESOPH-17\)](#)

[Surgical Outcomes/Clinical Pathologic Findings for Patients Who Have Received Preoperative Therapy \(ESOPH-18\)](#)

[Management of Disease for Non-Surgical Candidates \(ESOPH-19\)](#)

[Follow-up/Surveillance and Recurrence \(ESOPH-20\)](#)

[Palliative Management \(ESOPH-21\)](#)

#### **Squamous Cell Carcinoma and Adenocarcinoma**

[Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#)

[Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#)

[Principles of Surgery \(ESOPH-C\)](#)

[Principles of Genetic Risk Assessment for Esophageal and Esophagogastric Junction \(EGJ\) Cancers \(ESOPH-D\)](#)

[Principles of Multidisciplinary Team Approach for Esophagogastric Cancers \(ESOPH-E\)](#)

[Principles of Systemic Therapy \(ESOPH-F\)](#)

[Principles of Radiation Therapy \(ESOPH-G\)](#)

[Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#)

[Principles of Surveillance \(ESOPH-I\)](#)

[Principles of Survivorship \(ESOPH-J\)](#)

[Staging \(ST-1\)](#)

[Abbreviations \(ABBR-1\)](#)

Find an NCCN Member Institution:  
<https://www.nccn.org/home/member-institutions>.

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

**NCCN Categories of Preference:** All recommendations are considered appropriate.

See [NCCN Categories of Preference](#).

**NCCN Guidelines for Patients®**  
available at [www.nccn.org/patients](http://www.nccn.org/patients)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Evidence Blocks™ and NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Evidence Blocks™, NCCN Guidelines, and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2025.



#### NCCN EVIDENCE BLOCKS CATEGORIES AND DEFINITIONS

5					
4					
3					
2					
1					
	E	S	Q	C	A

**E = Efficacy of Regimen/Agent**  
**S = Safety of Regimen/Agent**  
**Q = Quality of Evidence**  
**C = Consistency of Evidence**  
**A = Affordability of Regimen/Agent**

#### Example Evidence Block

5					
4	■	■			
3	■	■	■	■	
2	■	■	■	■	
1	■	■	■	■	
	E	S	Q	C	A

**E = 4**  
**S = 4**  
**Q = 3**  
**C = 4**  
**A = 3**

#### Efficacy of Regimen/Agent

5	<b>Highly effective:</b> Cure likely and often provides long-term survival advantage
4	<b>Very effective:</b> Cure unlikely but sometimes provides long-term survival advantage
3	<b>Moderately effective:</b> Modest impact on survival, but often provides control of disease
2	<b>Minimally effective:</b> No, or unknown impact on survival, but sometimes provides control of disease
1	<b>Palliative:</b> Provides symptomatic benefit only

#### Safety of Regimen/Agent

5	<b>Usually no meaningful toxicity:</b> Uncommon or minimal toxicities; no interference with activities of daily living (ADLs)
4	<b>Occasionally toxic:</b> Rare significant toxicities or low-grade toxicities only; little interference with ADLs
3	<b>Mildly toxic:</b> Mild toxicity that interferes with ADLs
2	<b>Moderately toxic:</b> Significant toxicities often occur but life threatening/fatal toxicity is uncommon; interference with ADLs is frequent
1	<b>Highly toxic:</b> Significant toxicities or life threatening/fatal toxicity occurs often; interference with ADLs is usual and severe

**Note:** For significant chronic or long-term toxicities, score decreased by 1

#### Quality of Evidence

5	<b>High quality:</b> Multiple well-designed randomized trials and/or meta-analyses
4	<b>Good quality:</b> One or more well-designed randomized trials
3	<b>Average quality:</b> Low quality randomized trial(s) or well-designed non-randomized trial(s)
2	<b>Low quality:</b> Case reports or extensive clinical experience
1	<b>Poor quality:</b> Little or no evidence

#### Consistency of Evidence

5	<b>Highly consistent:</b> Multiple trials with similar outcomes
4	<b>Mainly consistent:</b> Multiple trials with some variability in outcome
3	<b>May be consistent:</b> Few trials or only trials with few patients, whether randomized or not, with some variability in outcome
2	<b>Inconsistent:</b> Meaningful differences in direction of outcome between quality trials
1	<b>Anecdotal evidence only:</b> Evidence in humans based upon anecdotal experience

#### Affordability of Regimen/Agent (includes drug cost, supportive care, infusions, toxicity monitoring, management of toxicity)

5	<b>Very inexpensive</b>
4	<b>Inexpensive</b>
3	<b>Moderately expensive</b>
2	<b>Expensive</b>
1	<b>Very expensive</b>



#### WORKUP

- History and physical (H&P)
- Esophagogastroduodenoscopy (EGD) and biopsy<sup>a</sup>
- Chest/abdomen CT with oral and IV contrast
- Pelvis CT with contrast as clinically indicated
- FDG-PET/CT evaluation (skull base to mid-thigh) if no evidence of M1 disease
- Complete blood count (CBC) and comprehensive chemistry profile
- Endoscopic ultrasound (EUS), if no evidence of M1 unresectable disease
- Endoscopic resection (ER) is recommended for the accurate staging of early-stage cancers (Tis, T1a or T1b).<sup>a,b</sup> Early-stage cancers can best be diagnosed by ER
- Biopsy of metastatic disease as clinically indicated
- Universal testing for microsatellite instability (MSI) by polymerase chain reaction (PCR)/next-generation sequencing (NGS) or mismatch repair (MMR) by immunohistochemistry (IHC) is recommended in all newly diagnosed patients<sup>c</sup>
- Universal testing for programmed death ligand 1 (PD-L1) is recommended in all newly diagnosed patients<sup>c</sup>
- HER2 testing if advanced/metastatic adenocarcinoma is documented/suspected<sup>c</sup>
- CLDN18.2 testing if advanced/metastatic adenocarcinoma is documented/suspected<sup>c</sup>
- NGS should be considered<sup>c</sup>
- Bronchoscopy, if tumor is at or above the carina with no evidence of M1 disease
- Assign Siewert category<sup>d</sup>
- Nutritional assessment and counseling
- Smoking cessation advice, counseling, and pharmacotherapy as indicated<sup>e</sup>
- Screen for family history<sup>f</sup>

<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>b</sup> ER may also be therapeutic for early-stage cancers.


<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>e</sup> [NCCN Guidelines for Smoking Cessation](#).

#### CLINICAL STAGE<sup>g</sup>

#### HISTOLOGIC CLASSIFICATION<sup>c</sup>



<sup>f</sup> See [Principles of Genetic Risk Assessment for Esophageal and Esophagogastric Junction \(EGJ\) Cancers \(ESOPH-D\)](#). Also see [NCCN Guidelines for Colorectal Cancer Screening, Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric](#), and [Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate](#).

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>h</sup> Celiac nodal involvement in cancers of the esophagogastric junction (EGJ)/distal esophagus should be considered for combined modality therapy.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### HISTOLOGY

#### CLINICAL STAGE<sup>g</sup>

#### ADDITIONAL EVALUATION (as clinically indicated)



<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>h</sup> Celiac nodal involvement in cancers of the EGJ/distal esophagus may still be considered for combined modality therapy.


<sup>i</sup> [Principles of Multidisciplinary Team Approach for Esophagogastric Cancers \(ESOPH-E\)](#).

<sup>j</sup> Percutaneous gastrostomy tube may be considered for patients with cervical esophageal tumors receiving definitive chemoradiation or for patients with marginally resectable disease. Multidisciplinary expertise is recommended prior to placement of percutaneous gastrostomy tube. The approach, timing, and location of the feeding tube should be discussed with the surgeon prior to its placement.

<sup>k</sup> Medically able to tolerate major surgery.

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit who decline surgery.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>m</sup> pTis, pT1a, superficial pT1b, pT1b, N0 tumor classifications are defined by pathology of the diagnostic ER specimen. See [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>n</sup> The initial diagnostic ER procedure may prove therapeutic for some patients, but for others additional therapy may be necessary prior to the start of surveillance.

<sup>o</sup> Preclinical staging cannot establish the number of positive nodes.

<sup>p</sup> For select patients, consider endoluminal stenting when appropriate.

See [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>q</sup> For pTis and pT1a, the level of evidence for ablation of SCC after ER is low.

However, additional ablation may be needed if there is multifocal high-grade dysplasia (HGD)/carcinoma in situ. Ablation may not be needed if all lesions are completely excised. For references, see [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>r</sup> ER followed by ablation may be used to completely eliminate residual dysplasia.

<sup>s</sup> Esophagectomy is indicated for patients with extensive carcinoma in situ (pTis or HGD) or pT1a, especially nodular disease that is not adequately controlled by ablation or ER followed by ablation.


<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>v</sup> Definitive chemoradiation may be an appropriate option for patients who decline surgery; see [\(ESOPH-8\)](#).

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.



<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>o</sup> Preclinical staging cannot establish the number of positive nodes.

<sup>p</sup> For select patients, consider endoluminal stenting when appropriate. See [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>w</sup> Histologic confirmation of suspected positive node is desirable.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>z</sup> For select patients, consider relieving dysphagia with induction systemic therapy. See [Principles of Systemic Therapy \(ESOPH-F 5 of 24\)](#) and [Principles of Best Supportive Care \(ESOPH-H\)](#).

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



**PRIMARY TREATMENT FOR PATIENTS WHO ARE MEDICALLY FIT WITH SQUAMOUS CELL CARCINOMA**

**RESPONSE ASSESSMENT**

**OUTCOME**

**ADDITIONAL MANAGEMENT**

Preoperative chemoradiation<sup>x,y,z</sup>

- FDG-PET/CT<sup>aa</sup>
- Chest/abdomen CT with oral and IV contrast (not required if FDG-PET/CT is done)<sup>bb</sup>
- EGD and biopsy<sup>cc</sup> (optional if surgery is planned)

No evidence of disease<sup>dd</sup>

Esophagectomy<sup>c,d,t,u</sup> or Observation<sup>cc</sup> (category 2B) (See Follow-up [\[ESOPH-9\]](#))

Surgical Outcomes After Esophagectomy ([\[ESOPH-7\]](#))

Persistent local disease

Esophagectomy<sup>c,d,t,u</sup> (preferred) or Palliative Management ([\[ESOPH-10\]](#))

Surgical Outcomes After Esophagectomy ([\[ESOPH-7\]](#))

Unresectable or Metastatic disease

Palliative Management ([\[ESOPH-10\]](#))

No evidence of disease<sup>dd</sup>

Observation<sup>dd</sup> or Esophagectomy<sup>c,d,u</sup>

Follow-up ([\[ESOPH-9\]](#))

Surgical Outcomes After Esophagectomy ([\[ESOPH-7\]](#))

Persistent local disease

Esophagectomy (preferred)<sup>c,d,u</sup> or Palliative Management ([\[ESOPH-10\]](#))

New metastatic disease

Palliative Management ([\[ESOPH-10\]](#))

Definitive chemoradiation<sup>x,y</sup>

- FDG-PET/CT<sup>aa</sup>
- Chest/abdomen CT with oral and IV contrast (not required if FDG-PET/CT is done)<sup>bb</sup>
- EGD and biopsy<sup>cc</sup>

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>z</sup> For select patients, consider relieving dysphagia with induction systemic therapy. See [Principles of Systemic Therapy \(ESOPH-F 5 of 24\)](#) and [Principles of Best Supportive Care \(ESOPH-H\)](#).

<sup>aa</sup> Assessment ≥5 to 8 weeks after completion of preoperative therapy.

<sup>bb</sup> Pelvis CT if clinically indicated.

<sup>cc</sup> [Post-Treatment Surveillance—Principles of Endoscopic Staging and Therapy \(ESOPH-A 6 of 8\)](#).

<sup>dd</sup> If surgery is not being considered for management, EGD and biopsy should be done.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**




#### SURGICAL OUTCOMES/CLINICAL PATHOLOGIC FINDINGS FOR SQUAMOUS CELL CARCINOMA

(Patients Have Not Received Preoperative Chemoradiation)


#### TUMOR CLASSIFICATION<sup>g</sup>

#### POSTOPERATIVE MANAGEMENT


R0 resection<sup>ee</sup>



R1 resection<sup>ee</sup>



R2 resection<sup>ee</sup>



Follow-up ([ESOPH-9](#))

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>ee</sup> R0 = No cancer at resection margins, R1 = Microscopic residual cancer, R2 = Macroscopic residual cancer or M1.


**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



**SURGICAL OUTCOMES/CLINICAL PATHOLOGIC FINDINGS FOR SQUAMOUS CELL CARCINOMA (Patients Have Received Preoperative Chemoradiation)**

**TUMOR CLASSIFICATION<sup>g,ee</sup>**

**POSTOPERATIVE MANAGEMENT**



<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>ee</sup> R0 = No cancer at resection margins, R1 = Microscopic residual cancer, R2 = Macroscopic residual cancer or M1.

<sup>ff</sup> The yp prefix is used to indicate cases in which staging is performed following preoperative therapy.


<sup>gg</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### TUMOR CLASSIFICATION<sup>g</sup> FOR SQUAMOUS CELL CARCINOMA

#### MANAGEMENT OF DISEASE FOR NON-SURGICAL CANDIDATES<sup>l</sup>



<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit who decline surgery.

<sup>m</sup> pTis, pT1a, superficial pT1b, pT1b, N0 tumor classifications are defined by pathology of the diagnostic ER specimen. See [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>n</sup> The initial diagnostic ER procedure may prove therapeutic for some patients, but for others additional therapy may be necessary prior to the start of surveillance.

<sup>o</sup> Preclinical staging cannot establish the number of positive nodes.

<sup>q</sup> For pTis and pT1a, the level of evidence for ablation of SCC after ER is low. However, additional ablation may be needed if there is multifocal HGD/carcinoma in situ. Ablation may not be needed if all lesions are completely excised. For references, see [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>r</sup> ER followed by ablation may be used to completely eliminate residual dysplasia.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>hh</sup> [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>ii</sup> Poor prognostic features include LVI, poorly differentiated histology, positive margin(s), and/or maximum tumor diameter ≥2 cm.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



#### FOLLOW-UP/SURVEILLANCE FOR SQUAMOUS CELL CARCINOMA<sup>jj,kk</sup>

- H&P
  - ▶ ▶ If asymptomatic: H&P every 3–6 mo for 1–2 y, every 6–12 mo for 3–5 y
- Chemistry profile and CBC, as clinically indicated
- Imaging studies as clinically indicated<sup>jj</sup>
- EGD and biopsy as clinically indicated<sup>cc,jj</sup>
- Dilatation for anastomotic stenosis
- Nutritional assessment and counseling

#### RECURRENCE

Locoregional recurrence: Prior esophagectomy, no prior chemoradiation

Locoregional recurrence: Prior chemoradiation, no prior esophagectomy

Metastatic disease

#### PALLIATIVE MANAGEMENT

Concurrent chemoradiation<sup>x,y</sup> (preferred) or Surgery<sup>c,d</sup> or Systemic therapy<sup>x</sup> or Palliative/Best supportive care<sup>hh</sup>

→

Resectable and medically operable

Unresectable or medically inoperable

→ Esophagectomy<sup>c,d,t,u</sup>

#### RESPONSE ASSESSMENT

Chest/abdomen CT with contrast<sup>jj</sup>

→ Recurrence →

Palliative Management (ESOPH-10)

→ Recurrence →

Palliative Management (ESOPH-10)

Palliative Management (ESOPH-10)

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\).](#)

<sup>d</sup> [Principles of Surgery \(ESOPH-C\).](#)

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\).](#)

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\).](#)

<sup>cc</sup> [Post-Treatment Surveillance—Principles of Endoscopic Staging and Therapy \(ESOPH-A 6 of 8\).](#)

<sup>hh</sup> [Principles of Palliative/Best Supportive Care \(ESOPH-H\).](#)

<sup>jj</sup> [Principles of Surveillance \(ESOPH-I\).](#)

<sup>kk</sup> [Principles of Survivorship \(ESOPH-J\).](#)


**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



#### FOR SQUAMOUS CELL CARCINOMA

#### PERFORMANCE STATUS

#### PALLIATIVE MANAGEMENT



<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>hh</sup> [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>II</sup> Further treatment after two sequential regimens should be dependent on performance status (PS) and availability of clinical trials.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**


[Back to Follow-up and Recurrence \(ESOPH-9\)](#)



#### HISTOLOGY

#### CLINICAL STAGE<sup>g</sup>

#### ADDITIONAL EVALUATION (as clinically indicated)



<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>h</sup> Celiac nodal involvement in cancers of the EGJ/distal esophagus may still be considered for combined modality therapy.


<sup>i</sup> [Principles of Multidisciplinary Team Approach for Esophagogastric Cancers \(ESOPH-E\)](#).

<sup>j</sup> Percutaneous gastrostomy tube may be considered for patients with cervical esophageal tumors receiving definitive chemoradiation or for patients with marginally resectable disease. Multidisciplinary expertise is recommended prior to placement of percutaneous gastrostomy tube. The approach, timing, and location of the feeding tube should be discussed with the surgeon prior to its placement.

<sup>k</sup> Medically able to tolerate major surgery.

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit who decline surgery.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**



<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>m</sup> pTis, pT1a, superficial pT1b, pT1b, N0 tumor classifications are defined by pathology of the diagnostic ER specimen. See [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>n</sup> The initial diagnostic ER procedure may prove therapeutic for some patients, but for others additional therapy may be necessary prior to the start of surveillance.

<sup>o</sup> Preclinical staging cannot establish the number of positive nodes.

<sup>p</sup> For select patients, consider endoluminal stenting when appropriate.

See [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.


<sup>mm</sup> Diagnostic ER can be considered to confirm the pathologic staging and for treatment in select patients.

<sup>nn</sup> ER followed by ablation may be used to completely eliminate residual dysplasia or Barrett epithelium.

<sup>oo</sup> Esophagectomy is indicated for patients with extensive carcinoma in situ (pTis or HGD), pT1a, or superficial pT1b, especially nodular disease that is not adequately controlled by ablation or ER followed by ablation.

<sup>pp</sup> Definitive chemoradiation may be an appropriate option for patients who decline surgery, see ([ESOPH-19](#)).

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



<sup>c</sup> Principles of Pathologic Review and Biomarker Testing (ESOPH-B).

<sup>d</sup> Principles of Surgery (ESOPH-C).

<sup>g</sup> See Staging (ST-1) for tumor classification.

<sup>o</sup> Preclinical staging cannot establish the number of positive nodes.

<sup>p</sup> For select patients, consider endoluminal stenting when appropriate.

See Principles of Palliative/Best Supportive Care (ESOPH-H).

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>w</sup> Histologic confirmation of suspected positive node is desirable.

<sup>x</sup> Principles of Systemic Therapy (ESOPH-F).

<sup>y</sup> Principles of Radiation Therapy (ESOPH-G).

<sup>qq</sup> Preoperative chemoradiation may be considered for a tumor that is borderline resectable or patient is medically unfit for surgery, or who is not a candidate for the FLOT regimen. Postoperative checkpoint inhibitor therapy may be given as warranted after surgery (ESOPH-18).

<sup>rr</sup> For select patients, consider relieving dysphagia with induction systemic therapy. See Perioperative Systemic Therapy in Principles of Systemic Therapy (ESOPH-F 3 of 24) and Principles of Best Supportive Care (ESOPH-H).

<sup>ss</sup> In patients with an MSI-H/dMMR tumor, perioperative immunotherapy should be considered in consultation with a multidisciplinary team. The role of surgery after biopsy proven and radiologic/metabolic complete response on neoadjuvant immunotherapy is unclear.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated.




**PRIMARY TREATMENT FOR PATIENTS WHO ARE MEDICALLY FIT WITH ADENOCARCINOMAS**

**RESPONSE ASSESSMENT**

**OUTCOME**

**ADDITIONAL MANAGEMENT**



<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>aa</sup> Assessment ≥5 to 8 weeks after completion of preoperative therapy.

<sup>bb</sup> Pelvis CT if clinically indicated.

<sup>cc</sup> [Post-Treatment Surveillance—Principles of Endoscopic Staging and Therapy \(ESOPH-A 6 of 8\)](#).

<sup>tt</sup> Repeat multidisciplinary consultation is recommended before proceeding to surgery for post-neoadjuvant T4a and bulky multiple nodal station N3.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### PRIMARY TREATMENT FOR PATIENTS WHO ARE MEDICALLY FIT WITH ADENOCARCINOMAS

#### RESPONSE ASSESSMENT

#### OUTCOME

#### ADDITIONAL MANAGEMENT

Surgical Outcomes After Esophagectomy ([ESOPH-18](#))

Preoperative chemoradiation<sup>x,y,rr</sup>

- FDG-PET/CT<sup>aa</sup>
- Chest/abdomen CT with oral and IV contrast (not required if FDG-PET/CT is done)<sup>bb</sup>
- EGD and biopsy<sup>cc</sup> (optional if surgery is planned)

No evidence of disease<sup>cc</sup>

Esophagectomy<sup>c,d,t,u</sup> (preferred) or Observation<sup>dd</sup> (category 2B) (See Follow-up [ESOPH-20](#))

Persistent local disease

Esophagectomy<sup>c,d,t,u</sup> (preferred) or Palliative Management ([ESOPH-21](#))

Unresectable or Metastatic disease

Palliative Management ([ESOPH-21](#))

Surgical Outcomes After Esophagectomy ([ESOPH-18](#))

Definitive chemoradiation<sup>x,y</sup>

- FDG-PET/CT<sup>aa</sup>
- Chest/abdomen CT with oral and IV contrast (not required if FDG-PET/CT is done)<sup>bb</sup>
- EGD and biopsy<sup>cc</sup>

No evidence of disease<sup>cc</sup>

Observation<sup>dd</sup> (preferred) or Esophagectomy<sup>c,d,u</sup>

Follow-up ([ESOPH-20](#))

Persistent local disease

Esophagectomy (preferred)<sup>c,d,u</sup> or Palliative Management ([ESOPH-21](#))

Surgical Outcomes After Esophagectomy ([ESOPH-18](#))

New metastatic disease

Palliative Management ([ESOPH-21](#))

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>aa</sup> Assessment ≥5 to 8 weeks after completion of preoperative therapy.

<sup>bb</sup> Pelvis CT if clinically indicated.

<sup>cc</sup> [Post-Treatment Surveillance—Principles of Endoscopic Staging and Therapy \(ESOPH-A 6 of 8\)](#).

<sup>dd</sup> If surgery is not being considered for management, EGD and biopsy should be done.

<sup>rr</sup> For select patients, consider relieving dysphagia with induction systemic therapy. See Perioperative Systemic Therapy in [Principles of Systemic Therapy \(ESOPH-F 3 of 24\)](#) and [Principles of Best Supportive Care \(ESOPH-H\)](#).

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**




**PRIMARY TREATMENT FOR PATIENTS WHO ARE MEDICALLY FIT WITH ADENOCARCINOMAS**

**RESPONSE ASSESSMENT**

**OUTCOME**

**ADDITIONAL MANAGEMENT**



<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>aa</sup> Assessment ≥5 to 8 weeks after completion of preoperative therapy.

<sup>bb</sup> Pelvis CT if clinically indicated.

<sup>cc</sup> [Post-Treatment Surveillance—Principles of Endoscopic Staging and Therapy \(ESOPH-A 6 of 8\)](#).

<sup>ss</sup> In patients with an MSI-H/dMMR tumor, perioperative immunotherapy should be considered in consultation with a multidisciplinary team. The role of surgery after biopsy proven and radiologic/metabolic complete response on neoadjuvant immunotherapy is unclear.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**




#### SURGICAL OUTCOMES/CLINICAL PATHOLOGIC FINDINGS FOR ADENOCARCINOMAS

(Patients Have Not Received Preoperative  
Chemoradiation or Systemic Therapy)

#### TUMOR CLASSIFICATION<sup>g</sup>

#### POSTOPERATIVE MANAGEMENT



<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>ee</sup> R0 = No cancer at resection margins, R1 = Microscopic residual cancer, R2 = Macroscopic residual cancer or M1.

<sup>uu</sup> Smalley SR, et al. J Clin Oncol 2012;30:2327-2333. See [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>vv</sup> Postoperative chemoradiation is recommended for patients who have had suboptimal surgery with poor nodal harvest or patients who were understaged at diagnosis.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**




#### SURGICAL OUTCOMES/CLINICAL PATHOLOGIC FINDINGS FOR ADENOCARCINOMAS

(Patients Have Received Preoperative Chemoradiation or Systemic therapy)

#### TUMOR CLASSIFICATION<sup>9</sup>

#### POSTOPERATIVE MANAGEMENT



<sup>9</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>ee</sup> R0 = No cancer at resection margins, R1 = Microscopic residual cancer, R2 = Macroscopic residual cancer or M1.

<sup>ff</sup> The yp prefix is used to indicate cases in which staging is performed following preoperative therapy.

<sup>99</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>ww</sup> Based on current data, adjuvant chemoradiation is not recommended for patients who are at high risk.


<sup>xx</sup> Al-Batran SE, et al. Lancet 2019;393:1948-1957.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### TUMOR CLASSIFICATION<sup>g</sup> FOR ADENOCARCINOMAS

#### MANAGEMENT OF DISEASE FOR NON-SURGICAL CANDIDATES<sup>l</sup>



<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>g</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit who decline surgery.

<sup>m</sup> pTis, pT1a, superficial pT1b, pT1b, N0 tumor classifications are defined by pathology of the diagnostic ER specimen. See [Principles of Endoscopic Staging and Therapy \(ESOPH-A\)](#).

<sup>n</sup> The initial diagnostic ER procedure may prove therapeutic for some patients, but for others additional therapy may be necessary prior to the start of surveillance.

<sup>o</sup> Preclinical staging cannot establish the number of positive nodes.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).

<sup>hh</sup> [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>ii</sup> Poor prognostic features include LVI, poorly differentiated histology, positive margin(s), and/or maximum tumor diameter ≥2 cm.

<sup>nn</sup> ER followed by ablation may be used to completely eliminate residual dysplasia or Barrett epithelium.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



#### FOLLOW-UP/SURVEILLANCE FOR ADENOCARCINOMAS<sup>jj,kk</sup>

- H&P
  - ▶ If asymptomatic: H&P every 3–6 mo for 1–2 y, every 6–12 mo for 3–5 y
- Chemistry profile and CBC, as clinically indicated
- Imaging studies as clinically indicated<sup>jj</sup>
- EGD and biopsy as clinically indicated<sup>cc,jj</sup>
- Dilatation for anastomotic stenosis
- Nutritional assessment and counseling

#### RECURRENCE

Locoregional recurrence:  
Prior esophagectomy,  
no prior chemoradiation

Locoregional recurrence:  
Prior chemoradiation,  
no prior esophagectomy

Metastatic disease

#### PALLIATIVE MANAGEMENT

Concurrent chemoradiation<sup>x,y</sup> (preferred) or Surgery<sup>c,d</sup> or Systemic therapy<sup>x</sup> or Palliative/ Best supportive care<sup>hh</sup>

Resectable and medically operable

Unresectable or medically inoperable

Esophagectomy<sup>c,d,t,u</sup>

#### RESPONSE ASSESSMENT

Chest/abdomen CT with contrast<sup>jj</sup>

Chest/abdomen CT with contrast<sup>jj</sup>

Recurrence

Recurrence

Palliative Management (ESOPH-21)

Palliative Management (ESOPH-21)

Palliative Management (ESOPH-21)

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\).](#)

<sup>d</sup> [Principles of Surgery \(ESOPH-C\).](#)

<sup>t</sup> Transhiatal or transthoracic, or minimally invasive; gastric reconstruction preferred.

<sup>u</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\).](#)

<sup>y</sup> [Principles of Radiation Therapy \(ESOPH-G\).](#)

<sup>cc</sup> [Post-Treatment Surveillance—Principles of Endoscopic Staging and Therapy \(ESOPH-A 6 of 8\).](#)

<sup>hh</sup> [Principles of Palliative/Best Supportive Care \(ESOPH-H\).](#)

<sup>jj</sup> [Principles of Surveillance \(ESOPH-I\).](#)

<sup>kk</sup> [Principles of Survivorship \(ESOPH-J\).](#)


**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### FOR ADENOCARCINOMAS

#### PERFORMANCE STATUS

#### PALLIATIVE MANAGEMENT



<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>x</sup> [Principles of Systemic Therapy \(ESOPH-F\)](#).

<sup>hh</sup> [Principles of Palliative/Best Supportive Care \(ESOPH-H\)](#).

<sup>II</sup> Further treatment after two sequential regimens should be dependent upon PS and availability of clinical trials.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**

[Back to Follow-up and Recurrence \(ESOPH-20\)](#)



### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

Endoscopy has become an important tool in the diagnosis, staging, treatment, and surveillance of patients with esophageal and EGJ cancers.

#### Diagnosis

- Diagnostic and surveillance endoscopies are performed with the goal of determining the presence and location of esophageal neoplasia and to biopsy any suspicious lesions. Thus, an adequate endoscopic exam addresses both of these components.
- The location of the tumor relative to the teeth and EGJ, the length of the tumor, the extent of circumferential involvement, and the degree of obstruction should be carefully recorded to assist with treatment planning. If present, the location, length, and circumferential extent of BE should be characterized in accordance with the Prague criteria,<sup>1</sup> and mucosal nodules should be carefully documented.
- High-resolution endoscopic imaging and narrow-band imaging are presently available and may enhance visualization during endoscopy, with improved detection of lesions in BE and non-BE and stomach.<sup>2</sup> Use of a cap to improve the visualization of the EGJ should be considered.
- Multiple biopsies, six to eight, using standard size endoscopy forceps should be performed to provide sufficient material for histologic and molecular interpretation.<sup>3</sup> Larger forceps are recommended during surveillance endoscopy of BE for the detection of dysplasia.<sup>4</sup>
- Following successful ER, resection and/or ablation of remaining Barrett's neoplasia may be necessary. Furthermore, close endoscopic surveillance is needed.

#### Screening

- Screening of the general public in the United States for esophageal cancer has not been recommended by any professional organization at this time; however, some GI societies have recently recommended screening certain individuals at risk for pre-malignant conditions as outlined below. These guidelines were created based on very limited evidence and as such have been published as conditional recommendations. The references to each of these guidelines is provided below.
- In 2019 the ASGE published that, "There is insufficient evidence on the effectiveness of screening for BE. However, if screening endoscopy for BE is performed, we suggest a screening strategy that identifies an at-risk population. An at-risk population is defined as individuals with a family history of EAC or BE (high-risk) or patients with GERD plus at least 1 other risk factor (moderate risk)" and "The additional risk factors were age >50, obesity/central adiposity, history of smoking, or male gender."<sup>5</sup>
- In 2022 the AGA published a Clinical Practice Update suggesting "Screening with standard upper endoscopy may be considered in individuals with at least 3 established risk factors for Barrett's esophagus (BE) and esophageal adenocarcinoma, including individuals who are male, non-Hispanic white, age >50 years, have a history of smoking, chronic gastroesophageal reflux disease, obesity, or a family history of BE or esophageal adenocarcinoma."<sup>6</sup>
- The 2022 ACG guidelines recommended "a single screening endoscopy in patients with chronic GERD symptoms and 3 or more additional risk factors for BE, including male sex, age >50 years, white race, tobacco smoking, obesity, and family history of BE or EAC in a first-degree relative." They also suggested that "a swallowable, nonendoscopic capsule sponge device combined with a biomarker is an acceptable alternative to endoscopy for screening for BE." (very low quality of evidence and conditional strength of recommendation)<sup>7</sup>
- Individuals considered to be at significant risk for esophageal SCC may also benefit from screening and surveillance endoscopy. This includes individuals from countries at high risk for esophageal SCC, especially if they have a long history of tobacco and alcohol or beetle nut consumption, a personal history of head and neck cancer, achalasia, or previous esophageal caustic injury.<sup>8</sup>

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.


[Continued](#)  
[References](#)

ESOPH-A  
1 OF 8



#### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

#### Endoscopic Therapy for Early-Stage Esophageal Squamous Neoplasia<sup>9,10</sup>



<sup>a</sup> Principles of Endoscopic Staging and Therapy, [Diagnosis Section \(ESOPH-A 1 of 8\)](#).

<sup>b</sup> ESD may be preferred for lesions >10 mm in size; morphology suspicious for deep submucosal invasion should be specifically considered for ESD.

<sup>c</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>d</sup> [Principles of Radiation Therapy \(ESOPH-G\)](#).


<sup>e</sup> [Principles of Systemic Therapy \(ESOPH-F 3 of 24\)](#).

<sup>f</sup> The resected endoscopy specimen should be evaluated by a pathologist with expertise in GI pathology. Any deep muscularis mucosa or submucosal invasion or presence of other high-risk features (not well differentiated or presence of LVI) on final pathology should be considered for additional therapy after multidisciplinary review. If endoscopically cured, ensure all remaining squamous dysplasia is endoscopically eradicated.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**

#### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

#### Endoscopic Therapy for Early-Stage Esophageal High-Grade Dysplasia (HGD)/Adenocarcinoma<sup>9,10</sup>



After ER of early-stage esophageal HGD/adenocarcinoma, all visible residual BE should be either endoscopically resected or ablated.

<sup>a</sup> [Principles of Endoscopic Staging and Therapy, Diagnosis Section \(ESOPH-A 1 of 8\)](#).

<sup>c</sup> [Principles of Surgery \(ESOPH-C\)](#).

<sup>g</sup> Morphology suspicious for deep submucosal invasion should be specifically considered for ESD.

<sup>h</sup> The resected endoscopy specimen should be evaluated by a pathologist with expertise in GI pathology. Invasion of <500 µm without other high-risk features (not poorly differentiated and no LVI) on final pathology can be considered curative. Ensure all remaining BE is endoscopically eradicated.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

##### Staging

- EUS performed prior to any treatment is important in the initial clinical staging of neoplastic disease. Careful attention to ultrasound images provides evidence of depth of tumor invasion (T designation), presence of abnormal or enlarged lymph nodes likely to harbor cancer (N designation), and occasionally signs of distant spread, such as lesions in surrounding organs (M designation).<sup>7</sup>
- Hypoechoic (dark) expansion of the esophageal wall layers identifies the location of tumor, with gradual loss of the layered pattern of the normal esophageal wall corresponding with greater depths of tumor penetration, correlating with higher T-categories. A dark expansion of layers 1–3 corresponds with infiltration of the superficial and deep mucosa plus the submucosa, T1 disease. Isolated thickening of the mucosal layer alone may be difficult to appreciate resulting in loss of sensitivity of EUS for superficial disease. Similarly, standard EUS scopes, with 7.5–12 MHz frequency transducers, may lack the resolution to accurately distinguish the penetration of the tumor through the muscularis mucosa, or superficial from deep penetration of the submucosa.<sup>11,12</sup> A dark expansion of layers 1–4 correlates with penetration into the muscularis propria, T2 disease, and expansion beyond the smooth outer border of the muscularis propria correlates with invasion of the adventitia, T3 disease. Loss of a bright tissue plane between the area of tumor and surrounding structures such as the pleura, diaphragm, and pericardium correlates with T4a disease, while invasion of surrounding structures such as the trachea, aorta, lungs, heart, liver, or pancreas correlates with T4b disease.
- For small, nodular lesions  $\leq 2$  cm, ER is encouraged as it provides a more accurate depth of invasion than the results of EUS.<sup>12</sup> A decision to proceed to further therapy such as resection or ablation, or to consider the ER completely therapeutic would depend on the final pathologic assessment of the resection specimen.
- Mediastinal and perigastric lymph nodes are readily seen by EUS, and the identification of enlarged, hypoechoic (dark), homogeneous, well-circumscribed, rounded structures in these areas correlates with the presence of malignant or inflammatory lymph nodes. The accuracy of this diagnosis is significantly increased with the combination of features, but is also confirmed with the use of fine-needle aspiration (FNA) biopsy for cytology assessment.<sup>13</sup> FNA of suspicious lymph nodes should be performed if it can be performed without traversing an area of primary tumor or major blood vessels, and if it will impact treatment decisions. The pre-procedure review of CT and FDG-PET scans is recommended, when available, prior to esophagogastroduodenoscopy (EGD)/EUS, to become fully familiar with the nodal distribution for possible FNA.
- Obstructing tumors may increase the risk of perforation while performing staging EUS exams. The use of wire-guided EUS probes, or miniprbes, may permit EUS staging with a lower risk of perforation. In certain cases, dilating the malignant stricture to allow completion of staging may be appropriate, but there is increased risk of perforation after dilation.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

[Continued](#)  
[References](#)

ESOPH-A  
4 OF 8



### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

#### Primary Treatment

- The goal of endoscopic therapy [by EMR, ESD, and/or ablation] is the complete removal or eradication of early-stage disease (ie, pTis, pT1a, selected superficial pT1b without LVI) and pre-neoplastic tissue (BE).
- Early-stage disease, Tis, also known as HGD, needs to be fully characterized, including evaluating presence of nodularity, lateral spread, and ruling out multifocal disease, as well as ruling out lymph node metastases by EUS in select higher risk cases. This is important to permit decisions on endoscopic therapy with ablative methods such as radiofrequency ablation (RFA), cryoablation, photodynamic therapy (PDT), and/or ER.<sup>14-17</sup> Areas of nodularity or ulceration should be resected rather than ablated. Completely flat, small lesions ( $\leq 2$  cm) of squamous cell HGD/Tis (carcinoma in situ) and BE associated with flat HGD should be treated by ER as it provides more accurate histologic assessment of the lesion. Larger flat lesions ( $>2$  cm) can be treated effectively by ER, but this is associated with greater risk of complications. Such lesions can be effectively treated by ablation alone, but there are very limited data on treating squamous cell HGD by ablation alone.<sup>14,15,18-21</sup>
- Lesions that are found to be pathologically limited to the lamina propria or muscularis mucosae (pT1a), or the superficial submucosa (pT1b), in the absence of evidence of lymph node metastases, LVI, or poor differentiation grade can be treated with full ER.<sup>22-24</sup> However, a thorough and detailed discussion regarding comparative risk of esophagectomy versus potential for concurrent nodal disease should be undertaken, preferably between patient and surgeon, especially in cases with larger tumors or deeper invasion. Ablative therapy of residual BE should be performed following ER.<sup>19</sup> Complete eradication of BE can also be performed with more aggressive application of EMR (widefield EMR) or ESD at the initial intervention, if necessary to completely resect an area of superficial tumor or mucosal nodularity  $\leq 2$  cm in maximal dimension.<sup>25</sup>
- The level of evidence for ablation of SCC after ER is low. However, additional ablation may be needed if there is multifocal HGD/carcinoma in situ elsewhere in the esophagus. Ablation may not be needed for lesions that are completely excised.<sup>18,26,27</sup>
- Endoscopic therapy is considered “preferred” for patients with limited early-stage disease (Tis and T1a,  $\leq 2$  cm, and well or moderately differentiated carcinoma), because the risk of harboring lymph node metastases, local or distant recurrence, and death from esophageal cancer is low following endoscopic therapy.<sup>19</sup>

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

##### Treatment of Symptoms

- Esophageal dilation can be performed with the use of dilating balloons or bougies to temporarily relieve obstruction from tumors, or treatment-related strictures. Caution should be exercised to avoid overdilation, to minimize the risk of perforation.
- Long-term palliation of dysphagia can be achieved with endoscopic tumor ablation by Nd:YAG laser, PDT and cryoablation, or endoscopic and radiographic-assisted insertion of expandable metal or plastic stents.<sup>28,29</sup>
- Long-term palliation of anorexia, dysphagia, or malnutrition may be achieved with endoscopic or radiographic-assisted placement of feeding gastrostomy or jejunostomy. The placement of a gastrostomy in the preoperative setting may compromise the gastric vasculature, thereby interfering with the creation of the gastric conduit in the reconstruction during esophagectomy and should be avoided.

##### Post-Treatment Surveillance

- Consider deferring assessment endoscopy with biopsy to 6 weeks or later after completion of preoperative therapy in patients whom avoidance of surgery is being considered.<sup>30</sup>
- EUS exams performed after chemotherapy or RT have a reduced ability to accurately determine the present stage of disease.<sup>31</sup> Similarly, biopsies performed after chemotherapy or RT may not accurately diagnose the presence of residual disease.<sup>30</sup>
- Endoscopic surveillance following definitive treatment of esophageal cancer requires careful attention to detail for mucosal surface changes, and multiple biopsies of any visualized abnormalities. Strictures should be biopsied to rule out neoplastic cause. EUS-guided FNA should be performed if suspicious lymph nodes or areas of wall thickening are seen on cross-sectional imaging.
- Endoscopic surveillance after ablative therapy or ER of early-stage esophageal cancer should continue after completion of treatment ([ESOPH-I](#)). Biopsies should be taken of the neosquamous mucosa even in the absence of mucosal abnormalities as dysplasia may occasionally be present beneath the squamous mucosa.
- Endoscopic surveillance should also include a search for the presence of BE and four-quadrant biopsies to detect residual or recurrent dysplasia. The ablation of residual or recurrent high-grade and low-grade dysplasia using RFA or cryoablation should be considered.
- Patients who have received therapeutic ER should have endoscopic surveillance ([ESOPH-I](#)).

#### [References](#)

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY REFERENCES

- 1 Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. *Gastroenterology* 2006;131:1392-1399.
- 2 Mannath J, Subramanian V, Hawkey CJ, Ragnath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. *Endoscopy* 2010;42:351-359.
- 3 Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. *Gastroenterology* 1982;82:228-231.
- 4 Komanduri S, Swanson G, Keefer L, Jakate S. Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies. *Gastrointest Endosc* 2009;70:1072-1078.e1.
- 5 ASGE STANDARDS OF PRACTICE COMMITTEE; Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointest Endosc* 2019;90:335-359.e2.
- 6 Muthusamy VR, Wani S, Gyawali CP, et al; CGIT Barrett's Esophagus Consensus Conference Participants. AGA clinical practice update on new technology and innovation for surveillance and screening in Barrett's esophagus: Expert review. *Clin Gastroenterol Hepatol* 2022;20:2696-2706.e1.
- 7 Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: An updated ACG guideline. *Am J Gastroenterol* 2022;117:559-587.
- 8 Roshandel G, Nourouzi A, Pourshams A, et al. Endoscopic screening for esophageal squamous cell carcinoma. *Arch Iran Med* 2013;16:351-357.
- 9 Forbes N, Elhanafi SE, Al-Haddad MA, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. *Gastrointest Endosc* 2023;98:271-284.
- 10 Pimentel-Nunes P, Libânio D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. *Endoscopy* 2022;54:591-622.
- 11 Barbour AP, Rizk NP, Gerdes H, et al. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. *J Am Coll Surg* 2007;205:593-601.
- 12 Thosani N, Singh H, Kapadia A, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. *Gastrointest Endosc* 2012;75:242-253.
- 13 Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. *Gastrointest Endosc* 2009;69:1210-1217.
- 14 Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med* 2009;360:2277-2288.
- 15 Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. *Gastrointest Endosc* 2010;71:680-685.
- 16 Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. *Gastrointest Endosc* 2007;66:460-468.
- 17 Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. *Gut* 2008;57:1200-1206.
- 18 Bergman JJ, Zhang YM, He S, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. *Gastrointest Endosc* 2011;74:1181-1190.
- 19 Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. *Gastroenterology* 2014;146:652-660.
- 20 Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology* 2011;141:460-468.
- 21 Chadwick G, Groene O, Markar SR, et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett's esophagus: a critical assessment of histologic outcomes and adverse events. *Gastrointest Endosc* 2014;79:718-731.
- 22 Nentwich MF, von Loga K, Reeh M, et al. Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus. *J Gastrointest Surg* 2014;18:242-249; discussion 249.
- 23 Leggett CL, Lewis JT, Wu TT, et al. Clinical and histologic determinants of mortality for patients with Barrett's esophagus-related T1 esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2015;13:658-664.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY REFERENCES

- <sup>24</sup> Lee L, Ronellenfitch U, Hofstetter WL, et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. *J Am Coll Surg* 2013;217:191-199.
- <sup>25</sup> van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. *Gut* 2011;60:765-773.
- <sup>26</sup> van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Radiofrequency ablation for the endoscopic eradication of esophageal squamous high grade intraepithelial neoplasia and mucosal squamous cell carcinoma. *Endoscopy* 2011;43:282-290.
- <sup>27</sup> Becker V, Bajbouj M, Schmid RM, Meining A. Multimodal endoscopic therapy for multifocal intraepithelial neoplasia and superficial esophageal squamous cell carcinoma - a case series. *Endoscopy* 2011;43:360-364.
- <sup>28</sup> Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. *Gastrointest Endosc* 1995;42:507-512.
- <sup>29</sup> Vakil N, Morris AI, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. *Am J Gastroenterol* 2001;96:1791-1796.
- <sup>30</sup> Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. *Ann Surg* 2009;249:764-767.
- <sup>31</sup> Ribeiro A, Franceschi D, Parra J, et al. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. *Am J Gastroenterol* 2006;101:1216-1221.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).**  
**All recommendations are category 2A unless otherwise indicated.**



**Table 1 Pathologic Review**

**PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING**

Specimen Type	Analysis/Interpretation/Reporting <sup>a</sup>
<b>Biopsy</b>	<p>Include in pathology report:</p> <ul style="list-style-type: none"> <li>• Invasion, if present; HGD in BE is reported for staging purposes as intraepithelial neoplasia (dysplasia) (Tis)<sup>b,c,d</sup></li> <li>• Histologic type<sup>e</sup></li> <li>• Grade<sup>f</sup></li> <li>• Presence or absence of BE</li> <li>• Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients</li> </ul>
<b>Endoscopic resection</b>	<p>Include in pathology report:</p> <ul style="list-style-type: none"> <li>• Invasion, if present<sup>b,d</sup></li> <li>• Histologic type<sup>e</sup></li> <li>• Grade<sup>f</sup></li> <li>• Depth of tumor invasion</li> <li>• Vascular/lymphatic invasion</li> <li>• Status of mucosal and deep margins</li> <li>• Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients</li> </ul>
<b>Esophagogastrectomy, without prior chemoradiation</b>	<p>For pathology report, include all elements as for EMR plus:</p> <ul style="list-style-type: none"> <li>• Location of tumor midpoint in relationship to EGJ<sup>g</sup></li> <li>• Whether tumor crosses EGJ</li> <li>• Lymph node status and number of lymph nodes recovered<sup>h</sup></li> <li>• Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients, if not previously performed</li> </ul>
<b>Esophagogastrectomy, with prior chemoradiation</b>	<ul style="list-style-type: none"> <li>• Tumor site should be thoroughly sampled, with submission of entire EGJ or ulcer/tumor bed for specimens status post neoadjuvant therapy without grossly obvious residual tumor</li> <li>• For pathology report, include all elements as for resection without prior chemoradiation plus assessment of treatment effect with tumor regression score</li> </ul>

<sup>a</sup> Use of a standardized minimum dataset such as the College of American Pathologists Cancer Protocols (available at <http://www.cap.org>) for reporting pathologic findings is recommended.

<sup>b</sup> For purposes of data reporting, BE with HGD in an esophageal resection specimen is reported as “intraepithelial neoplasia (dysplasia) (Tis).”<sup>1</sup>

<sup>c</sup> Biopsies showing BE with suspected dysplasia should be reviewed by a second expert GI pathologist for confirmation.<sup>2</sup>

<sup>d</sup> Invasion of a thickened and duplicated muscularis mucosae should not be misinterpreted as invasion of the muscularis propria in BE.<sup>3</sup>

<sup>e</sup> A specific diagnosis of SCC or adenocarcinoma should be established when possible for staging and treatment purposes. Mixed adenosquamous carcinomas and carcinomas not otherwise classified are staged using the tumor node metastasis (TNM) system for SCC.<sup>1</sup>

<sup>f</sup> Pathologic grade is needed for stage grouping in the AJCC TNM 8th edition.<sup>1</sup>

<sup>g</sup> Midpoint of tumors arising in the proximal 2 cm of the stomach and crossing the EGJ are classified for purposes of staging as esophageal carcinomas.<sup>1</sup>

<sup>h</sup> For patients with surgically managed cancer, ≥16 regional lymph nodes are removed and pathologically examined during resection for curative intent therapy.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



**PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING**

**Assessment of Treatment Response**

Response of the primary tumor to previous chemotherapy and/or RT should be reported. Residual primary tumor in the resection specimen following neoadjuvant therapy is associated with shorter overall survival for both adenocarcinoma<sup>4-6</sup> and SCC of the esophagus.<sup>7</sup>

Although scoring systems for tumor response in esophageal cancer have not been uniformly adopted, in general, three-category systems provide good reproducibility among pathologists.<sup>6,8,9</sup> The modified Ryan scheme in the CAP Cancer Protocol for Esophageal Carcinoma (available at <http://www.cap.org>)<sup>8,9</sup> should be used. Sizable pools of acellular mucin may be present after chemoradiation but should not be interpreted as representing residual tumor. Although the system described by Wu was originally limited to assessment of the primary tumor, it is recommended that lymph nodes be included in the regression score<sup>10</sup> because of the impact of residual nodal metastases on survival.

**Table 2<sup>i</sup>**

Tumor Regression Score <sup>9</sup>	CAP Cancer Protocol Description
0 (Complete response)	No viable cancer cells, including lymph nodes
1 (Near complete response)	Single cells or rare small groups of cancer cells
2 (Partial response)	Residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells
3 (Poor or no response)	Extensive residual cancer with no evident tumor regression

**Number of Lymph Nodes Retrieved**

- Although it is suggested that ≥16 regional lymph nodes be pathologically assessed, removal and assessment of >30 lymph nodes is desirable<sup>1</sup>

<sup>i</sup> Reproduced and adapted with permission from Shi C, Berlin J, Branton PA et al, Protocol for the examination of specimens from patients with carcinoma of the esophagus. In: Cancer Protocol Templates. Northfield, IL: College of American Pathologists; 2017 (available at <http://www.cap.org>).

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



**PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING**

**Assessment of Overexpression or Amplification of HER2 in Esophageal and EGJ Cancers**

For patients with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the esophagus or EGJ for whom trastuzumab<sup>j</sup> therapy is being considered, assessment for tumor HER2 overexpression using IHC and fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) methods is recommended.<sup>11</sup> NGS offers the opportunity to assess numerous mutations simultaneously, along with other molecular events such as amplification, deletions, tumor mutation burden, and MSI status. IHC/ISH/targeted PCR is the preferred approach to assess biomarkers initially. However, NGS testing through a CLIA-approved laboratory may be considered later in the clinical course of patients with sufficient tumor tissue available for testing. Repeat biomarker testing may be considered at clinical or radiologic progression for patients with advanced/metastatic esophageal/EGJ adenocarcinoma.

**Table 3** Immunohistochemical Criteria for Scoring HER2 Expression in Esophageal and EGJ Cancers<sup>k,l</sup>

	Surgical Specimen Expression Pattern, Immunohistochemistry	Biopsy Specimen Expression Pattern, Immunohistochemistry	HER2 Overexpression Assessment
0	No reactivity or membranous reactivity in <10% of cancer cells	No reactivity or no membranous reactivity in any cancer cell	Negative
1+	Faint or barely perceptible membranous reactivity in ≥10% of cancer cells; cells are reactive only in part of their membrane	Cluster of five or more cancer cells with a faint or barely perceptible membranous reactivity irrespective of percentage of cancer cells positive	Negative
2+	Weak to moderate complete, basolateral or lateral membranous reactivity in ≥10% of cancer cells	Cluster of five or more cancer cells with a weak to moderate complete, basolateral, or lateral membranous reactivity irrespective of percentage of cancer cells positive	Equivocal
3+	Strong complete, basolateral, or lateral membranous reactivity in ≥10% of cancer cells	Cluster of five or more cancer cells with a strong complete, basolateral, or lateral membranous reactivity irrespective of percentage of cancer cells positive	Positive

<sup>j</sup> An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.

<sup>k</sup> The NCCN Guidelines Panel recommends that HER2 IHC be ordered/performed first, followed by ISH methods in cases showing 2+ (equivocal) expression by IHC. Positive (3+) or negative (0 or 1+) HER2 IHC results do not require further ISH testing. Cases with *HER2:CEP17* ratio ≥2 or an average HER2 copy number ≥6.0 signals/cell are considered positive by ISH/FISH.

<sup>l</sup> Reprinted and adapted from Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *J Clin Oncol* 2017;35:446-464 with permission from the American Society of Clinical Oncology.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



**PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING**

**Assessment of Positivity of Claudin 18 Isoform 2 (CLDN18.2) in Esophageal and EGJ Adenocarcinomas<sup>12-14</sup>**

- For patients with untreated inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the esophagus or EGJ for whom zolbetuximab therapy is being considered.

**Table 4: Immunohistochemical Criteria for Assessing CLDN18.2 Expression in Esophageal and EGJ Adenocarcinomas**

CLDN18.2 Assessment	Biopsy or Surgical Specimen Expression Pattern by IHC
Positive	≥75% viable tumor cells demonstrating moderate to strong membrane CLDN18.2 staining (2+ or 3+ intensity)
Negative	<75% viable tumor cells demonstrating moderate to strong membrane CLDN18.2 staining

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



**PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING**

**Microsatellite Instability (MSI) or Mismatch Repair (MMR) Testing<sup>m</sup>**

• **Universal testing for MSI by PCR, NGS, or MMR by IHC should be performed for all newly diagnosed esophageal and EGJ cancers.<sup>15</sup> The testing is performed on formalin-fixed paraffin-embedded (FFPE) tissue and results are interpreted as MSI-H or dMMR in accordance with [CAP DNA Mismatch Repair Biomarker Reporting Guidelines](#).<sup>16</sup> Testing should be performed only in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories. Patients with MSI-H or dMMR tumors should be referred to a genetics counselor for further assessment in the appropriate clinical context.**

▶ **MMR Interpretation**

- ◊ **No loss of nuclear expression of MMR proteins: No evidence of dMMR (low probability of MSI-H)**
- ◊ **Loss of nuclear expression of one or more MMR proteins: dMMR**

▶ **MSI Interpretation**

- ◊ **Microsatellite stable (MSS)**
- ◊ **MSI-low (MSI-L)**
  - **1%–29% of the markers exhibit instability**
  - **1 of the 5 National Cancer Institute (NCI) or mononucleotide markers exhibits instability**
- ◊ **MSI-H**
  - **≥30% of the markers exhibit instability**
  - **≥2 of the 5 NCI or mononucleotide markers exhibit instability**

**PD-L1 Testing**

• **Universal testing for PD-L1 by IHC should be performed for all newly diagnosed patients with esophageal and EGJ cancer who are candidates for treatment with programmed cell death protein 1 (PD-1) or PD-L1 inhibitors. A companion diagnostic test for use on FFPE tissue should be used in identifying patients for treatment with PD-1/PD-L1 inhibitors. PD-L1 testing should be performed only in CLIA-approved laboratories.**

• **Assessment of PD-L1 Protein Expression in Esophageal and EGJ Cancers**

- ▶ **This is a qualitative immunohistochemical assay using anti-PD-L1 antibodies for the detection of PD-L1 protein in FFPE tissues from esophageal or EGJ cancers. A minimum of 100 tumor cells must be present in the PD-L1–stained slide for the specimen to be considered adequate for PD-L1 evaluation. A specimen is considered to have PD-L1 expression if the combined positive score (CPS) is ≥1. CPS is the number of PD-L1 staining cells (ie, tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.**
- ▶ **CPS and tumor area positivity (TAP) score have high concordance and may be interchangeable.<sup>17,18</sup>**

<sup>m</sup> PCR/NGS for MSI and IHC for MMR proteins measure different biological effects caused by dMMR function.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING

##### Next-Generation Sequencing (NGS):

- At present, several targeted therapeutic agents ([ESOPH-F](#)) have been approved by the FDA for use in esophageal and EGJ cancers. IHC/ISH/targeted PCR is the preferred approach to assess biomarkers initially. However, NGS testing through a CLIA-approved laboratory may be considered later in the clinical course of patients with sufficient tumor tissue available for testing. The list of targeted biomarkers includes:
  - ▶ HER2 overexpression/amplification
  - ▶ PD-L1 expression
  - ▶ MSI
  - ▶ CLDN18.2
  - ▶ Tumor mutational burden (TMB)
  - ▶ *NTRK* gene fusion
  - ▶ *RET* gene fusion
  - ▶ *BRAF* V600E mutation

##### Liquid Biopsy<sup>19,20</sup>

- The genomic alterations of solid cancers may be identified by evaluating circulating tumor DNA (ctDNA) in the blood, hence a form of “liquid biopsy.” The detection of mutations/alterations or fusions in DNA shed from esophageal or EGJ carcinomas can identify targetable alterations or the evolution of clones with altered treatment response profiles. Therefore, when limited tissue is available or for patients who have metastatic or advanced esophageal/esophagogastric cancers who are not able to undergo a traditional biopsy, testing using a validated NGS-based comprehensive genomic profiling assay performed in a CLIA-approved laboratory may be considered. A negative result should be interpreted with caution, as this does not exclude the presence of tumor.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

#### [References](#)



### PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING REFERENCES

- 1 Amin MB, Edge SB, Greene FL, et al (eds). AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer 2017.
- 2 Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-797.
- 3 Abraham SC, Krasinskas AM, Correa AM, et al. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. AM J Surg Pathol 2007;31:1719-1725.
- 4 Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:1347-1355.
- 5 Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:1349-1355.
- 6 Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007;31:58-64.
- 7 Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006;106:2119-2127.
- 8 Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47:141-146.
- 9 Shi C, Berlin J, Branton PA, et al. Protocol for the examination of specimens from patients with carcinoma of the esophagus. College of American Pathologists Cancer Protocols 2017;1-17 (available at <http://www.cap.org>).
- 10 Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006;106:1017-1025.
- 11 Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society of Clinical Pathology, and American Society of Clinical Oncology. J Clin Oncol 2017;35:446-464.
- 12 Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023;29:2133-2141.
- 13 Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023;401:1655-1668.
- 14 Shitara K, Xu RH, Ajani JA, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 2024;27:1058-1068.
- 15 Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
- 16 Bartley AN, Fitzgibbons PL, Broadus RR, Shi C. Template for Reporting Results of DNA Mismatch Repair Testing in Patients Being Considered for Checkpoint Inhibitor Immunotherapy. College of American Pathologists. 2018.
- 17 Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 2024;385:e078876.
- 18 Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023;24:483-495.
- 19 Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res 2018;24:6248-6256.
- 20 Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res 2019;25:7035-7045.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SURGERY

- Prior to surgery, clinical staging should be performed to assess resectability with CT scan of the chest and abdomen, whole body FDG-PET (integrated FDG-PET/CT is preferred), and EUS.
- Prior to starting therapy all patients should be assessed by an esophageal surgeon for physiologic ability to undergo esophageal resection.<sup>1</sup> Esophageal resection should be considered for all patients who are physiologically fit with resectable esophageal cancer (>5 cm from cricopharynx).
- Siewert Classification
  - ▶ Siewert tumor type should be assessed in all patients with adenocarcinomas involving the EGJ.<sup>2,3</sup>
    - ◊ Siewert Type I: adenocarcinoma of the lower esophagus with the epicenter located within 1 cm to 5 cm above the anatomic EGJ.
    - ◊ Siewert Type II: true carcinoma of the cardia with the tumor epicenter within 1 cm above and 2 cm below the EGJ.
    - ◊ Siewert Type III: subcardial carcinoma with the tumor epicenter between 2 cm and 5 cm below the EGJ, which infiltrates the EGJ and lower esophagus from below.
  - ▶ The treatment of Siewert types I and II is as described in the NCCN Guidelines for Esophageal and EGJ Cancers, and a variety of surgical approaches may be used.
  - ▶ Siewert type III lesions are considered gastric cancers, and thus the [NCCN Guidelines for Gastric Cancer](#) should be followed. In some cases additional esophageal resection may be needed in order to obtain adequate margins.<sup>2,4,5</sup>
- Laparoscopy may be useful in select patients in detecting radiographically occult metastatic disease, especially in patients with Siewert II and III tumors.<sup>1</sup>
- Positive peritoneal cytology (performed in the absence of visible peritoneal implants) is associated with poor prognosis and is defined as M1 disease. In patients with advanced tumors, clinical T3 or N+ disease should be considered for laparoscopic staging with peritoneal washings.
- Cervical or cervicothoracic esophageal carcinomas <5 cm from the cricopharynx should be treated with definitive chemoradiation.
- Resectable esophageal or EGJ cancer:
  - ▶ T1a tumors, defined as tumors involving the mucosa but not invading the submucosa, may be considered for EMR + ablation or esophagectomy in experienced centers.<sup>6-10</sup>
  - ▶ Tumors in the submucosa (T1b) or deeper may be treated with esophagectomy.
  - ▶ T1–T3 tumors are resectable even with regional nodal metastases (N+), although bulky; multistation lymphatic involvement is a relative contraindication to surgery, to be considered in conjunction with age and performance status (PS).
  - ▶ T4a tumors with involvement of pericardium, pleura, or diaphragm are resectable.
- Unresectable esophageal cancer:
  - ▶ cT4b tumors with involvement of the heart, great vessels, trachea, or adjacent organs including liver, pancreas, lung, and spleen are unresectable.
  - ▶ Most patients with multistation, bulky lymphadenopathy should be considered unresectable, although lymph node involvement should be considered in conjunction with other factors, including age, PS, and response to therapy.
  - ▶ Patients with EGJ and supraclavicular lymph node involvement should be considered unresectable.
  - ▶ Patients with distant (including nonregional lymph nodes) metastases (stage IV) are unresectable.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

[Continued](#)  
[References](#)

ESOPH-C  
1 OF 3



#### PRINCIPLES OF SURGERY

- The type of esophageal resection is dictated by the location of the tumor, the available choices for conduit, as well as by the surgeon's experience and preference and the patient's preference.
- In patients who are unable to swallow well enough to maintain nutrition during induction therapy, esophageal dilatation or a feeding jejunostomy tube (J-tube) are preferred to a gastrostomy (which may compromise the integrity of gastric conduit for reconstruction).
- Acceptable operative approaches for resectable esophageal or EGJ cancer:
  - ▶ Ivor Lewis esophagogastrectomy (laparotomy + right thoracotomy)
  - ▶ McKeown esophagogastrectomy (right thoracotomy + laparotomy + cervical anastomosis)
  - ▶ Minimally invasive Ivor Lewis esophagogastrectomy (laparoscopy + limited right thoracotomy)<sup>11,12</sup>
  - ▶ Minimally invasive McKeown esophagogastrectomy (right thoracoscopy + limited laparotomy/laparoscopy + cervical anastomosis)
  - ▶ Transhiatal esophagogastrectomy (laparotomy + cervical anastomosis)
  - ▶ Robotic minimally invasive esophagogastrectomy
  - ▶ Left transthoracic or thoracoabdominal approaches with anastomosis in chest or neck
- Acceptable conduits:
  - ▶ Gastric (preferred)
  - ▶ Colon
  - ▶ Jejunum
- Acceptable lymph node dissections<sup>13</sup>:
  - ▶ Standard
  - ▶ Extended (en-bloc)
- In patients undergoing esophagectomy without induction chemoradiation, at least 16 lymph nodes should be removed and assessed to achieve adequate nodal staging. The optimum number of nodes after preoperative chemoradiation is unknown, although similar lymph node resection is recommended.<sup>14</sup>
- Patients who develop localized, resectable esophageal cancer after definitive chemoradiation can be considered for esophagectomy if they do not have distant recurrence.<sup>15</sup>
- Patients with potentially resectable esophageal cancer should undergo multidisciplinary review. Esophageal resection, EMR, and other ablative techniques should be performed in high-volume esophageal centers by experienced surgeons and endoscopists.<sup>16</sup>

#### [References](#)

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SURGERY REFERENCES

- <sup>1</sup> Steyerberg EW, Neville BA, Kopper LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. *J Clin Oncol* 2006;24:4277-4284.
- <sup>2</sup> Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. *Dis Esophagus* 1996;9:173-182.
- <sup>3</sup> Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction. Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg* 2000;232:353-361.
- <sup>4</sup> Rusch VW. Are Cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several. *Semin Oncol* 2004;31:444-449.
- <sup>5</sup> Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. *Scand J Surg* 2006; 95:260-269.
- <sup>6</sup> Fujita H, Sueyoshi S, Yamana H, et al. Optimum treatment strategy for superficial esophageal cancer: Endoscopic mucosal resection versus radical esophagectomy. *World J Surg* 2001;25:424-431.
- <sup>7</sup> Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med* 2009;360:2277-2288.
- <sup>8</sup> Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high-grade dysplasia and intramucosal carcinoma. *Endoscopy* 2007;39:1086-1091.
- <sup>9</sup> Lopes CV, Hela M, Pesenti C, et al. Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma. *Surg Endosc* 2007;21:820-824.
- <sup>10</sup> Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. *Gastrointest Endosc* 2008;68:35-40.
- <sup>11</sup> Levy RM, Wizorek J, Shende M, Luketich JD. Laparoscopic and thoracoscopic esophagectomy. *Adv Surg* 2010;44:101-116.
- <sup>12</sup> Decker G, Coosemans W, DeLeyn P, et al. Minimally invasive esophagectomy for cancer. *Eur J Cardiothorac Surg* 2009;35:13-20.
- <sup>13</sup> Hofstetter WL. Lymph Node Dissection in Esophageal Cancer. In: Yang SC, Cameron DE, eds. *Current Therapies in Thoracic and Cardiovascular Surgery*. Mosby, Inc.; 2004:360-363.
- <sup>14</sup> Rizk NP, Ishwaran H, Rice T, et al. Optimum lymphadenectomy for esophageal cancer. *Ann Surg* 2010;251:46-50.
- <sup>15</sup> Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. *J Thorac Cardiovasc Surg* 2002;123:175-183.
- <sup>16</sup> Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002;346:1128-1137.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



### PRINCIPLES OF GENETIC RISK ASSESSMENT FOR ESOPHAGEAL AND EGJ CANCERS

#### Criteria for Further Risk Evaluation for High-Risk Syndromes:

- Referral to a cancer genetics professional is recommended for an individual with a known high-risk syndrome associated with esophageal and EGJ cancers.
- Although early age of onset, multiple family members with the same or related cancer, and individuals with multiple primary cancers are all signs of hereditary cancer, specific referral guidelines for esophageal and EGJ cancers risk assessment are not possible at this time.
- The most efficient strategy to identify a causative gene mutation in a family is to test a close relative with cancer. If the relative is either unwilling or unavailable for testing, then consider testing of an unaffected relative. A detailed discussion of genetic counseling and testing can be found in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#) and [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate](#).

#### Hereditary Cancer Predisposition Syndromes Associated with an Increased Risk for Esophageal and EGJ Cancers

- Esophageal Cancer, Tylosis with Non-epidermolytic Palmoplantar Keratoderma (PPK), and Howel-Evans Syndrome<sup>1,2</sup>
  - ▶ Tylosis with esophageal cancer (TEC) is a very rare condition with an autosomal dominant pattern of inheritance and is caused by germline mutations in the *RHBDF2* gene. Individuals with germline *RHBDF2* mutations have an increased risk for SCC of the esophagus. PPK is divided into diffuse, punctate, or focal patterns of skin thickening on palms and soles. The non-epidermolytic PPK is associated with high risk of SCC of the middle and distal esophagus.
- Familial Barrett Esophagus<sup>3</sup>
  - ▶ Familial Barrett esophagus (FBE) includes adenocarcinoma of the esophagus and EGJ. Development of BE is strongly associated with gastroesophageal reflux disease (GERD). FBE may be associated with one or more autosomally inherited dominant susceptibility alleles. Several candidate genes have been identified, but not validated.
- Bloom Syndrome<sup>4</sup>
  - ▶ Bloom syndrome (BS) is characterized by mutations of the *BLM* gene at 15q26.1 and is associated with strikingly elevated sister chromatid exchange rates in all cells. Chromosomal quadraradials with breakage may be used to diagnose individuals with BS who often are affected by acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or lymphoid neoplasms at an early age, but then also cancers affecting many organs including the SCC of the esophagus after 20 years of age.
- Fanconi Anemia<sup>1,2</sup>
  - ▶ The genes involved in Fanconi anemia (FA) include FA complementation groups A–E, with FA-A (FANCA) located at 16q24.3; FA-B (FANCB), unknown; FA-C (FANCC) at 9q22.3; FA-D (FANCD) at 3p26–p22; and FA-E (FANCE), unknown. Mutations in FANCA and FANCC have been identified. Individuals are identified by pancytopenia and chromosome breakage and hematologic abnormalities, including anemia, bleeding, and easy bruising. Increased frequency of SCC of the esophagus as well as other squamous epithelium is observed. Karyotyping does not identify individuals with FA, but enhanced chromosome breakage with mitomycin C can identify homozygotes but not heterozygotes.

<sup>1</sup> Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998;90:1039-1071.

<sup>2</sup> Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008;1-93.

<sup>3</sup> Sun X, Elston R, Barnholtz-Sloan J, et al. A segregation analysis of Barrett's esophagus and associated adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2010;19:666-674.

<sup>4</sup> Ellis NA, German J. Molecular genetics of Bloom's syndrome. Hum Mol Genet 1996;5 Spec No:1457-1463.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

[Continued](#)

ESOPH-D  
1 OF 2



### PRINCIPLES OF GENETIC RISK ASSESSMENT FOR ESOPHAGEAL AND EGJ CANCERS

#### Screening Recommendations

Screening upper endoscopy with biopsies should be considered for patients who have the hereditary cancer predisposition syndromes as indicated below.

Syndrome	Gene(s)	Inheritance Pattern	Screening Recommendations
Esophageal cancer, tylosis with non-epidermolytic palmoplantar keratosis (PPK), and Howel-Evans syndrome <sup>1,2</sup>	<i>RHBDF2</i>	Autosomal dominant	Screening by upper GI endoscopy is recommended in family members with tylosis after 20 years of age.
Familial Barrett esophagus (FBE) <sup>3</sup>	Candidate genes have not been validated	Autosomal dominant	<ul style="list-style-type: none"> <li>Potential family history of BE, esophageal adenocarcinoma, or EGJ adenocarcinoma should be determined for patients presenting with GERD, especially white males &gt;40 years of age.</li> <li>Screening for BE by upper GI endoscopy is recommended in family members with FBE after 40 years of age, especially if the individual has a history of GERD.</li> </ul>
Bloom syndrome (BS) <sup>4</sup>	<i>BLM/RECQL3</i>	Autosomal recessive	Screening for GERD with or without endoscopy to screen for early cancer after 20 years of age may be considered.
Fanconi anemia (FA) <sup>1,2</sup>	<i>FANCD1, BRCA2, FANCN (PALB2)</i>	Autosomal recessive	Endoscopy of the esophagus may be considered as a screening strategy in individuals identified with FA.

<sup>1</sup> Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998;90:1039-1071.

<sup>2</sup> Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008:1-93.

<sup>3</sup> Sun X, Elston R, Barnholtz-Sloan J, et al. A segregation analysis of Barrett's esophagus and associated adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2010;19:666-674.

<sup>4</sup> Ellis NA, German J. Molecular genetics of Bloom's syndrome. Hum Mol Genet 1996;5 Spec No:1457-1463.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.**  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF MULTIDISCIPLINARY TEAM APPROACH FOR ESOPHAGOGASTRIC CANCERS

**Category 1 evidence supports the notion that the combined modality therapy is effective for patients with localized esophagogastric cancer.<sup>1,2,3</sup> The NCCN Panel believes in an infrastructure that encourages multidisciplinary treatment decision-making by members of all disciplines taking care of this group of patients.**

**The combined modality therapy for patients with localized esophagogastric cancer may be optimally delivered when the following elements are in place:**

- **The involved institution and individuals from relevant disciplines are committed to jointly reviewing the detailed data on patients on a regular basis. Frequent meetings (either once a week or once every two weeks) are encouraged.**
- **Optimally at each meeting, all relevant disciplines should be encouraged to participate and these may include: surgical oncology, medical oncology, gastroenterology, radiation oncology, radiology, and pathology. In addition, the presence of nutritional services, social workers, nurses, palliative care specialists, and other supporting disciplines are also desirable.**
- **All long-term therapeutic strategies are best developed after adequate staging procedures are completed, but ideally prior to any therapy that is rendered.**
- **Joint review of the actual medical data is more effective than reading reports for making sound therapy decisions.**
- **A brief documentation of the consensus recommendation(s) by the multidisciplinary team for an individual patient may prove useful.**
- **The recommendations made by the multidisciplinary team may be considered advisory to the primary group of treating physicians of the particular patient.**
- **Re-presentation of select patient outcomes after therapy is rendered may be an effective educational method for the entire multidisciplinary team.**
- **A periodic formal review of relevant literature during the course of the multidisciplinary meeting is highly encouraged.**

<sup>1</sup> Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.

<sup>2</sup> Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999;281:1623-1627.

<sup>3</sup> Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**



### PRINCIPLES OF SYSTEMIC THERAPY

- Systemic therapy regimens recommended for advanced esophageal adenocarcinoma, EGJ adenocarcinoma, and gastric adenocarcinoma may be used interchangeably (except as indicated). Systemic therapy regimens recommended for advanced SCC of the esophagus have been separately included.
- Regimens should be chosen in the context of PS, comorbidities, and toxicity profile.
- Trastuzumab should be added to first-line chemotherapy for advanced HER2 overexpression-positive adenocarcinoma.
- Two-drug cytotoxic regimens are preferred for patients with advanced disease because of lower toxicity. The use of three cytotoxic drugs in a regimen should be reserved for patients who are medically fit with excellent PS and easy access to frequent toxicity evaluations.
- Modifications of category 1 regimen or use of category 2A or 2B regimens may be preferred (as indicated), with evidence supporting more favorable toxicity profile without compromising efficacy.<sup>1</sup>
- Doses and schedules for any regimen that is not derived from category 1 evidence is a suggestion, and subject to appropriate modifications depending on the circumstances.
- Alternate combinations and schedules of cytotoxics based on the availability of the agents, practice preferences, and contraindications are permitted.
- Perioperative systemic therapy is preferred for patients with resectable esophageal or EGJ adenocarcinoma who are medically fit with access to frequent toxicity evaluation (also see GAST-2 and GAST-F in the [NCCN Guidelines for Gastric Cancer](#)). Preoperative chemoradiation may be considered for patients who are borderline resectable due to medical or surgical conditions. For patients who are not candidates for perioperative FLOT, then perioperative FOLFOX/CAPOX or preoperative chemoradiation may be considered as an option.<sup>2,3,4</sup> Preoperative chemoradiation is preferred for esophageal SCC.
- In the adjuvant setting, upon completion of systemic therapy or chemoradiation, patients should be monitored for any long-term treatment-related complications.
- An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.
- A checkpoint inhibitor should be added to first-line chemotherapy for patients with advanced disease with PD-L1 CPS ≥1.
  - ▶ CPS and TAP score have high concordance and may be interchangeable.<sup>5,6</sup>
- Nivolumab and hyaluronidase-nvhy is not approved for concurrent use with IV ipilimumab; however, for nivolumab monotherapy, nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab.

#### References

- <sup>1</sup> Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991-4997.
- <sup>2</sup> van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012;366:2074-2084.
- <sup>3</sup> Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
- <sup>4</sup> Hoepfner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. *N Engl J Med* 2025;392:323-335.
- <sup>5</sup> Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ* 2024;385:e078876.
- <sup>6</sup> Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *Lancet Oncol* 2023;24:483-495.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

**Continued**

**ESOPH-F  
1 OF 24**



#### PRINCIPLES OF SYSTEMIC THERAPY

**The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.**

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**

[Continued](#)

**ESOPH-F  
2 OF 24**



#### PRINCIPLES OF SYSTEMIC THERAPY

<b>Perioperative Systemic Therapy</b>
<b>Preferred Regimen</b>
<ul style="list-style-type: none"> <li>Fluorouracil,<sup>a</sup> leucovorin, oxaliplatin, and docetaxel (FLOT)<sup>1,2</sup> (category 1)</li> <li>FLOT<sup>a</sup> + durvalumab<sup>b</sup> for PD-L1 CPS ≥1 or TAP ≥1%<sup>c</sup> (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma)<sup>d,*</sup></li> </ul>
<b>Other Recommended Regimens</b>
<ul style="list-style-type: none"> <li>Fluorouracil and cisplatin (category 1)<sup>3</sup></li> <li>Fluoropyrimidine and oxaliplatin<sup>a,e</sup></li> </ul>

<b>Preoperative Chemoradiation</b> (Infusional fluorouracil <sup>a</sup> can be replaced with capecitabine)
<b>Preferred Regimens</b>
<ul style="list-style-type: none"> <li>Paclitaxel and carboplatin (category 1)<sup>4</sup></li> <li>Fluorouracil<sup>a</sup> and oxaliplatin (category 1)<sup>5-7</sup></li> </ul>
<b>Other Recommended Regimens</b>
<ul style="list-style-type: none"> <li>Fluorouracil and cisplatin (category 1)<sup>8-9</sup></li> <li>Irinotecan and cisplatin (category 2B)<sup>10</sup></li> <li>Paclitaxel and fluoropyrimidine (fluorouracil or capecitabine) (category 2B)<sup>11</sup></li> </ul>

<b>Neoadjuvant or Perioperative Immunotherapy</b>
<b>Useful in Certain Circumstances</b>
<ul style="list-style-type: none"> <li>MSI-H/dMMR tumors<sup>c</sup> <ul style="list-style-type: none"> <li>Nivolumab and ipilimumab followed by nivolumab<sup>b,12</sup></li> <li>Pembrolizumab<sup>b,13,14</sup></li> </ul> </li> <li>Tremelimumab and durvalumab for neoadjuvant therapy only<sup>b,15,16</sup></li> </ul>

#### See Evidence Blocks on EB-1

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>d</sup> In the MATTERHORN trial, diffuse type gastric or EGJ adenocarcinoma showed no EFS advantage when durvalumab was added to FLOT.

<sup>e</sup> The use of this regimen and dosing schedules is based on extrapolations from published literature and clinical practice.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**

<b>Definitive Chemoradiation</b> (Infusional fluorouracil can be replaced with capecitabine)
<b>Preferred Regimens</b>
<ul style="list-style-type: none"> <li>Paclitaxel and carboplatin<sup>4</sup></li> <li>Fluorouracil<sup>a</sup> and oxaliplatin (category 1)<sup>5,6</sup></li> </ul>
<b>Other Recommended Regimens</b>
<ul style="list-style-type: none"> <li>Fluorouracil and cisplatin (category 1)<sup>17</sup></li> <li>Cisplatin with docetaxel or paclitaxel<sup>18-20</sup></li> <li>Irinotecan and cisplatin (category 2B)<sup>10</sup></li> <li>Paclitaxel and fluoropyrimidine (fluorouracil or capecitabine) (category 2B)<sup>11</sup></li> </ul>

<b>Postoperative Systemic Therapy</b>
<b>Preferred Regimens</b>
<ul style="list-style-type: none"> <li>Nivolumab only after preoperative chemoradiation with R0 resection and residual disease (category 1)<sup>b,21</sup></li> </ul>
<b>Other Recommended Regimens</b>
<ul style="list-style-type: none"> <li>Capecitabine and oxaliplatin<sup>22</sup></li> <li>Fluorouracil<sup>a</sup> and oxaliplatin</li> <li>Fluoropyrimidine (infusional fluorouracil<sup>a</sup> or capecitabine) before and after fluoropyrimidine-based chemoradiation<sup>23</sup></li> </ul>

[See Evidence Blocks EB-2](#)



### PRINCIPLES OF SYSTEMIC THERAPY

#### Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease (where local therapy is not indicated)

#### ADENOCARCINOMA

##### First-Line Therapy

- Oxaliplatin is preferred over cisplatin due to lower toxicity.

##### Preferred Regimens

- HER2 overexpression positive<sup>C</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and trastuzumab
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, trastuzumab, and pembrolizumab for PD-L1 CPS ≥1 (category 1)<sup>b,f,24,25</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and trastuzumab (category 1)<sup>26</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, trastuzumab and pembrolizumab for PD-L1 CPS ≥1 (category 1)<sup>b,f,24,25</sup>
- HER2 overexpression negative<sup>C</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>b,f,27</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>b,f,28,29</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and tislelizumab-jsgr for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>b,f,30</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and zolbetuximab-clzb for CLDN18.2 positive<sup>C</sup> (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma)<sup>31,32</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine) and oxaliplatin<sup>33-35</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and pembrolizumab for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>b,f,28,29</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and tislelizumab-jsgr for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>b,f,30</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine) and cisplatin<sup>33,36-38</sup>
- MSI-H/dMMR tumors (independent of PD-L1 status)
  - ▶ Pembrolizumab<sup>b,f,39-41</sup>
  - ▶ Dostarlimab-gxly<sup>b,f,42</sup>
  - ▶ Nivolumab and ipilimumab<sup>b,f,27</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab<sup>b,f,27</sup>
  - ▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>b,f,28</sup>

##### Other Recommended Regimens

- Fluorouracil<sup>a,9</sup> and irinotecan<sup>h,43</sup>
- Paclitaxel with or without carboplatin or cisplatin<sup>h,44-48</sup>
- Docetaxel with or without cisplatin<sup>h,49-52</sup>
- Fluoropyrimidine<sup>h,37,53,54</sup> (fluorouracil<sup>a</sup> or capecitabine)
- Docetaxel, cisplatin or oxaliplatin, and fluorouracil<sup>a,h,55,56</sup>

[See Evidence Blocks on EB-3 and EB-4](#)

##### Useful in Certain Circumstances

- Entrectinib, larotrectinib, or repotrectinib for *NTRK* gene fusion-positive tumors (category 2B)<sup>57-59</sup>

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SYSTEMIC THERAPY FOOTNOTES FOR ESOPH-F 4 OF 24

- <sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).
- <sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).
- <sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).
- <sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.
- <sup>g</sup> Capecitabine cannot be used interchangeably with fluorouracil in regimens containing irinotecan.
- <sup>h</sup> Trastuzumab should be added to first-line chemotherapy for HER2 overexpression-positive adenocarcinoma.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SYSTEMIC THERAPY

#### Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease (where local therapy is not indicated)

SQUAMOUS CELL CARCINOMA
<p><b>First-Line Therapy</b></p> <ul style="list-style-type: none"> <li>• Oxaliplatin is preferred over cisplatin due to lower toxicity.</li> </ul>
<p><b>Preferred Regimens</b></p> <ul style="list-style-type: none"> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab for PD-L1 CPS ≥1 (category 1)<sup>b,f,60</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab for PD-L1 CPS ≥1 (category 1)<sup>b,f,28</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and tislelizumab-jsgr for PD-L1 CPS ≥1 (category 1)<sup>b,f,61</sup></li> <li>• Oxaliplatin, paclitaxel, and tislelizumab-jsgr for PD-L1 CPS ≥1<sup>b,f,61</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine) and oxaliplatin<sup>33-35</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and nivolumab for PD-L1 CPS ≥1 (category 1)<sup>b,f,60</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and pembrolizumab for PD-L1 CPS ≥1 (category 1)<sup>b,f,28</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and tislelizumab-jsgr for PD-L1 CPS ≥1 (category 1)<sup>b,f,61</sup></li> <li>• Cisplatin, paclitaxel, and tislelizumab-jsgr for PD-L1 CPS ≥1<sup>b,f,61</sup></li> <li>• Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine) and cisplatin<sup>33,36-38</sup></li> <li>• Nivolumab and ipilimumab for PD-L1 CPS ≥1<sup>b,f,60</sup></li> <li>• MSI-H/dMMR tumors (independent of PD-L1 status)<sup>c</sup> <ul style="list-style-type: none"> <li>▶ Pembrolizumab<sup>b,f,39-41</sup></li> <li>▶ Dostarlimab-gxly<sup>b,f,42</sup></li> <li>▶ Nivolumab and ipilimumab<sup>d,e,27</sup></li> <li>▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab<sup>b,f,27</sup></li> <li>▶ Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>b,f,28</sup></li> </ul> </li> </ul>
<p><b>Other Recommended Regimens</b></p> <ul style="list-style-type: none"> <li>• Fluorouracil<sup>a,9</sup> and irinotecan<sup>43</sup></li> <li>• Paclitaxel with or without carboplatin or cisplatin<sup>44-48</sup></li> <li>• Docetaxel with or without cisplatin<sup>49-52</sup></li> <li>• Fluoropyrimidine<sup>37,53,54</sup> (fluorouracil<sup>a</sup> or capecitabine)</li> <li>• Docetaxel, cisplatin or oxaliplatin, and fluorouracil<sup>a,55,56</sup></li> </ul>
<p><b>Useful in Certain Circumstances</b></p> <ul style="list-style-type: none"> <li>• Entrectinib, larotrectinib, or repotrectinib for <i>NTRK</i> gene fusion-positive tumors (category 2B)<sup>57-59</sup></li> </ul>

#### See Evidence Blocks on EB-5

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>g</sup> Capecitabine cannot be used interchangeably with fluorouracil in regimens containing irinotecan.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

#### PRINCIPLES OF SYSTEMIC THERAPY

#### Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease (where local therapy is not indicated)

ADENOCARCINOMA
<p><b>Second-Line or Subsequent Therapy</b></p> <ul style="list-style-type: none"> <li>• Dependent on prior therapy and PS</li> </ul>
<p><b>Preferred Regimens</b></p> <ul style="list-style-type: none"> <li>• Ramucirumab and paclitaxel (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma)<sup>62</sup></li> <li>• Fam-trastuzumab deruxtecan-nxki for HER2 overexpression positive<sup>63</sup></li> <li>• Docetaxel (category 1)<sup>51,52</sup></li> <li>• Paclitaxel (category 1)<sup>47,48,64</sup></li> <li>• Irinotecan (category 1)<sup>64-67</sup></li> <li>• Fluorouracil<sup>a,9</sup> and irinotecan<sup>65,68,69</sup></li> <li>• Trifluridine and tipiracil for third-line or subsequent therapy for EGJ adenocarcinoma (category 1)<sup>70</sup></li> </ul>
<p><b>Other Recommended Regimens</b></p> <ul style="list-style-type: none"> <li>• Ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma)<sup>71</sup></li> <li>• Irinotecan and cisplatin<sup>34,72</sup></li> <li>• Fluorouracil and irinotecan + ramucirumab<sup>a,9,73</sup></li> <li>• Irinotecan and ramucirumab<sup>74</sup></li> <li>• Docetaxel and irinotecan (category 2B)<sup>75</sup></li> </ul>
<p><b>Useful in Certain Circumstances<sup>c</sup></b></p> <ul style="list-style-type: none"> <li>• Entrectinib, larotrectinib, or repotrectinib<sup>i</sup> for <i>NTRK</i> gene fusion-positive tumors<sup>57-59</sup></li> <li>• Pembrolizumab<sup>b,f</sup> for MSI-H/dMMR tumors<sup>39-41</sup></li> <li>• Nivolumab and ipilimumab<sup>b,f</sup> for MSI-H/dMMR tumors<sup>27</sup></li> <li>• Pembrolizumab<sup>b,f</sup> for TMB-high (TMB-H) (≥10 mutations/megabase) tumors<sup>76</sup></li> <li>• Dostarlimab-gxly<sup>b,f,j</sup> for MSI-H/dMMR tumors<sup>42</sup></li> <li>• Dabrafenib and trametinib for <i>BRAF</i> V600E-mutated tumors<sup>77</sup></li> <li>• Selpercatinib for <i>RET</i> gene fusion-positive tumors<sup>78</sup></li> </ul>

#### See Evidence Blocks on EB-6

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>g</sup> Capecitabine cannot be used interchangeably with fluorouracil in regimens containing irinotecan.

<sup>i</sup> Repotrectinib can be used in patients whose disease progressed on a prior *NTRK* targeted therapy.

<sup>j</sup> For patients whose cancer is progressing on or following prior treatment (that did not include a checkpoint inhibitor like PD-1i, PD-L1i, or CTLA4i) and who have no satisfactory alternative treatment options. Prior use of immuno-oncology therapy in these patients will make them ineligible for dostarlimab-gxly.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated.**



#### PRINCIPLES OF SYSTEMIC THERAPY

#### Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease (where local therapy is not indicated)

SQUAMOUS CELL CARCINOMA
<p><b>Second-Line or Subsequent Therapy</b></p> <ul style="list-style-type: none"> <li>• Dependent on prior therapy and PS</li> </ul>
<p><b>Preferred Regimens</b></p> <ul style="list-style-type: none"> <li>• Nivolumab (category 1)<sup>b,f,79</sup></li> <li>• Pembrolizumab<sup>b,f</sup> for PD-L1 CPS ≥10 (category 1)<sup>80</sup></li> <li>• Docetaxel (category 1)<sup>51,52</sup></li> <li>• Paclitaxel (category 1)<sup>47,48,64</sup></li> <li>• Irinotecan (category 1)<sup>64-67</sup></li> <li>• Tislelizumab-jsgr (category 1)<sup>b,f,81-82</sup></li> <li>• Fluorouracil<sup>a,9</sup> and irinotecan<sup>65,68,69</sup></li> </ul>
<p><b>Other Recommended Regimens</b></p> <ul style="list-style-type: none"> <li>• Irinotecan and cisplatin<sup>34,72</sup></li> <li>• Docetaxel and irinotecan (category 2B)<sup>75</sup></li> </ul>
<p><b>Useful in Certain Circumstances<sup>c</sup></b></p> <ul style="list-style-type: none"> <li>• Entrectinib, larotrectinib, or repotrectinib<sup>i</sup> for <i>NTRK</i> gene fusion-positive tumors<sup>57-59</sup></li> <li>• Pembrolizumab<sup>b,f</sup> for MSI-H/dMMR tumors<sup>39-41</sup></li> <li>• Nivolumab and ipilimumab<sup>b,f</sup> for MSI-H/dMMR tumors<sup>27</sup></li> <li>• Pembrolizumab<sup>b,f</sup> for TMB-H (≥10 mutations/megabase) tumors<sup>76</sup></li> <li>• Dostarlimab-gxly<sup>b,f,j</sup> for MSI-H/dMMR tumors<sup>42</sup></li> <li>• Dabrafenib and trametinib for <i>BRAF</i> V600E-mutated tumors<sup>77</sup></li> <li>• Selpercatinib for <i>RET</i> gene fusion-positive tumors<sup>78</sup></li> </ul>

[See Evidence Blocks on EB-7](#)

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>c</sup> [Principles of Pathologic Review and Biomarker Testing \(ESOPH-B\)](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>9</sup> Capecitabine cannot be used interchangeably with fluorouracil in regimens containing irinotecan.

<sup>i</sup> Repotrectinib can be used in patients whose disease progressed on a prior *NTRK* targeted therapy.

<sup>j</sup> For patients whose cancer is progressing on or following prior treatment (that did not include a checkpoint inhibitor like PD-1i, PD-L1i, or CTLA4i) and who have no satisfactory alternative treatment options. Prior use of immuno-oncology therapy in these patients will make them ineligible for dostarlimab-gxly.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

##### PERIOPERATIVE SYSTEMIC THERAPY

##### PREFERRED REGIMENS

##### Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)<sup>a</sup>

(4 cycles preoperative and 4 cycles postoperative)

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Docetaxel 50 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days<sup>1,2</sup>

##### FLOT + durvalumab (for adenocarcinoma)<sup>a,b,d</sup>

Durvalumab 1500 mg IV on Day 1

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1 and 15

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1 and 15

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1 and 15

Docetaxel 50 mg/m<sup>2</sup> IV on Day 1 and 15

Cycled every 28 days

(2 cycles preoperative and 2 cycles postoperative, 4 cycles total)

followed by Durvalumab 1500 mg IV on Day 1

every 4 weeks for 10 additional cycles\*

##### OTHER RECOMMENDED REGIMENS

##### Fluorouracil and cisplatin

(4 cycles preoperative and 4 cycles postoperative)

Fluorouracil 2000 mg/m<sup>2</sup> IV continuous infusion over 48 hours on Days 1–2

Cisplatin 50 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days

##### Fluoropyrimidine and oxaliplatin<sup>a</sup>

(4 cycles preoperative and 4 cycles postoperative)

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>34</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1

Cycled every 14 days<sup>33</sup>

Capecitabine 1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>35</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>d</sup> In the MATTERHORN trial, diffuse type gastric or EGJ adenocarcinoma showed no EFS advantage when durvalumab was added to FLOT.

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

##### PREOPERATIVE CHEMORADIATION

###### PREFERRED REGIMENS

###### Paclitaxel and carboplatin

Paclitaxel 50 mg/m<sup>2</sup> IV on Day 1  
Carboplatin AUC 2 IV on Day 1  
Weekly for 5 weeks<sup>4</sup>

###### Fluorouracil<sup>a</sup> and oxaliplatin

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days for 3 cycles with radiation<sup>5,m</sup>

Fluorouracil 300 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily for 4 days (over 96 hours) weekly  
Oxaliplatin 85 mg/m<sup>2</sup> IV over 2 hours on Day 1  
Cycled every 14 days for 3 cycles with radiation<sup>7</sup>

###### Capecitabine and oxaliplatin

Oxaliplatin 85 mg/m<sup>2</sup> IV on Days 1, 15, and 29 for 3 doses  
Capecitabine 625 mg/m<sup>2</sup> PO BID on Days 1–5 weekly for 5 weeks<sup>83</sup>

##### OTHER RECOMMENDED REGIMENS

###### Fluorouracil and cisplatin

Cisplatin 75–100 mg/m<sup>2</sup> IV on Days 1 and 29  
Fluorouracil 750–1000 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–4 and 29–32  
35-day cycle<sup>8</sup>

Cisplatin 15 mg/m<sup>2</sup> IV daily on Days 1–5  
Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5  
Cycled every 21 days for 2 cycles<sup>9</sup>

###### Capecitabine and cisplatin

Cisplatin 30 mg/m<sup>2</sup> IV on Day 1  
Capecitabine 800 mg/m<sup>2</sup> PO BID on Days 1–5  
Weekly for 5 weeks<sup>84</sup>

###### Irinotecan and cisplatin

Irinotecan 65 mg/m<sup>2</sup> IV on Days 1, 8, 22, and 29  
Cisplatin 30 mg/m<sup>2</sup> IV on Days 1, 8, 22, and 29  
Cycled every 35 days<sup>10</sup>

###### Paclitaxel and fluoropyrimidine

Paclitaxel 45–50 mg/m<sup>2</sup> IV on Day 1 weekly  
Fluorouracil 300 mg/m<sup>2</sup> IV continuous infusion daily on Days 1–5  
Weekly for 5 weeks<sup>11</sup>

Paclitaxel 45–50 mg/m<sup>2</sup> IV on Day 1  
Capecitabine 625–825 mg/m<sup>2</sup> PO BID on Days 1–5  
Weekly for 5 weeks<sup>11</sup>

##### NEOADJUVANT OR PERIOPERATIVE IMMUNOTHERAPY USEFUL IN CERTAIN CIRCUMSTANCES

###### (MSI-H/dMMR tumors)

Nivolumab and ipilimumab followed by nivolumab<sup>b</sup>  
Nivolumab 240 mg IV every 2 weeks,  
Ipilimumab 1 mg/kg IV every 6 weeks (preoperative for at least 12 total weeks), followed by surgery and adjuvant nivolumab 480 mg IV every 4 weeks for 9 cycles<sup>12</sup>

###### Pembrolizumab<sup>b</sup>

Pembrolizumab 200 mg IV every 3 weeks for at least 12 total weeks followed by surgery and adjuvant pembrolizumab 200 mg IV every 3 weeks for 16 cycles<sup>13</sup>

###### Tremelimumab and durvalumab<sup>b</sup> (for neoadjuvant therapy only)

Tremelimumab 300 mg IV on Day 1  
Durvalumab 1500 mg IV on Day 1, 29, and 57  
For 12 weeks preoperatively for 1 cycle only<sup>15,16</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

<sup>m</sup> This regimen can be individualized and/or attenuated on a patient basis.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

##### DEFINITIVE CHEMORADIATION (NON-SURGICAL)

###### PREFERRED REGIMENS

###### Paclitaxel and carboplatin

Paclitaxel 50 mg/m<sup>2</sup> IV on Day 1  
Carboplatin AUC 2 IV on Day 1  
Weekly for 5 weeks<sup>4</sup>

###### Fluorouracil and oxaliplatin<sup>a</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV  
on Days 1, 15, and 29 for 3 doses  
Fluorouracil 180 mg/m<sup>2</sup> IV daily on Days 1–33<sup>6</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion  
over 24 hours daily on Days 1 and 2  
Cycled every 14 days for 3 cycles with radiation  
followed by 3 cycles without radiation<sup>5</sup>

###### Capecitabine and oxaliplatin

Oxaliplatin 85 mg/m<sup>2</sup> IV on Days 1, 15, and 29  
for 3 doses  
Capecitabine 625 mg/m<sup>2</sup> PO BID  
on Days 1–5 weekly for 5 weeks<sup>83</sup>

###### OTHER RECOMMENDED REGIMENS

###### Fluorouracil and cisplatin

Cisplatin 75–100 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 750–1000 mg/m<sup>2</sup> IV continuous  
infusion over 24 hours daily on Days 1–4  
Cycled every 28 days for 2 cycles with radiation  
followed by 2 cycles without radiation<sup>17</sup>

###### Capecitabine and cisplatin

Cisplatin 30 mg/m<sup>2</sup> IV on Day 1  
Capecitabine 800 mg/m<sup>2</sup> PO BID on Days 1–5  
Weekly for 5 weeks<sup>84</sup>

###### Taxane and cisplatin

Paclitaxel 60 mg/m<sup>2</sup> IV  
on Days 1, 8, 15, and 22  
Cisplatin 75 mg/m<sup>2</sup> IV on Day 1  
Given for 1 cycle<sup>18</sup>

Docetaxel 60 mg/m<sup>2</sup> IV on Days 1 and 22  
Cisplatin 60–80 mg/m<sup>2</sup> IV on Days 1 and 22  
Given for 1 cycle<sup>19</sup>

Docetaxel 20–30 mg/m<sup>2</sup> IV on Day 1  
Cisplatin 20–30 mg/m<sup>2</sup> IV on Day 1  
Weekly for 5 weeks<sup>20</sup>

###### Irinotecan and cisplatin

Irinotecan 65 mg/m<sup>2</sup> IV on Days 1, 8, 22, and 29  
Cisplatin 30 mg/m<sup>2</sup> IV on Days 1, 8, 22, and 29  
cycled every 35 days<sup>10</sup>

###### OTHER RECOMMENDED REGIMENS—continued

###### Paclitaxel and fluoropyrimidine

Paclitaxel 45–50 mg/m<sup>2</sup> IV on Day 1 weekly  
Fluorouracil 300 mg/m<sup>2</sup> IV continuous infusion  
daily on Days 1–5  
Weekly for 5 weeks<sup>11</sup>

Paclitaxel 45–50 mg/m<sup>2</sup> IV on Day 1  
Capecitabine 625–825 mg/m<sup>2</sup> PO BID on Days 1–5  
Weekly for 5 weeks<sup>11</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

##### POSTOPERATIVE SYSTEMIC THERAPY

##### PREFERRED REGIMEN

##### Nivolumab<sup>b</sup>

Nivolumab 240 mg IV every 14 days for 16 weeks followed by Nivolumab 480 mg IV every 28 days  
Maximum treatment duration of 1 year<sup>21</sup>

##### OTHER RECOMMENDED REGIMENS

##### Capecitabine and oxaliplatin

Capecitabine 1000 mg/m<sup>2</sup> PO BID on Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days<sup>22</sup>

##### Fluorouracil and oxaliplatin<sup>a</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days<sup>34</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 200 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1  
Cycled every 14 days<sup>33</sup>

##### POSTOPERATIVE SYSTEMIC THERAPY (continued)

##### OTHER RECOMMENDED REGIMENS

THE PANEL ACKNOWLEDGES THAT THE INTERGROUP 0116 TRIAL<sup>23,85</sup> FORMED THE BASIS FOR POSTOPERATIVE ADJUVANT CHEMORADIATION STRATEGY. HOWEVER, THE PANEL DOES NOT RECOMMEND THE DOSES AND SCHEDULE OF CYTOTOXIC AGENTS SPECIFIED IN THIS TRIAL DUE TO CONCERNS REGARDING TOXICITY. THE PANEL RECOMMENDS ONE OF THE FOLLOWING MODIFICATIONS INSTEAD:

##### Fluorouracil<sup>a</sup>

2 cycles before and 4 cycles after chemoradiation. For cycles after chemoradiation, begin chemotherapy 1 month after chemoradiation.  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days

##### With radiation

Fluorouracil 200–250 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5  
Weekly for 5 weeks<sup>86</sup>

##### Capecitabine

1 cycle before and 2 cycles after chemoradiation. For cycles after chemoradiation, begin chemotherapy 1 month after chemoradiation.  
Capecitabine 750–1000 mg/m<sup>2</sup> PO BID on Days 1–14  
Cycled every 21 days<sup>87</sup>

##### With radiation

Capecitabine 625–825 mg/m<sup>2</sup> PO BID on Days 1–5  
Weekly for 5 weeks<sup>88</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

##### FIRST-LINE THERAPY

##### HER2 overexpression-positive adenocarcinoma

##### Trastuzumab with chemotherapy

(See [ESOPH-F \[4 of 24\]](#) for list of regimens)

Trastuzumab 8 mg/kg IV loading dose on Day 1 of cycle 1, then Trastuzumab 6 mg/kg IV every 21 days<sup>26</sup> or

Trastuzumab 6 mg/kg IV loading dose on Day 1 of cycle 1, then 4 mg/kg IV every 14 days

##### PREFERRED REGIMENS

##### Fluoropyrimidine and oxaliplatin<sup>a</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days<sup>34</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 200 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1  
Cycled every 14 days<sup>33</sup>

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days<sup>35</sup>

Capecitabine 625 mg/m<sup>2</sup> PO BID on Days 1–14<sup>n,o</sup>  
Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days<sup>89</sup>

##### PREFERRED REGIMENS—continued

##### Fluoropyrimidine and cisplatin

Cisplatin 75–100 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 750–1000 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–4  
Cycled every 28 days<sup>36</sup>

Cisplatin 50 mg/m<sup>2</sup> IV daily on Day 1  
Leucovorin 200 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Day 1  
Cycled every 14 days<sup>33,37</sup>

Cisplatin 80 mg/m<sup>2</sup> IV daily on Day 1  
Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14  
Cycled every 21 days<sup>38</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

<sup>n</sup> Based on consensus opinion, the Panel revised the doses and schedule studied in level C of the GO2 trial.

<sup>o</sup> This regimen is recommended for patients who are frail and/or older.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

##### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS

Trastuzumab and pembrolizumab<sup>b,f</sup> with fluoropyrimidine and oxaliplatin or cisplatin (only for HER2 overexpression-positive adenocarcinoma)

Trastuzumab 8 mg/kg IV loading dose on Day 1 of cycle 1, then

Trastuzumab 6 mg/kg IV every 21 days<sup>25,26</sup>

or

Trastuzumab 6 mg/kg IV loading dose on Day 1 of cycle 1, then 4 mg/kg IV every 14 days

Pembrolizumab 200 mg IV on Day 1

Cycled every 3 weeks

or

Pembrolizumab 400 mg IV on Day 1

Cycled every 6 weeks<sup>24,25</sup>

##### PREFERRED REGIMENS—continued

Fluoropyrimidine and oxaliplatin<sup>a</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>34</sup>

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>35</sup>

##### PREFERRED REGIMENS—continued

Fluoropyrimidine and cisplatin

Cisplatin 80 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1–5

Cycled every 21 days<sup>24</sup>

Cisplatin 80 mg/m<sup>2</sup> IV daily on Day 1

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Cycled every 21 days<sup>38</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



**PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>**

**SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)**

**FIRST-LINE THERAPY**

**PREFERRED REGIMENS**

**Tislelizumab-jsgr<sup>b,f</sup> with fluoropyrimidine and oxaliplatin or cisplatin**

**(See [ESOPH-F \[4 of 24 and 5 of 24\]](#) for list of regimens)**

**Tislelizumab 200 mg IV on Day 1 every 21 days<sup>30,61</sup> in combination with:**

**Fluoropyrimidine and oxaliplatin<sup>a</sup>**

**Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1**

**Leucovorin 200 mg/m<sup>2</sup> IV on Day 1**

**Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion**

**over 24 hours daily on Days 1 and 2**

**Cycled every 14 days for 12 cycles<sup>30,61</sup>**

**Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14**

**Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)**

**Cycled every 21 days<sup>30,61</sup>**

**Fluoropyrimidine and cisplatin**

**Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1**

**Fluorouracil 750–800 mg/m<sup>2</sup> IV continuous infusion**

**over 24 hours daily on Days 1–5**

**Cycled every 21 days for 6 cycles<sup>30,61</sup>**

**Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)**

**Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14**

**Cycled every 21 days<sup>30,61</sup>**

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

**PREFERRED REGIMENS—continued**

**Tislelizumab-jsgr with oxaliplatin or cisplatin and paclitaxel (for SCC)**

**Oxaliplatin, paclitaxel, and tislelizumab-jsgr<sup>b,f</sup>**

**Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)**

**Paclitaxel 175 mg/m<sup>2</sup> IV on Day 1**

**Tislelizumab 200 mg IV on Day 1**

**Cycled every 21 days<sup>61</sup>**

**Cisplatin, paclitaxel, and tislelizumab-jsgr<sup>b,f</sup>**

**Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)**

**Paclitaxel 175 mg/m<sup>2</sup> IV on Day 1**

**Tislelizumab 200 mg IV on Day 1**

**Cycled every 21 days<sup>61</sup>**

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



**PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>**

**SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)**

**FIRST-LINE THERAPY**

**PREFERRED REGIMENS—continued**

Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab<sup>b,f</sup>

Nivolumab 360 mg IV on Day 1 (per study maximum of 2 years)  
Capecitabine 850–1000 mg/m<sup>2</sup> PO BID every Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days<sup>27,60</sup>

Nivolumab 240 mg IV on Day 1 (per study maximum of 2 years)  
Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days<sup>27,60</sup>

Fluoropyrimidine (fluorouracil or capecitabine), cisplatin and nivolumab (for SCC)<sup>b,f</sup>

Nivolumab 240 mg IV every 2 weeks (per study maximum of 2 years)  
Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5  
Cisplatin 80 mg/m<sup>2</sup> IV Day 1  
Cycled every 28 days<sup>60</sup>

Nivolumab 360 mg IV on Day 1 (per study maximum of 2 years)  
Cisplatin 80 mg/m<sup>2</sup> IV Day 1  
Capecitabine 850–1000 mg/m<sup>2</sup> PO BID every Days 1–14  
Cycled every 21 days<sup>38,60</sup>

**FIRST-LINE THERAPY**

**PREFERRED REGIMENS—continued**

Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>b,f</sup>

Pembrolizumab 200 mg IV every 21 days for up to 2 years  
Capecitabine 850–1000 mg/m<sup>2</sup> PO BID Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days for up to 6 cycles (total 18 weeks)<sup>29</sup>

Pembrolizumab 200 mg IV every 21 days for up to 2 years  
Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days for up to 9 cycles (total 18 weeks)<sup>29</sup>

Fluoropyrimidine (fluorouracil or capecitabine), cisplatin, and pembrolizumab<sup>b,f</sup>

Pembrolizumab 200 mg IV every 21 days for up to 2 years  
Cisplatin 80 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5  
Cycled every 21 days for up to 6 cycles<sup>28,29</sup>

Pembrolizumab 200 mg IV every 21 days for up to 2 years  
Cisplatin 80 mg/m<sup>2</sup> IV on Day 1  
Capecitabine 850–1000 mg/m<sup>2</sup> PO twice daily on Days 1–14  
Cycled every 21 days for a up of 6 cycles (total of 18 weeks)<sup>29</sup>

**FIRST-LINE THERAPY**

**PREFERRED REGIMENS—continued**

Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and zolbetuximab-clzb

(for HER2-negative, CLDN18.2-positive adenocarcinoma)  
Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 12 doses)  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Zolbetuximab-clzb 800 mg/m<sup>2</sup> IV (first-dose only) on Day 1 (subsequent doses 400 mg/m<sup>2</sup>)  
Cycled every 14 days<sup>31</sup>

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 8 doses)  
Zolbetuximab-clzb 800 mg/m<sup>2</sup> IV (first-dose only) on Day 1 (subsequent doses 600 mg/m<sup>2</sup>)  
Cycled every 21 days<sup>32</sup>

Nivolumab and ipilimumab (for SCC)<sup>b,f</sup>  
Nivolumab 3 mg/kg IV every 2 weeks  
Ipilimumab 1 mg/kg IV every 6 weeks (per study, maximum of 2 years)<sup>60</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the Discussion.

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

##### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

##### MSI-H/dMMR tumors

(independent of PD-L1 status)

##### Pembrolizumab<sup>b,f</sup>

Pembrolizumab 200 mg IV on Day 1  
Cycled every 21 days (up to 2 years)<sup>80</sup>

Pembrolizumab 400 mg IV on Day 1  
Cycled every 6 weeks (up to 2 years)<sup>90</sup>

##### Dostarlimab-gxly<sup>b,f</sup>

Dostarlimab-gxly 500 mg IV every 3 weeks for 4 doses  
followed by 1000 mg IV every 6 weeks<sup>42</sup>

##### Nivolumab and ipilimumab<sup>b,f</sup>

Nivolumab 1 mg/kg IV on Day 1  
Ipilimumab 3 mg/kg IV on Day 1  
Cycled every 21 days for 4 cycles  
followed by

Nivolumab 240 mg IV every 14 days  
(maximum to 2 years)<sup>27</sup>

THE PANEL ACKNOWLEDGES THAT THE CHECKMATE 649 TRIAL<sup>27</sup> FORMED THE BASIS FOR FIRST-LINE THERAPY STRATEGY FOR METASTATIC OR LOCALLY ADVANCED CANCER. HOWEVER, THE PANEL DOES NOT RECOMMEND THE DOSES AND SCHEDULE OF AGENTS SPECIFIED IN THIS TRIAL DUE TO CONCERNS REGARDING TOXICITY. THE PANEL RECOMMENDS THE FOLLOWING MODIFICATIONS INSTEAD:

##### Nivolumab and ipilimumab<sup>b,f</sup>

Nivolumab 240 mg IV every 2 weeks  
Ipilimumab 1 mg/kg IV every 6 weeks  
For 16 weeks, followed by  
Nivolumab 240 mg IV every 2 weeks or  
Nivolumab 480 mg IV every 4 weeks  
(maximum of 2 years)

##### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

##### MSI-H/dMMR tumors

(independent of PD-L1 status)

##### Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab<sup>b,f</sup>

Nivolumab 360 mg IV on Day 1  
(per study maximum of 2 years)  
Capecitabine 850–1000 mg/m<sup>2</sup> PO BID Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days<sup>27,60</sup>

Nivolumab 240 mg IV on Day 1  
(per study maximum of 2 years)  
Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days<sup>27,60</sup>

##### FIRST-LINE THERAPY

##### PREFERRED REGIMENS—continued

##### MSI-H/dMMR tumors

(independent of PD-L1 status)

##### Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>b,f</sup>

Pembrolizumab 200 mg IV  
every 21 days for up to 2 years  
Capecitabine 850–1000 mg/m<sup>2</sup> PO BID Days 1–14  
Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1  
Cycled every 21 days for up to 6 cycles  
(total 18 weeks)

Pembrolizumab 200 mg IV  
every 21 days for up to 2 years  
Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days for up to 9 cycles  
(total 18 weeks)

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

##### FIRST-LINE THERAPY—continued

##### OTHER RECOMMENDED REGIMENS—continued

##### Fluorouracil and irinotecan<sup>a</sup>

Irinotecan 180 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>43</sup>

##### Paclitaxel with or without carboplatin or cisplatin

Paclitaxel 200 mg/m<sup>2</sup> IV on Day 1

Carboplatin AUC 5 IV on Day 1

Cycled every 21 days<sup>46</sup>

Paclitaxel 135–200 mg/m<sup>2</sup> IV on Day 1

Cisplatin 75 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>44</sup>

Paclitaxel 90 mg/m<sup>2</sup> IV on Day 1

Cisplatin 50 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days<sup>45</sup>

Paclitaxel 135–250 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>47</sup>

Paclitaxel 80 mg/m<sup>2</sup> IV weekly

Cycled every 28 days<sup>48</sup>

##### OTHER RECOMMENDED REGIMENS—continued

##### Docetaxel with or without cisplatin

Docetaxel 70–85 mg/m<sup>2</sup> IV on Day 1

Cisplatin 70–75 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>49,50</sup>

Docetaxel 75–100 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>51,52</sup>

##### Fluoropyrimidine<sup>a</sup>

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>37</sup>

Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1–5

Cycled every 28 days<sup>53</sup>

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID on Days 1–14

Cycled every 21 days<sup>54</sup>

##### OTHER RECOMMENDED REGIMENS—continued

##### Docetaxel, cisplatin or oxaliplatin, and fluorouracil<sup>a</sup>

Docetaxel 40 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 1000 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cisplatin 40 mg/m<sup>2</sup> IV on Day 3

Cycled every 14 days<sup>55</sup>

Docetaxel 50 mg/m<sup>2</sup> IV on Day 1

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>56</sup>

##### USEFUL IN CERTAIN CIRCUMSTANCES

##### Entrectinib, larotrectinib, or repotrectinib (for NTRK gene fusion-positive tumors)

Entrectinib 600 mg PO once daily<sup>57</sup>

Larotrectinib 100 mg PO twice daily<sup>58</sup>

##### Repotrectinib<sup>59</sup>

160 mg PO daily Days 1–14 of cycle 1

160 mg PO BID Days 15–28 of cycle 1

160 mg PO BID Days 1–28 of cycle 2 and beyond

Cycled every 28 days

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED) SECOND-LINE AND SUBSEQUENT THERAPY

##### PREFERRED REGIMENS

##### Nivolumab<sup>b,f</sup>

(for second-line therapy for esophageal SCC)

Nivolumab 240 mg IV on Day 1

Cycled every 14 days<sup>79</sup>

or

Nivolumab 480 mg IV on Day 1

Cycled every 28 days

##### Pembrolizumab<sup>b,f</sup>

(for second-line therapy for esophageal SCC  
with PD-L1 expression levels by CPS of ≥10)

Pembrolizumab 200 mg IV on Day 1

Cycled every 21 days<sup>80</sup>

Pembrolizumab 400 mg IV on Day 1

Cycled every 6 weeks<sup>90</sup>

##### PREFERRED REGIMENS—continued

##### Ramucirumab and paclitaxel

(for adenocarcinoma only)

Ramucirumab 8 mg/kg IV on Days 1 and 15

Paclitaxel 80 mg/m<sup>2</sup> on Days 1, 8, and 15

Cycled every 28 days<sup>62</sup>

##### Fam-trastuzumab deruxtecan-nxki

(for HER2 overexpression-positive adenocarcinoma)

6.4 mg/kg IV on Day 1

Cycled every 21 days<sup>p,63</sup>

##### Taxane

Docetaxel 75–100 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>51,52</sup>

Paclitaxel 135–250 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>47</sup>

Paclitaxel 80 mg/m<sup>2</sup> IV weekly

Cycled every 28 days<sup>48</sup>

Paclitaxel 80 mg/m<sup>2</sup> IV on Days 1, 8, and 15

Cycled every 28 days<sup>64</sup>

##### PREFERRED REGIMENS—continued

##### Irinotecan

Irinotecan 150–180 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days<sup>64,65</sup>

Irinotecan 125 mg/m<sup>2</sup> IV on Days 1 and 8

Cycled every 21 days<sup>67</sup>

Irinotecan 250–350 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>66</sup>

##### Fluorouracil and irinotecan<sup>a</sup>

Irinotecan 180 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>65</sup>

##### Tislelizumab-jsg<sup>b,f</sup> (for esophageal SCC)

200 mg IV on Day 1

Cycled every 21 days<sup>81,82</sup>

##### Trifluridine and tipiracil (for third-line or subsequent therapy for EGJ adenocarcinoma)

Trifluridine and tipiracil 35 mg/m<sup>2</sup> up to a maximum  
dose of 80 mg per dose

(based on the trifluridine component)

PO twice daily on Days 1–5 and 8–12

Repeat every 28 days<sup>70</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).

<sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

<sup>p</sup> Fam-trastuzumab deruxtecan-nxki is approved for metastatic HER2-positive breast cancer at a different dose of 5.4 mg/kg IV on Day 1, cycled every 21 days.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**



#### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k,l</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

#### SECOND-LINE AND SUBSEQUENT THERAPY

##### OTHER RECOMMENDED REGIMENS

##### Ramucirumab (for adenocarcinoma only)

Ramucirumab 8 mg/kg IV on Day 1  
Cycled every 14 days<sup>71</sup>

##### Irinotecan and cisplatin

Irinotecan 65 mg/m<sup>2</sup> IV on Days 1 and 8  
Cisplatin 25–30 mg/m<sup>2</sup> IV on Days 1 and 8  
Cycled every 21 days<sup>34,72</sup>

##### Fluorouracil and irinotecan + ramucirumab<sup>a</sup> (only for adenocarcinoma)

Ramucirumab 8 mg/kg IV on Day 1  
Irinotecan 180 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous  
infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days<sup>91</sup>

##### Irinotecan and ramucirumab (only for adenocarcinoma)

Irinotecan 150 mg/m<sup>2</sup> IV on Day 1  
Ramucirumab 8 mg/kg IV on Day 1  
Cycled every 14 days<sup>74</sup>

##### Docetaxel and irinotecan

Docetaxel 35 mg/m<sup>2</sup> IV on Days 1 and 8  
Irinotecan 50 mg/m<sup>2</sup> IV on Days 1 and 8  
Cycled every 21 days<sup>75</sup>

##### USEFUL IN CERTAIN CIRCUMSTANCES

##### Entrectinib, larotrectinib, or repotrectinib

(for *NTRK* gene fusion-positive tumors)  
Entrectinib 600 mg PO once daily<sup>57</sup>

Larotrectinib 100 mg PO twice daily<sup>58</sup>

##### Repotrectinib<sup>i,59</sup>

160 mg PO Daily Days 1–14 of cycle 1  
160 mg PO BID Days 15–28 of cycle 1  
160 mg PO BID Days 1–28 of cycle 2 and beyond  
Cycled every 28 days

##### Pembrolizumab<sup>b,f</sup>

(for MSI-H/dMMR tumors or  
TMB-H (≥10 mutations/megabase) tumors)

Pembrolizumab 200 mg IV on Day 1  
Cycled every 21 days<sup>80</sup>

Pembrolizumab 400 mg IV on Day 1  
Cycled every 6 weeks<sup>90</sup>

##### Nivolumab and ipilimumab<sup>b,f</sup> (for MSI-H/dMMR tumors)

Nivolumab 1 mg/kg IV on Day 1  
Ipilimumab 3 mg/kg IV on Day 1  
Cycled every 21 days for 4 cycles  
followed by  
Nivolumab 240 mg IV every 14 days  
(maximum to 2 years)<sup>27</sup>

THE PANEL ACKNOWLEDGES THAT THE CHECKMATE 649 TRIAL<sup>27</sup> FORMED THE BASIS FOR THERAPEUTIC STRATEGY FOR METASTATIC OR LOCALLY ADVANCED CANCER. HOWEVER, THE PANEL DOES NOT RECOMMEND THE DOSES AND SCHEDULE OF CYTOTOXIC AGENTS SPECIFIED IN THIS TRIAL DUE TO CONCERNS REGARDING TOXICITY. THE PANEL RECOMMENDS THE FOLLOWING MODIFICATIONS INSTEAD:

##### Nivolumab and ipilimumab<sup>b,f</sup>

Nivolumab 240 mg IV every 2 weeks  
Ipilimumab 1 mg/kg IV every 6 weeks  
For 16 weeks, followed by  
Nivolumab 240 mg IV every 2 weeks or Nivolumab 480 mg IV every 4 weeks  
(maximum of 2 years)

##### USEFUL IN CERTAIN CIRCUMSTANCES (continued)

##### Dostarlimab-gxly<sup>b,f,j</sup>

(for MSI-H/dMMR tumors)  
Dostarlimab-gxly 500 mg IV every 3 weeks for 4 doses  
followed by 1000 mg IV every 6 weeks<sup>42</sup>

##### Dabrafenib and trametinib (for *BRAF* V600E-mutated tumors)

Dabrafenib 150 mg PO twice daily  
Trametinib 2 mg PO daily<sup>77</sup>

##### Selpercatinib (for *RET* gene fusion-positive tumors)

##### Selpercatinib

Patients ≥50 kg: 160 mg PO twice daily  
Patients <50 kg: 120 mg PO twice daily<sup>78</sup>

#### [Footnotes on ESOPH-F 19A of 24](#)

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

#### FOOTNOTES FOR [ESOPH-F 19 OF 24](#)

- <sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see the [Discussion](#).
- <sup>b</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).
- <sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.
- <sup>i</sup> Repotrectinib can be used in patients whose disease progressed on a prior *NTRK* targeted therapy.
- <sup>j</sup> For patients whose cancer is progressing on or following prior treatment (that did not include a checkpoint inhibitor like PD-1i, PD-L1i, or CTLA4i) and who have no satisfactory alternative treatment options. Prior use of immuno-oncology therapy in these patients will make them ineligible for dostarlimab-gxly.
- <sup>k</sup> Systemic therapy regimen dosing and schedules are based on extrapolations from published literature and clinical practice.
- <sup>l</sup> Unless stated otherwise, all regimens/dosing schedules are recommended for both adenocarcinoma and SCC.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SYSTEMIC THERAPY REFERENCES

- \* Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. *N Engl J Med* 2025;393:217-230.
- <sup>1</sup> Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019;393:1948-1957.
- <sup>2</sup> Hoepfner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. *N Engl J Med* 2025;392:323-335.
- <sup>3</sup> Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
- <sup>4</sup> van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012;366:2074-2084.
- <sup>5</sup> Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314.
- <sup>6</sup> Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844-2850.
- <sup>7</sup> Goodman KA, Ou FS, Hall NC, et al. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. *J Clin Oncol* 2021;39:2803-2815.
- <sup>8</sup> Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.
- <sup>9</sup> Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160-1168.
- <sup>10</sup> Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). *J Clin Oncol* 2009;27:e15619.
- <sup>11</sup> Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.
- <sup>12</sup> Andre T, Tougeron D, Piessen G, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. *J Clin Oncol* 2023;41:255-265.
- <sup>13</sup> Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. *J Clin Oncol* 2023;41:2181-2190.
- <sup>14</sup> Liu L, Woo Y, D'Apuzzo M, et al. Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability-High Gastric Cancer: A Case Series. *J Natl Compr Canc Netw* 2022;20:857-865.
- <sup>15</sup> Kelly RJ, Lee J, Bang YJ, et al. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. *Clin Cancer Res* 2020;26:846-854.
- <sup>16</sup> Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). *Journal of Clinical Oncology* 2023;41:358-358.
- <sup>17</sup> Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.
- <sup>18</sup> Urba SG, Orringer MB, Iannettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. *Cancer* 2003;98:2177-2183.
- <sup>19</sup> Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus* 2010;23:253-259.
- <sup>20</sup> Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. *Br J Cancer* 2011;104:265-271.
- <sup>21</sup> Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med* 2021;384:1191-1203.
- <sup>22</sup> Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:1389-1396.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

**Continued**

**ESOPH-F  
20 OF 24**



#### PRINCIPLES OF SYSTEMIC THERAPY REFERENCES

- <sup>23</sup> Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333.
- <sup>24</sup> Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature* 2021;600:727-730.
- <sup>25</sup> Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. *Lancet* 2023;402:2197-2208.
- <sup>26</sup> Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
- <sup>27</sup> Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021;398:27-40.
- <sup>28</sup> Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. *Lancet* 2021;398:759-771.
- <sup>29</sup> Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2023;24:1181-1195.
- <sup>30</sup> Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ* 2024;385:e078876.
- <sup>31</sup> Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* 2023;401:1655-1668.
- <sup>32</sup> Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* 2023;29:2133-2141.
- <sup>33</sup> Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.
- <sup>34</sup> Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. *J Clin Oncol* 2016;34:2736-2742.
- <sup>35</sup> Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
- <sup>36</sup> Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673.
- <sup>37</sup> Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. *J Clin Oncol* 2004;22:4319-4328.
- <sup>38</sup> Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.
- <sup>39</sup> Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509-2520.
- <sup>40</sup> Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-413.
- <sup>41</sup> Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol* 2020;38:1-10.2.
- <sup>42</sup> Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. *J Clin Oncol* 2021;39:2564-2564.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.

[Continued](#)



#### PRINCIPLES OF SYSTEMIC THERAPY REFERENCES

- 43 Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase iii study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. *J Clin Oncol* 2014;32:3520-3526.
- 44 Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.
- 45 Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511-514.
- 46 Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.
- 47 Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.
- 48 Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898-902.
- 49 Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.
- 50 Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
- 51 Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.
- 52 Ford ER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78-86.
- 53 Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59.
- 54 Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.
- 55 Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874-3879.
- 56 Blum Murphy MA, Qiao W, Mewada N, et al. A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. *Am J Clin Oncol* 2018;41:321-325.
- 57 Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21:271-282.
- 58 Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018;378:731-739.
- 59 Solomon BJ, Drilon A, Lin JJ, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. *Annals of Oncology* 2023;34:S787-S788.
- 60 Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. *N Engl J Med* 2022;386:449-462.
- 61 Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *Lancet Oncol* 2023;24:483-495.
- 62 Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014;15:1224-1235.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.

[Continued](#)

**ESOPH-F  
22 OF 24**



**PRINCIPLES OF SYSTEMIC THERAPY  
REFERENCES**

- <sup>63</sup> Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. *N Engl J Med* 2020;382:2419-2430.
- <sup>64</sup> Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial *J Clin Oncol* 2013;31:4438-4444.
- <sup>65</sup> Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. *Cancer Chemother Pharmacol* 2013;71:481-488.
- <sup>66</sup> Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer* 2011;47:2306-2314.
- <sup>67</sup> Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. *J Clin Oncol* 2003;21:807-814.
- <sup>68</sup> Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. *Am J Clin Oncol* 2008;31:151-156.
- <sup>69</sup> Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. *Ann Oncol* 2004;15:64-69.
- <sup>70</sup> Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2018;19:1437-1448.
- <sup>71</sup> Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014;383:31-39.
- <sup>72</sup> Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. *Oncology (Williston Park)* 2004;18:22-25.
- <sup>73</sup> Klemptner SJ, Maron SB, Chase L, et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. *Oncologist* 2019;24:475-482.
- <sup>74</sup> Sakai D, Boku N, Kodera Y, et al. An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBERG trial). *J Clin Oncol* 2018;36:TPS4138.
- <sup>75</sup> Burtress B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. *Ann Oncol* 2009;20:1242-1248.
- <sup>76</sup> Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020;21:1353-1365.
- <sup>77</sup> Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H. *J Clin Oncol* 2020;38:3895-3904.
- <sup>78</sup> Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol* 2022;23:1261-1273.
- <sup>79</sup> Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019;20:1506-1517.
- <sup>80</sup> Kojima T, Shah MA, Muro K, et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *J Clin Oncol* 2020;38:4138-4148.
- <sup>81</sup> Ajani J, El Hajbi F, Cunningham D, et al. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. *ESMO Open* 2024;9:102202. Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. *J Clin Oncol* 2022;40:3065-3076.
- <sup>82</sup> Shen L, Kato K, Kim SB, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. *J Clin Oncol* 2022;40:3065-3076.
- <sup>83</sup> Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.

[Continued](#)



### PRINCIPLES OF SYSTEMIC THERAPY REFERENCES

- <sup>84</sup> Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.
- <sup>85</sup> Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.
- <sup>86</sup> Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
- <sup>87</sup> Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys* 2007;69:1424-1428.
- <sup>88</sup> Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
- <sup>89</sup> Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial. *J Clin Oncol* 2019;37:4006.
- <sup>90</sup> Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. *Eur J Cancer* 2020;131:68-75.
- <sup>91</sup> Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol* 2015;16:499-508.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



### PRINCIPLES OF RADIATION THERAPY

#### General Guidelines

- Treatment recommendations should be made after joint consultation and/or discussion by a multidisciplinary team including surgical, radiation, and medical oncologists, radiologists, gastroenterologists, and pathologists.
- CT scans, barium swallow, EUS, endoscopy reports, and FDG-PET or FDG-PET/CT scans, when available, should be reviewed by the multidisciplinary team. This will allow an informed determination of treatment volume and field borders prior to simulation.
- All available information from pre-treatment diagnostic studies should be used to determine the target volume.
- In general, Siewert I and II tumors should be managed with RT guidelines applicable to esophageal and EGJ cancers. Patients with Siewert III tumors may receive perioperative systemic therapy or preoperative chemoradiation depending on institutional preference, and are generally more appropriately managed with radiation according to guidelines applicable to gastric cancers. These recommendations may be modified depending on the location of the bulk of the tumor.

#### Simulation and Treatment Planning

- CT simulation and conformal treatment planning should be used with either three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). Proton beam therapy<sup>a</sup> is appropriate in clinical settings where reduction in dose to organs at risk (eg, heart, lungs) is required that cannot be achieved by 3D techniques, ideally within a clinical trial or registry study.<sup>1,2</sup>
- It is optimal to treat patients in the supine position as the setup is generally more stable and reproducible.
- The patient should be instructed to avoid intake of a heavy meal 3 hours before simulation and treatment for lesions requiring therapy of the proximal stomach.
- When clinically appropriate, IV and/or oral contrast for CT simulation may be used to aid in target localization.
- Use of an immobilization device is strongly recommended for reproducibility of daily setup.
- Respiratory motion may be significant for distal esophageal and EGJ lesions. When four-dimensional (4D)-CT planning or other motion management techniques are used, margins may be modified to account for observed motion and may also be reduced if justified. The 4D-CT data may also be used to create an internal target volume (ITV) from which subsequent clinical target volume (CTV) and planning target volume (PTV) expansions can be made.
- Target volumes need to be carefully defined and encompassed while designing IMRT plans. Uncertainties from variations in stomach filling and respiratory motion should be taken into account. For structures such as the lungs, attention should be given to the lung volume receiving low to moderate doses, as well as the volume receiving high doses. Attention should be paid to sparing the uninvolved stomach that may be used for future reconstruction (ie, anastomosis site).

<sup>a</sup> Data regarding proton beam therapy are early and evolving. Ideally, patients should be treated with proton beam therapy within a clinical trial.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF RADIATION THERAPY

##### Target Volume (General Guidelines):

- **Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on the planning scan and other pre-treatment diagnostic studies listed in the General Guidelines section above.**
- **CTV may include the areas at risk for microscopic disease. CTV is defined as the primary tumor plus a 3- to 4-cm expansion superiorly and inferiorly along the length of the esophagus and cardia and a 1-cm radial expansion.<sup>3</sup> The nodal CTV should be defined by a 0.5- to 1.5-cm expansion from the nodal GTV. CTV should also include coverage of elective nodal regions such as the celiac axis; however, this decision would depend on the location of the primary tumor within the esophagus and EGJ.**
- **PTV expansion should be 0.5 to 1 cm. The uncertainties arising from respiratory motion should also be taken into consideration.**
- **Elective treatment of node-bearing regions depends on the location of the primary tumor in the esophagus and EGJ.**
  - ▶ ▶ **Cervical esophagus: Consider treatment of the supraclavicular nodes and treatment of higher echelon cervical nodes, especially if the nodal stage is ≥N1.**
  - ▶ ▶ **Proximal third of the esophagus: Consider treatment of para-esophageal lymph nodes and supraclavicular lymph nodes.**
  - ▶ ▶ **Middle third of the esophagus: Consider treatment of para-esophageal lymph nodes.**
  - ▶ ▶ **Distal third of esophagus and EGJ: Consider para-esophageal, lesser curvature, splenic nodes, and celiac axis nodal regions.**

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**

[Continued](#)  
[References](#)

**ESOPH-G**  
**2 OF 5**



**PRINCIPLES OF RADIATION THERAPY**

**Normal Tissue Tolerance Dose-Limits<sup>4,5</sup>**

- Treatment planning is essential to reduce unnecessary dose to organs at risk.
- Lung dose may require particular attention, especially in the preoperatively treated patient. It is recognized that these dose guidelines may be appropriately exceeded based on clinical circumstances.

<p><b>Lungs<sup>b</sup></b></p> <ul style="list-style-type: none"> <li>• <math>V_{40Gy} \leq 10\%</math></li> <li>• <math>V_{30Gy} \leq 15\%</math></li> <li>• <math>V_{20Gy} \leq 20\%</math></li> <li>• <math>V_{10Gy} \leq 40\%</math></li> <li>• <math>V_{05Gy} \leq 50\%</math></li> <li>• Mean &lt;20 Gy</li> </ul>	<p><b>Left Kidney, Right Kidney</b> (evaluate each one separately):</p> <ul style="list-style-type: none"> <li>• <math>V_{20Gy} \leq 33\%</math></li> <li>• Mean &lt;18 Gy</li> </ul>
<p><b>Spinal Cord</b></p> <ul style="list-style-type: none"> <li>• Max <math>\leq 45</math> Gy</li> </ul>	<p><b>Liver</b></p> <ul style="list-style-type: none"> <li>• <math>V_{30Gy} \leq 33\%</math></li> <li>• Mean &lt;25 Gy</li> </ul>
<p><b>Bowel</b></p> <ul style="list-style-type: none"> <li>• Max dose &lt;54 Gy</li> <li>• <math>V_{45Gy} &lt;195</math> cc</li> </ul>	<p><b>Stomach</b></p> <ul style="list-style-type: none"> <li>• Mean &lt;45 Gy</li> <li>• Max dose &lt;54 Gy</li> </ul>
<p><b>Heart</b></p> <ul style="list-style-type: none"> <li>• <math>V_{30Gy} \leq 30\%</math> (closer to 20% preferred)</li> <li>• Mean &lt;30 Gy (closer to 26 Gy preferred)</li> </ul>	

<sup>b</sup> Lung dose-volume histogram (DVH) parameters as predictors of pulmonary complications in patients with esophageal cancer treated with concurrent chemoradiotherapy should be strongly considered, though consensus on optimal criteria has not yet emerged. Every effort should be made to keep the lung volume and doses to a minimum. Treating physicians should be aware that the DVH reduction algorithm is hardly the only risk factor for pulmonary complications. Important considerations may also include plans for post-treatment surgery, pretreatment pulmonary function, and relevant comorbidities. DVH parameters as predictors of pulmonary complications in patients with esophageal cancer are an area of active development among the NCCN Member Institutions and others.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**

**[Continued](#)**  
**[References](#)**

**ESOPH-G**  
**3 OF 5**



### PRINCIPLES OF RADIATION THERAPY

#### RT Dosing

- Preoperative RT: 41.4–50.4 Gy (1.8–2.0 Gy/day) (total 23–28 fractions)<sup>c</sup>
- Postoperative RT: 45–50.4 Gy (1.8–2.0 Gy/day) (total 25–28 fractions)
- Definitive RT: 50–50.4 Gy (1.8–2.0 Gy/day)<sup>6</sup> (total 25–28 fractions)

#### Supportive Care

- Treatment interruptions or dose reductions for manageable acute toxicities should be avoided. Careful patient monitoring and aggressive supportive care are preferable to treatment interruptions.
- During the radiation treatment course, patients should be seen for status check at least once a week with notation of vital signs, weight, and blood counts.
- Antiemetics should be given on a prophylactic basis when appropriate. Antacid, proton pump inhibitors, and antidiarrheal medications may be prescribed when needed.
- If estimated caloric intake is <1500 kcal/day, oral and/or enteral nutrition should be considered. When indicated, feeding J-tubes or nasogastric feeding tubes may be placed to ensure adequate caloric intake. During surgery, a J-tube may be placed for postoperative nutritional support.
- Adequate enteral and/or IV hydration is necessary throughout chemoradiation and recovery.

<sup>c</sup> Patients who are at risk for not having surgery due to comorbidities or other risk factors should receive radiation doses of 50–50.4 Gy (1.8–2.0 Gy/day) because the lower preoperative therapy dose may not be adequate.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

#### [References](#)



#### PRINCIPLES OF RADIATION THERAPY REFERENCES

- <sup>1</sup> Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. *J Clin Oncol* 2020;38:1569-1579.
- <sup>2</sup> Chuong MD, Hallemeier CL, Jabbour S, et al. Improving outcomes for esophageal cancer using proton beam therapy. *Int J Radiat Oncol Biol Phys* 2016;95:488-497.
- <sup>3</sup> Gao XS, Qiao X, Wu F, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. *Int J Radiat Oncol Biol Phys* 2007;67:389-396.
- <sup>4</sup> Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76(3 Suppl):S77-S85.
- <sup>5</sup> Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. *Int J Radiat Oncol Biol Phys* 2010;76(3 Suppl):S101-S107.
- <sup>6</sup> Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF PALLIATIVE/BEST SUPPORTIVE CARE<sup>1-7</sup>

The goal of best supportive care is to prevent and relieve suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. For esophageal cancer, interventions undertaken to relieve major symptoms may result in significant prolongation of life. This appears to be particularly true when a multimodality interdisciplinary approach is pursued and, therefore, a multimodality interdisciplinary approach to palliative care of the patient with esophageal cancer is encouraged.<sup>a</sup>

#### Dysphagia

- Assess the extent of disease and the functional degree of swallowing impairment, preferably through a standardized scoring scale and confirm the etiology of dysphagia
- Dysphagia grading scale<sup>8</sup>
  - ▶ ▶ Grade 0: Able to eat solid food without special attention to bite size or chewing
  - ▶ ▶ Grade 1: Able to swallow solid food cut into pieces <18 mm in diameter and thoroughly chewed
  - ▶ ▶ Grade 2: Able to swallow semisolid food (consistency of baby food)
  - ▶ ▶ Grade 3: Able to swallow liquids only
  - ▶ ▶ Grade 4: Unable to swallow liquids or saliva
- Dysphagia arising from esophageal cancer most often is due to obstruction, but on occasion may be primarily due to tumor-related dysmotility.
- Patients with dysphagia who are not candidates for curative surgery should be considered for palliation of their dysphagia symptoms, based on symptom severity. This can be achieved through multiple modalities, although placement of an esophageal stent is most commonly utilized. In contrast, stent placement is generally not advised in patients who may undergo curative surgery or during chemoradiation therapy, due to concerns that stent-related adverse events may preclude curative surgery or increase acute toxicity during chemoradiation therapy.<sup>9,10,11</sup>

<sup>a</sup> For patients who have immune-mediated toxicity, see [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF PALLIATIVE/BEST SUPPORTIVE CARE<sup>1-7</sup>

##### Obstruction

- **Complete esophageal obstruction**
  - ▶ Endoscopic lumen restoration, generally performed via simultaneous retrograde (via a gastrostomy tract) and antegrade endoscopy
  - ▶ Establish enteral access for purposes of hydration and nutrition if endoscopic lumen restoration is not undertaken or is unsuccessful.
    - ◇ Surgical or radiologic placement of J-tube or gastrostomy tube
  - ▶ External beam radiation therapy (EBRT)
  - ▶ Brachytherapy may be considered in place of EBRT if a lumen can be restored that allows for the use of appropriate applicators. Brachytherapy should only be performed by practitioners experienced with the delivery of esophageal brachytherapy.
  - ▶ PDT can effectively treat esophageal obstruction, but is less commonly performed due to associated photosensitivity and costs.<sup>12</sup>
  - ▶ Chemotherapy
  - ▶ Surgery may on occasion be useful in carefully selected patients.
- **Severe esophageal obstruction (able to swallow liquids only)**
  - ▶ Wire-guided dilation or balloon dilation (caution should be exercised when dilating malignant strictures as this may be associated with an increased risk of perforation)
  - ▶ Endoscopy or fluoroscopy-guided placement of partially or fully covered expandable metal stents
    - ◇ There are data suggesting a lower migration and stent occlusion rates with the larger diameter covered expandable metal stents, but an increased risk of other complications such as bleeding and esophago-respiratory fistula.<sup>13</sup>
    - ◇ If possible, the distal end of the stent should remain above the EGJ to reduce symptoms of reflux and risk of aspiration.
  - ▶ EBRT<sup>14</sup> and brachytherapy both effectively treat malignant dysphagia.
    - ◇ The onset of symptom relief for EBRT or brachytherapy is slower compared to endoscopic palliation but is also likely to be more durable.<sup>1,15</sup>
  - ▶ Other measures as stated above
- **Moderate esophageal obstruction (able to swallow semisolid food)**
  - ▶ ▶ Measures stated above may be considered, but should be balanced with the associated risks.

##### Pain

- **If patient is experiencing tumor-related pain, then the pain should be assessed and treated in accordance with the [NCCN Guidelines for Adult Cancer Pain](#).**
  - ▶ Severe uncontrolled pain following esophageal stent placement should be treated with endoscopic removal of the stent once the uncontrollable nature of the pain is established.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

##### [References](#)



### PRINCIPLES OF PALLIATIVE/BEST SUPPORTIVE CARE<sup>1-7</sup>

#### Bleeding

- **Acute bleeding from esophageal cancer may represent a pre-terminal event secondary to tumor-related aorto-esophageal fistulization. Endoscopic assessment and intervention may lead to precipitous exsanguination, and therefore should be undertaken cautiously.**
  - ▶ ▶ **If bleeding appears to be primarily from the tumor surface, then endoscopic electrocoagulation techniques such as bipolar electrocoagulation or argon plasma coagulation may be useful for control of bleeding; however, limited data suggest that while endoscopic therapies may initially be effective, the rate of recurrent bleeding is very high.<sup>16</sup>**
- **Chronic blood loss from esophageal cancer**
  - ▶ ▶ **EBRT**

#### Nausea/Vomiting

- **If the patient is experiencing nausea and vomiting, then they should be treated in accordance with the [NCCN Guidelines for Antiemesis](#).**
- **Nausea and vomiting may be associated with luminal obstruction, so endoscopic or fluoroscopic evaluation should be performed to determine if luminal enhancement is indicated.**

<sup>1</sup> Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. *Lancet* 2004;364:1497-1504.

<sup>2</sup> Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. *J Clin Oncol* 1999;17:3270-3275.

<sup>3</sup> Ross WA, Alkassab F, Lynch PM, et al. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. *Gastrointest Endosc* 2007;65:70-76.

<sup>4</sup> Shin JH, Song HY, Kim JH, et al. Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. *J Vasc Interv Radiol* 2005;16:67-74.

<sup>5</sup> Vakil N, Morris A, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. *Am J Gastroenterol* 2001;96:1791-1799.

<sup>6</sup> Verschuur EM, Repici A, Kuipers EJ, et al. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. *Am J Gastroenterol* 2008;103:304-312.

<sup>7</sup> Fan Y, Song HY, Kim JH, et al. Evaluation of the incidence of esophageal complications associated with balloon dilation and their management in patients with malignant esophageal strictures. *AJR Am J Roentgenol* 2012;198:213-218.

<sup>8</sup> Blazeby JM, Williams MH, Brookes ST, et al. Quality of life measurement in patients with oesophageal cancer. *Gut* 1995;37:505-508.

<sup>9</sup> Francis SR, Orton A, Thorpe C, et al. Toxicity and outcomes in patients with and without esophageal stents in locally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 2017;99:884-894.

<sup>10</sup> Jones CM, Griffiths EA. Should oesophageal stents be used before neoadjuvant therapy to treat dysphagia in patients awaiting oesophagectomy? Best evidence topic (BET). *Int J Surg* 2014;12:1172-1180.

<sup>11</sup> Mariette C, Gronnier C, Duhamel A, et al. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes. *J Am Coll Surg* 2015;220:287-296.

<sup>12</sup> Petersen BT, Chuttani R, Croffie J, et al. Photodynamic therapy for gastrointestinal disease. *Gastrointest Endosc* 2006;63:927-932.

<sup>13</sup> White RE, Chepkwony R, Mwachiro M, et al. Randomized trial of small-diameter versus large-diameter esophageal stents for palliation of malignant esophageal obstruction. *J Clin Gastroenterol* 2015;49:660-665.

<sup>14</sup> Murray LJ, Din OS, Kumar VS, et al. Palliative radiotherapy in patients with esophageal carcinoma: A retrospective review. *Pract Radiat Oncol* 2012;2:257-264.

<sup>15</sup> Hanna WC, Sudarshan M, Roberge D, et al. What is the optimal management of dysphagia in metastatic esophageal cancer? *Curr Oncol* 2012;19:e60-66.

<sup>16</sup> Sheibani S, Kim JJ, Chen B, et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. *Aliment Pharmacol Ther* 2013;38:144-150.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.**



### PRINCIPLES OF SURVEILLANCE

- The surveillance strategies after successful therapy for esophageal and EGJ cancers remain controversial, with no high-level evidence to guide development of algorithms that balance benefits and risks (including cost) within this cohort.
- The goal of this document is to provide guidance for stage-specific surveillance based on the currently available retrospectively analyzed literature<sup>1-6</sup> and the expertise of the Panel members to individualize surveillance recommendations. It is hoped that prospective data will emerge and we will be able to propose surveillance recommendations based on the evidence.
- It should be noted that although the majority (~90%) of relapses occur within the first 2 years after completion of local therapy, potentially actionable relapses have been recognized sometimes >5 years after local therapy. Metachronous malignancy (a second cancer in the residual esophagus or in the case of SCC in a different organ) is also a consideration in long-term survivors.
- The recommendations outlined below are following completion of local therapy.

#### p-Stage 0–I (Tis, T1a, and T1b)

Differences in follow-up for early-stage esophageal cancer reflect a heterogeneous potential for relapse and overall survival.<sup>7-13</sup> Whereas fully treated Tis and T1a, N0 disease have prognoses that approximate a non-cancer cohort, T1b disease does not perform as well. Thus, recommendations vary according to the depth of invasion and treatment modality. Evidence-based guidelines have not been established for all stages of completely treated early-stage esophageal cancer. The following suggestions are based on results from trials and current practice.

#### Stage II or III (T2–T4, N0–N+, T4b) treated with bimodality therapy (definitive chemoradiation)

Literature suggests that locoregional relapses are common after bimodality therapy.<sup>3</sup> Therefore, EGD is a valuable surveillance tool in these patients. Most relapses (95%) occur within 24 months. Thus, surveillance for at least 24 months is recommended for these patients.<sup>3</sup>

#### Stage II or III (T2–T4, N0–N+, T4b) treated with trimodality therapy

Literature suggests that locoregional relapses are uncommon; therefore, EGD surveillance is recommended as clinically indicated.<sup>1,2,4</sup> The risk and rate of relapse have been correlated with surgical pathology (yp) stage. For example, patients with yp stage III have a much higher rate of relapse (and relapses occurring early during surveillance) than patients with yp stage 0 (relapses are not frequent in these patients). Literature also suggests that 90% of relapses occur within 36 months of surgery; therefore, surveillance for at least 36 months is recommended.

See Table 1 ([ESOPH-I 2 of 3](#)) for specific surveillance recommendations.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



**PRINCIPLES OF SURVEILLANCE**

**TABLE 1**

<b>Tumor Classification</b>	<b>Type of Therapy Rendered</b>	<b>Surveillance Recommendations</b>
<b>Tis or T1a with/without BE</b>	<b>ER/ablation</b>	<ul style="list-style-type: none"> <li>Once eradication of all neoplasia/high-risk preneoplasia has been achieved, endoscopic surveillance is recommended.</li> <li>EGD should be performed every 3 months for the first year, then every 6 months for the second year, and then annually indefinitely.<sup>14</sup></li> <li>Imaging studies as a surveillance tool are not recommended.</li> </ul>
<b>Tis, T1a, N0</b>	<b>Esophagectomy</b>	Although the goal of the resection would be to resect all areas of Tis or T1a and BE, patients with incompletely resected BE should undergo ablation and then endoscopic surveillance as above (Tis/T1a ER/ablation). Otherwise, EGD as needed based on symptoms. Imaging studies as a surveillance tool are not recommended.
<b>T1b<sup>a</sup> (N0 on EUS)</b>	<b>ER/ablation</b>	<ul style="list-style-type: none"> <li>Once eradication of all cancer/HGD has been achieved, endoscopic surveillance is recommended.</li> <li>EGD every 3 months for the first year, every 4–6 months for the second year, then annually indefinitely. EUS may be considered in conjunction with EGD. Further therapy will be determined if either BE, cancer, or malignant lymphadenopathy is diagnosed at surveillance.</li> <li>Imaging (CT chest/abdomen with oral and IV contrast unless contraindicated) may be considered every 6 months for the first 2 years and annually for up to 5 years.</li> </ul>
<b>T1b or greater, Any N<sup>a</sup> or T1a N+</b>	<b>Esophagectomy ± adjuvant therapy</b>	<ul style="list-style-type: none"> <li>Imaging (CT chest/abdomen with oral and IV contrast unless contraindicated) should be considered every 6 months for the first 2 years and annually for up to 5 years.<sup>b</sup></li> <li>EGD as needed based on symptoms and radiographic findings.</li> <li>Although the goal of the resection would be to resect all areas of T1b and BE, patients with incompletely resected BE should undergo ablation and EGD should be performed every 3 months for the first year, then every 6 months for the second year, and then annually indefinitely.<sup>14</sup></li> </ul>
<b>Any T, Any N</b>	<b>Neoadjuvant therapy or Chemoradiotherapy followed by esophagectomy (± adjuvant treatment)</b>	<ul style="list-style-type: none"> <li>Imaging studies (CT chest/abdomen with oral and IV contrast unless contraindicated) should be considered every 6 months for up to 2 years and then annually for up to 5 years.<sup>b</sup></li> <li>EGD as clinically indicated.</li> </ul>
<b>Pretreatment Tumor Classification: T1b–T4, N0–N+, T4b</b>	<b>Definitive chemoradiation (without esophagectomy)</b>	<ul style="list-style-type: none"> <li>Imaging studies (CT chest/abdomen with oral and IV contrast unless contraindicated) should be considered every 3–6 months for the first 2 years and annually for up to 5 years.</li> <li>EGD every 3–6 months for the first 2 years then annually for 3 more years.</li> </ul>

<sup>a</sup> ER/ablation for T1b can be considered for superficial disease or for non-surgical candidates.

<sup>b</sup> CT scan preferred. For patients who cannot undergo CT scan, alternative imaging such as PET/CT or MRI as clinically indicated.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.

[References](#)



### PRINCIPLES OF SURVEILLANCE REFERENCES

- <sup>1</sup> Dorth JA, Pura JA, Palta M, et al. Patterns of recurrence after trimodality therapy for esophageal cancer. *Cancer* 2014;120:2099-2105.
- <sup>2</sup> Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. *J Clin Oncol* 2014;32:385-391.
- <sup>3</sup> Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. *J Clin Oncol* 2014;32:3400-3405.
- <sup>4</sup> Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. *J Clin Oncol* 2013;31:4306-4310.
- <sup>5</sup> Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. *J Thorac Oncol* 2013;8:1558-1562.
- <sup>6</sup> Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. *J Natl Compr Canc Netw* 2014;12:1139-1144.
- <sup>7</sup> Katada C, Muto M, Manabe T, et al. Local recurrence of squamous-cell carcinoma of the esophagus after EMR. *Gastrointest Endosc* 2005;61:219-225.
- <sup>8</sup> Haidry RJ, Butt MA, Dunn J, et al. Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes from United Kingdom registry. *World J Gastroenterol* 2013;19:6011-6019.
- <sup>9</sup> Perry KA, Walker JP, Salazar M, et al. Endoscopic management of high-grade dysplasia and intramucosal carcinoma: experience in a large academic medical center. *Surg Endosc* 2014;28:777-782.
- <sup>10</sup> Yasuda K, Choi SE, Nishioka NS, et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. *Dig Dis Sci* 2014;59:1560-1566.
- <sup>11</sup> Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. *Clin Gastroenterol Hepatol* 2014;12:1840-1847.
- <sup>12</sup> Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). *Endoscopy* 2014;46:6-12.
- <sup>13</sup> Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. *Gastroenterology* 2014;146:652-660.
- <sup>14</sup> Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: Diagnosis and management of Barrett's esophagus. *Am J Gastroenterol* 2016;111:30-50.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



#### PRINCIPLES OF SURVIVORSHIP

**Surveillance:** See [ESOPH-9](#), [ESOPH-20](#), and Principles of Surveillance ([ESOPH-I](#))

- Surveillance should be performed in conjunction with good routine medical care, including routine health maintenance, preventive care, and cancer screening.
- In general, routine esophageal/EGJ cancer-specific surveillance is not recommended for >5 years following the end of treatment.
- Annual H&P exam is reasonable as potential second primary cancers (second cancer in residual esophagus or second primary squamous cell cancer in a separate organ) are possible.

#### Management of Long-Term Sequelae of Disease or Treatment

• For common survivorship issues, see [NCCN Guidelines for Survivorship](#)

• Esophageal/EGJ cancer-specific issues<sup>1-6</sup>:

▶ GI issues<sup>7-10</sup>:

◊ Malnutrition/malabsorption<sup>11-13</sup>:

- Monitor weight regularly after esophagectomy to ensure stability, recognizing that progressive weight loss is expected in the first 6 months
- Monitor for malnutrition, especially during initial 6 months after surgery<sup>14,15</sup>
  - Consider monitoring vitamin B, folic acid, vitamin D, and calcium levels
- Consider referral to dietician or nutrition services for individualized counseling
- Assess for and address contributing medical and/or psychosocial factors

◊ Delayed gastric emptying<sup>16</sup>:

- Encourage small portions and more frequent eating (5 small meals/day)
- Minimize high fat and fiber content in food
- Consider referral to gastroenterology for refractory symptoms<sup>a</sup>

◊ Dumping syndrome:

- Encourage frequent meals scheduled throughout the day (5 small meals/day)
- Consume a diet high in protein and fiber, and low in simple carbohydrates or concentrated sweets
- Avoid fluid consumption with meals

◊ Reflux symptoms:

- Avoid lying flat after eating
- Use a foam wedge (triangular) pillow in bed and avoid full prone sleeping position at night
- Consider proton pump inhibitors, although it is usually biliary reflux that exacerbates reflux symptoms

◊ Dysphagia:

- Evaluate for anastomotic stricture

<sup>a</sup> Consider botulinum toxin injection of pylorus if emptying procedure was not performed at original surgery.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



### PRINCIPLES OF SURVIVORSHIP

#### Management of Long-Term Sequelae of Disease or Treatment (continued)

##### • Esophageal/EGJ cancer-specific issues<sup>1-6</sup>:

###### ▶ ▶ Other issues:

- ◇ Monitor patients who are on anti-hypertensive therapy, as hypertension will improve in many patients with weight loss in the first 6 months after esophagectomy
- ◇ Monitor patients with glucose intolerance, as hyperglycemia will improve in many patients with weight loss in the first 6 months after esophagectomy
- ◇ Radiation-induced cardiotoxicity<sup>17-20</sup>:
  - Encourage coordination with primary care physician (PCP) for age-appropriate cardiac risk factor (eg, hypertension, diabetes, lipids, obesity) management/modification
  - Encourage health behaviors as listed below
  - Consider referral to cardiologist for management as clinically indicated
- ◇ Chemotherapy-induced neuropathy:
  - Consider duloxetine for painful neuropathy only (not effective for numbness or tingling)
  - See [NCCN Guidelines for Survivorship \(SPAIN-3\)](#) and [NCCN Guidelines for Adult Cancer Pain \(PAIN-F\)](#)
- ◇ Fatigue:
  - Encourage physical activity and energy conservation measures as tolerated
  - Assess and address contributing medical and/or psychosocial factors
  - [NCCN Guidelines for Survivorship \(SFAT-1\)](#) and [NCCN Guidelines for Cancer-Related Fatigue](#)

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.

[Continued](#)  
[References](#)

ESOPH-J  
2 OF 4



#### PRINCIPLES OF SURVIVORSHIP

##### Counseling Regarding Health Behaviors:

- [NCCN Guidelines for Survivorship \(HL-1\)](#)
- Maintain a healthy body weight throughout life.
- Adopt a physically active lifestyle and avoid inactivity. Goal: at least 30 minutes of moderate-intensity activity most days of the week. Modify physical activity recommendations based on treatment sequelae (ie, neuropathy).
- Consume a healthy diet with emphasis on plant sources, with modifications as needed based on treatment sequelae (ie, dumping syndrome, reflux, delayed gastric emptying).
- Limit alcohol consumption.
- Encourage smoking cessation as appropriate. See [NCCN Guidelines for Smoking Cessation](#).
- Additional preventive health measures and immunizations should be performed as indicated under the care of or in conjunction with a PCP.

##### Cancer Screening Recommendations (for average-risk survivors):

- Breast Cancer: [NCCN Guidelines for Breast Cancer Screening and Diagnosis](#)
- Colorectal Cancer: [NCCN Guidelines for Colorectal Cancer Screening](#)
- Prostate Cancer: [NCCN Guidelines for Prostate Cancer Early Detection](#)
- Lung Cancer: [NCCN Guidelines for Lung Cancer Screening](#)

##### Survivorship Care Planning and Coordination of Care:

- [NCCN Guidelines for Survivorship \(SURV-1 through SURV-B\)](#)
- [NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#)
- Encourage maintenance of a therapeutic relationship with a PCP throughout life. The oncologist and PCP should have defined roles in survivorship care, with roles communicated to the patient.
- Planning for ongoing survivorship care
  - Information on treatment received including all surgeries, RT, and systemic therapies
  - Information regarding follow-up care, surveillance, and screening recommendations
  - Information on post-treatment needs, including information regarding acute, late and long-term treatment-related effects, and health risks when possible (see [NCCN Guidelines for Treatment by Cancer Type](#))
  - Delineation regarding roles of oncologists, PCPs, and subspecialty care physicians in long-term care and the timing of transfer of care if appropriate
  - Healthy behavior recommendations (see [NCCN Guidelines for Survivorship \[HL-1\]](#))
  - Periodic assessment of ongoing needs and identification of appropriate resources

<sup>b</sup> From Commission on Cancer. Optimal Resources for Cancer Care (2020 Standards): [https://www.facs.org/-/media/files/quality-programs/cancer/coc/optimal\\_resources\\_for\\_cancer\\_care\\_2020\\_standards.ashx](https://www.facs.org/-/media/files/quality-programs/cancer/coc/optimal_resources_for_cancer_care_2020_standards.ashx) and [NCCN Guidelines for Survivorship](#).

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.



**PRINCIPLES OF SURVIVORSHIP  
REFERENCES**

- <sup>1</sup> Jacobs M, Macefield RC, Elbers RG, et al. Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. *Qual Life Res* 2014;23:1155-1176.
- <sup>2</sup> Donohoe CL, McGillicuddy E, Reynolds JV. Long-term health-related quality of life for disease-free esophageal cancer patients. *World J Surg* 2011;35:1853-1860.
- <sup>3</sup> de Boer AGEM, Oñorbe Genovesi PI, Sprangers MAG, et al. Quality of life in long-term survivors after curative transhiatal oesophagectomy for oesophageal carcinoma. *Br J Surg* 2000;87:1716-1721.
- <sup>4</sup> Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: A prospective population-based study. *J Clin Oncol* 2012;30:413-418.
- <sup>5</sup> Wikman A, Johar A, Lagergren P. Presence of symptom clusters in surgically treated patients with esophageal cancer: implications for survival. *Cancer* 2014;120:286-293.
- <sup>6</sup> Ginex P, Thom B, Jingeleski M, et al. Patterns of symptoms following surgery for esophageal cancer. *Oncol Nurs Forum* 2013;40:E101-E107.
- <sup>7</sup> Poghosyan T, Gaujoux S, Chirica M, et al. Functional disorders and quality of life after esophagectomy and gastric tube reconstruction for cancer. *J Visc Surg* 2011;148:e327-e335.
- <sup>8</sup> Paul M, Baker M, Williams RN, Bowrey DJ. Nutritional support and dietary interventions following esophagectomy: challenges and solutions. *Nutr Diet Suppl* 2017;9:9-21.
- <sup>9</sup> Donington JS. Functional conduit disorders after esophagectomy. *Thorac Surg Clin* 2006;16:53-62.
- <sup>10</sup> Deldycke A, Van Daele E, Ceelen W, et al. Functional outcome after Ivor Lewis esophagectomy for cancer. *J Surg Oncol* 2016;113:24-28.
- <sup>11</sup> Heneghan HM, Zaborowski A, Fanning M, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. *Ann Surg* 2015;262:803-807.
- <sup>12</sup> Ouattara M, D'Journo XB, Loundou A, et al. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. *Eur J Cardiothorac Surg* 2012;41:1088-1093.
- <sup>13</sup> D'Journo XB, Ouattara M, Loundou A, et al. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer. *Dis Esophagus* 2012;25:527-534.
- <sup>14</sup> Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. *Br J Surg* 2009;96:1308-1314.
- <sup>15</sup> Baker M, Halliday V, Williams RN, Bowrey DJ. A systematic review of the nutritional consequences of esophagectomy. *Clin Nutr* 2016;35:987-994.
- <sup>16</sup> Lee HS, Kim MS, Lee JM, et al. Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer. *Ann Thorac Surg* 2005;80:443-447.
- <sup>17</sup> Panjwani N, Fero KE, Murphy JD. Cardiac toxicity with radiation therapy in esophageal cancer. *Int J Radiat Oncol Biol Phys* 2016;96:S151-S152.
- <sup>18</sup> Beukema JC, van Luijk P, Widder J, et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? *Radiother Oncol* 2015;114:85-90.
- <sup>19</sup> Frandsen J, Boothe D, Gaffney DK, et al. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. *J Gastrointest Oncol* 2015;6:516-523.
- <sup>20</sup> Gharzai L, Verma V, Denniston KA, et al. Radiation therapy and cardiac death in long-term survivors of esophageal cancer: An analysis of the surveillance, epidemiology, and end result database. *PLOS ONE* 2016;11:e0158916.

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).  
All recommendations are category 2A unless otherwise indicated.**



4						E = Efficacy of Regimen/Agent
3						S = Safety of Regimen/Agent
2						Q = Quality of Evidence
1						C = Consistency of Evidence
						A = Affordability of Regimen/Agent
	E	S	Q	C	A	

**EVIDENCE BLOCKS FOR PREOPERATIVE AND PERIOPERATIVE TREATMENT REGIMENS**

**Perioperative Systemic Therapy Following Resection for Potentially Resectable Locoregional Esophageal/EGJ Cancer (ESOPH-13) and (ESOPH-18)**

Preferred Regimens	
Fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT)	
FLOT + durvalumab for PD-L1 CPS ≥1 or TAP ≥1%	*
Other Recommended Regimens	
Fluorouracil/cisplatin	
Fluorouracil/oxaliplatin/leucovorin	
Capecitabine/oxaliplatin	

**Preoperative Chemoradiation for Potentially Resectable Locoregional Esophageal/EGJ Cancer (ESOPH-4, and ESOPH-13)**

Preferred Regimens	
Paclitaxel/carboplatin + RT	
Fluorouracil/oxaliplatin/leucovorin + RT	
Capecitabine/oxaliplatin + RT	
Other Recommended Regimens	
Fluorouracil/cisplatin + RT	
Capecitabine/cisplatin + RT	
Irinotecan/cisplatin +RT	
Paclitaxel/fluorouracil + RT	
Paclitaxel/capecitabine + RT	

**Neoadjuvant or Perioperative Immunotherapy for Potentially Resectable Locoregional Esophageal/EGJ Adenocarcinomas (ESOPH-13) and (ESOPH-18)**

Useful in Certain Circumstances	
MSI-H/dMMR tumors	
Nivolumab and ipilimumab followed by nivolumab	*
Pembrolizumab	*
Tremelimumab and durvalumab for neoadjuvant therapy only	*

\*Evidence Block development in progress

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.**



4						<b>E = Efficacy of Regimen/Agent</b>
3						<b>S = Safety of Regimen/Agent</b>
2						<b>Q = Quality of Evidence</b>
1						<b>C = Consistency of Evidence</b>
						<b>A = Affordability of Regimen/Agent</b>
						<b>E S Q C A</b>

**EVIDENCE BLOCKS FOR DEFINITIVE CHEMORADIATION AND POSTOPERATIVE TREATMENT REGIMENS**

**Definitive Chemoradiation for Locoregional Esophageal/EGJ Cancer**  
**([ESOPH-4](#), [ESOPH-8](#), [ESOPH-13](#), [ESOPH-19](#))**

Preferred Regimens	
Paclitaxel/carboplatin + RT	
Fluorouracil/oxaliplatin/leucovorin + RT	
Capecitabine/oxaliplatin + RT	
Other Recommended Regimens	
Fluorouracil/cisplatin + RT	
Capecitabine/cisplatin + RT	
Cisplatin/docetaxel + RT	
Cisplatin/paclitaxel + RT	
Irinotecan/cisplatin + RT	
Paclitaxel/fluorouracil + RT	
Paclitaxel/capecitabine + RT	

**Postoperative Systemic Therapy**  
**([ESOPH-17](#))**

Preferred Regimen	
Nivolumab	
Other Recommended Regimens	
Capecitabine and oxaliplatin	
Fluorouracil/oxaliplatin/leucovorin	
Infusional fluorouracil/leucovorin (before and after chemoradiation)	
Capecitabine (before and after chemoradiation)	
Infusional fluorouracil + RT	
Capecitabine + RT	

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).



5					
4					
3					
2					
1					
	E	S	Q	C	A

**Efficacy of Regimen/Agent**  
S = Safety of Regimen/Agent  
Q = Quality of Evidence  
C = Consistency of Evidence  
A = Affordability of Regimen/Agent

**EVIDENCE BLOCKS FOR FIRST-LINE THERAPY FOR UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC ADENOCARCINOMA**

**HER2 Overexpression Positive ([ESOPH-21](#))**

Preferred Regimens		Other Recommended Regimens	
Fluorouracil/oxaliplatin/ leucovorin/trastuzumab		Fluorouracil/irinotecan/ leucovorin/trastuzumab	
Capecitabine/oxaliplatin/ trastuzumab		Paclitaxel/trastuzumab	
Fluorouracil/oxaliplatin/ leucovorin/trastuzumab/ pembrolizumab	*	Paclitaxel/carboplatin/ trastuzumab	
Capecitabine/oxaliplatin/ trastuzumab/pembrolizumab	*	Paclitaxel/cisplatin/ trastuzumab	
Fluorouracil/cisplatin/ trastuzumab		Docetaxel/trastuzumab	
Capecitabine/cisplatin/ trastuzumab		Docetaxel/cisplatin/ trastuzumab	
Fluorouracil/cisplatin/ trastuzumab/pembrolizumab	*	Fluorouracil/trastuzumab	
Capecitabine/cisplatin/ trastuzumab/pembrolizumab	*	Fluorouracil/leucovorin/ trastuzumab	
		Capecitabine/trastuzumab	
		Dose-modified DCF/ leucovorin/trastuzumab	
		Docetaxel/oxaliplatin/ fluorouracil/trastuzumab	

\*Evidence Block development in progress

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).**



4					
3					
2					
1					
	E	S	Q	C	A

**E = Efficacy of Regimen/Agent**  
**S = Safety of Regimen/Agent**  
**Q = Quality of Evidence**  
**C = Consistency of Evidence**  
**A = Affordability of Regimen/Agent**

**EVIDENCE BLOCKS FOR FIRST-LINE THERAPY FOR UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC ADENOCARCINOMA**  
**HER2 Overexpression Negative (ESOPH-21)**

Preferred Regimens		Preferred Regimens (continued)	
Fluorouracil/oxaliplatin/leucovorin/nivolumab for PD-L1 CPS ≥5	*	Fluorouracil/cisplatin/tislelizumab-jsgr for PD-L1 CPS ≥1	*
Fluorouracil/oxaliplatin/leucovorin/nivolumab for PD-L1 CPS ≥1	*	Capecitabine/cisplatin/tislelizumab-jsgr for PD-L1 CPS ≥5	*
Capecitabine/oxaliplatin/nivolumab for PD-L1 CPS ≥5	*	Capecitabine/cisplatin/tislelizumab-jsgr for PD-L1 CPS ≥1	*
Capecitabine/oxaliplatin/nivolumab for PD-L1 CPS ≥1	*	Fluorouracil/cisplatin	
Fluorouracil/oxaliplatin/leucovorin/pembrolizumab for PD-L1 CPS ≥5	*	Fluorouracil/cisplatin/leucovorin	
Fluorouracil/oxaliplatin/leucovorin/pembrolizumab for PD-L1 CPS ≥1	*	Capecitabine/cisplatin	
Capecitabine/oxaliplatin/pembrolizumab for PD-L1 CPS ≥5	*	<b>Other Recommended Regimens</b>	
Capecitabine/oxaliplatin/pembrolizumab for PD-L1 CPS ≥1	*	Fluorouracil/irinotecan/leucovorin	
Fluorouracil/oxaliplatin/zolbetuximab-clzb	*	Paclitaxel	
Capecitabine/oxaliplatin/zolbetuximab-clzb	*	Paclitaxel/carboplatin	
Fluorouracil/oxaliplatin/leucovorin/tislelizumab-jsgr for PD-L1 CPS ≥5	*	Paclitaxel/cisplatin	
Fluorouracil/oxaliplatin/leucovorin/tislelizumab-jsgr for PD-L1 CPS ≥1	*	Docetaxel	
Capecitabine/oxaliplatin/tislelizumab-jsgr for PD-L1 CPS ≥5	*	Docetaxel/cisplatin	
Capecitabine/oxaliplatin/tislelizumab-jsgr for PD-L1 CPS ≥1	*	Fluorouracil	
Fluorouracil/oxaliplatin/leucovorin		Fluorouracil/leucovorin	
Capecitabine/oxaliplatin		Capecitabine	
Fluorouracil/cisplatin/pembrolizumab PD-L1 CPS ≥5	*	Dose-modified DCF/leucovorin	
Fluorouracil/cisplatin/pembrolizumab for PD-L1 CPS ≥1	*	Docetaxel/oxaliplatin/fluorouracil	
Capecitabine/cisplatin/pembrolizumab for PD-L1 CPS ≥5	*		
Capecitabine/cisplatin/pembrolizumab for PD-L1 CPS 1 to ≥1	*		
Fluorouracil/cisplatin/tislelizumab-jsgr for PD-L1 CPS ≥5	*		

**MSI-H/dMMR Tumors (ESOPH-21)**

Preferred Regimens	
Pembrolizumab	*
Dostarlimab-gxly	*
Nivolumab and ipilimumab	*
Fluorouracil/oxaliplatin/leucovorin/nivolumab	*
Capecitabine/oxaliplatin/nivolumab	*
Fluorouracil/oxaliplatin/leucovorin/pembrolizumab	*
Capecitabine/oxaliplatin/pembrolizumab	*
Useful in Certain Circumstances	
Entrectinib for <i>NTRK</i> gene fusion-positive tumors	*
Larotrectinib for <i>NTRK</i> gene fusion-positive tumors	*
Repotrectinib for <i>NTRK</i> gene fusion-positive tumors	*

\*Evidence Block development in progress

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.**



4					E = Efficacy of Regimen/Agent
3					S = Safety of Regimen/Agent
2					Q = Quality of Evidence
1					C = Consistency of Evidence
					A = Affordability of Regimen/Agent
	E	S	Q	C	A

**EVIDENCE BLOCKS FOR FIRST-LINE THERAPY FOR UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC SQUAMOUS CELL CARCINOMA**  
**First-Line Therapy for Squamous Cell Carcinoma (ESOPH-10)**

Preferred Regimens	
Fluorouracil/oxaliplatin/leucovorin/nivolumab	
Capecitabine/oxaliplatin/nivolumab	
Fluorouracil/oxaliplatin/leucovorin/pembrolizumab	
Capecitabine/oxaliplatin/pembrolizumab	
Fluorouracil/oxaliplatin/leucovorin/tislelizumab-jsgr	*
Capecitabine/oxaliplatin/tislelizumab-jsgr	*
Oxaliplatin/paclitaxel/tislelizumab-jsgr	*
Fluorouracil/oxaliplatin/leucovorin	
Capecitabine/oxaliplatin	
Fluorouracil/cisplatin/nivolumab	
Capecitabine/cisplatin/nivolumab	
Fluorouracil/cisplatin/pembrolizumab	
Capecitabine/cisplatin/pembrolizumab	
Fluorouracil/cisplatin/tislelizumab-jsgr	*
Capecitabine/cisplatin/tislelizumab-jsgr	*
Cisplatin/paclitaxel/tislelizumab-jsgr	*
Fluorouracil/cisplatin	
Fluorouracil/cisplatin/leucovorin	
Capecitabine/cisplatin	
Nivolumab/ipilimumab	

Preferred Regimens (continued)	
<b>MSI-H/dMMR tumors</b>	
Pembrolizumab	*
Dostarlimab-gxly	*
Nivolumab and ipilimumab	*
Fluorouracil/oxaliplatin/leucovorin/nivolumab	*
Capecitabine/oxaliplatin/nivolumab	*
Fluorouracil/oxaliplatin/leucovorin/pembrolizumab	*
Capecitabine/oxaliplatin/pembrolizumab	*

Other Recommended Regimens	
Fluorouracil/irinotecan/leucovorin	
Paclitaxel	
Paclitaxel/carboplatin	
Paclitaxel/cisplatin	
Docetaxel	
Docetaxel/cisplatin	
Fluorouracil	
Fluorouracil/leucovorin	
Capecitabine	
Dose-modified DCF/leucovorin	
Docetaxel/oxaliplatin/fluorouracil	

Useful in Certain Circumstances	
Entrectinib for <i>NTRK</i> gene fusion-positive tumors	*
Larotrectinib for <i>NTRK</i> gene fusion-positive tumors	*
Repotrectinib for <i>NTRK</i> gene fusion-positive tumors	*

\*Evidence Block development in progress

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.**



4				
3				
2				
1				
	E	S	Q	A

**Efficacy of Regimen/Agent**  
S = Safety of Regimen/Agent  
Q = Quality of Evidence  
C = Consistency of Evidence  
A = Affordability of Regimen/Agent

**EVIDENCE BLOCKS FOR SECOND-LINE OR SUBSEQUENT THERAPY FOR UNRESECTABLE LOCALLY ADVANCED, RECURRENT OR METASTATIC ADENOCARCINOMA (ESOPH-21)**

Preferred Regimens	
Ramucirumab/paclitaxel	
Fam-trastuzumab deruxtecan-nxki (for HER2 overexpression positive)	
Docetaxel	
Paclitaxel	
Irinotecan	
Fluorouracil/irinotecan/leucovorin	
Trifluridine and tipiracil (third-line or subsequent therapy for EGJ)	
Other Recommended Regimens	
Ramucirumab	
Irinotecan/cisplatin	
Fluorouracil/irinotecan/leucovorin/ramucirumab	
Irinotecan/ramucirumab	
Docetaxel/irinotecan	

Useful in Certain Circumstances	
Entrectinib for <i>NTRK</i> gene fusion-positive tumors	
Larotrectinib for <i>NTRK</i> gene fusion-positive tumors	
Repotrectinib for <i>NTRK</i> gene fusion-positive tumors	*
Pembrolizumab for MSI-H/dMMR tumors	
Nivolumab and ipilimumab for MSI-H/dMMR tumors	*
Pembrolizumab for TMB high (≥10 mutations/megabase) tumors	
Dostarlimab-gxly for MSI-H/dMMR tumors	
Dabrafenib and trametinib for <i>BRAF</i> V600E mutated tumors	
Selpercatinib for <i>RET</i> gene fusion-positive tumors	

\*Evidence Block development in progress

**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.**





**American Joint Committee on Cancer (AJCC)  
TNM Staging Classification for Carcinoma of the Esophagus and Esophagogastric Junction (8th ed., 2017)  
Squamous Cell Carcinoma and Adenocarcinoma**

**Table 1. Definitions for T, N, M**

<b>T</b>	<b>Primary Tumor</b>
<b>TX</b>	Primary tumor cannot be assessed
<b>T0</b>	No evidence of primary tumor
<b>Tis</b>	High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane
<b>T1</b>	Tumor invades the lamina propria, muscularis mucosae, or submucosa
<b>T1a</b>	Tumor invades the lamina propria or muscularis mucosae
<b>T1b</b>	Tumor invades the submucosa
<b>T2</b>	Tumor invades the muscularis propria
<b>T3</b>	Tumor invades adventitia
<b>T4</b>	Tumor invades adjacent structures
<b>T4a</b>	Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum
<b>T4b</b>	Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway
<b>N</b>	<b>Regional Lymph Nodes</b>
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No regional lymph node metastasis
<b>N1</b>	Metastasis in one or two regional lymph nodes
<b>N2</b>	Metastasis in three to six regional lymph nodes
<b>N3</b>	Metastasis in seven or more regional lymph nodes

<b>M</b>	<b>Distant Metastasis</b>
<b>M0</b>	No distant metastasis
<b>M1</b>	Distant metastasis
<b>G</b>	<b>Histologic Grade</b>
<b>GX</b>	Grade cannot be assessed
<b>G1</b>	Well differentiated
<b>G2</b>	Moderately differentiated
<b>G3</b>	Poorly differentiated, undifferentiated

**Squamous Cell Carcinoma**

<b>Location</b>	<b>Location Criteria</b>
<b>X</b>	Location unknown
<b>Upper</b>	Cervical esophagus to lower border of azygos vein
<b>Middle</b>	Lower border of azygos vein to lower border of inferior pulmonary vein
<b>Lower</b>	Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction

*Note:* Location is defined by the position of the epicenter of the tumor in the esophagus.

[Continued](#)

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.



#### American Joint Committee on Cancer (AJCC)

#### TNM Staging Classification for Carcinoma of the Esophagus and Esophagogastric Junction (8th ed., 2017)

**Table 2. AJCC Prognostic Stage Groups (Squamous Cell Carcinoma)**

Clinical Staging (cTNM)			Pathological (pTNM)					Postneoadjuvant Therapy (ypTNM)					
	cT	cN	M		pT	pN	M	G	Location		ypT	ypN	M
<b>Stage 0</b>	Tis	N0	M0	<b>Stage 0</b>	Tis	N0	M0	N/A	Any	<b>Stage I</b>	T0-2	N0	M0
<b>Stage I</b>	T1	N0-1	M0	<b>Stage IA</b>	T1a	N0	M0	G1	Any	<b>Stage II</b>	T3	N0	M0
<b>Stage II</b>	T2	N0-1	M0	<b>Stage IB</b>	T1a	N0	M0	GX	Any	<b>Stage IIIA</b>	T0-2	N1	M0
	T3	N0	M0		T1a	N0	M0	G2-3	Any	<b>Stage IIIB</b>	T3	N1	M0
<b>Stage III</b>	T3	N1	M0		T1b	N0	M0	G1-3	Any		T0-3	N2	M0
	T1-3	N2	M0		T1b	N0	M0	GX	Any		T4a	N0	M0
<b>Stage IVA</b>	T4	N0-2	M0	<b>Stage IIA</b>	T2	N0	M0	G1	Any	<b>Stage IVA</b>	T4a	N1-2	M0
	Any T	N3	M0		T2	N0	M0	G2-3	Any		T4a	NX	M0
<b>Stage IVB</b>	Any T	Any N	M1		T2	N0	M0	GX	Any		T4b	N0-2	M0
					T3	N0	M0	G1-3	Lower		Any T	N3	M0
				<b>Stage IIB</b>	T3	N0	M0	G1	Upper/middle	<b>Stage IVB</b>	Any T	Any N	M1
					T3	N0	M0	G2-3	Upper/middle				
					T3	N0	M0	GX	Lower/upper/middle				
					T3	N0	M0	Any	Location X				
				<b>Stage IIIA</b>	T1	N1	M0	Any	Any				
					T1	N2	M0	Any	Any				
				<b>Stage IIIB</b>	T2	N1	M0	Any	Any				
					T2	N2	M0	Any	Any				
					T3	N1-2	M0	Any	Any				
				<b>Stage IVA</b>	T4a	N0-1	M0	Any	Any				
					T4a	N2	M0	Any	Any				
					T4b	N0-2	M0	Any	Any				
					Any T	N3	M0	Any	Any				
				<b>Stage IVB</b>	Any T	Any N	M1	Any	Any				

[Continued](#)

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.



**American Joint Committee on Cancer (AJCC)  
TNM Staging Classification for Carcinoma of the Esophagus and Esophagogastric Junction (8th ed., 2017)**

**Table 3. AJCC Prognostic Stage Groups (Adenocarcinoma)**

Clinical Staging (cTNM)				Pathological (pTNM)				Postneoadjuvant Therapy (ypTNM)				
	cT	cN	M		pT	pN	M	G		ypT	ypN	M
<b>Stage 0</b>	Tis	N0	M0	<b>Stage 0</b>	Tis	N0	M0	N/A	<b>Stage I</b>	T0-2	N0	M0
<b>Stage I</b>	T1	N0	M0	<b>Stage IA</b>	T1a	N0	M0	G1	<b>Stage II</b>	T3	N0	M0
<b>Stage IIA</b>	T1	N1	M0		T1a	N0	M0	GX	<b>Stage IIIA</b>	T0-2	N1	M0
<b>Stage IIB</b>	T2	N0	M0	<b>Stage IB</b>	T1a	N0	M0	G2	<b>Stage IIIB</b>	T3	N1	M0
<b>Stage III</b>	T2	N1	M0		T1b	N0	M0	G1-2		T0-3	N2	M0
	T3	N0-1	M0		T1b	N0	M0	GX		T4a	N0	M0
	T4a	N0-1	M0	<b>Stage IC</b>	T1	N0	M0	G3	<b>Stage IVA</b>	T4a	N1-2	M0
<b>Stage IVA</b>	T1-4a	N2	M0		T2	N0	M0	G1-2		T4a	NX	M0
	T4b	N0-2	M0	<b>Stage IIA</b>	T2	N0	M0	G3		T4b	N0-2	M0
	Any T	N3	M0		T2	N0	M0	GX		Any T	N3	M0
<b>Stage IVB</b>	Any T	Any N	M1	<b>Stage IIB</b>	T1	N1	M0	Any	<b>Stage IVB</b>	Any T	Any N	M1
					T3	N0	M0	Any				
				<b>Stage IIIA</b>	T1	N2	M0	Any				
					T2	N1	M0	Any				
				<b>Stage IIIB</b>	T2	N2	M0	Any				
					T3	N1-2	M0	Any				
					T4a	N0-1	M0	Any				
				<b>Stage IVA</b>	T4a	N2	M0	Any				
					T4b	N0-2	M0	Any				
					Any T	N3	M0	Any				
				<b>Stage IVB</b>	Any T	Any N	M1	Any				

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.



#### ABBREVIATIONS

<b>3D-CRT</b>	<b>three-dimensional conformal radiation therapy</b>	<b>ESD</b>	<b>endoscopic submucosal dissection</b>	<b>MMR</b>	<b>mismatch repair</b>
<b>4D-CT</b>	<b>four-dimensional computed tomography</b>	<b>EUS</b>	<b>endoscopic ultrasound</b>	<b>MSI</b>	<b>microsatellite instability</b>
<b>ALL</b>	<b>acute lymphoblastic leukemia</b>	<b>FA</b>	<b>Fanconi anemia</b>	<b>MSI-H</b>	<b>microsatellite instability-high</b>
<b>AML</b>	<b>acute myeloid leukemia</b>	<b>FBE</b>	<b>familial Barrett esophagus</b>	<b>MSI-L</b>	<b>microsatellite instability-low</b>
<b>AUC</b>	<b>area under the curve</b>	<b>FDG</b>	<b>fluorodeoxyglucose</b>	<b>MSS</b>	<b>microsatellite stable</b>
<b>BE</b>	<b>Barrett esophagus</b>	<b>FFPE</b>	<b>formalin-fixed paraffin embedded</b>	<b>NGS</b>	<b>next-generation sequencing</b>
<b>BS</b>	<b>Bloom syndrome</b>	<b>FISH</b>	<b>fluorescence in situ hybridization</b>	<b>PCP</b>	<b>primary care physician</b>
<b>CBC</b>	<b>complete blood count</b>	<b>FNA</b>	<b>fine-needle aspiration</b>	<b>PCR</b>	<b>polymerase chain reaction</b>
<b>CLIA</b>	<b>Clinical Laboratory Improvement Amendments</b>	<b>GERD</b>	<b>gastroesophageal reflux disease</b>	<b>PD-1</b>	<b>programmed cell death protein 1</b>
<b>CPS</b>	<b>combined positive score</b>	<b>GI</b>	<b>gastrointestinal</b>	<b>PD-L1</b>	<b>programmed death ligand 1</b>
<b>ctDNA</b>	<b>circulating tumor DNA</b>	<b>GTV</b>	<b>gross tumor volume</b>	<b>PDT</b>	<b>photodynamic therapy</b>
<b>CTV</b>	<b>clinical target volume</b>	<b>H&amp;P</b>	<b>history and physical</b>	<b>PPK</b>	<b>palmoplantar keratoderma</b>
<b>dMMR</b>	<b>mismatch repair deficient</b>	<b>HGD</b>	<b>high-grade dysplasia</b>	<b>PS</b>	<b>performance status</b>
<b>DVH</b>	<b>dose-volume histogram</b>	<b>ICI</b>	<b>immune checkpoint inhibitor</b>	<b>PTV</b>	<b>planning target volume</b>
<b>EBRT</b>	<b>external beam radiation therapy</b>	<b>IHC</b>	<b>immunohistochemistry</b>	<b>RFA</b>	<b>radiofrequency ablation</b>
<b>ECOG</b>	<b>Eastern Cooperative Oncology Group</b>	<b>IMRT</b>	<b>intensity-modulated radiation therapy</b>	<b>SCC</b>	<b>squamous cell carcinoma</b>
<b>EGD</b>	<b>esophagogastroduodenoscopy</b>	<b>ISH</b>	<b>in situ hybridization</b>	<b>TEC</b>	<b>tylosis with esophageal cancer</b>
<b>EGJ</b>	<b>esophagogastric junction</b>	<b>ITV</b>	<b>internal target volume</b>	<b>TMB</b>	<b>tumor mutational burden</b>
<b>EMR</b>	<b>endoscopic mucosal resection</b>	<b>J-tube</b>	<b>jejunostomy tube</b>	<b>TMB-H</b>	<b>tumor mutational burden-high</b>
<b>ER</b>	<b>endoscopic resection</b>	<b>LVI</b>	<b>lymphovascular invasion</b>	<b>TNM</b>	<b>tumor node metastasis</b>



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### NCCN Evidence Blocks™

NCCN Categories of Evidence and Consensus	
<b>Category 1</b>	Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
<b>Category 2A</b>	Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
<b>Category 2B</b>	Based upon lower-level evidence, there is NCCN consensus (≥50%, but <85% support of the Panel) that the intervention is appropriate.
<b>Category 3</b>	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference	
<b>Preferred intervention</b>	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
<b>Other recommended intervention</b>	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
<b>Useful in certain circumstances</b>	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### Discussion

This discussion corresponds to the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers. Last updated on March 10, 2023

### Table of Contents

Overview .....	MS-2	Combined Modality Therapy.....	MS-23
Literature Search Criteria and Guidelines Update Methodology .....	MS-2	Preoperative Chemoradiation Therapy .....	MS-23
Hereditary Cancer Predisposition Syndromes Associated with an Increased Risk for Esophageal and EGJ Cancers.....	MS-3	Perioperative Chemotherapy .....	MS-26
Tylosis.....	MS-3	Definitive Chemoradiation Therapy .....	MS-27
Familial Barrett Esophagus .....	MS-3	Postoperative Therapy.....	MS-28
Bloom Syndrome.....	MS-4	Postoperative Chemoradiation Therapy .....	MS-28
Fanconi Anemia .....	MS-4	Systemic Therapy for Locally Advanced or Metastatic Disease.....	MS-29
Staging.....	MS-5	First-Line Therapy.....	MS-29
Siewert Classification of EGJ Adenocarcinoma.....	MS-7	Second-Line and Subsequent Therapy .....	MS-31
Barrett Esophagus.....	MS-7	Targeted Therapies.....	MS-32
Pathologic Review and Biomarker Testing.....	MS-9	Trastuzumab.....	MS-32
Principles of Pathologic Review.....	MS-9	Nivolumab .....	MS-33
Assessment of Treatment Response .....	MS-10	Pembrolizumab.....	MS-35
Principles of Biomarker Testing.....	MS-12	Ramucirumab .....	MS-36
Assessment of HER2 Overexpression.....	MS-12	Fam-trastuzumab deruxtecan-nxki.....	MS-37
MSI and MMR Testing.....	MS-13	Entrectinib and Larotrectinib .....	MS-38
PD-L1 Testing.....	MS-13	Dostarlimab-gxly.....	MS-39
Liquid Biopsy.....	MS-14	Dabrafenib and Trematinib.....	MS-39
Surgery .....	MS-14	Selpercatinib.....	MS-39
Principles of Surgery .....	MS-14	Treatment Guidelines.....	MS-40
Surgical Approaches .....	MS-15	Workup.....	MS-40
Endoscopic Therapies .....	MS-18	Additional Evaluation .....	MS-41
Principles of Endoscopy .....	MS-18	Primary Treatment.....	MS-41
Diagnosis.....	MS-18	Response Assessment and Additional Management.....	MS-42
Staging .....	MS-19	Postoperative Management .....	MS-42
Treatment .....	MS-19	Follow-up/Surveillance.....	MS-43
Surveillance .....	MS-20	Unresectable, Locally Advanced, Recurrent or Metastatic Disease .....	MS-44
Radiation Therapy .....	MS-20	Leucovorin Shortage.....	MS-45
Principles of Radiation Therapy.....	MS-22	Palliative/Best Supportive Care.....	MS-46
General Guidelines .....	MS-22	Survivorship.....	MS-48
Simulation and Treatment Planning.....	MS-22	Summary .....	MS-49
Target Volume .....	MS-23	References .....	MS-51
Normal Tissue Tolerance and Dose Limits .....	MS-23		
Supportive Care.....	MS-23		



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### Overview

Upper gastrointestinal (GI) tract cancers originating in the esophagus or esophagogastric junction (EGJ) constitute a major global health problem.<sup>1</sup> Globally, there were an estimated 604,000 new cases and more than 544,000 deaths in 2020, making esophageal cancer the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related deaths in the world.<sup>2,3</sup> The global incidence of esophageal and EGJ cancers shows wide geographic variation, with a 60-fold difference between high- and low-incidence regions.<sup>4</sup> The highest-incidence area, often referred to as the “esophageal cancer belt,” spans from northern Iran through Central Asia and into Northern China.<sup>1,5</sup> Other high-incidence areas include Southern and Eastern Africa and Northern France.<sup>6</sup> In contrast, esophageal cancer is one of the least frequently diagnosed cancers in North America. It is the twentieth most frequently diagnosed cancer and the eleventh leading cause of cancer-related deaths in the United States.<sup>7</sup> In 2023, an estimated 21,560 people are expected to be diagnosed and 16,120 people are expected to die of this disease in the United States.<sup>8</sup> Although still relatively rare, incidence rates have been increasing in the United States over the past several years and the 5-year survival rate remains low.<sup>8</sup>

Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor location, therapeutics, and prognosis.<sup>9</sup> In contrast to esophageal adenocarcinoma, which usually affects the lower esophagus, esophageal SCC is more likely to localize at or higher than the tracheal bifurcation. SCC also has a proclivity for earlier lymphatic spread and is associated with a poorer prognosis.<sup>9,10</sup> SCC is the most common histology in Eastern Europe and Asia, while adenocarcinoma is most common in North America and Western Europe. Tobacco and alcohol consumption are major risk factors for SCC, whereas tobacco use is a moderate risk factor for adenocarcinoma.<sup>11-13</sup> The risk for SCC decreases substantially

after smoking cessation, whereas the risk for adenocarcinoma remains unchanged even several years after smoking cessation.<sup>14,15</sup> SCC has become less common in North America and Western Europe in recent decades due to reduced tobacco and alcohol use, and now accounts for less than 30% of all esophageal cancers in the United States and Western Europe.<sup>1</sup>

In contrast, the incidence of esophageal adenocarcinoma has increased in North America and Western Europe, likely reflecting rising rates of obesity.<sup>1</sup> High body mass index (BMI) has been established as the strongest risk factor for adenocarcinoma of the esophagus.<sup>12,16,17</sup> Obesity contributes to the development of gastroesophageal reflux disease (GERD), a major underlying cause of esophageal adenocarcinoma.<sup>18-20</sup> GERD is associated with the development of Barrett esophagus, a precancerous condition in which the normal squamous epithelium of the esophagus is replaced by a metaplastic, columnar, or glandular epithelium that is predisposed to malignancy.<sup>21</sup> Patients with Barrett esophagus have a 30 to 60 times greater risk of developing adenocarcinoma of the esophagus than the general population.<sup>19</sup> Older age, male gender assigned at birth, long-standing GERD, hiatal hernia size, and the length of Barrett esophagus are strongly associated with higher grades of dysplasia and increased risk of esophageal adenocarcinoma development.<sup>22-24</sup>

### Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers, an electronic search of the PubMed database was performed to obtain key literature published since the last Guidelines update, using the following search terms: esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, EGJ cancer, and



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

gastroesophageal junction cancer. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.<sup>25</sup>

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles selected by the panel for review during the Guidelines update meeting as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

NCCN recommendations have been developed to be inclusive of individuals of all sexual and gender identities to the greatest extent possible. When citing published studies and recommendations from other organizations, the terms used (eg, male, female) reflect the cited sources.

The complete details of the Development and Update of the NCCN Guidelines are available at [www.NCCN.org](http://www.NCCN.org).

### Hereditary Cancer Predisposition Syndromes Associated with an Increased Risk for Esophageal and EGJ Cancers

Although early age of onset and family history are associated with hereditary cancer, specific recommendations for esophageal and EGJ cancer risk assessment are not possible at this time due to limited data. Referral to a cancer genetics professional is recommended for individuals with a known high-risk syndrome associated with esophageal and EGJ

cancers. The most common hereditary cancer predisposition syndromes are discussed in detail below.

#### Tylosis

Tylosis (also known as focal non-epidermolytic palmoplantar keratoderma [PPK] or Howel-Evans syndrome) is a very rare autosomal dominant syndrome caused by germline mutations in the *RHBDF2* gene.<sup>26</sup> PPK is a complex group of hereditary syndromes characterized by abnormal skin thickening on the palms of the hands and soles of the feet. PPK is classified as diffuse, punctate, or focal based on the patterns of skin thickening, and as epidermolytic or non-epidermolytic based on histology. The focal non-epidermolytic form of PPK (tylosis) is specifically associated with a higher lifetime risk of developing SCC of the middle and distal esophagus.<sup>27,28</sup> In individuals with tylosis, the average age at diagnosis of esophageal SCC is 45 years. The risk of developing SCC of the esophagus has been reported to be 40% to 90% by age 70 years.<sup>29,30</sup> Routine screening by upper GI endoscopy is recommended for patients with tylosis and their family members after age 20 years.<sup>27</sup>

#### Familial Barrett Esophagus

Barrett esophagus is a condition in which the normal squamous epithelium of the esophagus is replaced by a metaplastic, columnar, or glandular epithelium that is predisposed to the development of adenocarcinoma (see *Barrett Esophagus* below).<sup>21</sup> The familial aggregation of Barrett esophagus and adenocarcinoma of the esophagus or EGJ is termed familial Barrett esophagus (FBE).<sup>31-33</sup> Reviews of hospital case series indicate that between 5% and 7% of patients with Barrett esophagus and esophageal adenocarcinoma report a family history of either disease.<sup>34</sup> In one cohort study, family history was identified as an independent predictor for the presence of Barrett esophagus and adenocarcinoma of the esophagus or EGJ, after adjusting for age, sex, and the presence of obesity 10 or more



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

years prior to study enrollment.<sup>32</sup> A study by Chak et al identified Barrett esophagus in 21% of first-degree relatives of patients with Barrett esophagus or esophageal adenocarcinoma.<sup>35</sup> Furthermore, Barrett esophagus was identified significantly more often in siblings and offspring of FBE probands than in probands with isolated cases of Barrett esophagus.

FBE may be associated with one or more autosomally inherited dominant susceptibility alleles.<sup>36</sup> Reports have identified germline mutations in a variety of susceptibility genes that may be associated with the development of Barrett esophagus; however, none has been validated.<sup>37,38</sup> Since development of Barrett esophagus is strongly associated with GERD, it is possible that GERD is inherited, with Barrett esophagus occurring as a consequence. However, since GERD is not always observed in patients with FBE, and there is an unusually high rate of progression to adenocarcinoma in families with FBE, additional genetic factors may be required for the development of FBE.<sup>34</sup> A recent study using whole exome sequencing (WES) on four distant relatives from a multiplex, multigenerational family with FBE identified the uncharacterized gene *VSIG10L* as a candidate FBE susceptibility gene, with a putative role in maintaining normal esophageal homeostasis.<sup>39</sup> However, future studies on the prevalence of *VSIG10L* mutations in this population are needed to allow for risk stratification of FBE susceptibility.

Potential family history of Barrett esophagus and adenocarcinoma of the esophagus or EGJ should be determined for patients presenting with GERD, especially white patients over 40 years who were assigned male gender at birth. Screening for Barrett esophagus by upper GI endoscopy is recommended in family members with FBE after age 40 years, especially if the individual has a history of GERD.

### Bloom Syndrome

Bloom syndrome (BS) is a rare autosomal recessive syndrome belonging to a group of chromosomal breakage syndromes. BS is characterized by mutations in the *BLM/RECQL3* gene at 15q26.1 and is associated with strikingly elevated sister chromatid exchange rates in all cells, resulting in an increased predisposition to a wide variety of malignancies.<sup>40</sup> Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoid neoplasms, and Wilms tumor are the predominant cancers diagnosed before age 20 years, whereas carcinomas of many different organ sites including SCC of the esophagus are diagnosed after age 20 years.<sup>27,41</sup> Individuals with BS are often diagnosed with cancers at an earlier age than the general population. The presence of chromosomal quadriradials with breakage may be used for the diagnosis of BS.<sup>27</sup> Screening for GERD (with or without endoscopy to detect early esophageal cancer) after age 20 years may be considered.

### Fanconi Anemia

Fanconi anemia (FA) is an autosomal recessive disorder characterized by congenital malformations, progressive pancytopenia, and an increased predisposition to the development of hematologic malignancies and solid tumors.<sup>27</sup> FA is caused by mutations in one of 15 genes encoding the FA pathway, with *FANCA*, *FANCC*, *FANCG*, and *FANCD2* being the most common.<sup>42</sup> AML is the most common cancer occurring in patients with FA; however, patients with FA are also at an increased risk of developing SCC of the head, neck, and esophagus.<sup>27,43,44</sup> Individuals with FA are identified by pancytopenia, chromosomal breakage, and hematologic abnormalities, including anemia, bleeding, and easy bruising. Karyotyping does not identify individuals with FA, but enhanced chromosomal breakage with mitomycin C can identify homozygotes.<sup>27,45</sup> Endoscopy of the esophagus may be considered as a screening strategy in individuals with FA.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### Staging

The tumor (T), node (N), and metastasis (M) staging system used by the American Joint Committee on Cancer (AJCC) is the internationally accepted standard for cancer staging and is a major factor influencing prognosis and treatment decisions. Staging recommendations for esophageal and EGJ cancers presented in the Eighth Edition of the AJCC Cancer Staging Manual include clinical staging (cTNM; newly diagnosed, not-yet-treated patients), pathologic staging (pTNM; patients undergoing resection without prior treatment), and post neoadjuvant pathologic staging (ypTNM; patients receiving preoperative therapy).<sup>10</sup> The Eighth Edition also introduced modifications regarding tumors located at the EGJ. Using this system, tumors with an epicenter located greater than 2 cm into the proximal stomach are now staged as gastric carcinomas, even if the EGJ is involved. Tumors involving the EGJ with an epicenter less than or equal to 2 cm into the proximal stomach will still be staged as esophageal carcinomas.

The Eighth Edition of the AJCC Cancer Staging Manual provides additional resources for esophageal and EGJ cancers not available in the Seventh Edition, including the incorporation of newly constructed cTNM and ypTNM stage groupings, to fulfill unmet needs in staging patients under different circumstances. The stage groupings presented in the Eighth Edition are based on updated data with a significantly increased sample size and number of risk adjustment variables. The current stage groupings were determined using a risk-adjusted random survival forest analysis of collated data generated by the Worldwide Esophageal Cancer Collaboration (WECC) for 22,654 patients spanning six continents who were treated with esophagectomy alone or esophagectomy with preoperative and/or postoperative therapy.<sup>10</sup> Use of these data reflects the current preference for treating locally advanced esophageal cancers with preoperative therapy and represents a major advancement over the seventh edition, which was entirely based on data

from patients treated with esophagectomy alone. The availability of these data led to the ability to explicitly define cTNM and ypTNM cohorts and stages. The larger dataset also allowed for better separation of SCC and adenocarcinoma staging.<sup>10</sup> However, limitations of this dataset still remain, including missing patient variables, heterogeneity of clinical staging among different centers, and poor representation of patients who are untreatable or inoperable, such as those with T4b and M1 cancers. Additionally, the exact modalities used to arrive at the initial clinical stages were not available for analysis. Nevertheless, the Eighth Edition of the AJCC Cancer Staging Manual represents the best worldwide clinical esophageal cancer staging data currently available. Survival analysis of this data set revealed that survival decreased with increasing anatomic tumor size and depth (pT), presence of regional lymph node metastases (pN), presence of distant metastases (pM), increasing histologic grade (G1–4), and advancing age.<sup>46,47</sup> Survival increased with a more distal location of cancer within the esophagus. In addition, survival was significantly affected by histopathologic type, with SCC having worse survival than adenocarcinoma.<sup>47</sup> Analysis of this larger dataset also illuminated significant differences in outcome when comparing the same stage groups between patients receiving preoperative therapy versus those treated with surgery alone, emphasizing the importance of having separate pTNM and ypTNM stage groupings to stage patients more accurately within each treatment algorithm.

In esophageal cancer, patient survival is best correlated with the final pathologic stage, regardless of whether the patient has received preoperative therapy.<sup>10</sup> Although surgical pathology yields the most accurate staging, advances in endoscopic techniques and imaging modalities such as endoscopic ultrasound (EUS), CT, and 18-fluorodeoxyglucose (FDG)-PET/CT have greatly improved the accuracy of clinical staging.<sup>48</sup> In general, initial staging of locoregional



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

disease is usually best done with a combination of CT and EUS, while staging of possible distant metastatic disease is best assessed with FDG-PET/CT.<sup>49</sup> Locoregional staging with preoperative EUS provides the most accuracy for cT staging and is the only method capable of delineating the layers of the esophageal wall.<sup>50</sup> In a meta-analysis of 49 studies, EUS provided good sensitivity and specificity for accurately cT staging advanced-stage disease.<sup>51</sup> However, EUS has shown poor accuracy for distinguishing between early-stage tumors limited to the mucosa (cT1a) from those extending into the submucosa (cT1b).<sup>51-54</sup> Therefore, endoscopic resection (ER), which is essential for the accurate staging of early-stage cancers, should be performed for early-stage tumors (cT1a and cT1b  $\leq$  2 cm) as it provides more accurate information on the depth of tumor invasion than EUS.<sup>55,56</sup> Ultimately, a cancer that is completely removed by ER should be assigned pathologic staging.<sup>10</sup>

CT of the chest and abdomen with oral and IV contrast or FDG-PET/CT from skull base to mid-thigh can be used to determine the location of the primary tumor and its proximity to other structures. Although FDG-PET/CT has higher sensitivity for detecting esophageal cancer than CT alone, it has a limited role in cT staging other than for determining invasion of the mediastinum.<sup>57</sup> The diagnostic benefit of FDG-PET/CT is particularly limited in early-stage (cT1) tumors because of the low prevalence of distant metastases and the high rate of false-positive FDG-PET/CT findings.<sup>58,59</sup> FDG-PET/CT also has limited ability to differentiate between cT1, cT2, and cT3 tumors.<sup>10,49</sup> Although the intensity of FDG uptake and cT category are positively related, this association is weak.<sup>58,60,61</sup> Therefore, chest/abdominal CT scan should be performed with oral and IV contrast in all patients as part of the initial workup (as well as pelvic CT scan with contrast if clinically indicated) while FDG-PET/CT should be reserved for patients with no evidence of M1 disease.

While CT and FDG-PET/CT may be used to describe the locoregional lymph nodes (cN), these techniques are suboptimal for detecting

locoregional nodal metastasis because of their low sensitivity.<sup>50,60,62-65</sup> CT has a pooled sensitivity of 30% to 60% for detecting enlarged nodes greater than 1 cm.<sup>48</sup> FDG-PET/CT also has a low pooled sensitivity (~51%) in locoregional nodal assessment since these nodes are often obscured by the metabolic activity in the primary tumor.<sup>66</sup> In contrast, EUS has high sensitivity (~85%) for assessing the degree of nodal involvement.<sup>51</sup> Furthermore, the addition of fine-needle aspiration (FNA) to EUS (EUS-FNA) has shown greater sensitivity and accuracy than either EUS alone or CT scan in the evaluation of cN staging, especially in assessing locoregional and celiac lymph nodes.<sup>51,67-69</sup> In a study that compared the performance characteristics of EUS and EUS-FNA for preoperative cN staging in 74 patients with esophageal cancer, EUS-FNA was more sensitive (93% vs. 63%;  $P = .01$ ) and accurate (93% vs. 70%;  $P = .02$ ) when compared to EUS alone.<sup>68</sup> In another study that compared the performance characteristics of CT, EUS, and EUS-FNA for preoperative cN staging in 125 patients with esophageal cancer, EUS-FNA was more sensitive than CT (83% vs. 29%;  $P < .001$ ) and more accurate than CT (87% vs. 51%;  $P < .001$ ) or EUS alone (87% vs. 74%;  $P = .012$ ).<sup>69</sup> Additionally, a retrospective review of 148 patients with esophageal cancer who underwent nodal staging with EUS-FNA and FDG-PET found that the addition of FDG-PET did not alter nodal staging in any patient with complete EUS-FNA, suggesting a limited role for FDG-PET alone in detecting locoregional metastatic nodes.<sup>70</sup>

While contrast-enhanced CT is the most widely used modality for detecting distant metastases in esophageal cancer, FDG-PET/CT is more sensitive than CT alone for staging cM disease.<sup>10,49,60,62,71</sup> The addition of FDG-PET improves the detection of distant metastases that may remain occult on CT scan of the chest and abdomen, thereby allowing proper patient selection for surgical resection.<sup>10,49</sup> In a prospective multicenter trial of 129 patients with esophageal cancer without definite distant metastases, PET identified metastatic sites in



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

41% of cases and altered management in 38% of cases.<sup>72</sup> However, potential pitfalls of FDG-PET/CT include the poor detection of hepatic metastases when the CT component is performed without IV contrast and the high rate of false-positive FDG-PET findings.<sup>58,59,64,65</sup>

In North America, where screening programs for early detection of esophageal and EGJ cancers are not in use or practical because of low incidence, diagnosis is often made late in the disease course. At diagnosis, nearly 50% of patients have cancer that extends beyond the locoregional confines of the primary tumor. Fewer than 60% of patients with locoregional cancers can undergo a curative resection. Approximately 70% to 80% of resected specimens harbor metastases in the regional lymph nodes. Thus, patients in North America often have advanced-stage disease at the time of initial diagnosis, which is reflected by the low survival rates seen with esophageal and EGJ cancers in this region.

### Siewert Classification of EGJ Adenocarcinoma

In 1996, Siewert et al classified EGJ adenocarcinoma into three types based purely on the anatomic location of the epicenter of the tumor or the majority of the tumor mass.<sup>73</sup> In 2000, this classification was slightly changed.<sup>74</sup> Siewert Type I tumors are now defined as an adenocarcinoma of the lower esophagus with the tumor epicenter located within 1 to 5 cm above the anatomic EGJ. Siewert Type II tumors are defined as a true carcinoma of the cardia with the tumor epicenter located within 1 cm above and 2 cm below the EGJ. Siewert Type III tumors are defined as a subcardial carcinoma with the tumor epicenter located between 2 to 5 cm below the EGJ, which infiltrates the EGJ and the lower esophagus from below.

In the Eighth Edition of the AJCC Cancer Staging Manual, EGJ tumors with epicenters located within 2 cm of the proximal stomach (Siewert Types I and II) are staged as esophageal adenocarcinoma.<sup>10</sup> EGJ tumors

with epicenters located greater than 2 cm into the stomach (Siewert Type III) are now staged using the gastric cancer staging system. In general, Siewert Types I and II tumors should be managed in accordance with the NCCN Guidelines for Esophageal and Esophagogastric Cancers, while Siewert Type III tumors are more appropriately managed in accordance with the [NCCN Guidelines for Gastric Cancer](#). Therapeutic decisions may be refined according to the location of the individual tumor, nodal distribution, and specific requirements for local control. However, the management approach for Siewert Type III tumors remains a subject of disagreement and debate. An individualized therapeutic approach may be preferred for specific patients and tumor locations, based on thorough pretreatment staging.

### Barrett Esophagus

Barrett esophagus is a condition in which the normal squamous epithelium of the esophagus is replaced by a metaplastic, columnar, or glandular epithelium that is predisposed to the development of dysplasia.<sup>21</sup> Barrett esophagus can progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and in some cases to adenocarcinoma of the esophagus.<sup>19</sup> In a large case-controlled study, severe and frequent GERD symptoms, nocturnal GERD symptoms, and a family history of GERD were the factors most strongly associated with an increased risk of developing Barrett esophagus in the general population.<sup>75</sup> A recent systematic review and meta-analysis also identified obesity, family history of Barrett esophagus, and male gender assigned at birth as risk factors for the development of Barrett esophagus.<sup>76</sup> Patients with Barrett esophagus are at a greater risk of developing adenocarcinoma of the esophagus than the general population. Older age, male gender assigned at birth, long-standing GERD, hiatal hernia size, and the length of Barrett esophagus are strongly associated with the progression of Barrett esophagus to



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

adenocarcinoma.<sup>20,22-24,77-79</sup> Additionally, biomarkers such as aneuploidy and loss of heterozygosity of *p53* have also been associated with an increased risk of progression of Barrett esophagus to HGD and/or adenocarcinoma.<sup>77</sup> However, these biomarkers require further prospective evaluation as predictors of risk for the development of HGD and adenocarcinoma of the esophagus in patients with Barrett esophagus.

### Diagnosis

Endoscopy should be performed on patients with severe symptoms of GERD, especially those with a family history of Barrett esophagus or esophageal cancer. Multiple biopsies (6–8) using larger size endoscopy forceps should be performed to provide sufficient material for histologic and molecular interpretation.<sup>80</sup> The location, length, and circumferential extent of Barrett esophagus should be characterized in accordance with the Prague classification and mucosal nodules should be carefully documented.<sup>81</sup> For patients with metaplasia or LGD, GERD can be controlled with histamine receptor antagonists or proton pump inhibitors (PPIs). The use of wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D), a relatively new sampling technique combining an abrasive brush biopsy of the Barrett esophagus mucosa with computer-assisted pathology analysis to highlight abnormal cells, may help increase the detection of esophageal dysplasia in patients with Barrett esophagus. In a multicenter prospective trial, patients with Barrett esophagus (n = 160) were randomized to receive biopsy sampling in conjunction with WATS or biopsy sampling alone. Results showed that the addition of WATS to biopsy sampling was feasible and yielded an additional 23 cases of HGD/esophageal adenocarcinoma (absolute increase, 14.4%).<sup>82</sup> Two other studies have reported similar results.<sup>83,84</sup> However, the utility and accuracy of WATS for detecting HGD/adenocarcinoma in patients with Barrett esophagus needs to be evaluated in larger phase III randomized trials.

### Treatment

ER, either by endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), followed by radiofrequency ablation (RFA) has become the standard treatment for most patients with Barrett esophagus and HGD. Alternative strategies include cryoablation or photodynamic therapy (PDT).<sup>85-87</sup> Surgical resection is reserved for patients with HGD and characteristics that are unfavorable for non-surgical therapy, such as nodularity or long-segment involvement. Initial concerns regarding the use of ESD for Barrett esophagus involved the perceived increased risk of complications, including stricture formation, associated with deep submucosal dissection. However, a recent retrospective analysis found no increase in complication rates with the use of ESD compared to EMR followed by RFA.<sup>88</sup> Additionally, a meta-analysis by Yang et al found that ESD for the management of early Barrett esophagus was associated with a high en-bloc resection rate, acceptable safety profile, and low recurrence rate after curative resection. These data suggest that ESD is safe and highly effective for the management of Barrett esophagus neoplasia.<sup>89</sup>

Based on randomized trials, RFA alone may also be useful for patients with Barrett esophagus with confirmed LGD or HGD.<sup>90-93</sup> In a multicenter randomized clinical trial that enrolled 136 patients with Barrett esophagus and LGD, RFA was found to be safe and effectively eradicated LGD and reduced the rate of progression from LGD to HGD and adenocarcinoma over 3 years of follow-up.<sup>92</sup> A study reporting the long-term outcome of this trial confirmed that RFA of Barrett esophagus with LGD significantly reduced the risk of malignant progression after a median follow-up of 73 months.<sup>94</sup> In a multicenter randomized trial involving patients with HGD, complete eradication occurred in 81% of those in the RFA group compared to 19% of those in the control group ( $P < .001$ ).<sup>90</sup>



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### Surveillance

Some studies suggest that the rate of progression of Barrett esophagus to adenocarcinoma of the esophagus is much lower than previously reported.<sup>95,96</sup> However, recent data have demonstrated an increased prevalence of HGD and adenocarcinoma on index endoscopy in patients with Barrett esophagus over the past 25 years.<sup>97</sup> Endoscopic surveillance with multiple biopsies (6–8) should be performed to evaluate the progression of Barrett esophagus from metaplasia to LGD, HGD, or adenocarcinoma. Larger forceps are recommended during surveillance endoscopy of Barrett esophagus for the detection of dysplasia.<sup>80</sup>

The current clinical guidelines from the American College of Gastroenterology recommend endoscopic surveillance in patients with Barrett esophagus at intervals determined by the presence and grade of dysplasia.<sup>91</sup> Given the low risk of progression of Barrett esophagus to esophageal adenocarcinoma, endoscopic surveillance at 3- to 5-year intervals is reasonable for patients without dysplasia. The presence of dysplasia of any grade should be confirmed by a second pathologist with expertise in GI pathology. Patients with confirmed LGD should receive endoscopic therapy. If endoscopic therapy is not performed, annual surveillance is recommended until two consecutive examinations are negative for dysplasia, after which time surveillance intervals for non-dysplastic Barrett esophagus can be followed (every 3–5 years). If HGD is confirmed, patients should be managed with endoscopic therapy unless they have life-limiting comorbidity. Typically, endoscopic surveillance should use four-quadrant biopsies at 2-cm intervals in patients without dysplasia and 1-cm intervals in patients with prior dysplasia. For patients with results indefinite for dysplasia, endoscopy should be repeated after treatment for 3 to 6 months with acid-suppressive medications. If the “indefinite for dysplasia” reading is confirmed on this examination, a surveillance interval of 12 months is recommended. A retrospective study found that Barrett esophagus

indefinite for dysplasia was associated with a similar risk of progression to adenocarcinoma as Barrett esophagus with LGD.<sup>98</sup> A recent systematic review and meta-analysis reached the same conclusion.<sup>99</sup> Therefore, surveillance for these patients should follow the recommendations for LGD.

### Pathologic Review and Biomarker Testing

Pathologic review and biomarker testing play important roles in the diagnosis, classification, and molecular characterization of esophageal and EGJ cancers. Classification based on histologic subtype and molecular features helps to improve early diagnosis and has implications for therapy. An accumulation of genetic aberrations occurs during esophageal carcinogenesis, including overexpression of growth factors and/or receptors, alterations in DNA damage response, and loss of genomic stability. Characterization of these pathways has enabled the application of molecular pathology to aid in the management of esophageal and EGJ cancers.

### Principles of Pathologic Review

A specific diagnosis of esophageal SCC or adenocarcinoma should be established for staging and treatment purposes. Mixed adenosquamous carcinomas and carcinomas not otherwise specified are staged using the TNM staging system for SCC.<sup>10</sup> In addition to the histologic type, the pathology report (regardless of the specimen type) should include specifics about tumor invasion and pathologic grade, which are required for staging. The pathology report of a biopsy or endoscopic mucosal resection specimen should also document the presence or absence of Barrett esophagus. Biopsies showing Barrett esophagus with suspected dysplasia should be reviewed by a second expert GI pathologist for confirmation.<sup>91</sup> Barrett esophagus with HGD is reported as intraepithelial neoplasia (dysplasia) (Tis) for staging purposes.<sup>10</sup>



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

In the case of ER specimens, the depth of tumor invasion, presence of lymphovascular invasion (LVI), and status of mucosal and deep margins should also be reported. The pathology report for esophagectomy specimens without prior chemoradiation should include all elements as for ER specimens plus the location of the tumor midpoint in relation to the EGJ, whether the tumor crosses the EGJ, the lymph node status, and the number of lymph nodes recovered. In the case of esophagectomy with prior chemoradiation and without grossly obvious residual tumor, the tumor site should be thoroughly sampled, with submission of the entire EGJ or ulcer/tumor bed for specimens. The pathology report should include all elements as for esophagectomy without prior chemoradiation, plus assessment of the treatment response.

### Assessment of Treatment Response

Response of the primary tumor to previous chemotherapy and/or radiation therapy (RT) should be reported. The prognostic significance of pathologic complete response (pCR) after induction therapy in patients with esophageal cancer has been demonstrated in several studies.<sup>100-106</sup>

Residual primary tumor in the resection specimen following preoperative therapy is associated with shorter overall survival (OS) for both SCC and adenocarcinoma of the esophagus.<sup>101,103,107,108</sup> In a retrospective study of 235 patients, post-treatment pathologic stage was the best predictor of survival outcome for patients with locoregional carcinoma of the esophagus or EGJ who underwent preoperative chemoradiation followed by esophagectomy.<sup>107</sup>

Although scoring systems for tumor response in esophageal cancer have not been uniformly adopted, the panel recommends using the modified Ryan scheme in the College of American Pathologists (CAP) Cancer Protocol for Esophageal Carcinoma because it generally provides good reproducibility among pathologists.<sup>109,110</sup> The following scheme is suggested: 0 (complete response; no viable cancer cells, including lymph

nodes); 1 (near complete response; single cells or rare small groups of cancer cells); 2 (partial response; residual cancer cells with evident tumor regression, but more than single cells or rare small groups of cancer cells); and 3 (poor or no response; extensive residual cancer with no evident tumor regression). Because of the impact of residual nodal metastases on survival, it is recommended that lymph nodes be included in the regression score.<sup>111</sup> Sizable pools of acellular mucin may be present after chemoradiation, but they should not be interpreted as representing residual tumor.

### Role of FDG-PET Scans in the Assessment of Treatment Response

The prognostic significance of metabolic response after preoperative therapy, as measured by a decrease in 18-FDG standardized uptake value (SUV) on post-treatment PET scan, has been evaluated in many studies in patients with locally advanced esophageal or EGJ cancer.<sup>112-137</sup> In many retrospective studies, a decrease in FDG SUV on post-treatment PET scan was a predictive factor that correlated with pathologic response and improved survival.<sup>112-123</sup> However, the cut-off values for the reduction in FDG SUV between pre- and post-treatment scans and the percent change in FDG SUV between pre- and post-treatment scans used to distinguish metabolic responders from non-responders varied widely between studies. In a study by Cerfolio et al, the median SUV of esophageal cancer decreased by 72% in patients who were complete pathologic responders, by 58% in patients who were partial responders, and by 37% in patients who had a minimal pathologic response.<sup>116</sup> In this study, patients were likely to be complete pathologic responders when the SUV decreased by more than 64% ( $P = .003$ ) between pre- and post-treatment FDG-PET scans. In a similar study, Smith et al reported that patients who had a decrease in SUV greater than 50% had a 12-month disease-free survival (DFS) advantage over patients who had a decrease in SUV less than 50% (93% vs. 43%;  $P = .025$ ).<sup>117</sup> Regardless of the cut-off values used, these studies all

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

concluded that FDG-PET is predictive of pathologic response and survival in patients with esophageal cancer who undergo preoperative treatment.

The prognostic significance of FDG-PET has also been evaluated in prospective studies.<sup>124-129</sup> However, many of these prospective studies are limited by their small sample size, with the exception of the MUNICON II trial, which included 110 patients with locally advanced adenocarcinoma of the EGJ.<sup>125</sup> In this study, metabolic responders were defined as those with a decrease of greater than or equal to 35% in SUV following preoperative therapy. After a median follow-up of 2.3 years, median OS was not reached in metabolic responders, whereas the median OS was 25.8 months in non-responders ( $P = .015$ ). Median event-free survival (EFS) was 29.7 months and 14 months, respectively, for metabolic responders and non-responders ( $P = .002$ ). Major histologic remissions (<10% of residual cancer) were noted in 58% of metabolic responders but in 0% of non-responders. This study prospectively demonstrated that metabolic response as measured by FDG-PET is predictive of pathologic response and survival in patients with gastroesophageal carcinoma following preoperative therapy. Additional studies have reported similar outcomes.<sup>138-140</sup>

Although adding induction chemotherapy to chemoradiation and surgery has not been shown to improve survival over chemoradiation and surgery alone, response on FDG-PET scan to induction chemotherapy was shown in the MUNICON-1 trial to be a biomarker of benefit from chemotherapy.<sup>125</sup> FDG-PET non-responders in this trial had chemotherapy terminated and were referred for earlier surgery as they do not clearly benefit from therapy continuation. MUNICON-2 indicated that FDG-PET non-responders to induction chemotherapy did not benefit from the subsequent addition of RT to chemotherapy prior to surgery.<sup>141</sup> The CALGB 80803 trial used FDG-PET scan response to induction chemotherapy to direct either continuation of the same chemotherapy

regimen during chemoradiation (infusional fluorouracil/oxaliplatin or carboplatin/paclitaxel) in FDG-PET responders, or to cross over to an alternative regimen during chemoradiation in FDG-PET non-responders.<sup>142,143</sup> The primary endpoint, to enhance pCR rate at surgery in FDG-PET non-responders who changed chemotherapy during radiation, was met, indicating the potential for FDG-PET scan to direct selection of chemotherapy during chemoradiation after induction chemotherapy. The most promising results of this trial were in patients who were FDG-PET responders receiving mFOLFOX followed by infusional fluorouracil/oxaliplatin/radiation and surgery, providing additional support for the use of fluorouracil/oxaliplatin combined with RT as preoperative treatment. This strategy needs to be further developed before adoption into clinical practice.

In contrast, other studies have reported that FDG-PET has a limited utility for assessing response to preoperative therapy in patients with esophageal cancer, except for the detection of distant metastases.<sup>130-137,144,145</sup> However, FDG-PET was performed either during preoperative therapy or soon after the completion of preoperative therapy in many of these studies, which may reflect an inflammatory effect of radiation that obscures tumor-specific metabolic changes.<sup>135,146</sup> RT and chemoradiation often cause local inflammatory reactions in the esophagus. Uptake of FDG in these inflammatory lesions occurs commonly, resulting in false-positive results on PET scan. Therefore, increased FDG uptake due to radiation-induced inflammation limits the use of FDG-PET for early response assessment of esophageal carcinomas.<sup>146</sup> To reduce the incidence of false-positive results due to inflammation, the guidelines recommend that FDG-PET/CT (preferred) or FDG-PET should be performed at least 5 to 8 weeks after the completion of preoperative therapy. However, the guidelines caution that post-treatment FDG-PET results should not be used to select patients for

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

surgery since FDG-PET cannot distinguish microscopic residual disease.<sup>112,114,132</sup>

### Principles of Biomarker Testing

Presently, immunohistochemistry (IHC) and/or molecular testing for human epidermal growth factor receptor 2 (HER2)/*ERBB2* status, microsatellite instability (MSI) or mismatch repair (MMR) status, programmed death ligand 1 (PD-L1) expression, tumor mutational burden-high (TMB-H) status, neurotrophic tropomyosin-related kinase (*NTRK*) gene fusions, rearranged during transfection (*RET*) gene fusions and *BRAF* V600E mutations are utilized in the clinical management of advanced esophageal and EGJ cancers. When limited tissue is available for testing or the patient is unable to undergo a traditional biopsy, comprehensive genomic profiling via a validated next-generation sequencing (NGS) assay performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved environment may be used for the identification of *ERBB2* amplification, MSI status, MMR deficiency, TMB, *NTRK* gene fusions, *RET* gene fusions and *BRAF* V600E mutations. The use of IHC, in situ hybridization (ISH), or targeted polymerase chain reaction (PCR) should be considered first, followed by NGS testing as appropriate. The biomarker panel is expected to enlarge as more subgroups are identified.

### Assessment of HER2 Overexpression

Overexpression of the HER2 protein or amplification of the *ERBB2* gene has been implicated in the development of esophageal and EGJ cancers.<sup>147</sup> However, unlike in breast cancer, the prognostic significance of HER2 status in esophageal and EGJ cancer is unclear. Some studies have reported that HER2 positivity is correlated with tumor invasion and lymph node metastasis, and thus indicates a poor prognosis.<sup>148,149</sup> HER2 positivity also seems to be associated with poorer survival in patients with SCC of the esophagus.<sup>150</sup> While further studies are needed to assess the

prognostic significance of HER2 status in esophageal cancer, the addition of HER2 monoclonal antibodies to chemotherapy regimens is a promising treatment option for patients with HER2 overexpression positive disease.

The reported rates of HER2 positivity in esophageal and EGJ cancers vary widely (2%–45%)<sup>148</sup> and are more frequently seen in adenocarcinoma of the esophagus (15%–30%) than in SCC (5%–13%).<sup>150-153</sup> Additionally, HER2 positivity has been reported to be higher in patients with EGJ adenocarcinomas than in patients with gastric adenocarcinomas.<sup>154-156</sup> The HER-EAGLE study, which examined the HER2 positivity rate in a large multinational population of nearly 5000 patients with gastric or EGJ adenocarcinoma, reported that 14.2% of samples were HER2 overexpression positive.<sup>157</sup> HER2 positivity was significantly higher in EGJ tumors versus stomach tumors and in intestinal subtypes versus diffuse subtypes. In the ToGA trial, HER2-positivity rates were 33% and 21%, respectively, for patients with EGJ and gastric cancers.<sup>158</sup> Therefore, classification of gastroesophageal cancers based on histologic subtype and primary tumor location may have implications for therapy.

HER2 testing is recommended for patients with esophageal or EGJ adenocarcinoma at the time of diagnosis if metastatic adenocarcinoma is documented or suspected. In concordance with HER2 testing guidelines from CAP, the American Society for Clinical Pathology (ASCP), and the American Society for Clinical Oncology (ASCO),<sup>159</sup> the NCCN Guidelines recommend using IHC and, if needed, ISH techniques to assess HER2 status in esophageal and EGJ cancers. NGS can be considered instead of sequential testing for single biomarkers when limited diagnostic tissue is available or when the patient is unable to undergo a traditional biopsy. The use of IHC/ISH should be considered first, followed by NGS testing as appropriate. Repeat biomarker testing may be considered at clinical or radiologic progression of metastatic adenocarcinoma.

IHC evaluates the membranous immunostaining of tumor cells, including the intensity and extent of staining and the percentage of



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

immunoreactive tumor cells, with scores ranging from 0 (negative) to 3+ (positive). In 2008, Hofmann et al refined this 4-tiered scoring system to assess HER2 status in gastric cancer by using a cut-off of greater than or equal to 10% immunoreactive tumor cells in resection specimens.<sup>156,160</sup> It should be noted that when scoring a biopsy specimen, a cluster with 5% immunoreactive tumor cells is sufficient for scoring. In a subsequent validation study (n = 447, prospective diagnostic gastric cancer specimens), this scoring system was found to be reproducible between different pathologists.<sup>161</sup> This modified HER2 scoring system is therefore recommended by the panel. A score of 0 (membranous reactivity in <10% of cancer cells) or 1+ (faint membranous reactivity in ≥10% of cancer cells) is considered to be HER2-negative. A score of 2+ (weak to moderate membranous reactivity in ≥10% of cancer cells) is considered equivocal and should be additionally examined by fluorescence in situ hybridization (FISH) or other ISH methods. FISH/ISH results are expressed as the ratio between the number of copies of the *ERBB2* gene and the number of chromosome 17 centromeres (CEP17) within the nucleus counted in at least 20 cancer cells (*ERBB2*:CEP17). Alternatively, FISH/ISH results may be given as the average *ERBB2* copy number per cell. Cases that have an IHC score of 3+ (strong membranous reactivity in ≥10% of cancer cells) or an IHC score of 2+ and are FISH/ISH positive (*ERBB2*:CEP17 ratio ≥2 or average *ERBB2* copy number ≥6 signals/cell) are considered HER2 positive. Positive (3+) or negative (0 or 1+) HER2 IHC results do not require further ISH testing. See *Principles of Pathologic Review and Biomarker Testing: Assessment of Overexpression or Amplification of HER2 in Esophageal and Esophagogastric Junction Cancers - Table 3* in the algorithm for more information.

### **MSI and MMR Testing**

Testing for MSI by PCR/NGS or MMR by IHC should be considered on locally advanced, recurrent, or metastatic esophageal and EGJ cancers in patients who are candidates for treatment with programmed cell death protein 1 (PD-1) inhibitors.<sup>162</sup> MSI status is assessed by PCR or NGS to measure gene expression levels of microsatellite markers (ie, *BAT25*, *BAT26*, *MONO27*, *NR21*, *NR24*).<sup>163</sup> MMR deficiency is evaluated by IHC to assess nuclear expression of proteins involved in DNA mismatch repair (ie, MLH1, MSH2, MSH6, PMS2).<sup>164</sup> PCR/NGS for MSI and IHC for MMR proteins measure different biological effects caused by deficient MMR function. Testing is performed on formalin-fixed, paraffin-embedded (FFPE) tissue and results are interpreted in accordance with [CAP DNA Mismatch Repair Biomarker Reporting Guidelines](#).<sup>165</sup> Testing may be performed only in CLIA-approved laboratories. Patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors should be referred to a genetics counselor for further assessment in the appropriate clinical context.

### **PD-L1 Testing**

PD-L1 testing may be considered on locally advanced, recurrent, or metastatic esophageal and EGJ cancers in patients who are candidates for treatment with PD-1 inhibitors. A companion diagnostic test should be used to identify patients for treatment with PD-1 inhibitors. The companion diagnostic test is a qualitative IHC assay using anti-PD-L1 antibodies for the detection of PD-L1 protein levels in FFPE tumor tissue. A minimum of 100 tumor cells must be present in the PD-L1-stained slide for the specimen to be adequately evaluated. Combined positive score (CPS) is determined by the number of PD-L1–stained cells (ie, tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells evaluated, multiplied by 100. A specimen is considered to have PD-L1 expression if the CPS is greater than or equal to 1. PD-L1 testing



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

should be performed only in CLIA-approved laboratories. Determination of the PD-L1 tumor proportion score (TPS) is also considered an option.

### Liquid Biopsy

The genomic alterations of solid cancers may be identified by evaluating circulating tumor DNA (ctDNA) in the blood, hence a form of liquid biopsy.<sup>149,166</sup> Liquid biopsy is being used in patients who are unable to have a clinical biopsy for disease surveillance and management. The detection of mutations/alterations in DNA shed from esophageal and EGJ carcinomas can identify targetable alterations or the evolution of clones with altered treatment response profiles. In a study that analyzed the genomic alterations of 55 patients with advanced gastroesophageal adenocarcinomas using NGS performed on plasma-derived ctDNA, 69% of patients had one or more characterized alterations theoretically targetable by an FDA-approved agent (on- or off-label).<sup>149</sup> Therefore, for patients who have advanced or metastatic esophageal/EGJ cancers and who may be unable to undergo a traditional biopsy or for disease progression monitoring, testing using a validated NGS-based comprehensive genomic profiling assay performed in a CLIA-approved laboratory may be considered. A negative result should be interpreted with caution, as this does not exclude the presence of tumor mutations or amplifications.

### Surgery

Surgery is a major component of treatment for locoregional esophageal and EGJ cancers. Improvements in staging techniques, patient selection, post-surgical care, and surgical experience have led to a marked reduction in surgical morbidity and mortality in recent years. Additionally, randomized trials have shown that preoperative chemoradiation<sup>167</sup> and perioperative chemotherapy<sup>168</sup> have significantly improved survival in

patients with resectable, locoregionally advanced esophageal and EGJ cancers.

### Principles of Surgery

All patients should be evaluated to determine whether they are medically fit enough to tolerate general anesthesia and major abdominal and/or thoracic surgery.<sup>169</sup> Prior to surgery, clinical staging should be performed to assess resectability with CT scan of the chest and abdomen, whole-body FDG-PET (integrated FDG-PET/CT scan is preferred), and EUS.<sup>49</sup> Esophagectomy should be considered for all patients with resectable esophageal cancer (>5 cm from cricopharyngeus) who are medically fit. Cervical or cervicothoracic esophageal cancers less than 5 cm from the cricopharyngeus should be treated with definitive chemoradiation. Enteral nutritional support should be considered for patients with significant dysphagia and/or weight loss prior to or during induction therapy. A jejunostomy feeding tube is preferred over a gastrostomy feeding tube for preoperative nutritional support since placement of a gastrostomy tube may compromise the integrity of gastric conduit for reconstruction. In certain patients, careful Savary dilation may be adequate.

The Siewert tumor type should be assessed in all patients with adenocarcinomas involving the EGJ. The surgical approaches for Siewert Type I and II tumors are similar to those described above. Siewert Type III tumors are considered gastric cancers and the surgical approach for these tumors is described in the [NCCN Guidelines for Gastric Cancer](#).<sup>73,170,171</sup> In some cases, additional esophageal resection may be necessary to obtain adequate surgical margins. Laparoscopy may be useful in select patients for the detection of radiographically occult metastatic disease, especially in patients with Siewert Type II and III tumors.<sup>172</sup> Positive peritoneal cytology in the absence of visible peritoneal metastases is associated with poor prognosis in patients with EGJ adenocarcinoma.<sup>173</sup> Patients with advanced



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

tumors or node-positive tumors should be considered for laparoscopic staging with peritoneal washings.

Lymph node dissection (lymphadenectomy) can be performed using the standard or extended (en-bloc) technique. The number of lymph nodes removed has been shown to be an independent predictor of survival after esophagectomy.<sup>174,175</sup> In a retrospective analysis of 4882 patients in the SEER database, patients diagnosed with invasive esophageal cancer who had 12 or more lymph nodes examined had significantly reduced mortality compared to those who had 0 to 11 lymph nodes examined; patients who had 30 or more lymph nodes examined had the lowest mortality of any group.<sup>176</sup> A report from the WECC database, which analyzed 4627 patients who had esophagectomy without preoperative therapy, suggested that a greater extent of lymphadenectomy was associated with increased survival for all patients with node-positive cancers.<sup>175</sup> Based on this study, optimum lymphadenectomy in node-positive cancers was 10 nodes for pT1, 15 nodes for pT2, and 29 to 50 nodes for pT3/T4. Therefore, the NCCN Guidelines® for Esophageal and Esophagogastric Junction Cancers recommend that a thorough dissection be performed to identify all lymph nodes with at least 15 lymph nodes submitted for pathologic evaluation and adequate nodal staging in patients undergoing esophagectomy without preoperative chemoradiation. The optimum number of nodes to be removed and examined after preoperative chemoradiation is unknown, although a recent study by Guo et al showed that resection of 13 to 29 nodes was associated with improved progression-free survival (PFS) and OS in patients with locally advanced esophageal SCC receiving preoperative chemoradiation.<sup>177</sup> However, it is important to note that extensive lymphadenectomy (>29 nodes) did not seem to be correlated with increased survival in these patients.<sup>177,178</sup> A recently published meta-analysis demonstrated a survival benefit for an increased lymph node yield from esophagectomy regardless of whether or not patients had received preoperative therapy.<sup>179</sup> Therefore, the NCCN

Guidelines for Esophageal and Esophagogastric Junction Cancers also recommended resection of at least 15 lymph nodes for patients with esophageal cancer who received preoperative therapy.

Patients with Tis or T1a tumors may be treated with endoscopic therapies (see below). Patients with positive deep margins after ER or with tumors invading into the submucosa (T1b) or deeper may be treated with esophagectomy. Patients with T1–T3 tumors are considered to be potentially resectable, even in the presence of regional nodal metastases, although patients with bulky tumors and/or multi-station nodal involvement have poor OS. T4a tumors with involvement of the pericardium, pleura, or diaphragm may be resectable; however, T4a tumors with distant metastases including non-regional lymph node involvement, EGJ tumors with supraclavicular lymph node involvement, and T4b tumors with involvement of the heart, great vessels, trachea, or adjacent organs including liver, pancreas, lung, and spleen are considered unresectable.

Surgery is usually performed with curative intent but may be included as a component of palliative care for dysphagia or fistula. Palliative resections, however, should be avoided when possible in patients with clearly unresectable or advanced cancer with comorbidities, including severe cardiac or pulmonary disease. These patients may benefit from noninvasive palliative interventions. Palliative esophagectomy can also be considered for patients with cervical esophageal cancer who develop localized resectable recurrence or untreatable stricture after definitive chemoradiation if there is no distant recurrence.<sup>180</sup>

### Surgical Approaches

The type of esophageal resection is dictated by the tumor location as well as the available choices for conduit. Several operative techniques are acceptable for esophagectomy in patients with resectable esophageal or EGJ cancers.<sup>181</sup> The two most common surgical approaches are Ivor Lewis and McKeown transthoracic esophagectomy. Transhiatal



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

esophagectomy and left transthoracic or thoracoabdominal esophagectomy are other recommended techniques; however, transhiatal esophagectomy should not be used as a routine approach. These techniques are described in detail below. The panel emphasizes that esophagectomy should always be performed in high-volume centers by experienced surgeons.<sup>182</sup>

### ***Ivor Lewis and McKeown Transthoracic Esophagectomy***

Ivor Lewis transthoracic esophagectomy (right thoracotomy and laparotomy)<sup>183</sup> and McKeown transthoracic esophagectomy (right thoracotomy followed by laparotomy and cervical anastomosis)<sup>184</sup> are the two most commonly used surgical techniques. Ivor Lewis esophagectomy, the most frequently used procedure for transthoracic esophagectomy, uses laparotomy and right thoracotomy, with upper thoracic esophagogastric anastomosis at or above the azygos vein.<sup>183</sup> Mobilization of the stomach for use as the conduit is performed, with dissection of the celiac and left gastric lymph nodes, division of the left gastric artery, and preservation of the gastroepiploic and right gastric arteries. This approach may be used for distal thoracic lesions, but the proximal esophageal margin will be inadequate for tumors in the middle esophagus. McKeown esophagectomy, with an anastomosis in the cervical region, is similar in conduct, but with the advantage of being applicable for tumors in the upper, middle, and lower thoracic esophagus.

### ***Transhiatal Esophagectomy***

Transhiatal esophagectomy (laparotomy and cervical anastomosis) is performed using abdominal and left cervical incisions.<sup>185</sup> The mobilization of the stomach for use as the conduit is performed as in the Ivor Lewis esophagectomy. This procedure is completed through the abdominal incision, and the gastric conduit is drawn through the posterior mediastinum and exteriorized in the cervical incision for the

esophagogastric anastomosis. This approach may be used for lesions at any thoracic location; however, transhiatal dissection of large, middle esophageal tumors adjacent to the trachea is difficult and may be hazardous. In a prospective trial involving 220 patients with adenocarcinoma of the mid-to-distal esophagus or gastric cardia, transhiatal esophagectomy was associated with lower post-surgical morbidity than transthoracic esophagectomy with extended en-bloc lymphadenectomy.<sup>186</sup> In a large population-based study that assessed outcomes after transthoracic and transhiatal esophagectomy, transhiatal esophagectomy offered an early survival advantage. However, long-term survival was similar for the two surgical approaches.<sup>187</sup> Although long-term survival differences have not been demonstrated, many experts believe that the lower lymph node retrieval associated with transhiatal esophagectomy represents a less effective oncologic approach. Therefore, transhiatal esophagectomy should not be used as a routine approach.

### ***Left Transthoracic or Thoracoabdominal Esophagectomy***

Left transthoracic or thoracoabdominal esophagectomy uses a contiguous abdominal and left thoracic incision through the eighth intercostal space.<sup>188</sup> Mobilization of the stomach for use as the conduit is performed as previously described, and esophagectomy is accomplished through the left thoracotomy. Esophagogastric anastomosis is performed in the left chest, usually just superior to the inferior pulmonary vein, although it may be performed higher if the conduit is tunneled under the aortic arch. This approach may be used for lesions in the distal esophagus, particularly bulky tumors.<sup>188</sup>

### ***Minimally Invasive Esophagectomy***

Minimally invasive esophagectomy (MIE) strategies include minimally invasive Ivor Lewis esophagectomy (laparoscopy and limited right



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

thoracotomy) and minimally invasive McKeown esophagectomy (right thoracoscopy, limited laparotomy/laparoscopy, and cervical anastomosis). MIE strategies may be associated with decreased postoperative mortality, shorter recovery times, and increased long-term survival. In a phase II multicenter prospective study involving 104 patients with HGD or esophageal cancer of the mid-to-distal esophagus, the Ivor Lewis MIE strategy was shown to be safe and feasible, as demonstrated by low perioperative mortality (2.1%) and good oncologic results.<sup>189</sup> Another study of MIE (mainly using thoracoscopic mobilization) involving 222 patients reported a mortality rate of only 1.4% and an average hospital stay of only 7 days, which is significantly less than most open procedures.<sup>190</sup> However, it is important to note that 62% of patients in this study had early-stage disease. In a systematic review and meta-analysis of studies reporting long-term outcomes, patients had 18% lower 5-year all-cause mortality following MIE compared with open esophagectomy.<sup>191</sup> In a multicenter randomized trial of 115 patients with esophageal or EGJ cancers, patients receiving MIE procedures had significantly lower rates of pulmonary infection than those receiving an open procedure.<sup>192</sup> A randomized controlled trial found that a hybrid MIE approach, in which surgeons combined a laparoscopic abdominal access route with an open thoracotomy, resulted in lower incidence of postoperative complications.<sup>193</sup> However, no statistically significant differences in either 3-year OS or DFS were observed. A retrospective analysis of 551 patients showed that patients who received MIE (n = 145) had significantly improved DFS and OS rates compared to patients who received open esophagectomy (n = 406; 3-year DFS rate, 81.7 vs. 69.3%,  $P = .021$ ; 3-year OS rate, 89.9 vs. 79.2%,  $P = .007$ ).<sup>194</sup> Open esophagectomy may be preferred over MIE for certain patients with previous abdominal surgery, large and/or bulky tumors, possibly unusable gastric conduit, and difficulty with lymph node dissection. Although MIE is an evolving treatment option for patients with esophageal cancer, it is reasonable to replace invasive open procedures

with MIE when possible, especially in older patients or those with significant comorbidities.<sup>195-197</sup>

Robotic-assisted MIE is an emerging technique that offers a realistic three-dimensional (3D) view that facilitates dissection in the narrow working environment; however, it is expensive and typically requires longer operation time.<sup>198</sup> The safety and feasibility of robotic-assisted MIE as compared to conventional MIE was analyzed in a systematic review and meta-analysis that reported similar rates of R0 resection, 30- and 90-day mortality, postoperative complications, and length of hospital stay between the two techniques.<sup>198</sup> In a randomized controlled trial involving 112 patients, robotic-assisted MIE was associated with a lower percentage of postoperative and cardiopulmonary complications, decreased pain, improved functional recovery, and better postoperative quality of life compared to open esophagectomy.<sup>199</sup> Oncologic outcomes were comparable at a median follow-up of 40 months. Another prospective trial involving 106 patients also reported lower postoperative pain severity and decreased pulmonary and infectious complications in patients receiving robotic-assisted MIE versus open esophagectomy.<sup>200</sup> However, larger randomized controlled studies are needed to evaluate the benefits and risks of robotic-assisted MIE in patients with esophageal cancer.

### ***Anastomosis and Choice of Conduit***

The optimal location of the anastomosis has been debated. Potential advantages of a cervical anastomosis include more extensive resection of the esophagus, possibility of avoiding thoracotomy, less severe symptoms of reflux, and less severe complications related to anastomotic leakage. Advantages of a thoracic anastomosis may include lower incidence of anastomotic leakage, lower stricture rate, and lower rate of left recurrent nerve injury. In a prospective randomized trial, cervical and thoracic anastomoses after esophageal resection were equally safe when performed in a standardized way.<sup>201</sup> Gastric conduit is preferred for

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

esophageal reconstruction by the majority of esophageal surgeons.<sup>202</sup> Colon interposition is usually reserved for patients who have undergone previous gastric surgery or other procedures that might have devascularized the stomach.<sup>203</sup>

### Endoscopic Therapies

Endoscopic therapies including ER (EMR or ESD) and endoscopic ablation (cryoablation or RFA) have been used as alternatives to surgery for the treatment of early-stage esophageal and EGJ cancers, with much less treatment-related morbidity than surgical resection. Several retrospective studies have demonstrated that ER and endoscopic ablation procedures are effective treatment options for select patients with Barrett esophagus and early-stage esophageal or EGJ cancers.<sup>204-207</sup> In a SEER database analysis of 1458 patients with T1N0 esophageal cancer, the OS rates were similar after treatment with surgery or endoscopic therapy (EMR, RFA, cryoablation, or PDT). However, patients treated with endoscopic therapy had improved cancer-specific survival and decreased morbidity, supporting the use of endoscopic therapy as an effective treatment option for patients with early-stage disease.<sup>206</sup>

EMR is widely used for the treatment of early esophageal SCC in Japan and is gaining acceptance in Western countries for the treatment of Barrett esophagus and superficial adenocarcinomas.<sup>208-211</sup> Complete Barrett eradication EMR (CBE-EMR) has been shown to be a highly effective long-term treatment option for patients with Barrett esophagus and HGD.<sup>212-216</sup> ESD has also been established as a safe and effective procedure for patients with early-stage esophageal and EGJ cancers, resulting in high en-bloc resection rates and lower rates of major complications.<sup>217-220</sup> Retrospective studies have reported significantly better en-bloc resection and local recurrence rates for ESD than for EMR in patients with early-stage SCC of the esophagus.<sup>221,222</sup>

RFA alone or in combination with ER is an effective treatment option for the complete eradication of residual dysplasia or Barrett esophagus.<sup>90,94,204,205,223-226</sup> Endoscopic cryoablation has also been reported to be safe and well-tolerated in patients with Barrett esophagus and early-stage esophageal cancers.<sup>227,228</sup> PDT with porfimer sodium or 5-aminolevulinic acid has produced excellent long-term results in patients with Barrett esophagus and HGD.<sup>229-231</sup> However, the use of PDT as an endoscopic therapy for esophageal cancers is losing popularity due to the potential for long-term complications.

### Principles of Endoscopy

Endoscopy has become an important tool in the diagnosis, staging, treatment, and surveillance of patients with esophageal and EGJ cancers. Most endoscopy procedures are performed with the aid of conscious sedation or monitored anesthesia provided by the endoscopist, nurse, nurse anesthetist, or anesthesiologist. Some patients who are at risk of aspiration during endoscopy may require general anesthesia. Endoscopic procedures are best performed in centers with experienced physicians.

### Diagnosis

Diagnostic endoscopies are performed to determine the presence and location of esophageal neoplasia and to biopsy suspicious lesions. The location of the tumor relative to the teeth and EGJ, the length of the tumor, the degree of obstruction, and the extent of circumferential involvement should be carefully recorded to assist with treatment planning. Tumor length has been identified as an independent predictor of long-term survival in patients with esophageal adenocarcinoma, with improved 5-year survival rates for patients with a tumor length less than or equal to 2 cm compared to those with a tumor length greater than 2 cm.<sup>232</sup> High-resolution endoscopic imaging and narrow-band imaging may be used to enhance visualization during endoscopy, with improved detection of



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

lesions in the esophagus and stomach.<sup>233-235</sup> Multiple biopsies (6–8), using standard-size endoscopy forceps, should be performed to provide sufficient material for histologic and molecular interpretation.<sup>109</sup> Cytologic brushings or washings are rarely adequate in the initial diagnosis, but can be useful in confirming persistent disease following treatment.

ER of focal nodules should be performed in the setting of early-stage disease to provide accurate information on the depth of invasion, the degree of differentiation, and the presence of LVI.<sup>236-238</sup> The depth of tumor invasion, evidence of LVI, and the status of resection margins have been identified as the strongest predictors of OS.<sup>239-241</sup> ER may be fully therapeutic when a lesion is fully removed and histopathologic assessment demonstrates extension no deeper than the superficial submucosa and negative deep margins. However, patients with poorly differentiated tumors, deep submucosal invasion, and/or LVI are at significantly higher risk of lymph node involvement.<sup>239,242,243</sup>

### Staging

EUS should be performed prior to any treatment to provide evidence of the depth of tumor invasion (T), presence of abnormal or enlarged lymph nodes likely to harbor cancer (N), and signs of distant metastasis, such as lesions in surrounding organs (M).<sup>51,52</sup> Mediastinal and perigastric lymph nodes are readily identified by EUS, and the identification of enlarged, hypoechoic (dark), homogeneous, well-circumscribed, and rounded structures in these areas indicates the presence of malignant or inflammatory lymph nodes. The accuracy of this diagnosis is significantly increased with the combination of features, but can also be confirmed with the use of FNA biopsy for cytology assessment.<sup>67-69</sup> Review of CT and FDG-PET scans prior to EUS is recommended to become familiar with the nodal distribution for FNA biopsy. FNA of suspicious lymph nodes should be performed without traversing an area of primary tumor or major blood vessels. Obstructing tumors may increase the risk of perforation while

performing staging EUS. The use of wire-guided EUS probes, or mini probes, may permit EUS staging with a lower risk of perforation. In certain cases, dilating the malignant stricture to allow completion of staging may be appropriate, but there is increased risk of perforation after dilation.

ER is recommended for small nodular lesions ( $\leq 2$  cm), as it provides more accurate depth of invasion information than EUS.<sup>55,56</sup> A decision to proceed with further treatment, such as ablation or surgical resection, or to consider the ER completely therapeutic would depend on the final pathologic assessment of the ER specimen.

### Treatment

The goal of endoscopic therapy is the complete removal or eradication of early-stage disease and Barrett esophagus. Endoscopic therapy is preferred for patients with early-stage cancer because the risk of lymph node metastases, local or distant recurrence, and death from esophageal cancer following endoscopic therapy is relatively low.<sup>244,245</sup> However, a thorough and detailed discussion regarding the comparative risk of esophagectomy versus the potential for concurrent nodal disease should be undertaken between patient and surgeon, especially in cases with larger tumors or deeper invasion.

Early-stage disease (ie, pTis, pT1a, select superficial pT1b without LVI) and HGD can be effectively treated with ER and/or ablation.<sup>240,244-248</sup> Full characterization evaluating the presence of nodularity, lateral spread, multifocal disease, and lymph node metastasis is important to permit decisions on endoscopic therapies with ablative methods and/or ER.<sup>90,228,231,249</sup> Areas of nodularity or ulceration should be resected rather than ablated. Completely flat, small lesions ( $\leq 2$  cm) of squamous cell Tis or HGD as well as Barrett esophagus associated with flat HGD should be treated with ER as it provides more accurate histologic assessment.<sup>56</sup> Ablative therapy of residual Barrett esophagus should be performed following ER.<sup>207</sup> Larger flat lesions ( $> 2$  cm) can also be treated



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

effectively with ER, but this is associated with a greater risk of complications.<sup>224,250</sup> Such lesions can be treated effectively by ablation alone; however, there are limited data available on treating squamous cell HGD by ablation alone.<sup>90,204,205,207,228,250</sup>

Endoscopic therapies also play a role in palliative care. Esophageal dilation can be performed with the use of dilating balloons or bougies for temporary relief from tumor obstruction or strictures. However, caution must be exercised to avoid overdistention, as this may lead to perforation. Long-term relief from dysphagia can be achieved with endoscopic tumor ablation, PDT and cryoablation, or endoscopic placement of self-expanding metal stents (SEMS).<sup>251</sup> Long-term palliation of anorexia, dysphagia, or malnutrition may be achieved with endoscopic- or radiographic-assisted placement of a feeding gastrostomy or jejunostomy tube. However, the placement of a feeding gastrostomy tube should be avoided prior to esophagectomy since it may compromise the gastric vasculature and interfere with the use of the stomach as a conduit.

### Surveillance

Endoscopic surveillance following treatment of esophageal and EGJ cancers requires careful attention to detail for mucosal surface changes and multiple biopsies of any visualized abnormalities. EUS has a high sensitivity for detecting recurrent disease.<sup>252,253</sup> EUS-FNA should be performed if suspicious lymph nodes or areas of wall thickening are seen on cross-sectional imaging. It should be noted that following chemotherapy or RT, EUS exams have a reduced ability to accurately determine the present stage of the disease.<sup>254</sup> Similarly, biopsies may not accurately detect the presence of residual disease following chemotherapy or RT.<sup>255</sup> Consider deferring assessment endoscopy with biopsy to 6 or more weeks after completion of preoperative therapy in patients whom avoidance of surgery is being considered.

Endoscopic surveillance should include a search for the presence of Barrett esophagus and four-quadrant biopsies to detect residual or recurrent dysplasia. The ablation of residual or recurrent HGD and LGD using RFA or cryoablation should be considered. Ablation of non-dysplastic Barrett esophagus is not recommended. Endoscopic surveillance after completion of ER or ablation for early-stage disease should continue after completion of treatment. Biopsies of the neo-squamous mucosa are recommended, even in the absence of mucosal abnormalities, as dysplasia may occasionally be present beneath the squamous mucosa.

### Radiation Therapy

Several historical series have reported results of using RT alone to treat patients with esophageal cancer with unfavorable features, such as patients with cT4 tumors or those who are not medically fit for surgery.<sup>256-258</sup> Overall, the 5-year survival rate for patients treated with conventional doses of RT alone is 0% to 10%.<sup>256-258</sup> Shi et al reported a 33% 5-year survival rate with the use of late-course accelerated fractionation to a total dose of 68.4 Gy.<sup>259</sup> However, in the RTOG 85-01 trial, all patients in the RT-alone arm who received 64 Gy at 2 Gy per day with conventional techniques died of cancer within 3 years.<sup>260</sup> In the adjuvant setting, randomized trials have not shown a survival advantage for preoperative or postoperative RT.<sup>261-263</sup> A meta-analysis from the Esophageal Cancer Collaborative Group showed no clear evidence of a survival advantage with preoperative RT.<sup>264</sup> Therefore, the panel recommends that RT alone should generally be reserved for palliation or for patients who are medically unable to receive chemotherapy.

Brachytherapy is also a palliative modality and results in a local control rate of 25% to 35% and a median survival time of approximately 5 months. In a randomized trial, Sur et al reported no significant difference in local control or survival with high-dose brachytherapy compared with external



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

beam RT (EBRT).<sup>265</sup> In the RTOG 92-07 trial, 75 patients received the RTOG 85-01 combined modality regimen (fluorouracil and cisplatin with 50 Gy of EBRT) followed by an intraluminal boost.<sup>266</sup> The local failure rate was 27%, and acute toxicity rates were 58% (grade 3), 26% (grade 4), and 8% (grade 5). The cumulative incidence of treatment-related esophageal fistula was 18% per year, and the crude incidence was 14%. Therefore, the additional benefit of adding intraluminal brachytherapy to RT or combined modality therapy, although reasonable, remains unclear. Alternative RT techniques, such as hypoxic cell sensitizers and hyperfractionation, have also not resulted in a clear survival advantage for patients with esophageal or EGJ cancers. Experience with intraoperative RT as an alternative to EBRT in esophageal cancer is limited.<sup>267</sup>

Intensity-modulated RT (IMRT) has also been investigated in patients with esophageal cancer.<sup>268-271</sup> Retrospective studies comparing 3D conformal RT (3D-CRT) versus IMRT for patients with esophageal cancer have generally shown superior dose conformity and homogeneity as well as a reduction of RT dose delivered to the lungs and heart with IMRT.<sup>268,269</sup>

Additionally, Roeder et al reported that IMRT with concurrent chemotherapy in the definitive treatment of esophageal cancer is feasible and yields good results with acceptable toxicity and low side effects to the skin, lungs, and heart.<sup>271</sup> A phase II trial of postoperative IMRT with concurrent chemotherapy for node-positive esophageal SCC also showed this regimen to be safe and effective with 1-year OS and PFS rates of 91.2% and 80.4%, respectively, and controllable toxicities.<sup>272</sup> Two recent phase III trials have safely used IMRT with concurrent chemotherapy as definitive treatment of esophageal cancer.<sup>273,274</sup>

An emerging RT technique that may offer further sparing of normal tissues is proton beam therapy (PBT). Protons have a minimal exit dose beyond the target volume, which limits exposure of adjacent organs to radiation.<sup>275,276</sup> Therefore, the use of PBT may improve the therapeutic ratio by limiting cardiopulmonary toxicities while simultaneously delivering

high radiation doses to the target area.<sup>276-278</sup> A direct comparison between IMRT, 3D-CRT, and PBT in 10 patients with esophageal cancer showed that PBT significantly reduced radiation doses to various volumes of the heart and lungs.<sup>279</sup> Furthermore, PBT was shown to be consistently superior to IMRT in lowering mean lung/heart radiation doses, especially when certain parameters such as beam arrangements and weighting were optimized to enhance normal tissue sparing.<sup>275</sup> A phase IIb trial that randomized 145 patients to receive IMRT or PBT reported that PBT reduced the risk and severity of adverse events while maintaining similar rates of 3-year PFS (50.8% for IMRT and 51.2% for PBT) and 3-year OS (44.5% for both).<sup>280</sup> PBT is also associated with lower rates of postoperative complications, including pulmonary, cardiac, GI, and wound complications, as well as reduced length of hospital stays.<sup>281,282</sup> However, data regarding PBT are early and evolving. Therefore, it is recommended that patients with esophageal cancer be treated with PBT within a clinical trial. An ongoing phase III study comparing PBT to photon therapy for patients with esophageal cancer is currently recruiting patients (Clinical Trial ID: [NCT03801876](https://clinicaltrials.gov/ct2/show/study/NCT03801876)).

Intensity-modulated PBT (IMPT), also referred to as pencil beam scanning, is a more recent technological advancement in which magnets are used to steer the proton beam toward the target volume.<sup>282</sup> A study from the Mayo Clinic showed significantly improved sparing of the lungs, heart, kidneys, liver, and small bowel using IMPT compared with IMRT in patients with distal esophageal cancer.<sup>282</sup> Additionally, a study comparing IMPT with ordinary PBT in patients with distal esophageal or EGJ cancer found that IMPT was associated with significant reductions in mean RT dose to the heart and liver.<sup>283</sup> However, the evidence supporting the use of IMPT is currently limited to dosimetric comparisons. Clinical outcomes of IMPT for esophageal cancer are needed, and prospective evaluation is ongoing.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### Principles of Radiation Therapy

#### General Guidelines

RT (preoperative, postoperative, or palliative) can be an integral part of treatment for esophageal and EGJ cancers. In general, Siewert Type I and II tumors should be managed with RT guidelines applicable to esophageal and EGJ cancers. Siewert Type III tumors are generally more appropriately managed with RT guidelines applicable to gastric cancer (see the [NCCN Guidelines for Gastric Cancer](#)). These recommendations may be modified depending on the location of the bulk of the tumor. The panel recommends involvement of a multidisciplinary team, which should include medical, radiation, and surgical oncologists; radiologists; gastroenterologists; and pathologists to determine optimal treatment recommendations. All available information from pretreatment diagnostic studies (EUS, endoscopy reports, and FDG-PET or FDG-PET/CT scans) should be reviewed by the multidisciplinary team and used to determine the target volume and field borders prior to simulation. Image guidance may be used appropriately to enhance clinical targeting.

A dose range of 41.4 to 50.4 Gy is recommended by the panel for preoperative RT. The recommended dose range for postoperative RT is 45 to 50.4 Gy. Non-surgical candidates should receive RT doses of 50 to 50.4 Gy because lower doses may not be adequate. There is no evidence from randomized trials to support the additional benefit of this higher dose range.<sup>273,274,284</sup> All RT doses should be delivered in fractions of 1.8 to 2 Gy per day. It is optimal to treat patients in the supine position as this setup is generally more stable and reproducible.

#### Simulation and Treatment Planning

CT simulation and conformal treatment planning should be used. When clinically appropriate, IV and/or oral contrast may be used for CT simulation to aid in target localization. The use of an immobilization device

is strongly recommended for reproducibility. Respiratory motion may be particularly significant for distal esophageal and EGJ lesions. When 4D-CT planning or other motion management techniques are used, margins may be modified to account for observed respiratory motion and may also be reduced if justified. The 4D-CT data can also be used to create an internal target volume (ITV) from which subsequent clinical target volume (CTV) and planning target volume (PTV) expansions can be made. A small trial involving 15 patients with esophageal carcinoma evaluated the use of 4D-PET/CT in PTV delineation.<sup>285</sup> Overlap analysis demonstrated that approximately 20% of the PTV delineated by 4D-PET/CT is not included in the PTV delineated by 4D-CT. This may lead to under-coverage of target volume and a potential geometric miss with the use of 4D-CT. However, the potential value of 4D-PET/CT for PTV delineation needs to be confirmed in larger randomized trials in patients with esophageal and EGJ cancers.

IMRT or PBT may be used in clinical settings where dose reduction to organs at risk is required and cannot be achieved by 3D techniques.<sup>268,269</sup> IMRT is now standardly used in the preoperative, definitive, and postoperative treatment of esophageal and esophagogastric cancer. Target volumes need to be carefully defined and encompassed when designing IMRT plans. In designing IMRT for organs at risk, such as the lungs, attention should be given to the volume receiving low to moderate doses, as well as the volume receiving high doses. In addition, the uninvolved stomach that may be used for future reconstruction should also be spared from high doses. Uncertainties from variations in stomach filling and respiratory motion should also be considered. Patients should be instructed to avoid intake of a heavy meal 3 hours before simulation and treatment.

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### Target Volume

The gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified by pre-treatment diagnostic studies as described above. The CTV includes areas at risk for microscopic disease and is defined as the primary tumor plus a 3- to 4-cm superior and inferior expansion and a 1-cm radial expansion.<sup>286</sup> The nodal CTV includes a 0.5- to 1.5-cm expansion from the nodal GTV. The CTV should also include coverage of elective nodal regions such as the celiac axis; however, this decision depends on the location of the primary tumor. The PTV should include the CTV plus an expansion margin of 0.5 to 1 cm.

### Normal Tissue Tolerance and Dose Limits

Treatment planning is essential to reduce unnecessary RT doses to organs at risk (liver, kidneys, spinal cord, heart, and lungs) and to limit the volume of organs at risk receiving high RT doses. Particular effort should be made to keep RT doses to the left ventricle of the heart to a minimum. Additionally, use of lung dose-volume histogram (DVH) parameters as predictors of pulmonary complications in patients treated with concurrent chemoradiation should be strongly considered, although consensus on optimal criteria has not yet emerged. Please see *Principles of Radiation Therapy* in the algorithm for recommended criteria for DVH parameters.<sup>287,288</sup> Although every effort should be made to minimize RT doses to organs at risk, it is recognized that these dose guidelines may be appropriately exceeded based on clinical circumstances.

### Supportive Care

Careful monitoring and management of acute toxicities with aggressive supportive care is essential to avoid treatment interruptions or dose reductions. During an RT treatment course, patients' vital signs, weight, and blood counts should be measured at least once per week. Prophylactic antiemetics should be given when appropriate. Additionally,

antacids, PPIs, and antidiarrheal medications may be prescribed when needed. If the estimated caloric intake is inadequate (<1500 kcal/day), oral and/or enteral nutrition should be considered. Feeding jejunostomy tubes or nasogastric feeding tubes may be placed if clinically indicated. Adequate enteral and/or IV hydration is necessary throughout chemoradiation and recovery.

### Combined Modality Therapy

Combined modality therapy has been shown to significantly increase survival in patients with esophageal and EGJ cancer with locoregional disease compared to resection alone.<sup>289-291</sup> Preoperative chemoradiation for planned esophagectomy is the preferred approach for localized resectable disease.<sup>167</sup> Perioperative chemotherapy is also an option for adenocarcinoma of the thoracic esophagus or EGJ.<sup>292,293</sup> Other treatment options include postoperative therapy with nivolumab,<sup>294</sup> chemoradiation,<sup>295,296</sup> or chemotherapy.<sup>297</sup> Definitive chemoradiation should be reserved for patients with unresectable disease or those who decline surgery.<sup>284,298-300</sup>

### Preoperative Chemoradiation Therapy

Preoperative chemoradiation is associated with improved OS, DFS, and pCR compared with preoperative chemotherapy or surgery alone in patients with locoregional esophageal cancer.<sup>301-307</sup> Results from the multicenter phase III randomized CROSS trial, the largest trial in its class, showed that preoperative chemoradiation with paclitaxel and carboplatin significantly improved OS and DFS compared to surgery alone in patients with resectable (T2–T3, N0–1, M0) esophageal or EGJ cancers (n = 366; 75% had adenocarcinoma and 23% had SCC).<sup>167</sup> Median OS was 49 months in the preoperative chemoradiation arm (n = 178) compared to 24 months in the surgery alone arm (n = 188; hazard ratio [HR], .657; 95% CI, 0.495–0.871; P = .003). The R0 resection rate was also higher in the



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

preoperative chemoradiation arm compared to the surgery alone arm (92% vs. 69%;  $P < .001$ ). The 1-, 2-, 3-, and 5-year OS rates were 82%, 67%, 58%, and 47%, respectively, in the preoperative chemoradiation arm compared to 70%, 50%, 44%, and 34%, respectively, in the surgery alone arm. Although the rate of pCR was higher in patients with SCC than those with adenocarcinoma (49% vs. 23%;  $P = .008$ ), the histologic subtype was not a prognostic factor for survival.<sup>167</sup> After a minimum follow-up of 24 months, the overall rate of recurrence was 35% in the preoperative chemoradiation arm compared to 58% in the surgery alone arm.<sup>308</sup> Additionally, preoperative chemoradiation significantly reduced locoregional recurrence from 34% to 14% ( $P < .001$ ) and peritoneal carcinomatosis from 14% to 4% ( $P < .001$ ).<sup>308</sup> Importantly, preoperative chemoradiation did not negatively impact postoperative health-related quality of life compared to surgery alone in patients participating in the CROSS trial.<sup>309</sup> A study reporting the long-term results of the CROSS trial verified that median OS was significantly improved in the preoperative chemoradiation group.<sup>310</sup> After a median follow-up of 84.1 months, median OS was 48.6 months in the preoperative chemoradiation group compared to 24 months in the surgery alone group (HR, 0.68; 95% CI, 0.53–0.88;  $P = .003$ ). Median OS for patients with SCC was 81.6 months in the preoperative chemoradiation group and 21.1 months in the surgery alone group ( $P = .008$ ); for patients with adenocarcinomas, median OS was 43.2 months and 27.1 months, respectively ( $P = .038$ ). The results of these studies confirmed the survival benefit for preoperative chemoradiation therapy with paclitaxel and carboplatin in patients with resectable esophageal or EGJ cancers. Therefore, the panel recommends combined paclitaxel and carboplatin as a category 1 preferred regimen for preoperative chemoradiation.

The panel also recommends fluorouracil and oxaliplatin (FOLFOX) as a category 1 preferred option for preoperative chemoradiation. The efficacy and safety of preoperative FOLFOX combined with RT was evaluated in a

single-arm phase II SWOG trial involving 93 patients with clinically staged II or III esophageal adenocarcinoma.<sup>311</sup> Twenty-six patients (28%) had confirmed pCR (95% CI, 19.1–38.2) and 19.4% of patients experienced grade 4 treatment-related toxicities. At a median follow-up of 39.2 months, estimates of median and 3-year OS were 28.3 months and 45.1%, respectively. A small trial of 38 patients with stage II–IV esophageal adenocarcinoma also showed that FOLFOX combined with RT is safe and effective in the preoperative setting, with 38% of patients achieving pCR.<sup>312</sup> PROTECT is an ongoing randomized phase II trial that will compare preoperative chemoradiation with FOLFOX to paclitaxel and carboplatin, both with concurrent RT (41.4 Gy), in patients with resectable stage IIB–III esophageal and EGJ cancers of SCC or adenocarcinoma histology.<sup>313</sup> This trial will directly compare two standards of preoperative chemoradiation in the setting of resectable, locally advanced esophageal or EGJ cancers. Participation in this trial is highly encouraged (Clinical Trial ID: [NCT02359968](https://clinicaltrials.gov/ct2/show/study/NCT02359968)).

Other recommended regimens for preoperative chemoradiation include fluorouracil and cisplatin (category 1),<sup>314,315</sup> irinotecan and cisplatin (category 2B),<sup>316</sup> and paclitaxel and a fluoropyrimidine (fluorouracil or capecitabine [category 2B]).<sup>317</sup> CALGB 9781 was a prospective phase III trial that randomized patients ( $n = 56$ ) with stage I–III esophageal cancers to receive preoperative chemoradiation with fluorouracil and cisplatin followed by surgery ( $n = 30$ ) or surgery alone ( $n = 26$ ).<sup>314</sup> After a median follow-up of 6 years, the median OS was 4.5 years in the preoperative chemoradiation group versus 1.8 years in the surgery alone group ( $P = .002$ ). Patients receiving preoperative chemoradiation also had an improved 5-year OS rate (39% vs. 16%). The results from this trial reflect a long-term survival advantage with the use of preoperative chemoradiotherapy with fluorouracil and cisplatin in the treatment of esophageal cancer. Irinotecan and cisplatin showed modest activity in a single-institution retrospective trial involving patients ( $n = 44$ ) with locally

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

advanced esophageal carcinoma.<sup>316</sup> All patients underwent R0 resection and the pCR rate was 25%. The median DFS and OS were 24 months and 34 months, respectively, and the 3-year OS rate was 46%.

Studies have compared preoperative chemoradiation with chemoradiation alone in patients with esophageal SCC. A trial by Stahl et al randomized 172 patients with esophageal SCC to receive either induction chemotherapy followed by preoperative chemoradiation plus surgery or induction chemotherapy followed by chemoradiation alone.<sup>318</sup> Although the 2-year PFS rate was better in the preoperative chemoradiation group (64.3%) than in the chemoradiation alone group (40.7%), there was no difference in OS. Additionally, the preoperative chemoradiation group had significantly higher treatment-related mortality than the chemoradiation alone group (12.8% vs. 3.5%, respectively). Long-term results with a median follow-up time of 10 years also showed no clear difference in survival between the two groups.<sup>319</sup> The FFCD 9102 trial also showed that adding surgery to chemoradiation provides little benefit compared to treatment with additional chemoradiation alone in patients with locally advanced SCC of the esophagus who responded to initial chemoradiation therapy.<sup>315</sup> A meta-analysis of randomized controlled trials compared chemoradiation plus surgery with chemoradiation alone in patients with at least T3 and/or N+ thoracic esophageal cancer (93% had SCC).<sup>320</sup> The authors concluded that the addition of surgery to chemoradiation in locally advanced esophageal SCC has little impact on OS, and may be associated with higher treatment-related mortality. The addition of surgery may delay locoregional recurrence; however, this endpoint was not well-defined in the included studies. In contrast, a follow-up study that analyzed long-term outcomes in patients not eligible for randomization in the FFCD 9102 trial (ie, those with no clinical response to initial chemoradiation) found that median OS was longer in clinical non-responders who underwent surgery compared to non-surgical patients (17 vs. 5.5 months, respectively).<sup>321</sup>

A recent phase III trial (NEOCRTEC5010) compared safety and survival outcomes of preoperative chemoradiation plus surgery (n = 224) with surgery alone (n = 227) in patients with locally advanced esophageal SCC.<sup>322</sup> Compared with the surgery alone group, the preoperative chemoradiation group had a higher R0 resection rate (98.4% vs. 91.2%;  $P = .002$ ), improved median OS (100.1 vs. 66.5 months; HR, 0.71; 95% CI, 0.53–0.96;  $P = .025$ ), and prolonged DFS (100.1 vs. 41.7 months; HR, 0.58; 95% CI, 0.43–0.78;  $P < .001$ ). Incidences of postoperative complications were similar between the two groups. This trial shows that preoperative chemoradiation improves survival over surgery alone among patients with locally advanced esophageal SCC, with acceptable toxicities.

### ***Preoperative Sequential Chemotherapy and Chemoradiation Therapy***

Preoperative induction chemotherapy followed by concurrent chemoradiation has also been evaluated in clinical trials for patients with locally advanced esophageal and EGJ cancers.<sup>323–331</sup> In a phase III study, Stahl et al compared preoperative chemotherapy (fluorouracil and cisplatin) with preoperative chemotherapy followed by concurrent chemoradiation therapy using the same regimen in 119 patients with locally advanced adenocarcinoma of the lower esophagus or EGJ.<sup>327</sup> Patients were randomized to receive chemotherapy followed by surgery (arm A) or chemotherapy followed by chemoradiation and surgery (arm B). Patients in arm B had a higher probability of achieving pCR (15.6% vs. 2.0%, respectively) and tumor-free lymph nodes at resection (64.4% vs. 37.7%, respectively) than patients in arm A. Patients in arm B also had improved 3-year OS rates (47.4% vs. 27.7% in arm A). Although the study was closed prematurely due to low accrual and statistical significance was not achieved, there was a trend towards a survival advantage for preoperative sequential chemotherapy and chemoradiation compared to preoperative chemotherapy alone in patients with EGJ adenocarcinoma.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

In a phase II study, preoperative chemotherapy with irinotecan and cisplatin followed by concurrent chemoradiation with the same regimen resulted in moderate response rates in patients with resectable, locally advanced gastric and EGJ adenocarcinoma.<sup>328</sup> R0 resection was achieved in 65% of patients and the median OS and actuarial 2-year survival rates were 14.5 months and 35%, respectively.<sup>328</sup> In another phase II trial that evaluated preoperative chemotherapy with irinotecan and cisplatin followed by concurrent chemoradiation, the rate of pCR (16%) was relatively low and the rates of R0 resection (69%), PFS (15.2 months), and OS (31.7 months) were either comparable or inferior to those observed for preoperative chemoradiation in phase II trials.<sup>330</sup>

In the phase II SAKK 75/02 trial, preoperative chemotherapy with docetaxel and cisplatin followed by chemoradiation with the same regimen was effective in patients with SCC or adenocarcinoma of the esophagus (n = 66). Of the 57 patients who underwent surgery, R0 resection was achieved in 52 of them. Median OS and EFS were 36.5 months and 22.8 months, respectively.<sup>329</sup> However, the results of another phase II trial showed that induction chemotherapy (oxaliplatin and fluorouracil) before preoperative chemoradiation with the same regimen resulted in a non-significant increase in the rate of pCR and did not prolong OS in patients with esophageal cancer.<sup>331</sup> Therefore, induction chemotherapy prior to preoperative chemoradiation therapy is feasible and may be appropriate for select patients. However, this approach needs to be further evaluated in phase III randomized clinical trials.

### Perioperative Chemotherapy

The survival benefit of perioperative chemotherapy in gastroesophageal cancers was first demonstrated in the landmark phase III MAGIC trial.<sup>332</sup> This study, which compared perioperative chemotherapy with epirubicin, cisplatin, and fluorouracil (ECF) to surgery alone, established that perioperative chemotherapy improves PFS and OS in patients with non-

metastatic stage II and higher gastric or EGJ adenocarcinoma. In the randomized controlled phase II/III FLOT4 trial, Al-Batran et al compared perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) to the standard ECF regimen in patients with resectable non-metastatic gastric or EGJ adenocarcinoma ( $\geq$ T2 and/or N+).<sup>168,293</sup> In the phase II part of the study, 265 patients were randomized to receive either three preoperative and postoperative cycles of ECF (n = 137) or four preoperative and postoperative cycles of FLOT (n = 128). Results showed that FLOT was associated with significantly higher proportions of patients achieving pCR than was ECF (16%; 95% CI, 10–23 vs. 6%; 95% CI, 3–11;  $P = .02$ ).<sup>293</sup> Additionally, FLOT was associated with a reduction in the percentage of patients experiencing at least one grade 3–4 adverse event, including neutropenia, leucopenia, nausea, infection, fatigue, and vomiting (40% of patients in the ECF group vs. 25% of patients in the FLOT group). In the phase III part of the trial, 716 patients were randomized to receive FLOT (n = 356) or ECF (n = 360).<sup>168</sup> Results showed that median OS was increased in the FLOT group compared with the ECF group (50 vs. 35 months; HR, 0.77; 95% CI, 0.63–0.94). The percentage of patients with serious chemotherapy-related adverse events was the same in the two groups (27% in the ECF group vs. 27% in the FLOT group). Therefore, ECF should no longer be recommended in this setting. However, because of considerable toxicity associated with the FLOT regimen, the panel recommends its use in select patients with good performance status. The preferred perioperative regimen for most patients who have good to moderate performance status is FOLFOX.

In the FNCLCC ACCORD 07 trial (n = 224 patients; 75% had adenocarcinoma of the lower esophagus or EGJ), Ychou et al reported that perioperative chemotherapy with fluorouracil and cisplatin significantly increased the curative resection rate, DFS, and OS in patients with resectable cancer.<sup>292</sup> At a median follow-up of 5.7 years, the 5-year OS rate was 38% for patients in the perioperative chemotherapy group and



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

24% for patients in the surgery alone group ( $P = .02$ ). The corresponding 5-year DFS rates were 34% and 19%, respectively. Although this trial was prematurely terminated due to low accrual, the panel feels that perioperative fluorouracil and cisplatin is a viable treatment option for patients with locally advanced resectable esophageal or EGJ cancers.

The recently published phase III NEO-AEGIS trial directly compared preoperative chemoradiation (CROSS regimen) to perioperative chemotherapy (modified MAGIC or FLOT regimen) in 377 patients with locoregional adenocarcinoma of the esophagus or EGJ.<sup>333</sup> At a median follow-up of 24.5 months, there were 143 deaths (70 in the CROSS arm and 73 in the MAGIC/FLOT arm), with 3-year estimated survival probabilities of 56% and 57%, respectively (HR, 1.02), indicating no survival difference between the two modalities. However, all pathologic endpoints (pCR rate, N0 and R0 resection status) favored preoperative chemoradiation. These data strongly suggest noninferiority of perioperative chemotherapy to preoperative chemoradiation, making perioperative chemotherapy a viable treatment option for patients with locoregional adenocarcinoma. The results of other prospective trials are awaited.

### Definitive Chemoradiation Therapy

Given the efficacy and safety of combined paclitaxel and carboplatin as a preoperative chemoradiation regimen as reported in the CROSS trial,<sup>167</sup> the NCCN Panel also recommends this regimen as a preferred option for definitive chemoradiation. In a retrospective comparison, definitive chemoradiation with paclitaxel and carboplatin resulted in superior OS, disease-specific survival, locoregional control, and palliation in patients with unresectable esophageal cancer compared to cisplatin and irinotecan.<sup>334</sup> The FOLFOX regimen as well as combined fluorouracil and cisplatin have also been proven as effective definitive chemoradiation regimens in clinical trials. The efficacy of chemoradiation therapy with

fluorouracil and cisplatin versus RT alone, each without resection, was studied in an early randomized trial (RTOG 85-01) involving patients with esophageal SCC or adenocarcinoma (cT1–cT3, N0–1, M0).<sup>260,335</sup> Compared to patients who received RT alone, patients who received chemoradiation showed a significant improvement in both median survival (14 vs. 9 months) and 5-year OS (27% vs. 0%) with projected 8- and 10-year survival rates of 22% and 20%, respectively. The incidence of local failure as the first site of failure (defined as local persistence plus recurrence) was also lower in the chemoradiation arm (47% vs. 65% in the RT alone arm). A follow-up trial (INT-0123) compared two different RT doses used with the same chemotherapy regimen (fluorouracil and cisplatin).<sup>284</sup> In this trial, 218 patients with esophageal cancer with either SCC (85%) or adenocarcinoma (15%) (cT1–cT4, N0–1, M0) were randomly assigned to receive the standard RT dose of 50.4 Gy or a higher dose of 64.8 Gy. No significant difference was observed in median survival (13 vs. 18 months), 2-year OS (31% vs. 40%), or locoregional failure (56% vs. 52%) rates between the high-dose and standard-dose RT arms. Two more recent phase III trials (ARTDECO and CONCORDE [PRODIGE-26]) have similarly shown no benefit to radiation dose escalation beyond 50 Gy in improving local control or survival.<sup>273,274</sup> These results support the use of RT at a dose of 50 to 50.4 Gy for definitive chemoradiation.

In a randomized phase III trial (PRODIGE5/ACCORD17), 267 patients with unresectable esophageal cancer or those medically unfit for surgery were randomized to receive definitive chemoradiation with either FOLFOX or fluorouracil and cisplatin.<sup>298</sup> The median PFS was 9.7 months in the FOLFOX group compared to 9.4 months in the fluorouracil and cisplatin group ( $P = .64$ ).<sup>298</sup> Although definitive chemoradiation with FOLFOX was not associated with a PFS benefit compared to fluorouracil and cisplatin, the investigators suggest that FOLFOX might be a more convenient option for patients with localized esophageal cancer who may not be candidates for surgery. Since FOLFOX is associated with fewer



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

treatment-related adverse events, FOLFOX is preferred over fluorouracil plus cisplatin although both are category 1 recommendations for definitive chemoradiation.

Reports have also confirmed the efficacy of definitive chemoradiation using other chemotherapy regimens.<sup>299,300,336</sup> Definitive chemoradiation with docetaxel and cisplatin resulted in a high overall response rate (ORR) (98.3%; 71% complete response) and a median OS of 23 months in a small study of 59 patients with esophageal SCC.<sup>299</sup> The 3-year locoregional PFS, overall PFS, and OS rates were 60%, 29%, and 37%, respectively. In a phase II trial, chemoradiation with paclitaxel and cisplatin was well-tolerated and resulted in a complete histologic response in 19% of patients with locoregional esophageal cancer.<sup>336</sup> Median OS was 24 months and 1-, 2-, and 3-year survival probabilities were 75%, 50%, and 34%, respectively. Therefore, cisplatin with either docetaxel or paclitaxel are recommended regimens for definitive chemoradiation. Definitive chemoradiation with irinotecan and cisplatin<sup>316</sup> or paclitaxel and a fluoropyrimidine (fluorouracil or capecitabine)<sup>317</sup> are category 2B recommendations.

### Postoperative Therapy

Nivolumab is a category 1, preferred recommendation for patients who have residual disease following preoperative chemoradiation and R0 resection.<sup>294</sup> See *Targeted Therapies* below for more information on nivolumab. The data for postoperative chemotherapy with capecitabine and oxaliplatin is derived from the phase III CLASSIC trial involving patients with stage II or IIIB gastric cancer.<sup>297,337</sup> In this study, patients who had not received preoperative therapy were randomized to receive either gastrectomy with D2 lymph node dissection alone (n = 515) or gastrectomy with D2 lymph node dissection followed by postoperative chemotherapy (n = 520). After a median follow-up of 34.2 months, postoperative chemotherapy with capecitabine and oxaliplatin significantly

improved 3-year DFS (74%) compared to surgery alone (59%) for all disease stages ( $P < .0001$ ).<sup>337</sup> After a median follow-up of 62.4 months, the estimated 5-year DFS rate was 68% for the postoperative chemotherapy group compared to 53% for the surgery alone group; the corresponding estimated 5-year OS rates were 78% and 69%, respectively.<sup>297</sup> Based on these data, the panel recommends capecitabine and oxaliplatin as an option for postoperative chemotherapy in patients with resectable esophageal or EGJ cancers who had not received preoperative therapy. The panel also endorses the use of FOLFOX in this setting.

### Postoperative Chemoradiation Therapy

The landmark INT-0116 trial investigated the effectiveness of surgery followed by postoperative chemotherapy plus chemoradiation on the survival of patients with resectable adenocarcinoma of the stomach or EGJ.<sup>295,296</sup> In this trial, 556 patients (stage IB–IV, M0) were randomized to receive surgery followed by postoperative chemotherapy plus chemoradiation (n = 281; bolus fluorouracil plus leucovorin before and after concurrent chemoradiation with the same regimen) or surgery alone (n = 275).<sup>296</sup> The majority of patients had T3 or T4 tumors (69%) and node-positive disease (85%). After a median follow-up of 5 years, median OS in the surgery-only group was 27 months compared to 36 months in the postoperative chemotherapy plus chemoradiation group ( $P = .005$ ). The postoperative chemotherapy plus chemoradiation group also had better 3-year OS (50% vs. 41%) and relapse-free survival (RFS) rates (48% vs. 31%) than the surgery-only group. There was also a decrease in local failure as the first site of failure in the chemoradiation group (19% vs. 29%). After a median follow-up of greater than 10 years, survival remained improved in patients treated with postoperative chemoradiation.<sup>295</sup> Additionally, data from a retrospective analysis showed that postoperative chemoradiation according to the INT-0116 protocol resulted in improved 3-year DFS rates after curative resection in patients (n = 211) with EGJ



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

adenocarcinoma and positive lymph nodes who did not receive neoadjuvant chemotherapy (37% vs. 24% after surgery alone).<sup>338</sup>

The results of the INT-0116 trial established the efficacy of postoperative chemoradiation in patients with resected gastric or EGJ adenocarcinoma who have not received preoperative therapy. However, the dosing and schedule of chemotherapy agents used in this trial was associated with high rates of grade 3–4 hematologic and GI toxicities (54% and 33%, respectively). Among the 281 patients assigned to the chemoradiation group, 17% discontinued treatment and three patients died as a result of chemoradiation-related toxicities, including pulmonary fibrosis, cardiac events, and myelosuppression. Therefore, the doses and schedule of chemotherapy agents used in the INT-0116 trial are not recommended by the panel due to concerns regarding toxicity. See *Principles of Systemic Therapy—Regimens and Dosing Schedules* in the algorithm for recommended modifications to this regimen.

In another trial that evaluated postoperative chemoradiation with cisplatin and fluorouracil in patients with poor-prognosis esophageal and EGJ adenocarcinoma, the projected rates of 4-year OS, RFS, distant metastatic control, and locoregional control were 51%, 50%, 56%, and 86%, respectively, for patients with node-positive T3 or T4 tumors, which were better than the historical outcomes observed with surgery alone in these patients.<sup>339</sup> A recent meta-analysis of 2165 patients with esophageal cancer showed that postoperative chemoradiation significantly improved OS and significantly reduced the locoregional recurrence rate compared to non-chemoradiation postoperative treatments (postoperative chemotherapy alone, postoperative RT alone, or observation).<sup>340</sup> However, no difference was seen in the rate of distant metastases between these groups. The authors concluded that postoperative chemoradiation yields significant survival benefits and improves locoregional control with tolerable toxicity. However, results of meta-analyses should be considered hypothesis-generating and cannot

change the standard of care. While the addition of postoperative chemoradiation has been associated with survival benefits in patients with node-positive locoregional esophageal cancer,<sup>341,342</sup> it is important to note that the efficacy of postoperative chemoradiation compared to surgery alone has not been demonstrated in a randomized trial in patients with esophageal cancer.

### Systemic Therapy for Locally Advanced or Metastatic Disease

#### First-Line Therapy

Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic esophageal or EGJ cancers.<sup>343-345</sup> First-line systemic therapy regimens with two cytotoxic drugs are preferred for patients with advanced disease because of their lower toxicity. The use of three cytotoxic drugs in a regimen should be reserved for medically fit patients with excellent PS and easy access to frequent toxicity evaluations.<sup>346</sup> Oxaliplatin is preferred over cisplatin due to lower toxicity.

Trastuzumab should be added to first-line chemotherapy for patients with advanced HER2 overexpression positive adenocarcinoma (combination with a fluoropyrimidine and a platinum agent is preferred).<sup>156</sup> An FDA-approved biologic medical product that is similar to trastuzumab (a biosimilar) is an appropriate substitute. Pembrolizumab can also be added to this regimen for treatment of advanced HER2 overexpression positive adenocarcinoma, provided no contraindications exist.<sup>347</sup> Preferred regimens for HER2 overexpression negative disease include nivolumab combined with fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin for adenocarcinoma tumors with PD-L1 expression levels by CPS of greater than or equal to 5 (category 1) or CPS of less than 5 (category 2B), and pembrolizumab combined with fluoropyrimidine

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

(fluorouracil or capecitabine) and either cisplatin (category 1) or oxaliplatin for adenocarcinoma or SCC tumors with PD-L1 expression levels by CPS of greater than or equal to 10 or CPS of less than 10 (category 2B).<sup>348,349</sup> Preferred regimens for SCC tumors also includes nivolumab combined with fluoropyrimidine (fluorouracil or capecitabine) and either cisplatin or oxaliplatin and nivolumab combined with ipilimumab.<sup>350</sup> See *Targeted Therapies* below for more information on nivolumab, pembrolizumab and ipilimumab.

The preferred regimens for HER2 negative disease also includes a fluoropyrimidine (fluorouracil or capecitabine) combined with either oxaliplatin<sup>351-353</sup> or cisplatin.<sup>351,354-356</sup> A phase III trial conducted by the German Study Group compared treatment with fluorouracil and cisplatin to FOLFOX in patients (n = 220) with previously untreated advanced adenocarcinoma of the stomach or EGJ.<sup>351</sup> Results showed that FOLFOX (referred to as FLO) was associated with significantly less toxicity and showed a trend towards improved median PFS (5.8 vs. 3.9 months;  $P = .77$ ) compared to fluorouracil and cisplatin (FLP). However, there was no significant difference in median OS (10.7 vs. 8.8 months, respectively) between the two groups. FOLFOX resulted in significantly superior response rates (41.3% vs. 16.7%;  $P = .12$ ), time to treatment failure (5.4 vs. 2.3 months;  $P < .001$ ), PFS (6.0 vs. 3.1 months;  $P = .029$ ), and improved OS (13.9 vs. 7.2 months) compared with FLP in patients over 65 years (n = 94). Therefore, FOLFOX offers reduced toxicity and similar efficacy compared to fluorouracil plus cisplatin and may also be associated with improved efficacy in older adult patients.

Recommendations for the use of regimens combining a platinum agent with capecitabine as first-line therapy have been extrapolated from trials involving patients with advanced gastric cancer.<sup>353,356-358</sup> Results of a meta-analysis suggest that OS was superior in patients with advanced gastroesophageal cancer treated with capecitabine-based combinations compared to patients treated with fluorouracil-based combinations,

although no significant difference in PFS between treatment groups was seen.<sup>359</sup> Therefore, capecitabine and oxaliplatin is also a preferred regimen for first-line treatment of patients with advanced esophageal or EGJ cancers. The GO2 phase III trial demonstrated that a low-dose capecitabine and oxaliplatin regimen (60% of the standard dose) was non-inferior in terms of PFS and resulted in significantly lower toxicities and better overall treatment utility in patients who are older and/or frail with advanced gastroesophageal cancers (n = 514).<sup>360</sup> Therefore, this low-dose regimen is recommended as an alternative to standard-dose capecitabine and oxaliplatin for older and/or frail patients with advanced or metastatic disease. See *Principles of Systemic Therapy - Regimens and Dosing Schedules* in the algorithm for recommended modifications to this regimen.

First-line treatment with irinotecan-based regimens has been explored extensively in clinical trials involving patients with advanced or metastatic gastroesophageal cancers.<sup>361-367</sup> The results of a randomized phase III study comparing fluorouracil and irinotecan (FOLFIRI) to cisplatin and fluorouracil (CF) in patients with advanced gastric or EGJ adenocarcinoma (n = 337) showed that FOLFIRI was noninferior to CF in terms of PFS, but not in terms of OS or time to progression.<sup>362</sup> FOLFIRI was also associated with a more favorable safety profile. A more recent phase III trial (French Intergroup Study) compared FOLFIRI with ECF as first-line treatment in patients (n = 416) with advanced or metastatic gastric or EGJ adenocarcinoma.<sup>367</sup> After a median follow-up of 31 months, median time to treatment failure was significantly longer with FOLFIRI than with ECF (5.1 vs. 4.2 months;  $P = .008$ ).<sup>367</sup> However, there were no significant differences in median PFS (5.3 vs. 5.8 months;  $P = .96$ ), median OS (9.5 vs. 9.7 months;  $P = .95$ ), or response rate (39.2% vs. 37.8%). Importantly, FOLFIRI was less toxic and better tolerated than ECF. Therefore, FOLFIRI may be recommended as a first-line therapy

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

option for patients with advanced or metastatic esophageal or EGJ adenocarcinoma.

Docetaxel, cisplatin, and fluorouracil (DCF) has also demonstrated activity in patients with locally advanced or metastatic gastroesophageal cancer.<sup>368,369</sup> An international phase III study (V325) that randomized 445 patients with untreated advanced gastric or EGJ cancer to receive either DCF or CF found that the addition of docetaxel to CF significantly improved time to progression, OS, and ORR.<sup>369</sup> However, DCF was associated with increased toxicities including myelosuppression and infectious complications.<sup>369</sup> Various modifications of the DCF regimen have demonstrated improved safety compared to the DCF regimen evaluated in the V325 study.<sup>370-373</sup> Therefore, due to concerns regarding toxicity, dose-modified DCF or other DCF modifications should be used as alternative options to the standard DCF regimen for first-line therapy. Additional regimens for first-line therapy include paclitaxel with either carboplatin or cisplatin,<sup>374-376</sup> docetaxel with cisplatin,<sup>368,377</sup> or single-agent fluoropyrimidine (fluorouracil or capecitabine),<sup>355,378,379</sup> docetaxel,<sup>343,380</sup> or paclitaxel.<sup>381,382</sup>

### Second-Line and Subsequent Therapy

The selection of regimens for second-line or subsequent therapy is dependent upon prior therapy and performance status. Ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) in combination with paclitaxel (preferred) or as a single agent are recommended for second-line or subsequent therapy.<sup>383,384</sup> Fam-trastuzumab deruxtecan-nxki is a second-line treatment option for HER2 overexpression positive adenocarcinoma patients who have received prior trastuzumab-based therapy.<sup>385</sup> Nivolumab is preferred for second-line or subsequent therapy for esophageal SCC (category 1).<sup>386</sup> Pembrolizumab is preferred for second-line therapy for esophageal SCC with PD-L1 expression levels by CPS of greater than or equal to 10

(category 1).<sup>387</sup> See *Targeted Therapies* below for more information on ramucirumab, nivolumab, pembrolizumab and fam-trastuzumab deruxtecan-nxki.

Single-agent docetaxel,<sup>343,380</sup> paclitaxel,<sup>381,382,388</sup> and irinotecan<sup>344,388-390</sup> are also category 1 preferred options for second-line or subsequent therapy. In a randomized phase III trial (COUGAR-02) single-agent docetaxel was shown to significantly increase 12-month OS compared to active symptom control alone (5.2 vs. 3.6 months, respectively; HR, 0.67;  $P = .01$ ).<sup>343</sup> A randomized phase III trial comparing second-line therapy with paclitaxel to irinotecan in patients with advanced gastric cancer found similar OS between the two groups (9.5 months in the paclitaxel group vs. 8.4 months in the irinotecan group; HR, 1.13;  $P = .38$ ).<sup>388</sup>

FOLFIRI is a preferred treatment option that can be safely used in the second-line setting if it was not previously used in first-line therapy.<sup>389,391,392</sup> A phase II trial investigating the efficacy and toxicity of FOLFIRI in patients ( $n = 40$ ) with refractory or relapsed esophageal or gastric cancer reported an ORR of 29% and median OS of 6.4 months. Another phase II trial reported similar results with an ORR of 20% and OS of 6.7 months in patients with advanced gastric cancer ( $n = 59$ ) treated with FOLFIRI in the second-line setting.<sup>389</sup> Additionally, FOLFIRI was shown to be an effective and safe treatment option in a cohort of patients with metastatic gastric or EGJ cancers refractory to docetaxel-based chemotherapy.<sup>393</sup> In this study, the ORR was 22.8% and median PFS and OS were 3.8 and 6.2 months, respectively. The most common grade 3–4 toxicities were neutropenia (28.5%) and diarrhea (14.5%).

The trifluridine and tipiracil regimen was approved by the FDA in 2019 for previously treated recurrent or metastatic gastric and EGJ adenocarcinoma<sup>394</sup> based on results of the global phase III TAGS trial, in which 507 patients with heavily pretreated metastatic gastric or EGJ adenocarcinoma were randomized 2:1 to receive trifluridine and tipiracil plus best supportive care ( $n = 337$ ) or placebo plus best supportive care



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

(n = 170).<sup>395</sup> This study reported an improvement in median OS by 2.1 months with the trifluridine and tipiracil regimen compared to placebo (HR, 0.69; 95% CI, 0.56–0.85; *P* = .0003). PFS was also significantly longer in the trifluridine and tipiracil group (2.0 vs. 1.7 months; HR, 0.57; 95% CI, 0.47–0.70; *P* < .0001). The most frequently reported grade 3–4 toxicities were neutropenia (38%), leukopenia (21%), anemia (19%), and lymphocytopenia (19%). Patients aged 65 years or over had a higher incidence of moderate renal impairment compared to the overall study population (31% vs. 17%).<sup>396</sup> Improvements in median OS and PFS and a similar safety profile were observed in a subgroup analysis of patients with metastatic EGJ adenocarcinoma (n = 145).<sup>397</sup> Trifluridine and tipiracil is recommended as a preferred category 1 treatment option for patients with recurrent or metastatic EGJ adenocarcinoma in the third-line or subsequent setting. However, trifluridine and tipiracil did not result in any partial or complete responses and produced substantial grade 3–4 toxicities. Therefore, this treatment should be considered for a very select population of patients with low-volume EGJ adenocarcinoma who have minimal or no symptoms and the ability to swallow pills.

Other recommended regimens for second-line or subsequent therapy include irinotecan and cisplatin,<sup>352,361</sup> ramucirumab combined with irinotecan<sup>398</sup> or FOLFIRI (for adenocarcinoma only),<sup>399</sup> and irinotecan and docetaxel (category 2B).<sup>364</sup> Options that are useful in certain circumstances include pembrolizumab<sup>162,164,400</sup> or dostarlimab-gxly<sup>401</sup> for MSI-H/dMMR tumors, pembrolizumab for TMB-H (≥10 mutations/megabase) tumors,<sup>402</sup> entrectinib or larotrectinib for *NTRK* gene fusion-positive tumors,<sup>403,404</sup> dabrafenib and trametinib for *BRAF* V600E mutated tumors<sup>405</sup> and seliperatinib for *RET* gene fusion positive tumors.<sup>406</sup> See *Targeted Therapies* below for more information on these agents.

### Targeted Therapies

At present, several targeted therapeutic agents, trastuzumab, pembrolizumab, nivolumab, entrectinib/larotrectinib, seliperatinib, and dabrafenib/trametinib, have been approved by the FDA for use in advanced esophageal and EGJ cancers. Treatment with trastuzumab is based on testing for HER2 overexpression.<sup>141</sup> Treatment with pembrolizumab or nivolumab is based on testing for MSI by PCR/NGS or MMR by IHC, PD-L1 expression by IHC, or high TMB by NGS.<sup>162,164,348,400,402,407,408</sup> The FDA has granted approval for the use of select TRK inhibitors for *NTRK* gene fusion-positive solid tumors,<sup>409,410</sup> seliperatinib for *RET* gene fusion-positive tumors,<sup>406</sup> and dabrafenib/trametinib for tumors with *BRAF* V600E mutations.<sup>405</sup> When limited tissue is available for testing or the patient is unable to undergo a traditional biopsy, comprehensive genomic profiling via a validated NGS assay performed in a CLIA-approved laboratory may be used for the identification of *ERBB2* amplification, MSI status, MMR deficiency, TMB, *NTRK* gene fusions, *RET* gene fusions, and *BRAF* V600E mutations. The use of IHC/ISH/targeted PCR should be considered first, followed by NGS testing as appropriate.

### Trastuzumab

The ToGA trial was the first randomized prospective phase III trial that evaluated the efficacy and safety of trastuzumab in HER2 overexpression positive advanced gastric and EGJ adenocarcinoma.<sup>156</sup> In this trial, 594 patients with HER2 overexpression positive, locally advanced, recurrent, or metastatic gastric or EGJ adenocarcinoma were randomized to receive trastuzumab plus chemotherapy (cisplatin plus fluorouracil or capecitabine) or chemotherapy alone.<sup>156</sup> The majority of patients had gastric cancer (80% in the trastuzumab group and 83% in the chemotherapy group). Median follow-up time was 19 months and 17 months, respectively, in the two groups. Results showed significant



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

improvement in median OS with the addition of trastuzumab to chemotherapy in HER2 overexpression positive patients (13.8 vs. 11 months, respectively;  $P = .046$ ). This study established trastuzumab in combination with cisplatin and a fluoropyrimidine as the standard treatment for patients with HER2 overexpression positive advanced gastroesophageal adenocarcinoma. In a post-hoc subgroup analysis, the addition of trastuzumab to chemotherapy further improved OS in patients whose tumors were IHC 2+ and FISH positive or IHC 3+ ( $n = 446$ ; 16 vs. 11.8 months; HR, 0.65) compared to those with tumors that were IHC 0 or 1+ and FISH positive ( $n = 131$ ; 10 vs. 8.7 months; HR, 1.07).

The phase II HERXO trial assessed the combination of trastuzumab with capecitabine and oxaliplatin in the first-line treatment of patients with HER2 overexpression positive advanced gastric or EGJ adenocarcinoma ( $n = 45$ ).<sup>411</sup> At a median follow-up of 13.7 months, PFS and OS were 7.1 and 13.8 months, respectively, and 8.9%, 37.8%, and 31.1% of patients achieved a complete response, partial response, and stable disease. The most frequently reported grade 3 or higher adverse events were diarrhea (26.6%), fatigue (15.5%), nausea (20%), and vomiting (13.3%). In a retrospective study of 34 patients with HER2 overexpression positive metastatic gastric or EGJ adenocarcinoma, the combination of trastuzumab with a modified FOLFOX regimen (mFOLFOX6) improved tolerability compared with the cisplatin plus fluorouracil regimen in previously untreated patients with HER2 overexpression positive tumors.<sup>412</sup> The ORR with this regimen was 41% and median PFS and OS were 9.0 months and 17.3 months, respectively. The most frequent grade 3–4 toxicities were neutropenia (8.8%) and neuropathy (17.6%). These results suggest that the combinations of trastuzumab with capecitabine and oxaliplatin or with modified FOLFOX are effective regimens with acceptable safety profiles in patients with HER2 overexpression positive gastroesophageal cancers. Therefore, trastuzumab should be added to first-line chemotherapy in combination

with a fluoropyrimidine and a platinum agent (oxaliplatin is preferred over cisplatin due to lower toxicity) in patients with advanced HER2 overexpression positive adenocarcinoma. An FDA-approved biosimilar is an appropriate substitute for trastuzumab. Trastuzumab may be combined with other chemotherapy agents for first-line therapy, but should not be continued in second-line therapy.<sup>413</sup>

### Nivolumab

Nivolumab is a monoclonal PD-1 antibody that was approved by the FDA in May 2021 for the treatment of patients with completely resected esophageal or EGJ tumors with residual pathologic disease who had received preoperative chemoradiation.<sup>414</sup> This approval was based on results from the phase III Checkmate-577 trial, which evaluated the safety and efficacy of nivolumab ( $N = 532$ ) versus placebo ( $N = 262$ ) in this setting.<sup>294</sup> After a median follow-up of 24.4 months, median DFS was significantly longer in the nivolumab group compared to the placebo group (22.4 vs. 11 months; HR, .69;  $P < .001$ ). The DFS benefit with nivolumab was observed regardless of PD-L1 expression levels. Grade 3–4 adverse events occurred in 13% of patients in the nivolumab group and 6% in the placebo group. The most common adverse events in the nivolumab group were fatigue, rash, musculoskeletal pain, and pruritus. Postoperative nivolumab is a new effective treatment option for patients at high risk for recurrence due to the presence of residual pathologic disease following preoperative chemoradiation and R0 resection.

Nivolumab was also approved by the FDA in April 2021, in combination with fluoropyrimidine- and platinum-based chemotherapy, for the first-line treatment of patients with advanced or metastatic esophageal or EGJ adenocarcinoma.<sup>415</sup> This approval was based on results from the phase III Checkmate-649 trial, which randomized 1581 patients with previously untreated, HER2-negative, unresectable gastric, EGJ, or esophageal adenocarcinoma to receive chemotherapy alone or nivolumab plus



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

chemotherapy (capecitabine and oxaliplatin or modified FOLFOX).<sup>348</sup> The addition of nivolumab to chemotherapy resulted in significant improvements in OS (14.4 vs. 11.1 months; HR, .71;  $P < .0001$ ) and PFS (7.7 vs. 6 months; HR, .68;  $P < .0001$ ) compared to chemotherapy alone in patients with a PD-L1 CPS of greater than or equal to 5 ( $n = 955$ ). Additional results also showed some improvement in OS and PFS in patients with a PD-L1 CPS of greater than or equal to 1 ( $n = 1296$ ; OS = 14 vs. 11.3 months; HR, .77; PFS = 7.5 vs. 6.9; HR, .74) and in all randomly assigned patients (OS = 13.8 vs. 11.6; HR, .8; PFS = 7.7 vs. 6.9; HR, .77). Among all patients, 59% of those in the nivolumab plus chemotherapy group and 44% of those in the chemotherapy alone group experienced grade 3–4 treatment-related adverse events. The most common any-grade treatment-related adverse events were nausea, diarrhea, and peripheral neuropathy across both groups. Sixteen treatment-related deaths occurred in the nivolumab plus chemotherapy group compared to 4 in the chemotherapy alone group. Therefore, nivolumab plus fluoropyrimidine- and oxaliplatin-based chemotherapy is a preferred first-line treatment option for patients with HER2-negative esophageal or EGJ adenocarcinoma with PD-L1 expression levels by CPS of greater than or equal to 5 (category 1) or less than 5 (category 2B).

In May 2022, nivolumab was approved in combination with fluoropyrimidine- and platinum-based chemotherapy and in combination with ipilimumab for the first-line treatment of patients with advanced or metastatic esophageal SCC based on results of the phase III CheckMate-648 trial.<sup>350</sup> In this trial, 970 patients with previously untreated unresectable advanced, recurrent, or metastatic esophageal SCC were randomized to receive nivolumab plus chemotherapy, nivolumab plus the monoclonal antibody ipilimumab, or chemotherapy alone. Ipilimumab is an immune checkpoint inhibitor that targets CTLA-4. After a minimum 13-month follow-up, median OS was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone among patients with tumor

cell PD-L1 expression of 1% or greater (15 vs. 9 months; HR, .54;  $P < .001$ ) as well as in the overall population (13 vs. 11 months; HR, .74;  $P = .002$ ). OS was also significantly longer in the nivolumab plus ipilimumab group than in the chemotherapy alone group in patients with tumor cell PD-L1 expression of 1% or greater (14 vs. 9 months; HR, .64;  $P = .001$ ) and in the overall population (13 vs. 11 months; HR, .78;  $P = .01$ ). The incidence of grade 3 or 4 treatment-related adverse events was 47% with nivolumab plus chemotherapy, 32% with nivolumab plus ipilimumab, and 36% with chemotherapy alone. Based on this data, nivolumab combined with fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin or cisplatin as well as nivolumab plus ipilimumab are recommended as preferred regimens for treatment of esophageal SCC. Patients with tumor cell PD-L1 expression of 1% or greater, which was 91% of patients, benefited from both regimens. Therefore, the NCCN Panel recommends these two regimens irrespective of CPS score.

Nivolumab was FDA-approved in June 2020 for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal SCC after prior fluoropyrimidine- and platinum-based chemotherapy.<sup>416</sup> This approval was based on results from the international phase III ATTRACTION-3 trial, which compared nivolumab to chemotherapy in patients with advanced esophageal SCC refractory or intolerant to at least one fluoropyrimidine- and platinum-based regimen.<sup>386</sup> Patients ( $n = 419$ ) were randomized 1:1 to receive nivolumab or investigator's choice of chemotherapy (either docetaxel or paclitaxel). Median OS was significantly improved in patients receiving nivolumab compared to those receiving chemotherapy (10.9 vs. 8.4 months;  $P = .019$ ). Importantly, the OS benefit was observed regardless of tumor PD-L1 expression levels. The ORR was 19.3% in the nivolumab arm versus 21.5% in the chemotherapy arm, with a median response duration of 6.9 and 3.9 months, respectively. Grade 3–4 treatment-related adverse events occurred in 18% of patients in the nivolumab group, the most common being anemia, and in 63% of patients



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

in the chemotherapy group, the most common being decreased neutrophil count. Since nivolumab was associated with a significant improvement in OS and a favorable safety profile compared to chemotherapy, it is a category 1 recommendation in this setting and represents a new and effective second-line treatment option for patients with previously treated advanced esophageal SCC.

### Pembrolizumab

First-line treatment with the PD-1 antibody pembrolizumab in combination with fluoropyrimidine- and platinum-based chemotherapy was approved by the FDA in March 2021 for patients with locally advanced or metastatic esophageal or EGJ tumors.<sup>417</sup> This approval was based on data from the phase III KEYNOTE-590 trial, which randomized 749 patients with previously untreated, locally advanced, or metastatic esophageal SCC, esophageal adenocarcinoma, or EGJ adenocarcinoma to receive pembrolizumab plus chemotherapy or placebo plus chemotherapy.<sup>349</sup> At a median follow-up of 22.6 months, statistically significant improvements in OS and PFS were observed in patients randomized to pembrolizumab plus chemotherapy. Median OS was 13.9 months for the pembrolizumab arm versus 8.8 months for the chemotherapy arm in patients with SCC and PD-L1 CPS  $\geq 10$  (HR, 0.57;  $P < .0001$ ), 12.6 months versus 9.8 months in patients with SCC (HR, 0.72;  $P = .0006$ ), 13.5 versus 9.4 months in patients with PD-L1 expression  $\geq 10$  (HR, 0.62;  $P < .0001$ ), and 12.4 versus 9.8 months in all patients (HR, 0.73;  $P < .0001$ ).

Pembrolizumab plus chemotherapy was also superior to placebo plus chemotherapy for PFS in patients with SCC (6.3 vs. 5.8 months; HR, 0.65;  $P < .0001$ ), PD-L1 CPS  $\geq 10$  (7.5 vs. 5.5 months; HR, 0.51;  $P < .0001$ ), and in all patients (6.3 vs. 5.8 months; HR, 0.65;  $P < .0001$ ). The most common adverse events in patients who received pembrolizumab were nausea, constipation, diarrhea, vomiting, stomatitis, fatigue, decreased appetite, and weight loss. Grade 3 or higher treatment-related adverse events occurred in 72% of patients receiving pembrolizumab and 68% of

those receiving placebo. Based on these results, pembrolizumab plus fluoropyrimidine- and platinum-based chemotherapy may be used for the first-line treatment of patients with SCC or adenocarcinoma with PD-L1 expression levels by CPS of greater than or equal to 10 (category 1 in combination with cisplatin) or less than 10 (category 2B).

Pembrolizumab can also be added to first-line fluoropyrimidine, platinum, and trastuzumab based on the results of an interim analysis of the first 264 patients enrolled in the phase III KEYNOTE-811 trial, which compared pembrolizumab to placebo in combination with trastuzumab and the investigator's choice of chemotherapy with fluorouracil and cisplatin or capecitabine and oxaliplatin in patients with previously untreated advanced HER2-positive gastric or EGJ adenocarcinoma.<sup>347</sup> Results showed an improved ORR (74% vs. 52%;  $P = .00006$ ) and median duration of response (10.6 vs. 9.5 months) with the addition of pembrolizumab compared to placebo. Complete responses were also more frequent in the pembrolizumab group compared to placebo (11% vs. 3%). Similar incidence of adverse events was observed in the pembrolizumab and placebo groups (57% of participants in both groups), the most common being diarrhea, nausea and anemia. Therefore, pembrolizumab combined with trastuzumab and fluoropyrimidine and platinum-based chemotherapy is a preferred option for treatment of patients with advanced HER2 overexpression positive adenocarcinoma.

In 2019, the FDA approved pembrolizumab for the second-line treatment of esophageal SCC with PD-L1 expression levels by CPS of  $\geq 10$  based on the results of the KEYNOTE-180 and KEYNOTE-181 trials.<sup>418</sup> In the phase II single-arm KEYNOTE-180 trial, which evaluated pembrolizumab monotherapy in 121 patients with progressive disease following two or more prior lines of therapy, the ORR was 9.9% among all patients.<sup>419</sup> The ORR was 14.3% among patients with esophageal SCC ( $n = 63$ ), 5.2% among patients with adenocarcinoma ( $n = 58$ ), 13.8% among patients with PD-L1–positive tumors ( $n = 58$ ), and 6.3% among patients



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

with PD-L1–negative tumors (n = 63). Overall, 12.4% of patients had grade 3–5 treatment-related adverse events and five patients discontinued treatment because of toxicity. Long-term results demonstrated a durable clinical benefit for pembrolizumab in this treatment population.<sup>420</sup> These results demonstrated the efficacy and tolerability of pembrolizumab in heavily pretreated esophageal SCC with high PD-L1 expression. The phase III KEYNOTE-181 trial evaluated pembrolizumab versus investigator’s choice of chemotherapy (docetaxel, paclitaxel, or irinotecan) as second-line therapy in 628 patients with advanced SCC or adenocarcinoma of the esophagus or EGJ.<sup>387</sup> Patients (401 with SCC and 222 with PD-L1 CPS ≥10) were randomized to pembrolizumab or chemotherapy and randomization was stratified by histology (SCC vs. adenocarcinoma) and region (Asia vs. rest of world). Pembrolizumab significantly improved median OS (9.3 vs. 6.7 months;  $P = .007$ ) and 12-month OS rates (43% vs. 20%) compared to chemotherapy in patients with esophageal SCC tumors with PD-L1 CPS ≥10. Fewer patients had grade 3–5 treatment-related adverse events with pembrolizumab compared to chemotherapy (18% vs. 41%). Based on these data, pembrolizumab is a category 1, preferred second-line therapy option for patients with advanced esophageal SCC with PD-L1 expression levels by CPS of greater than or equal to 10.

Pembrolizumab was FDA approved in 2017 for the treatment of patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.<sup>421</sup> This first-ever tissue- and site-agnostic approval was based on data from 149 patients with MSI-H/dMMR cancers (90 patients had colorectal cancer) enrolled across five multicenter single-arm clinical trials.<sup>162,164,400</sup> The ORR was 39.6% and responses lasted 6 or more months for 78% of those who responded to pembrolizumab. There were 11 complete responses and 48 partial responses, and the ORR was similar irrespective of cancer type. Therefore, pembrolizumab is a second-

line or subsequent therapy option for patients with MSI-H/dMMR gastroesophageal tumors.

In June 2020, the FDA approved pembrolizumab for the treatment of patients with metastatic TMB-H solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.<sup>422</sup> This approval was based on a retrospective analysis of 102 patients enrolled in the KEYNOTE-158 trial who had tumors identified as TMB-H.<sup>402</sup> The ORR for these patients was 29%, with a 4% complete response rate. The median duration of response was not reached, with 50% of patients having response durations for 24 months or longer. Based on these data, pembrolizumab may be used for the second-line or subsequent treatment of patients with TMB-H gastroesophageal tumors. However, it should be noted that no patients with gastroesophageal cancer were included in the KEYNOTE-158 trial.

### Ramucirumab

Ramucirumab, a VEGFR-2 antibody, has shown favorable results in patients with previously treated advanced or metastatic gastroesophageal cancers in two phase III clinical trials.<sup>383,384</sup> An international randomized multicenter phase III trial (REGARD) demonstrated a survival benefit for ramucirumab in patients with advanced gastric or EGJ adenocarcinoma progressing after first-line chemotherapy.<sup>383</sup> In this study, 355 patients were randomized to receive ramucirumab (n = 238) or placebo (n = 117). Median OS was 5.2 months in patients treated with ramucirumab compared to 3.8 months for those in the placebo group ( $P = .047$ ). Ramucirumab was associated with higher rates of hypertension than placebo (16% vs. 8%), whereas rates of other adverse events were similar.

The international phase III RAINBOW trial evaluated paclitaxel with or without ramucirumab in patients (n = 665) with metastatic gastric or EGJ

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

adenocarcinoma progressing on first-line chemotherapy.<sup>384</sup> Patients randomized to receive ramucirumab plus paclitaxel (n = 330) had significantly longer median OS (9.63 months) compared to patients receiving paclitaxel alone (n = 335; 7.36 months;  $P < .0001$ ). The median PFS was 4.4 months and 2.86 months, respectively, and the ORR was 28% for ramucirumab plus paclitaxel compared to 6% for paclitaxel alone ( $P = .0001$ ). Neutropenia and hypertension were more common with ramucirumab plus paclitaxel. An exposure-response analysis revealed that ramucirumab was a significant predictor of OS and PFS in both studies.<sup>423</sup> Based on these results, ramucirumab (as a single agent or in combination with paclitaxel) was approved by the FDA for the treatment of patients with advanced gastric or EGJ adenocarcinoma refractory to or progressive following first-line therapy with platinum- or fluoropyrimidine-based chemotherapy. The guidelines recommend ramucirumab as a single agent (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) or in combination with paclitaxel (preferred) as treatment options for second-line or subsequent therapy in patients with advanced or metastatic esophageal or EGJ adenocarcinoma.<sup>383,384</sup>

Ramucirumab combined with FOLFIRI can be an option for second-line or subsequent therapy for patients with advanced esophageal or EGJ adenocarcinoma. In a multi-institutional retrospective analysis of 29 patients with advanced gastric or EGJ adenocarcinoma who received FOLFIRI plus ramucirumab in the second-line setting, the ORR was 23% with a disease control rate of 79%.<sup>399</sup> Median PFS was 6 months and median OS was 13.4 months. Six- and 12-month OS were 90% and 41%, respectively. No new safety signals were observed with the combination treatment, making FOLFIRI plus ramucirumab a safe, non-neurotoxic alternative to ramucirumab plus paclitaxel. Ramucirumab combined with irinotecan is also an option for second-line or subsequent therapy for patients with advanced adenocarcinoma.<sup>398</sup>

Due to the results of the international phase III RAINFALL trial, in which treatment with ramucirumab did not reduce the risk of disease progression or death in treatment-naïve patients with metastatic gastroesophageal adenocarcinoma, the addition of ramucirumab to first-line chemotherapy is not recommended at this time.<sup>424</sup>

### Fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki is an antibody-drug conjugate consisting of trastuzumab and a cytotoxic topoisomerase I inhibitor connected by a cleavable tetrapeptide-based linker. The efficacy and safety of fam-trastuzumab deruxtecan-nxki in advanced or metastatic gastric or EGJ adenocarcinoma was evaluated in the phase II DESTINY-Gastric01 trial, which included 188 patients with progressive disease following at least two prior lines of therapy, including trastuzumab.<sup>385</sup> Patients were randomized 2:1 to receive either fam-trastuzumab deruxtecan-nxki or physician's choice of chemotherapy (paclitaxel or irinotecan). The confirmed objective response rate for patients on fam-trastuzumab deruxtecan-nxki was 40.5% compared to 11% for those on chemotherapy. OS (12.5 vs. 8.4 months;  $P = .0097$ ), median PFS (5.6 vs. 3.5 months) and duration of response (11.3 vs. 3.9 months) were also higher in the fam-trastuzumab deruxtecan-nxki group compared to the chemotherapy group. Fam-trastuzumab deruxtecan-nxki resulted in more toxicities than systemic chemotherapy in this trial. The most common adverse events (grade 3 or higher) were a decreased neutrophil count (51% of the fam-trastuzumab deruxtecan-nxki group and 24% of the chemotherapy group), anemia (38% and 23%, respectively), and decreased white blood cell count (21% and 11%). Fam-trastuzumab deruxtecan-nxki-related interstitial lung disease or pneumonitis occurred in 12 patients resulting in one drug-related death (due to pneumonia). No drug-related deaths occurred in the physician's choice group. The FDA has approved fam-trastuzumab deruxtecan-nxki to treat HER2 overexpression positive tumor patients in second-line or subsequent



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

therapy. Therefore, fam-trastuzumab deruxtecan-nxki may be used as a second-line or subsequent treatment option for patients with HER2 overexpression positive adenocarcinoma following failure of prior trastuzumab-based regimen. However, careful patient selection and close monitoring of patients for excessive toxicity is recommended.

### Entrectinib and Larotrectinib

Gene fusions involving *NTRK1*, *NTRK2*, or *NTRK3* encode TRK fusion proteins (TRKA, TRKB, TRKC), which have increased kinase function and are implicated in the oncogenesis of many solid tumors including head and neck, thyroid, soft tissue, lung, and colon.<sup>404,425</sup> Although believed to be extremely rare in gastroesophageal cancers, one case report provides evidence that *NTRK* gene fusions occur in gastric adenocarcinoma and may be associated with an aggressive phenotype.<sup>426-428</sup> No such case report for *NTRK* gene fusions in esophageal or EGJ cancers has yet been published.

In 2018, the FDA granted accelerated approval to the TRK inhibitor larotrectinib for the treatment of adult and pediatric patients (aged ≥12 years) with solid tumors that have an *NTRK* gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.<sup>410</sup> This FDA approval was based on data from three multicenter single-arm clinical trials. Patients with prospectively identified *NTRK* gene fusion-positive cancers were enrolled into one of three protocols: a phase I trial involving adults (LOXO-TRK-14001), a phase I–II trial involving children (SCOUT), and a phase II trial involving adolescents and adults (NAVIGATE).<sup>404</sup> A total of 55 patients with unresectable or metastatic solid tumors harboring an *NTRK* gene fusion who experienced disease progression following systemic therapy were enrolled across the three protocols and treated with larotrectinib. The

most common cancer types represented were salivary gland tumors (22%), soft tissue sarcoma (20%), infantile fibrosarcoma (13%), and thyroid cancer (9%). The ORR across the three trials was 75%, with a complete response rate of 22%. At a median follow-up of 9.4 months, 86% of the patients with a response were either continuing treatment with larotrectinib or had undergone curative-intent surgery. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. Response duration was greater than or equal to 6 months for 73%, greater than or equal to 9 months for 63%, and greater than or equal to 12 months for 39% of patients. At the time of data analysis, the median duration of response and PFS had not been reached. Adverse events were predominantly grade 1, the most common being increased aspartate aminotransferase (AST) levels, vomiting, constipation, and dizziness. The SCOUT (Clinical Trial ID: [NCT02637687](#)) and NAVIGATE (Clinical Trial ID: [NCT02576431](#)) trials are still actively recruiting patients with *NTRK* gene fusion-positive tumors.

In 2019, the FDA approved the second TRK inhibitor, entrectinib, for the same indications as larotrectinib, as well as for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are *ROS1*-positive.<sup>409</sup> The approval of entrectinib for the treatment of *NTRK* gene fusion-positive tumors was based on data from three multicenter, single-arm, phase I and phase II clinical trials. A total of 54 patients aged 18 years or over with metastatic or locally advanced *NTRK* gene fusion-positive solid tumors were enrolled into one of the three protocols (ALKA-372-001, STARTRK-1, or STARTRK-2).<sup>403</sup> The most common cancer types represented were sarcoma, NSCLC, mammary analogue secretory carcinoma, breast, thyroid, and colorectal. The ORR across the three trials was 57%, with a complete response rate of 7%. Response duration was greater than or equal to 6 months for 68% of patients and greater than or equal to 12 months for 45% of patients. The median duration of



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

response was 10 months. The most common grade 3–4 treatment-related adverse events were increased weight and anemia while the most common serious treatment-related adverse events were nervous system disorders. STARTRK-2 (Clinical Trial ID: [NCT02568267](#)) is still actively recruiting patients with *NTRK* gene fusion-positive tumors. Based on these data, entrectinib and larotrectinib are recommended as second-line or subsequent treatment options for patients with *NTRK* gene fusion-positive gastroesophageal tumors.

### Dostarlimab-gxly

Dostarlimab-gxly, an anti-PD-1 antibody, was approved by the FDA in August 2021 for the treatment of patients with dMMR recurrent or advanced solid tumors that have progressed on or following prior treatment, who have no satisfactory alternative treatment options, and who had not previously received a PD-1 or PD-L1 inhibitor.<sup>429</sup> This approval was based on data from the nonrandomized phase 1 multi-cohort GARNET trial, which evaluated the safety and antitumor activity of dostarlimab-gxly in 209 patients with dMMR solid tumors who had not received prior PD-1, PDL-1, or CTLA4 inhibitors.<sup>401,430</sup> The majority of patients had endometrial or GI cancers. The ORR was 42%, with a 9% complete response rate and 33% partial response rate, and the median duration of response was 35 months. The most common treatment-related adverse events were fatigue, anemia, diarrhea, and nausea. Immune-mediated adverse events also occurred, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic toxicities. Based on these data, dostarlimab-gxly may be used for second-line or subsequent therapy for patients with MSI-H/dMMR gastroesophageal tumors.

### Dabrafenib and Trametinib

In June 2022, the FDA granted tumor agnostic approval for the combination of dabrafenib, a B-Raf inhibitor, and trametinib, a MEK inhibitor, for treatment of patients with unresectable or metastatic solid tumors with *BRAF* V600E mutations who have progressed following prior treatment and have no satisfactory alternative treatment options.<sup>431</sup> This approval was based in part on data from the phase II BRF117019 and NCI-MATCH trials, which enrolled a combined 131 adult patients with various *BRAF* V600E mutated tumors types.<sup>405,431</sup> In subprotocol H (EAY131-H) of the NCI-MATCH platform trial, patients with *BRAF* V600E mutated solid tumors (except for melanoma, thyroid cancer, or colorectal cancer) received combined dabrafenib and trametinib continuously until disease progression or intolerable toxicity. The ORR was 38% ( $P < .0001$ ) and PFS was 11.4 months.<sup>405</sup> The median OS in this cohort was 29 months. For the 131 patients across both trials, the ORR was 41%. The most common treatment-related adverse events included pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, and vomiting. Based on these data, dabrafenib and trametinib may be used for second-line or subsequent therapy for patients with *BRAF* V600E mutated gastroesophageal tumors.

### Selpercatinib

In September 2022, the FDA granted tumor agnostic approval for selpercatinib, a tyrosine kinase inhibitor, for treatment of patients with locally advanced or metastatic solid tumors with *RET* gene fusions who have progressed following prior treatment and have no satisfactory alternative treatment options.<sup>432</sup> This approval was based on an interim analysis of data from the ongoing phase I/II LIBRETTO-001 trial, which evaluated 41 patients with *RET* fusion-positive tumors (other than non-small cell lung cancer and thyroid cancer) who received selpercatinib until disease progression or unacceptable toxicity.<sup>406</sup> The ORR was 44%



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

with a duration of response of 25 months. The most common treatment-related adverse events included edema, diarrhea, fatigue, dry mouth, hypertension, and abdominal pain. The most common grade 3 or higher treatment-related adverse events were hypertension, increased alanine aminotransferase and increased aspartate aminotransferase. Based on these data, selpercatinib may be used for second-line or subsequent therapy for patients with *RET* gene fusion-positive gastroesophageal tumors.

### Treatment Guidelines

The management of patients with esophageal and EGJ cancers requires the expertise of several disciplines, including surgical oncology, medical oncology, gastroenterology, radiation oncology, radiology, and pathology. In addition, the presence of nutritional services, social workers, case managers, nurses, palliative care specialists, and other supporting disciplines are also desirable. Hence, the panel believes in an infrastructure that encourages multidisciplinary treatment decision-making by members of all disciplines taking care of patients with localized esophagogastric cancers. The recommendations made by the multidisciplinary team may be considered advisory to the primary group of treating physicians of the patient. See *Principles of Multidisciplinary Team Approach for Esophagogastric Cancers* in the algorithm for more information.

### Workup

Newly diagnosed patients should undergo a complete history and physical examination, complete blood count (CBC), comprehensive chemistry profile, and upper GI endoscopy with biopsy of the primary tumor. Histologic evaluation is required for correct diagnosis of SCC or adenocarcinoma; the extent of tumor involvement into the EGJ and cardia should be clearly documented, where applicable. CT scan (with

oral and IV contrast) of the chest and abdomen should also be performed. Pelvic CT with contrast should be obtained when clinically indicated. EUS and FDG-PET/CT evaluation from skull base to mid-thigh are recommended if metastatic disease is not evident. ER is recommended for the accurate staging of early-stage cancers (T1a or T1b). ER may also be therapeutic for early-stage disease. Biopsy of metastatic disease should be performed as clinically indicated and may be used for biomarker testing. Assessment of Siewert tumor type should also be included as part of the initial workup in all patients with EGJ adenocarcinoma.<sup>73,74</sup> If the tumor is located at or above the carina and there is no evidence of metastatic disease, bronchoscopy (including biopsy of any abnormalities and cytology of the washings) should be performed. For patients in whom the upper GI tract cannot be visualized, a double contrast barium study of the upper GI tract is an alternative option. Nutritional assessment and counseling as well as smoking cessation advice, counseling, and pharmacotherapy (as indicated) are recommended for all patients.

MSI and PD-L1 testing are recommended at the time of diagnosis if metastatic disease is documented or suspected. HER2 testing is recommended if metastatic adenocarcinoma is documented or suspected. NGS may be considered via a validated assay. The guidelines also recommend screening for family history of esophageal or EGJ cancers. Referral to a cancer genetics professional is recommended for those with a family history or a known high-risk syndrome associated with esophageal and EGJ cancers. See *Principles of Genetic Risk Assessment for Esophageal and Esophagogastric Junction (EGJ) Cancers* in the algorithm for more information.

Initial workup enables patients to be classified into two clinical stage groups:

- Locoregional cancer: stage I–IVA (except T4b or unresectable N3)



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

- Metastatic cancer: stage IVA (T4b or unresectable N3 only) and IVB

### Additional Evaluation

Additional evaluations are warranted to assess a patient's medical condition, their ability to tolerate major surgery, and the feasibility of resection. These evaluations may include pulmonary function studies, cardiac testing, and nutritional assessment. Laparoscopy is optional for EGJ adenocarcinoma if there is no evidence of metastatic disease. Colonoscopy may be warranted if colon interposition is planned as part of the surgical procedure. A superior mesenteric artery angiogram should be considered only in select patients when colon interposition is planned.

Additional evaluation enables patients with locoregional cancer to be further classified into the following groups:

- Medically fit for surgery
- Nonsurgical candidates (medically unable to tolerate major surgery or medically fit patients who decline surgery)

An enteric feeding tube should be considered in surgical candidates for preoperative nutritional support. A percutaneous gastrostomy tube may be considered for patients with cervical esophageal tumors receiving definitive chemoradiation or for patients with marginally resectable disease. Multidisciplinary expertise is recommended prior to placement of a percutaneous gastrostomy tube. The approach, timing, and location of the feeding tube should be discussed with the surgeon prior to its placement.

### Primary Treatment

#### **Medically Fit Patients: Squamous Cell Carcinoma**

Endoscopic therapies (ER with or without ablation) are the preferred primary treatment option for patients with pTis or pT1a tumors. Ablation alone may be appropriate for certain patients with pTis tumors. Available evidence indicates that ablation following ER may be effective for the complete removal of early-stage SCC of the esophagus.<sup>204,433</sup>

Esophagectomy is also indicated for patients with extensive pTis or pT1a tumors, especially those with nodular disease that is not adequately controlled by ER with ablation.<sup>239</sup> Esophagectomy is the recommended primary treatment option for patients with pT1b, N0 tumors and cT1b–cT2, N0 low-risk lesions (<3 cm in diameter and well-differentiated).

Preoperative chemoradiation or definitive chemoradiation are recommended for patients with cT2, N0 high-risk lesions (LVI, ≥3 cm, poorly differentiated) and cT1b–cT2, N+ or cT3–cT4a, any N tumors.<sup>315,318</sup> Histologic confirmation of suspected positive nodes is desirable. Definitive chemoradiation is an appropriate option for patients who decline surgery.<sup>284,335,434</sup> Definitive chemoradiation is also recommended for patients with cT4b (unresectable) tumors and occasionally can facilitate surgical resection in select patients.<sup>435</sup> Chemotherapy alone can be considered in the setting of invasion of the trachea, great vessels, vertebral body, or heart.

#### **Medically Fit Patients: Adenocarcinoma**

Primary treatment options for patients with pTis, pT1a or pT1b, N0 adenocarcinoma are similar to those described above for SCC. Some superficial pT1b tumors may be controlled by ER followed by ablation, while more invasive pT1b tumors, especially nodular disease that is not adequately controlled by ER with ablation, may require esophagectomy.<sup>239</sup> Esophagectomy is also indicated for patients with cT1b–cT2, N0 low-risk lesions (<3 cm in diameter and well-differentiated). Primary treatment



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

options for patients with cT2, N0 high-risk lesions (LVI,  $\geq 3$  cm, poorly differentiated), and cT1b–cT2, N+ or cT3–cT4a, any N tumors include preoperative chemoradiation for planned esophagectomy (category 1; preferred),<sup>167</sup> perioperative chemotherapy<sup>168,292</sup> and definitive chemoradiation (only for patients who decline surgery).<sup>284,298,335</sup> Histologic confirmation of suspected positive nodes is desirable. Repeat multidisciplinary consultation is recommended before proceeding to surgery for post-neoadjuvant T4a and bulky multiple nodal station N3. Definitive chemoradiation is the primary treatment option for patients with cT4b (unresectable) tumors and occasionally can facilitate surgical resection in select patients.<sup>435</sup> Chemotherapy alone can be considered in the setting of invasion of the trachea, great vessels, vertebral body, or heart.

### **Non-Surgical Candidates**

Endoscopic therapies (ER with or without ablation) are the recommended primary treatment option for patients with pTis, pT1a or pT1b, N0 SCC, or adenocarcinoma tumors. Ablation may not be needed if all lesions are completely excised by ER. Ablation alone may be an appropriate option for certain patients with pTis tumors. Definitive chemoradiation is recommended for non-surgical candidates with cT1b–cT4b, any N tumors who are able to tolerate chemoradiation. Palliative RT or palliative/best supportive care are the appropriate options for non-surgical candidates who are unable to tolerate chemoradiation.

### **Response Assessment and Additional Management**

Additional management options are based on the assessment of response to primary treatment. FDG-PET/CT scans are useful for the evaluation of patients after chemoradiation for the detection of distant lymphatic and hematogenous metastases.<sup>57,66</sup> Therefore, assessment with FDG-PET/CT (preferred) or FDG-PET scan should be done at least 5 to 8

weeks after the completion of preoperative therapy and prior to surgery. Chest/abdominal CT scan with contrast is recommended but is not required if FDG-PET/CT was done. Pelvic CT with contrast can be considered for distal lesions, if clinically indicated. Upper GI endoscopy and biopsy is recommended following definitive chemoradiation but is optional after preoperative chemoradiation if surgery is planned.

Esophagectomy (preferred for adenocarcinoma) or surveillance (category 2B) is recommended for patients with no evidence of disease following preoperative chemoradiation. Esophagectomy is preferred for those with persistent local disease following preoperative chemoradiation. Patients with no evidence of disease following definitive chemoradiation should be managed with surveillance, while esophagectomy is preferred for those with persistent local disease following definitive chemoradiation. Alternatively, patients with persistent local disease or unresectable/metastatic disease following either preoperative or definitive chemoradiation can be managed with palliative/best supportive care.

### **Postoperative Management**

Postoperative management is based on surgical margins, pathologic tumor stage, nodal status, histology, and previous treatment. The components of postoperative management have not been established in randomized trials for patients with esophageal cancer. Available evidence for the use of postoperative chemoradiation and postoperative chemotherapy comes from prospective randomized trials involving patients with gastric cancer.<sup>295-297</sup>

### **Patients with SCC Who Have Not Received Preoperative Chemoradiation**

Surveillance is recommended for patients with R0 resection (no cancer at resection margins), irrespective of their nodal status. Patients with R1 (microscopic residual cancer) or R2 (macroscopic residual cancer or M1)



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

resection should be treated with fluoropyrimidine-based chemoradiation. Alternatively, patients with R2 resection can receive palliative management.

### ***Patients with SCC Who Have Received Preoperative Chemoradiation***

Surveillance is recommended for patients with completely resected T0, N0 tumors. Nivolumab is recommended for patients with completely resected T+ and/or N+ tumors following preoperative chemoradiation (category 1).<sup>294</sup> Patients with R1 or R2 resection should be observed until disease progression or receive palliative management.

### ***Patients with Adenocarcinoma Who Have Not Received Preoperative Chemoradiation or Chemotherapy***

Surveillance is recommended for patients with R0 resection and negative nodal status. Chemoradiation is an alternative option for patients with pT3–pT4a tumors or select patients with pT2 tumors in the lower esophagus or EGJ and high-risk features (category 2B).<sup>295,296</sup> High-risk features include poorly differentiated or higher-grade cancer, LVI, perineural invasion, or age less than 50 years. Patients with node-negative pT3–pT4a tumors can also receive chemotherapy. For patients with R0 resection and N+, any T tumors, surveillance, chemoradiation,<sup>295,296</sup> or chemotherapy is recommended. Postoperative chemoradiation is recommended for patients who have had suboptimal surgery with poor nodal harvest or patients who were understaged at diagnosis. Patients with R1 resection should receive chemoradiation while those with R2 resection can receive either chemoradiation or palliative management.

### ***Patients with Adenocarcinoma Who Have Received Preoperative Chemoradiation or Chemotherapy***

Chemotherapy, if received perioperatively, is a category 1 recommendation for patients following complete resection. Nivolumab is a category 1 recommendation for patients with completely resected T+ and/or N+ tumors following preoperative chemoradiation.<sup>294</sup> Observation until disease progression is an alternative option for these patients. Based on current data, adjuvant chemoradiation is not recommended for patients who are node-positive following R0 resection.

Patients with R1 or R2 resection should be treated with chemoradiation if RT was not received preoperatively. Alternatively, patients with R1 resection can be observed until disease progression or considered for re-resection. Palliative management is an alternative option for patients with R2 resection.

### **Follow-up/Surveillance**

All patients should be followed systematically. However, surveillance strategies after successful therapy of esophageal and EGJ cancers remain controversial, with no high-level evidence to guide development of algorithms that balance benefits and risks (including cost) within this cohort. The stage-specific surveillance strategies provided in this guideline are based on currently available evidence from retrospective studies<sup>308,436-440</sup> and expert consensus. Although ~90% of recurrences occur within the first 2 years after the completion of local therapy, potentially actionable recurrences have sometimes been recognized more than 5 years after local therapy. Therefore, while routine esophageal/EGJ cancer-specific surveillance is generally not recommended for more than 5 years following the end of treatment, additional follow-up after 5 years may be considered based on risk factors and comorbidities.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

In general, follow-up for patients who are asymptomatic should include a complete history and physical examination every 3 to 6 months for the first 2 years and every 6 to 12 months for years 3 to 5. CBC, chemistry profile, upper GI endoscopy with biopsy, and imaging studies should be performed as clinically indicated. In addition, some patients may require dilatation of an anastomotic or a chemoradiation-induced stricture. Nutritional assessment and counseling are also recommended.

Differences in follow-up for early-stage disease reflect a heterogeneous potential for relapse and OS.<sup>207,441-446</sup> For example, whereas fully treated Tis and T1a, N0 disease have prognoses that approximate a non-cancer cohort, T1b disease does not perform as well. Thus, surveillance recommendations vary according to the depth of invasion as well as the treatment modality received by the patient. Endoscopic surveillance with EGD is recommended for patients with early-stage (Tis, T1a, and T1b) tumors treated with ER/ablation. EUS in conjunction with EGD may be considered for patients with T1b tumors treated with ER/ablation. In patients with Tis or T1a, N0 tumors treated with esophagectomy, EGD should be performed as clinically indicated based on symptoms. Imaging studies (chest/abdominal CT with contrast, unless contraindicated) should be considered during the surveillance of patients with T1b tumors. However, imaging studies as surveillance tools are not recommended for patients with Tis and T1a tumors.

Locoregional recurrence is relatively uncommon after preoperative chemoradiation or chemotherapy followed by esophagectomy with or without postoperative therapy, and most luminal recurrences can be detected by routine imaging studies. Therefore, EGD surveillance is not recommended. These patients should receive imaging studies (chest/abdominal CT with contrast, unless contraindicated) every 6 months for up to 2 years and then annually for up to 5 years. The same imaging schedule is also recommended for patients with T1b or greater, any N or T1a N+ tumors treated with esophagectomy with or without

postoperative therapy. CT scan is preferred but alternative imaging such as PET/CT or MRI can be considered as clinically indicated for patients who cannot undergo CT scan. EGD is recommended as needed based on symptoms and radiographic findings for patients with T1b or greater, any N or T1a N+ tumors treated with esophagectomy with or without postoperative therapy.<sup>308,437,438</sup> Unscheduled evaluation is recommended if a patient becomes symptomatic.

Locoregional recurrence is common after definitive chemoradiation,<sup>439</sup> making EGD a valuable surveillance tool in these patients. Routine surveillance for at least 24 months is recommended for patients with T1b–T4a, N0–N+ or T4b, any N tumors following definitive chemoradiation. Imaging studies (chest/abdominal CT with contrast, unless contraindicated) should be considered every 3 to 6 months for the first 2 years, and then annually for up to 5 years.<sup>439</sup> EGD should be performed every 3 to 6 months for the first 2 years and then annually for 3 more years.

See *Principles of Surveillance - Table 1* in the algorithm for specific recommendations.

### **Unresectable Locally Advanced, Recurrent, or Metastatic Disease**

When locoregional recurrence develops following prior chemoradiation therapy, the clinician should determine whether the patient is medically fit for surgery and if the recurrence is resectable. If both criteria are met, esophagectomy remains an option. Concurrent chemoradiation (preferred for those who had not previously received chemoradiation), surgery, chemotherapy, targeted agents, and palliative management/best supportive care are recommended options for patients who develop a locoregional recurrence following prior esophagectomy. Those who are medically unable to tolerate major surgery and those who develop an unresectable or metastatic recurrence should receive palliative management. If not done previously, MSI or MMR, PD-L1, and HER2



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

(only for adenocarcinoma) testing should be performed in patients with documented or suspected metastatic disease. NGS may be considered via a validated assay.

Palliative management and best supportive care are always indicated for patients with unresectable locally advanced, recurrent, or metastatic disease. The decision to offer palliative/best supportive care alone or with systemic therapy is dependent upon the patient's performance status. The [Eastern Cooperative Oncology Group Performance Status Scale](#) (ECOG PS) and the [Karnofsky Performance Status Scale](#) (KPS) are commonly used to assess the performance status of patients with cancer.<sup>447-449</sup>

Patients with higher ECOG PS scores are considered to have worse performance status while lower KPS scores are associated with worse survival for most serious illnesses. Patients with a KPS score less than 60% or an ECOG PS score greater than or equal to 3 should be offered palliative/best supportive care only. Systemic therapy can be offered in addition to palliative/best supportive care for patients with better performance status (KPS score  $\geq 60\%$  or ECOG PS score  $\leq 2$ ).

The survival benefit of systemic therapy compared to palliative/best supportive care alone has been demonstrated in small cohorts of patients with esophageal or EGJ adenocarcinoma included in gastric adenocarcinoma trials.<sup>343,344</sup> In a phase III randomized trial, the addition of docetaxel to best supportive care was associated with a survival benefit for patients with advanced adenocarcinoma of the esophagus (n = 33), EGJ (n = 59), or stomach (n = 76) that had progressed on or within 6 months of treatment with platinum and fluoropyrimidine-based combination chemotherapy.<sup>343</sup> After a median follow-up of 12 months, the median OS was 5.2 months for patients in the docetaxel and best supportive care group compared to 3.6 months for those in the best supportive care alone group ( $P = .01$ ). In another randomized phase III study, the addition of second-line chemotherapy with irinotecan significantly prolonged OS compared to best supportive care alone in

patients with metastatic or locally advanced gastric or EGJ adenocarcinoma (n = 40).<sup>344</sup> Median survival was 4 months in the irinotecan and best supportive care group compared to 2.4 months in the best supportive care alone group. However, the study was closed prematurely due to poor accrual.

A Cochrane database systematic review of five randomized controlled trials involving 750 patients with advanced esophageal or EGJ cancer demonstrated a benefit in OS for patients receiving chemotherapy and/or targeted therapy and best supportive care compared to those receiving best supportive care alone.<sup>345</sup> The only individual agent found by more than one study to improve both OS and PFS was ramucirumab. Although the addition of palliative chemotherapy or targeted therapy increased the frequency of grade  $\geq 3$  adverse events, treatment-related deaths did not increase. Importantly, patient-reported quality of life often improved with the addition of systemic therapy to best supportive care. Therefore, the addition of systemic therapy to best supportive care can improve the quality of life and may prolong survival in patients with advanced esophageal or EGJ cancers.

See *Principles of Systemic Therapy* in the algorithm for a full list of specific regimens for unresectable locally advanced, recurrent, or metastatic disease. Some of the regimens and dosing schedules included in the guidelines are based on extrapolations from published literature and clinical practice.

### Leucovorin Shortage

Leucovorin is indicated with certain fluorouracil-based regimens. However, there is currently a shortage of leucovorin in the United States.<sup>450</sup> There are no specific data to guide management under these circumstances, and all proposed strategies are empiric. One is the use of levoleucovorin, which is commonly used in Europe. A levoleucovorin dose of 200 mg/m<sup>2</sup> is equivalent to 400 mg/m<sup>2</sup> of standard leucovorin. Another option is to use



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

lower doses of leucovorin in all patients, since lower doses are likely to be as efficacious as higher doses based on several studies in patients with colorectal cancer.<sup>451-453</sup> However, the panel recommends use of these regimens without leucovorin in situations where leucovorin is not available.

### Palliative/Best Supportive Care

The goals of palliative/best supportive care are to prevent, reduce, and relieve suffering and improve the quality of life for patients and their caregivers, regardless of the stage of the disease or the need for other therapies. In patients with advanced or metastatic esophageal or EGJ cancer, palliative/best supportive care provides symptom relief and improvement in overall quality of life and may result in prolongation of life. This is especially true when a multimodality interdisciplinary approach is pursued. Therefore, a multimodality interdisciplinary approach to palliative/best supportive care of patients with esophageal and EGJ cancers is encouraged.

### Dysphagia

Dysphagia is the most common symptom in patients with esophageal cancer, especially those with locally advanced disease. Dysphagia most often arises due to obstruction but can also be associated with tumor-related dysmotility. Assessing the extent of disease and severity of swallowing impairment, preferably through a standardized scoring scale,<sup>454</sup> is essential to initiate appropriate interventions for long-term palliation of dysphagia in patients with esophageal cancer. Although various treatment options are available for the management of dysphagia, optimal treatment is still debated. Individualized management of esophageal cancer-related dysphagia is strongly encouraged. Patients with dysphagia who are not candidates for curative surgery should be considered for palliation of their symptoms. Palliative management of dysphagia can be achieved through multiple modalities, although placement of permanent or temporary SEMS

is the most common and can achieve long-term results.<sup>251</sup> However, the guidelines emphasize that stent placement is generally not advised in patients who are surgical candidates due to concerns that stent-related adverse events may preclude future curative surgery.

A clinical trial involving 45 patients with esophageal carcinoma found that temporary placement of SEMS with concurrent RT significantly reduced the total number of patients with one or more complications ( $P = .042$ ) and increased resultant PFS and OS rates ( $P = .005$  and  $P = .001$ , respectively) compared with permanent stent placement.<sup>455</sup> Additionally, membrane-covered stents have been shown to have significantly better palliation than conventional bare metal stents because of the decreased rate of tumor ingrowth, which in turn is associated with lower rates of endoscopic reintervention for dysphagia.<sup>251</sup> However, the optimal extent of the covering to prevent recurrent obstruction is unknown. In a recent trial of 98 patients with malignant dysphagia randomized to receive either a fully covered or partially covered SEMS, there was no significant difference in recurrent obstruction between the two stent types (19% for fully covered SEMS vs. 22% for partially covered SEMS;  $P = .65$ ).<sup>456</sup> The times to recurrent obstruction and the rates of adverse events were also similar. Another recent trial investigating stent migration found no significant differences in either migration distance or migration frequency between the two stent types.<sup>457</sup> However, there was a trend towards better dysphagia relief with the fully covered stents as measured by the Watson and Ogilvie dysphagia scores ( $P = .081$  and  $P = .067$ , respectively). These results suggest that fully covered SEMS may not lower the recurrent obstruction or stent migration rates compared to partially covered SEMS but may be more effective in the palliation of dysphagia.

The optimal stent diameter needed to effectively palliate dysphagia in patients with esophageal cancer is also unknown. While there are data suggesting lower migration and re-obstruction rates with larger-diameter covered expandable metal stents, there may be a higher risk of



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

stent-related complications.<sup>458</sup> In a prospective trial, 100 patients with unresectable esophageal cancer were randomized to receive a SEMS with either an 18- or 23-mm shaft diameter, but identical design, and followed until death.<sup>459</sup> Dysphagia was resolved after stent placement in 95% of patients in both groups. The incidence of adverse events was similar in both groups, but there was a trend toward longer survival in the small-diameter group (median survival, 5.9 vs. 3 months;  $P = .10$ ). After 6 months, the cumulative incidence of recurrent dysphagia was 38% versus 47% in the small-diameter versus large-diameter group, respectively ( $P = .23$ ). These data suggest that small- and large-diameter esophageal SEMS provide similar palliation of dysphagia, with a trend toward increased survival with the use of small-diameter stents.

A phase III randomized controlled trial compared the efficacy of chemoradiation versus RT alone for the palliation of malignant dysphagia in 220 patients with esophageal cancer.<sup>460</sup> Palliative chemoradiation showed a slight, but statistically insignificant, increase in the percentage of patients experiencing dysphagia relief compared with RT alone (45% vs. 35%;  $P = .13$ ), with minimal improvements in PFS (4.1 vs. 3.4 months;  $P = .58$ ) and OS (6.9 vs. 6.7 months;  $P = .88$ ). However, patients receiving chemoradiation experienced significantly higher rates of grade 3–4 toxicities than patients receiving RT alone (36% vs. 16%;  $P = .0017$ ). Therefore, a short course of RT alone may be used for palliation of dysphagia symptoms in patients with esophageal cancer.

### **Obstruction**

For patients with severe esophageal obstruction (those able to swallow liquids only), treatment options include endoscopy- or fluoroscopy-guided placement of fully or partially covered SEMS, as described above, as well as endoscopic lumen enhancement (wire-guided dilation or balloon dilation). Caution should be exercised when dilating malignant strictures, as this may be associated with an increased risk of perforation.<sup>461</sup> For

patients with complete esophageal obstruction, the guidelines recommend endoscopic lumen restoration, generally performed via simultaneous retrograde (via a gastrostomy tract) and antegrade endoscopy. Surgical or radiologic placement of a jejunostomy or gastrostomy tube may be necessary to provide adequate hydration and nutrition if endoscopic lumen restoration is not undertaken or is unsuccessful. Other options for palliation of esophageal obstruction include EBRT, chemotherapy, or surgery (in select patients). Brachytherapy may be considered instead of EBRT, if a lumen can be restored that allows for the use of appropriate applicators to decrease excessive RT dose to mucosal surfaces. Single-dose brachytherapy was associated with fewer complications and better long-term relief of obstruction compared with the use of metal stents.<sup>462</sup> However, brachytherapy should only be performed by practitioners experienced with the delivery of esophageal brachytherapy. PDT can effectively treat esophageal obstruction, but is less commonly performed due to associated photosensitivity and costs.

### **Pain**

Patients experiencing cancer-related pain should be assessed and treated according to the [NCCN Guidelines for Adult Cancer Pain](#). Severe, uncontrolled pain following stent placement should be treated with immediate endoscopic removal of the stent.

### **Bleeding**

Acute bleeding from esophageal cancer may represent a preterminal event secondary to tumor-related aorto-esophageal fistulization. Bleeding that occurs primarily from the tumor surface may be controlled with endoscopic electrocoagulation techniques such as bipolar electrocoagulation or argon plasma coagulation. However, limited data suggest that while endoscopic therapies may initially be effective, endoscopic intervention may lead to precipitous exsanguination and is



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

associated with a high rate of recurrent bleeding.<sup>463</sup> Chronic blood loss from esophageal cancer can be managed with EBRT.

### ***Nausea and Vomiting***

Patients experiencing nausea and vomiting should be treated according to the [NCCN Guidelines for Antiemesis](#). Nausea and vomiting may be associated with luminal obstruction, so endoscopic or fluoroscopic evaluation should be performed to determine if luminal enhancement is indicated.

### **Survivorship**

In addition to survivorship care relevant to all survivors of cancer (see [NCCN Guidelines for Survivorship](#)), survivors of esophageal and EGJ cancer have special long-term care needs due to the nature of their illness and treatments. Therefore, screening and management of long-term sequelae are important for all survivors of esophageal and EGJ cancer. However, due to a lack of large, randomized trials, the survivorship management recommendations provided by the panel are based on smaller studies and clinical experience. Survivorship care planning should include appropriate timing of transfer of care to a primary care physician and maintenance of a therapeutic relationship with the primary care physician throughout life. The oncology team and primary care physician should have clearly delineated roles in survivorship care, with these roles communicated to the patient. In general, routine esophageal/EGJ cancer-specific surveillance is not recommended for more than 5 years following the end of treatment. Surveillance should be performed in conjunction with good routine medical care, including routine health maintenance, preventive care, and cancer screening. Annual history and physical examination are reasonable as potential second primary cancers (second cancer in residual esophagus or second primary SCC in a separate organ) are possible. Survivors of esophageal and EGJ

cancer should be counseled to maintain a healthy body weight, adopt a physically active lifestyle, consume a healthy diet with an emphasis on plant-based sources, and limit alcohol intake. Smoking cessation should also be encouraged, as appropriate. Additional preventive health measures and immunizations should be performed as indicated under the care of or in conjunction with a primary care physician.

Common issues facing survivors of esophageal and EGJ cancer include GI issues, chemotherapy-induced neuropathy, RT-induced cardiotoxicity, and fatigue. Survivors of esophageal and EGJ cancers who underwent esophagectomy are at particular risk for clinically relevant long-term health issues, especially GI-related issues, which have been shown to negatively impact survivors' quality of life.<sup>464-467</sup> Several studies have indicated that survivors frequently experience GI dysfunctions such as malnutrition/malabsorption, dysphagia, dumping syndrome, delayed gastric emptying, and reflux symptoms following esophagectomy, which often persist many years after surgery.<sup>464-472</sup> As a result of GI dysfunctions, survivors who underwent esophagectomy have unique nutritional needs due to frequent vitamin and mineral deficiencies.<sup>470,473</sup> Studies have shown that substantial weight loss and long-term deficiencies in vitamin B<sub>12</sub>, folic acid, vitamin D, and calcium are common following esophagectomy.<sup>470,473-476</sup> Therefore, the weight and nutritional status of survivors of esophageal cancer should be carefully monitored, recognizing that progressive weight loss in the first 6 months is expected. Delayed gastric emptying after esophageal substitution with gastric conduit is another common GI-related long-term sequelae following esophagectomy, which affects as many as 37% of patients.<sup>469,471</sup> Eating smaller portions more frequently (5 small meals a day), as well as minimization of fat and fiber content in the diet, should be encouraged. Referral to gastroenterology should be considered for refractory symptoms.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Treatment with chemoradiation puts survivors at risk for RT-induced cardiotoxicity due to the close proximity of the esophagus to the heart.<sup>477-479</sup> Studies utilizing the SEER database to investigate the late cardiotoxic effects of RT in survivors of esophageal cancer revealed an increased risk for cardiac-related death in those who had received RT as part of their initial therapy compared to those who had not.<sup>478,479</sup> Receipt of RT was a predictive factor for cardiac-related death on univariate (HR, 1.53;  $P < .0001$ ) and multivariate (HR, 1.62;  $P < .0001$ ) analyses.<sup>478</sup> The risk for cardiac-related death became significant 8 months after diagnosis ( $P < .05$ ) and the median time to cardiac-related death was 289 months.<sup>478,479</sup> Therefore, the cardiac health of survivors of esophageal cancer should be carefully monitored following RT. The panel suggests coordination between the oncology care team, primary care physicians, and cardiologists for management of cardiac toxicities, as clinically indicated. Additionally, painful chemotherapy-induced neuropathy can be effectively treated with duloxetine. However, it should be noted that duloxetine is ineffective for numbness or tingling.

The panel recommends the development of a survivorship care plan that includes information on treatments received (surgeries, RT, and systemic therapies), follow-up care, surveillance, screening recommendations, and post-treatment needs regarding acute, late, and long-term treatment-related effects and health risks. Roles of oncologists, primary care physicians, and subspecialty care physicians in the survivorship care plan should be clearly delineated. Long-term survivorship care plans should also include a periodic assessment of ongoing needs and identification of appropriate resources, including timing of transfer of care, if appropriate.

### Summary

Cancers of the esophagus and EGJ are common in many parts of the world. SCC is the most common histology in Eastern Europe and Asia,

while adenocarcinoma has become increasingly more common in North America and Western Europe. Tobacco and alcohol use are major risk factors for developing SCC of the esophagus. Obesity, GERD, and Barrett esophagus are the major risk factors for developing adenocarcinoma of the esophagus or EGJ. In addition, some hereditary cancer predisposition syndromes are associated with an increased risk of developing esophageal and EGJ cancers. Referral to a cancer genetics professional is recommended for an individual with a genetic predisposition. The NCCN Panel strongly recommends multidisciplinary team management as essential for all patients with localized esophageal or EGJ cancer. Best supportive care is an integral part of treatment, especially in patients with unresectable locally advanced, recurrent, or metastatic disease.

ER (with or without ablation) is recommended for patients with early-stage (Tis, T1a, or superficial T1b) tumors. Esophagectomy is the preferred primary treatment option for patients who are medically fit with T1b–T2, N0 low-risk lesions. For patients who are medically fit with locally advanced resectable tumors (T2, N0 high-risk lesions, T1b–T2, N+ and T3–T4a, any N tumors), primary treatment options include preoperative chemoradiation (category 1, preferred for adenocarcinoma), perioperative chemotherapy (only for adenocarcinoma) or definitive chemoradiation (only in non-surgical candidates or patients who decline surgery). Definitive chemoradiation is the recommended treatment option for patients with T4b (unresectable) tumors, with chemotherapy alone reserved for the setting of invasion into the heart, vertebral body, trachea, or great vessels. Patients with unresectable or metastatic disease should be offered best supportive care and palliative management with or without systemic therapy, depending on performance status.

Targeted therapies have produced encouraging results in the treatment of patients with advanced esophageal and EGJ cancers. Trastuzumab plus chemotherapy with or without pembrolizumab is recommended as first-line therapy for patients with HER2 overexpression positive adenocarcinoma.

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Preferred regimens for HER2 overexpression negative disease include nivolumab combined with chemotherapy for adenocarcinoma tumors with PD-L1 expression levels by CPS of greater than or equal to 5 (category 1) or CPS of less than 5 (category 2B), and pembrolizumab combined with chemotherapy for adenocarcinoma or SCC tumors with PD-L1 CPS of greater than or equal to 10 or CPS of less than 10 (category 2B).

Preferred first-line regimens for SCC tumors also include nivolumab combined with chemotherapy and nivolumab combined with ipilimumab.

Ramucirumab, as a single agent or in combination with paclitaxel (preferred), and pembrolizumab (for MSI-H/dMMR or TMB-H tumors) are included as options for second-line or subsequent therapy for patients with metastatic disease. Dostarlimab-gxly is an alternative option to pembrolizumab for MSI-H/dMMR tumors. Nivolumab has been included as a preferred second-line therapy option for esophageal SCC and pembrolizumab has been included as a preferred second-line therapy option for esophageal SCC with PD-L1 expression levels by CPS of greater than or equal to 10. Other agents recommended for second-line or subsequent therapy include entrectinib and larotrectinib for *NTRK* gene fusion-positive tumors, selpercatinib for *RET* gene fusion-positive tumors and dabrafenib/trametinib for *BRAF* V600E mutated tumors. The panel encourages patients with esophageal and EGJ cancers to participate in well-designed clinical trials investigating novel therapeutic strategies to enable further advances in the management of these diseases.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

### References

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev* 2016;25:16-27. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26667886>.
2. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2020: oesophagus cancer fact sheet. 2020. Available at: <http://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf>. Accessed January 13, 2023.
3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30207593>.
4. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. *Int J Epidemiol* 2001;30:1415-1425. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11821356>.
5. Zhao JK, Wu M, Kim CH, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. *Eur J Cancer Prev* 2017;26:357-364. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27275735>.
6. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. *Ann Thorac Surg* 2003;76:S1367-1369. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14530066>.
7. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2020: United States of America cancer fact sheet. 2020. Available at: <http://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-fact-sheets.pdf>. Accessed January 13, 2023.
8. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin* 2023;73:17-48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36633525>.
9. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? *Semin Radiat Oncol* 2007;17:38-44. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17185196>.
10. Amin MB, Edge SB, Greene FL. *AJCC cancer staging manual* (ed 8). New York, NY: Springer; 2017.
11. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. *Int J Cancer* 2000;85:340-346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10652424>.
12. Engel LS, Chow W-H, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. *J Natl Cancer Inst* 2003;95:1404-1413. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/13130116>.
13. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. *Am J Epidemiol* 2007;165:1424-1433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17420181>.
14. Cook MB, Kamangar F, Whitman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. *J Natl Cancer Inst* 2010;102:1344-1353. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20716718>.
15. Wang QL, Xie SH, Li WT, Lagergren J. Smoking cessation and risk of esophageal cancer by histological type: systematic review and meta-analysis. *J Natl Cancer Inst* 2017;109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29933436>.
16. Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. *Ann Oncol* 2013;24:609-617. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22898040>.
17. Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Cancer Epidemiol 2011;35:309-319. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/21470937>.

18. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 2013;63:232-248. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/23818335>.

19. Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 2003;14:128-135. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/14653412>.

20. Cameron AJ, Romero Y. Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. Gut 2000;46:754-755. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/10807883>.

21. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009;361:2548-2556. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20032324>.

22. Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003;48:1537-1541. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12924649>.

23. Anandasabapathy S, Jhamb J, Davila M, et al. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 2007;109:668-674. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17211862>.

24. Chandrasekar VT, Hamade N, Desai M, et al. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus: a systematic review and meta-analysis. Endoscopy 2019;51:665-672. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/30939618>.

25. Jones RH, Vasey PA. Part I: testicular cancer-management of early disease. Lancet Oncol 2003;4:730-737. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/14662429>.

26. Blaydon DC, Etheridge SL, Risk JM, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012;90:340-346. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/22265016>.

27. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008:1-93. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18559331>.

28. Ellis A, Risk JM, Maruthappu T, Kelsell DP. Tylosis with oesophageal cancer: Diagnosis, management and molecular mechanisms. Orphanet J Rare Dis 2015;10:126. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26419362>.

29. Ellis A, Field JK, Field EA, et al. Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family--a review of six generations. Eur J Cancer B Oral Oncol 1994;30B:102-112. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/8032299>.

30. Stevens HP, Kelsell DP, Bryant SP, et al. Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol 1996;132:640-651. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/8651714>.

31. Chak A, Ochs-Balcom H, Falk G, et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006;15:1668-1673. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/16985029>.

32. Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and esophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51:323-328. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12171951>.

33. Verbeek RE, Spittuler LF, Peute A, et al. Familial clustering of Barrett's esophagus and esophageal adenocarcinoma in a European cohort. Clin



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Gastroenterol Hepatol 2014;12:1656-1663. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/24480679>.

34. To H, Clemons NJ, Duong CP, et al. The genetics of Barrett's esophagus: a familial and population-based perspective. Dig Dis Sci 2016;61:1826-1834. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26971090>.

35. Chak A, Faulx A, Kinnard M, et al. Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 2004;99:2107-2114. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15554988>.

36. Sun X, Elston R, Barnholtz-Sloan J, et al. A segregation analysis of Barrett's esophagus and associated adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2010;19:666-674. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20200424>.

37. Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011;306:410-419. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21791690>.

38. Ek WE, Levine DM, D'Amato M, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst 2013;105:1711-1718. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24168968>.

39. Fecteau RE, Kong J, Kresak A, et al. Association between germline mutation in VSIG10L and familial Barrett neoplasia. JAMA Oncol 2016;2:1333-1339. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27467440>.

40. Arora H, Chacon AH, Choudhary S, et al. Bloom syndrome. Int J Dermatol 2014;53:798-802. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/24602044>.

41. Cunniff C, Bassetti JA, Ellis NA. Bloom's syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol

2017;8:4-23. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/28232778>.

42. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res 2009;668:11-19. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19061902>.

43. Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008;93:511-517. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18322251>.

44. van Zeeburg HJT, Snijders PJF, Wu T, et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2008;100:1649-1653. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19001603>.

45. Oostra AB, Nieuwint AW, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia 2012;2012:238731. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22693659>.

46. Rice TW, Apperson-Hansen C, DiPaola LM, et al. Worldwide Esophageal Cancer Collaboration: clinical staging data. Dis Esophagus 2016;29:707-714. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27731549>.

47. Rice TW, Gress DM, Patil DT, et al. Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:304-317. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/28556024>.

48. Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009;29:403-421. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/19325056>.

49. Tirumani H, Rosenthal MH, Tirumani SH, et al. Esophageal carcinoma: current concepts in the role of imaging in staging and management. Can



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Assoc Radiol J 2015;66:130-139. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25770628>.

50. Choi J, Kim SG, Kim JS, et al. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010;24:1380-1386. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20033712>.

51. Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008;14:1479-1490. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18330935>.

52. Barbour AP, Rizk NP, Gerdes H, et al. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg 2007;205:593-601. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17903735>.

53. Blackshaw G, Lewis WG, Hopper AN, et al. Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer. Clin Radiol 2008;63:1092-1098. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18774355>.

54. Murata Y, Napoleon B, Odegaard S. High-frequency endoscopic ultrasonography in the evaluation of superficial esophageal cancer. Endoscopy 2003;35:429-435. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12701017>.

55. Hofstetter W. Treatment of clinical T2N0M0 esophageal cancer. Ann Surg Oncol 2014;21:3713-3714. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25063008>.

56. Thosani N, Singh H, Kapadia A, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 2012;75:242-253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22115605>.

57. Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 2006;21:137-145. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16770230>.

58. Cuellar SL, Carter BW, Macapinlac HA, et al. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol 2014;9:1202-1206. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25157774>.

59. Little SG, Rice TW, Bybel B, et al. Is FDG-PET indicated for superficial esophageal cancer? Eur J Cardiothorac Surg 2007;31:791-796. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17337344>.

60. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921-928. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11920459>.

61. Omloo JM, Sloof GW, Boellaard R, et al. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy 2008;40:464-471. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18543134>.

62. Lowe VJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005;7:422-430. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16270235>.

63. Takizawa K, Matsuda T, Kozu T, et al. Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol 2009;24:1687-1691. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19788609>.

64. Walker AJ, Spier BJ, Perlman SB, et al. Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

evaluation of esophageal cancer. *Mol Imaging Biol* 2011;13:166-171. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20379789>.

65. Findlay JM, Bradley KM, Maile EJ, et al. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. *Br J Surg* 2015;102:1488-1499. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26458070>.

66. van Westreenen HL, Westerterp M, Bossuyt PMM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. *J Clin Oncol* 2004;22:3805-3812. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15365078>.

67. Bergman JJ. The endoscopic diagnosis and staging of oesophageal adenocarcinoma. *Best Pract Res Clin Gastroenterol* 2006;20:843-866. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16997165>.

68. Vazquez-Sequeiros E, Norton ID, Clain JE, et al. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. *Gastrointest Endosc* 2001;53:751-757. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11375583>.

69. Vazquez-Sequeiros E, Wiersema MJ, Clain JE, et al. Impact of lymph node staging on therapy of esophageal carcinoma. *Gastroenterology* 2003;125:1626-1635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14724814>.

70. Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. *Gastrointest Endosc* 2009;69:1210-1217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19012886>.

71. van Westreenen HL, Heeren PA, van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. *J Gastrointest Surg* 2005;9:54-61. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15623445>.

72. Chatterton BE, Ho Shon I, Baldey A, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. *Eur J Nucl Med Mol Imaging* 2009;36:354-361. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18931839>.

73. Siewert JR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. *Dis Esophagus* 1996;9:173-182. Available at: <https://academic.oup.com/dote/article-abstract/9/3/173/2798630>.

74. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg* 2000;232:353-361. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10973385>.

75. Bakr O, Zhao W, Corley D. Gastroesophageal reflux frequency, severity, age of onset, family history and acid suppressive therapy predict Barrett esophagus in a large population. *J Clin Gastroenterol* 2018;52:873-879. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29356784>.

76. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. *Gastrointest Endosc* 2019;90:707-717. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31152737>.

77. Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett's esophagus: current knowledge and future directions. *Am J Gastroenterol* 2010;105:1490-1502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20104216>.

78. Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2017;7:1046-1055. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29199147>.

79. Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett's esophagus to



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2018;17:864-868. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30012433>.

80. Komanduri S, Swanson G, Keefer L, Jakate S. Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies. Gastrointest Endosc 2009;70:1072-1078. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19595312>.

81. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-1399. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17101315>.

82. Vennalaganti PR, Kaul V, Wang KK, et al. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. Gastrointest Endosc 2017;87:348-355. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28757316>.

83. Gross SA, Smith MS, Kaul V, Group USCWDS. Increased detection of Barrett's esophagus and esophageal dysplasia with adjunctive use of wide-area transepithelial sample with three-dimensional computer-assisted analysis (WATS). United European Gastroenterol J 2018;6:529-535. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29881608>.

84. Smith MS, Ikonomi E, Bhuta R, et al. Wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett's esophagus: analysis from a prospective multicenter community-based study. Dis Esophagus 2019;32. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30541019>.

85. Chennat J, Waxman I. Endoscopic treatment of Barrett's esophagus: From metaplasia to intramucosal carcinoma. World J Gastroenterol 2010;16:3780-3785. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20698040>.

86. Nealis TB, Washington K, Keswani RN. Endoscopic therapy of esophageal premalignancy and early malignancy. J Natl Compr Canc

Netw 2011;9:890-899. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21900219>.

87. Fitzgerald RC, di Pietro M, Raganath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24165758>.

88. Subramaniam S, Kandiah K, Chedgy F, et al. The safety and efficacy of radiofrequency ablation following endoscopic submucosal dissection for Barrett's neoplasia. Dis Esophagus 2018;31. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29211875>.

89. Yang D, Zou F, Xiong S, et al. Endoscopic submucosal dissection for early Barrett's neoplasia: a meta-analysis. Gastrointest Endosc 2017;87:1383-1393. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28993137>.

90. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-2288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19474425>.

91. Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016;111:30-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26526079>.

92. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014;311:1209-1217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24668102>.

93. Pandey G, Mulla M, Lewis WG, et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett's esophagus. Endoscopy 2018;50:953-960. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29689573>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

94. Pouw RE, Klaver E, Phoa KN, et al. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus: long-term outcome of a randomized trial. *Gastrointest Endosc* 2020;92:569-574. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32217112>.
95. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. *J Natl Cancer Inst* 2011;103:1049-1057. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21680910>.
96. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011;365:1375-1383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21995385>.
97. Desai M, Lieberman DA, Kennedy KF, et al. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium. *Gastrointest Endosc* 2019;89:257-263. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30342028>.
98. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. *Hum Pathol* 2001;32:379-388. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11331954>.
99. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. *Gastrointest Endosc* 2020;91:3-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31421077>.
100. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. *Cancer* 2001;91:2165-2174. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11391598>.
101. Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. *Cancer* 2005;104:1349-1355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16130133>.
102. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. *Ann Surg* 2005;242:684-692. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16244542>.
103. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. *Cancer* 2006;106:2119-2127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16607651>.
104. Langer R, Ott K, Feith M, et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. *Mod Pathol* 2009;22:1555-1563. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19801967>.
105. Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. *Ann Surg Oncol* 2010;17:1159-1167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20140529>.
106. Lorenzen S, Thuss-Patience P, Al-Batran SE, et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. *Ann Oncol* 2013;24:2068-2073. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23592699>.
107. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. *Cancer* 2005;103:1347-1355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15719440>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

108. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. *Am J Surg Pathol* 2007;31:58-64. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17197919>.
109. Shi C, Berlin J, Branton PA, et al. Protocol for the examination of specimens from patients with carcinoma of the esophagus. *Cancer Protocol Templates*. Northfield, IL: College of American Pathologists; 2017.
110. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology* 2005;47:141-146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16045774>.
111. Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. *Cancer* 2006;106:1017-1025. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16456809>.
112. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. *Cancer* 2004;101:1776-1785. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15386332>.
113. Westerterp M, Omloo JMT, Sloof GW, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. *Int J Hyperthermia* 2006;22:149-160. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16754598>.
114. Konski AA, Cheng JD, Goldberg M, et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2007;69:358-363. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17532577>.
115. Higuchi I, Yasuda T, Yano M, et al. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. *J Thorac Cardiovasc Surg* 2008;136:205-212. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18603077>.
116. Cerfolio RJ, Bryant AS, Talati AA, et al. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. *J Thorac Cardiovasc Surg* 2009;137:605-609. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19258075>.
117. Smith JW, Moreira J, Abood G, et al. The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma. *Am J Surg* 2009;197:308-312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19245906>.
118. Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [(1)F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? *J Clin Oncol* 2010;28:4714-4721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20876421>.
119. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. *Mol Imaging Biol* 2003;5:337-346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14630513>.
120. Wieder HA, Brucher BLDM, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. *J Clin Oncol* 2004;22:900-908. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14990646>.
121. Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

advanced, resectable esophageal cancer. *Int J Radiat Oncol Biol Phys* 2005;63:1053-1059. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15964705>.

122. Duong CP, Hicks RJ, Weih L, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. *Eur J Nucl Med Mol Imaging* 2006;33:770-778. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16550384>.

123. Kim MK, Ryu J-S, Kim S-B, et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. *Eur J Cancer* 2007;43:1385-1391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17512192>.

124. Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. *Ann Surg* 2006;243:472-478. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16552197>.

125. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. *Lancet Oncol* 2007;8:797-805. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17693134>.

126. Klaeser B, Nitzsche E, Schuller JC, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). *Onkologie* 2009;32:724-730. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20016233>.

127. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. *Ann Surg* 2001;233:300-309. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11224616>.

128. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. *Ann Oncol* 2002;13:361-368. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11996465>.

129. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. *J Clin Oncol* 2003;21:428-432. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12560430>.

130. Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. *Cancer* 2007;109:125-134. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17146785>.

131. Piessen G, Petyt G, Duhamel A, et al. Ineffectiveness of (1)(8)F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. *Ann Surg* 2013;258:66-76. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23470576>.

132. McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? *J Am Coll Surg* 2008;206:879-886. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18471715>.

133. Schmidt M, Bollschweiler E, Dietlein M, et al. Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. *Eur J Nucl Med Mol Imaging* 2009;36:735-744. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19096843>.

134. Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. *J Nucl Med* 2010;51:1863-1869. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21078796>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

135. Gillham CM, Lucey JA, Keogan M, et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. *Br J Cancer* 2006;95:1174-1179. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17024121>.

136. Vallbohmer D, Holscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. *Ann Surg* 2009;250:888-894. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19953708>.

137. Smithers BM, Couper GC, Thomas JM, et al. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. *Dis Esophagus* 2008;21:151-158. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18269651>.

138. Gabrielson S, Sanchez-Crespo A, Klevebro F, et al. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction. *Acta Radiol* 2019;60:578-585. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30111193>.

139. Sanchez-Izquierdo N, Perlaza P, Pages M, et al. Assessment of response to neoadjuvant chemoradiotherapy by 18F-FDG PET/CT in patients with locally advanced esophagogastric junction adenocarcinoma. *Clin Nucl Med* 2020;45:38-43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31714278>.

140. Tandberg DJ, Cui Y, Rushing CN, et al. Intratreatment response assessment with 18F-FDG PET: correlation of semiquantitative PET features with pathologic response of esophageal cancer to neoadjuvant chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2018;102:1002-1007. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30055238>.

141. zum Buschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. *J Nucl Med*

2011;52:1189-1196. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21764790>.

142. Goodman K, Niedzwiecki D, Hall N, et al. Initial results of CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. *J Clin Oncol* 2017;35:1. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4\\_suppl.1](https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.1).

143. Goodman KA, Hall N, Bekaii-Saab TS, et al. Survival outcomes from CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. *J Clin Oncol* 2018;36:4012. Available at: [https://doi.org/10.1200/JCO.2018.36.15\\_suppl.4012](https://doi.org/10.1200/JCO.2018.36.15_suppl.4012).

144. Kroese TE, Goense L, van Hillegersberg R, et al. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. *Dis Esophagus* 2018;31. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29917073>.

145. Valkema MJ, Noordman BJ, Wijnhoven BPL, et al. Accuracy of (18)F-FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. *J Nucl Med* 2019;60:1553-1559. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30877177>.

146. Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. *Methods Mol Biol* 2011;727:59-76. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21331929>.

147. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. *Arch Pathol Lab Med* 2012;136:691-697. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22646280>.

148. Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. *Patholog Res*



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Int 2010;2011:674182. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21188213>.

149. Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. *Clin Cancer Res* 2018;24:6248-6256. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30348637>.

150. Dreilich M, Wanders A, Brattstrom D, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. *Dis Esophagus* 2006;19:224-231. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16866851>.

151. Reichelt U, Duesedau P, Tsourlakis MC, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. *Mod Pathol* 2007;20:120-129. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17143264>.

152. Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. *Am J Surg Pathol* 2010;34:1868-1873. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21107094>.

153. Egebjerg K, Garbyal RS, Hasselby JP, et al. Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis. *Crit Rev Oncol Hematol* 2021;161:103339. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33865993>.

154. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. *Ann Oncol* 2008;19:1523-1529. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18441328>.

155. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Ann Oncol* 2005;16:273-278. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15668283>.

156. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20728210>.

157. Kim WH, Gomez-Izquierdo L, Vilardell F, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. *Appl Immunohistochem Mol Morphol* 2018;26:239-245. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27490762>.

158. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. *J Clin Oncol* 2009;27:4556. Available at:

<http://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.4556>.

159. Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *J Clin Oncol* 2017;35:446-464. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28129524>.

160. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008;52:797-805. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18422971>.

161. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. *Virchows Arch* 2010;457:299-307. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20665045>.

162. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509-2520. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26028255>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

163. Murphy KM, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. *J Mol Diagn* 2006;8:305-311. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16825502>.

164. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-413. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28596308>.

165. Bartley AN, Fitzgibbons PL, Broaddus RR, Shi C. Template for reporting results of DNA mismatch repair testing in patients being considered for checkpoint inhibitor immunotherapy. *College of American Pathologists* 2018. Available at: <https://documents.cap.org/protocols/cp-general-dnamismatchrepair-18biomarker-1001.pdf>.

166. Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. *Clin Cancer Res* 2019;25:7035-7045. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31383735>.

167. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012;366:2074-2084. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22646630>.

168. Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019;393:1948-1957. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30982686>.

169. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. *J Clin Oncol* 2006;24:4277-4284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16963730>.

170. Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? *Semin Oncol* 2004;31:444-449. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297937>.

171. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophagogastric junction. *Scand J Surg* 2006;95:260-269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17249275>.

172. de Graaf GW, Ayantunde AA, Parsons SL, et al. The role of staging laparoscopy in oesophagogastric cancers. *Eur J Surg Oncol* 2007;33:988-992. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17344017>.

173. Nath J, Moorthy K, Taniere P, et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. *Br J Surg* 2008;95:721-726. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18412292>.

174. Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. *Ann Surg* 2008;248:979-985. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19092342>.

175. Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. *Ann Surg* 2010;251:46-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20032718>.

176. Groth SS, Virnig BA, Whitson BA, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. *J Thorac Cardiovasc Surg* 2010;139:612-620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19709685>.

177. Guo JC, Lin CC, Huang TC, et al. Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy. *Anticancer Res* 2018;38:1569-1577. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29491087>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

178. Koen Talsma A, Shapiro J, Looman CW, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. *Ann Surg* 2014;260:786-792. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25379850>.

179. Visser E, Markar SR, Ruurda JP, et al. Prognostic value of lymph node yield on overall survival in esophageal cancer patients: a systematic review and meta-analysis. *Ann Surg* 2019;269:261-268. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29794846>.

180. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. *J Thorac Cardiovasc Surg* 2002;123:175-183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11782772>.

181. Ng T, Vezeridis MP. Advances in the surgical treatment of esophageal cancer. *J Surg Oncol* 2010;101:725-729. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20512949>.

182. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002;346:1128-1137. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11948273>.

183. Visbal AL, Allen MS, Miller DL, et al. Ivor Lewis esophagogastrectomy for esophageal cancer. *Ann Thorac Surg* 2001;71:1803-1808. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11426751>.

184. McKeown KC. Total three-stage oesophagectomy for cancer of the oesophagus. *Br J Surg* 1976;63:259-262. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1276657>.

185. Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. *Ann Surg* 2007;246:363-372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17717440>.

186. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for

adenocarcinoma of the esophagus. *N Engl J Med* 2002;347:1662-1669. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12444180>.

187. Chang AC, Ji H, Birkmeyer NJ, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. *Ann Thorac Surg* 2008;85:424-429. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18222237>.

188. Forshaw MJ, Gossage JA, Ockrim J, et al. Left thoracoabdominal esophagogastrectomy: still a valid operation for carcinoma of the distal esophagus and esophagogastric junction. *Dis Esophagus* 2006;19:340-345. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16984529>.

189. Luketich JD, Pennathur A, Franchetti Y, et al. Minimally invasive esophagectomy: results of a prospective phase II multicenter trial-the eastern cooperative oncology group (E2202) study. *Ann Surg* 2015;261:702-707. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25575253>.

190. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. *Ann Surg* 2003;238:486-495. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14530720>.

191. Gottlieb-Vedi E, Kauppila JH, Malietzis G, et al. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. *Ann Surg* 2019;270:1005-1017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30817355>.

192. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet* 2012;379:1887-1892. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22552194>.

193. Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. *N Engl J Med* 2019;380:152-162. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30625052>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

194. Yamashita K, Watanabe M, Mine S, et al. Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis. *Surg Endosc* 2018;32:4443-4450. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29644466>.

195. Perry Y, Fernando HC, Buenaventura PO, et al. Minimally invasive esophagectomy in the elderly. *JSLs* 2002;6:299-304. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12500826>.

196. Decker G, Coosemans W, De Leyn P, et al. Minimally invasive esophagectomy for cancer. *Eur J Cardiothorac Surg* 2009;35:13-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18952454>.

197. Levy RM, Wizorek J, Shende M, Luketich JD. Laparoscopic and thoracoscopic esophagectomy. *Adv Surg* 2010;44:101-116. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20919517>.

198. Jin D, Yao L, Yu J, et al. Robotic-assisted minimally invasive esophagectomy versus the conventional minimally invasive one: a meta-analysis and systematic review. *Int J Med Robot* 2019;15:e1988. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30737881>.

199. van der Sluis PC, van der Horst S, May AM, et al. Robot-assisted minimally invasive thoracoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial. *Ann Surg* 2019;269:621-630. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30308612>.

200. Sarkaria IS, Rizk NP, Goldman DA, et al. Early quality of life outcomes after robotic-assisted minimally invasive and open esophagectomy. *Ann Thorac Surg* 2019;108:920-928. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31026433>.

201. Walther B, Johansson J, Johnsson F, et al. Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with

stapled intrathoracic anastomosis. *Ann Surg* 2003;238:803-812. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14631217>.

202. Urschel JD, Blewett CJ, Bennett WF, et al. Handsewn or stapled esophagogastric anastomoses after esophagectomy for cancer: meta-analysis of randomized controlled trials. *Dis Esophagus* 2001;14:212-217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11869322>.

203. Klink CD, Binnebosel M, Schneider M, et al. Operative outcome of colon interposition in the treatment of esophageal cancer: a 20-year experience. *Surgery* 2010;147:491-496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20004440>.

204. Bergman JJ, Zhang YM, He S, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. *Gastrointest Endosc* 2011;74:1181-1190. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21839994>.

205. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology* 2011;141:460-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21679712>.

206. Berry MF, Zeyer-Brunner J, Castleberry AW, et al. Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. *J Thorac Oncol* 2013;8:796-802. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24614244>.

207. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. *Gastroenterology* 2014;146:652-660. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24269290>.

208. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. *Gastroenterology* 2000;118:670-677. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10734018>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

209. Fujita H, Sueyoshi S, Yamana H, et al. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. *World J Surg* 2001;25:424-431. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11344392>.

210. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol* 2005;23:4490-4498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16002839>.

211. Conio M, Repici A, Cestari R, et al. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. *World J Gastroenterol* 2005;11:6650-6655. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16425359>.

212. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. *Gastrointest Endosc* 2003;57:854-859. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12776032>.

213. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. *Endoscopy* 2007;39:1086-1091. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17701854>.

214. Lopes CV, Hela M, Pesenti C, et al. Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma. *Surg Endosc* 2007;21:820-824. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17294308>.

215. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. *Gastrointest Endosc* 2008;68:35-40. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18355819>.

216. Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-

grade dysplasia and intramucosal carcinoma--an American single-center experience. *Am J Gastroenterol* 2009;104:2684-2692. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19690526>.

217. Repici A, Hassan C, Carlino A, et al. Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective Western series. *Gastrointest Endosc* 2010;71:715-721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20363414>.

218. Ono S, Fujishiro M, Koike K. Endoscopic submucosal dissection for superficial esophageal neoplasms. *World J Gastrointest Endosc* 2012;4:162-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22624067>.

219. Higuchi K, Tanabe S, Azuma M, et al. A phase II study of endoscopic submucosal dissection for superficial esophageal neoplasms (KDOG 0901). *Gastrointest Endosc* 2013;78:704-710. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23680178>.

220. Omae M, Fujisaki J, Horiuchi Y, et al. Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer. *Gastric Cancer* 2013;16:147-154. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22692465>.

221. Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). *Gastrointest Endosc* 2010;72:255-264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20541198>.

222. Teoh AY, Chiu PW, Yu Ngo DK, et al. Outcomes of endoscopic submucosal dissection versus endoscopic mucosal resection in management of superficial squamous esophageal neoplasms outside Japan. *J Clin Gastroenterol* 2010;44:e190-194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20844363>.

223. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

early neoplasia. Clin Gastroenterol Hepatol 2010;8:23-29. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19602454>.

224. van Vilsteren FGI, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011;60:765-773. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21209124>.

225. Alvarez Herrero L, van Vilsteren FGI, Pouw RE, et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. Gastrointest Endosc 2011;73:682-690. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21292262>.

226. Neuhaus H, Terheggen G, Rutz EM, et al. Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus. Endoscopy 2012;44:1105-1113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22968641>.

227. Dumot JA, Vargo JJ, 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009;70:635-644. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19559428>.

228. Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010;71:680-685. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20363409>.

229. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16185958>.

230. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-

grade intraepithelial neoplasia. Gastrointest Endosc 2005;62:24-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15990815>.

231. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17643436>.

232. Gaur P, Sepesi B, Hofstetter WL, et al. Endoscopic esophageal tumor length: A prognostic factor for patients with esophageal cancer. Cancer 2011;117:63-69. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20803613>.

233. Anagnostopoulos GK, Yao K, Kaye P, et al. Novel endoscopic observation in Barrett's oesophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther 2007;26:501-507. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17635385>.

234. Mannath J, Subramanian V, Hawkey CJ, Ragunath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy 2010;42:351-359. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20200809>.

235. Yu T, Geng J, Song W, Jiang Z. Diagnostic accuracy of magnifying endoscopy with narrow band imaging and its diagnostic value for invasion depth staging in esophageal squamous cell carcinoma: a systematic review and meta-analysis. Biomed Res Int 2018;2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29888281>.

236. Maish MS, DeMeester SR. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma. Ann Thorac Surg 2004;78:1777-1782. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15511474>.

237. Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Gastrointest Endosc 2005;62:16-23. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15990814>.

238. Thomas T, Singh R, Raganath K. Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia. Surg Endosc 2009;23:1609-1613. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19296171>.

239. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg 2009;87:1048-1054. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/19324126>.

240. Leggett CL, Lewis JT, Wu TT, et al. Clinical and histologic determinants of mortality for patients with Barrett's esophagus-related T1 esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2015;13:658-664. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25151255>.

241. Merkow RP, Bilimoria KY, Keswani RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst 2014;106. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25031273>.

242. Westerterp M, Koppert LB, Buskens CJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 2005;446:497-504. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15838647>.

243. Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol 2008;15:3278-3288. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18726651>.

244. Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010;42:1030-1036. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20960392>.

245. Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011;253:271-278. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21119508>.

246. Cen P, Hofstetter WL, Correa AM, et al. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 2008;112:1020-1027. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18205187>.

247. Lee L, Ronellenfitch U, Hofstetter WL, et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg 2013;217:191-199. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23659947>.

248. Nentwich MF, von Loga K, Reeh M, et al. Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus. J Gastrointest Surg 2014;18:242-249; discussion 249. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24091912>.

249. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-1206. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/18460553>.

250. Chadwick G, Groene O, Markar SR, et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett's esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc 2014;79:718-731. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24462170>.

251. Vakil N, Morris AI, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001;96:1791-1796. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11419831>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

252. Muller C, Kahler G, Scheele J. Endosonographic examination of gastrointestinal anastomoses with suspected locoregional tumor recurrence. *Surg Endosc* 2000;14:45-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10653235>.

253. van der Bogt RD, Noordman BJ, Krishnadath KK, et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. *Endoscopy* 2018;51:326-332. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30497088>.

254. Ribeiro A, Franceschi D, Parra J, et al. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. *Am J Gastroenterol* 2006;101:1216-1221. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16771940>.

255. Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. *Ann Surg* 2009;249:764-767. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19387328>.

256. Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. *Clin Radiol* 1982;33:347-352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7075142>.

257. Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 1989;17:49-54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2745207>.

258. Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. *Int J Radiat Oncol Biol Phys* 1989;16:329-334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2921133>.

259. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. *Radiother Oncol* 1999;51:21-26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10386713>.

260. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326:1593-1598. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1584260>.

261. Wang M, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. *Int J Radiat Oncol Biol Phys* 1989;16:325-327. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2646253>.

262. Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. *French University Association for Surgical Research. Surg Gynecol Obstet* 1991;173:123-130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1925862>.

263. Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. *Radiother Oncol* 1992;24:108-113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1496141>.

264. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). *Int J Radiat Oncol Biol Phys* 1998;41:579-583. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9635705>.

265. Sur RK, Donde B, Levin VC, Mannell A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 1998;40:447-453. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9457834>.

266. Gaspar LE, Qian C, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. *Int J Radiat Oncol Biol Phys* 1997;37:593-599. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9112458>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

267. Hosokawa M, Shirato H, Ohara M, et al. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. *Cancer* 1999;86:6-13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10391557>.

268. Fu W-H, Wang L-H, Zhou Z-M, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. *World J Gastroenterol* 2004;10:1098-1102. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15069706>.

269. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. *Radiother Oncol* 2005;77:247-253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16298001>.

270. Mayo CS, Urie MM, Fitzgerald TJ, et al. Hybrid IMRT for treatment of cancers of the lung and esophagus. *Int J Radiat Oncol Biol Phys* 2008;71:1408-1418. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18262730>.

271. Roeder F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. *Radiat Oncol* 2014;9:191. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25175056>.

272. Tao H, Zhou Y, Yao C, et al. Phase II trial of intensity-modulated radiotherapy concurrent with chemotherapy for postoperative node-positive esophageal squamous cell carcinoma. *Oncol Res* 2017;25:1357-1362. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28315293>.

273. Hulshof M, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). *J Clin Oncol* 2021;39:2816-2824. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34101496>.

274. Crehan G, M'Vondo C, Bertaut A, et al. Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26). *International Journal of Radiation Oncology\*Biophysics* 2021;111:S5. Available at:

275. Wang J, Palmer M, Bilton SD, et al. Comparing proton beam to intensity modulated radiation therapy planning in esophageal cancer. *Int J Part Ther* 2015;1:866-877. Available at: <https://www.theijpt.org/doi/pdf/10.14338/IJPT-14-00018.1>.

276. Lin SH, Komaki R, Liao Z, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2012;83:345-351. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22417808>.

277. Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. *Int J Radiat Oncol Biol Phys* 2008;70:707-714. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18191334>.

278. Warren S, Partridge M, Bolsi A, et al. An analysis of plan robustness for esophageal tumors: comparing volumetric modulated arc therapy plans and spot scanning proton planning. *Int J Radiat Oncol Biol Phys* 2016;95:199-207. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27084641>.

279. Ling TC, Slater JM, Nookala P, et al. Analysis of intensity-modulated radiation therapy (IMRT), proton and 3D conformal radiotherapy (3D-CRT) for reducing perioperative cardiopulmonary complications in esophageal cancer patients. *Cancers (Basel)* 2014;6:2356-2368. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25489937>.

280. Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. *J Clin Oncol* 2020;38:1569-1579. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32160096>.

# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

281. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2013;86:885-891. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23845841>.
282. Chuong MD, Hallemeier CL, Jabbour SK, et al. Improving outcomes for esophageal cancer using proton beam therapy. *Int J Radiat Oncol Biol Phys* 2016;95:488-497. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27084662>.
283. Yu J, Zhang X, Liao L, et al. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. *Med Phys* 2016;43:1111-1118. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26936698>.
284. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11870157>.
285. Scarsbrook A, Ward G, Murray P, et al. Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume. *BMC Cancer* 2017;17:671. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28978306>.
286. Gao XS, Qiao X, Wu F, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. *Int J Radiat Oncol Biol Phys* 2007;67:389-396. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17236963>.
287. Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. *Int J Radiat Oncol Biol Phys* 2010;76:S101-107. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20171503>.
288. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76:S77-85. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20171522>.
289. Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. *Int J Surg* 2018;51:120-127. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29413875>.
290. Al-Batran SE, Lorenzen S. Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? *Hematol Oncol Clin North Am* 2017;31:441-452. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28501086>.
291. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. *J Clin Oncol* 2007;25:4110-4117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17827461>.
292. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21444866>.
293. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol* 2016;17:1697-1708. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27776843>.
294. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med* 2021;384:1191-1203. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33789008>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

295. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22585691>.

296. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11547741>.

297. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:1389-1396. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25439693>.

298. Conroy T, Galais M-P, Raoul J-L, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24556041>.

299. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus* 2010;23:253-259. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19732130>.

300. Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. *Br J Cancer* 2011;104:265-271. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21157450>.

301. Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. *Ann Surg Oncol* 2004;11:665-673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15197012>.

302. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. *Am J Surg* 2003;185:538-543. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12781882>.

303. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. *Gut* 2004;53:925-930. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15194636>.

304. Ma HF, Lv GX, Cai ZF, Zhang DH. Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis. *Onco Targets Ther* 2018;11:3441-3447. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29942136>.

305. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. *Lancet Oncol* 2011;12:681-692. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21684205>.

306. Swisher SG, Hofstetter W, Komaki R, et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. *Ann Thorac Surg* 2010;90:892-898; discussion 898-899. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20732514>.

307. Zhao X, Ren Y, Hu Y, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: a meta-analysis based on clinical trials. *PLoS One* 2018;13:e0202185. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30138325>.

308. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. *J Clin Oncol* 2014;32:385-391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24419108>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

309. Noordman BJ, Verdam MGE, Lagarde SM, et al. Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial. *J Clin Oncol* 2018;36:268-275. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29161204>.

310. Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol* 2015;16:1090-1098. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26254683>.

311. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. *J Clin Oncol* 2011;29:4555-4560. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22025151>.

312. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844-2850. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12065561>.

313. Messenger M, Mirabel X, Tresch E, et al. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. *BMC Cancer* 2016;16:318. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27194176>.

314. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18309943>.

315. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the

esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160-1168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17401004>.

316. Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). *J Clin Oncol* 2009;27:e15619. Available at: <http://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.e15619>.

317. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16921048>.

318. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. *J Clin Oncol* 2005;23:2310-2317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15800321>.

319. Stahl M, Wilke H, Lehmann N, Stuschke M. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. *J Clin Oncol* 2008;26:4530. Available at: [http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15\\_suppl.4530](http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.4530).

320. Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. *Cochrane Database Syst Rev* 2017;8:CD010511. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28829911>.

321. Vincent J, Mariette C, Pezet D, et al. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone. *Eur J Cancer* 2015;51:1683-1693. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26163097>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

322. Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. *J Clin Oncol* 2018;36:2796-2803. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30089078>.

323. Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. *Cancer* 2001;92:279-286. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11466680>.

324. Swisher SG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 2003;57:120-127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12909224>.

325. Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. *Cancer* 2004;100:2347-2354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15160337>.

326. Henry LR, Goldberg M, Scott W, et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. *Ann Surg Oncol* 2006;13:214-220. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16418887>.

327. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol* 2009;27:851-856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19139439>.

328. Rivera F, Galan M, Tabernero J, et al. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and

radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2009;75:1430-1436. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19540072>.

329. Ruhstaller T, Widmer L, Schuller JC, et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). *Ann Oncol* 2009;20:1522-1528. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19465425>.

330. Ilson DH, Minsky BD, Ku GY, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. *Cancer* 2012;118:2820-2827. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21990000>.

331. Ajani JA, Xiao L, Roth JA, et al. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. *Ann Oncol* 2013;24:2844-2849. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23975663>.

332. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16822992>.

333. Reynolds JV, Preston SR, O'Neill B, et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). *J Clin Oncol* 2021;39:4004-4004. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15\\_suppl.4004](https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4004).

334. Ruppert BN, Watkins JM, Shirai K, et al. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. *Am J Clin Oncol* 2010;33:346-352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19841574>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

335. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10235156>.

336. Urba SG, Orringer MB, Iannettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98:2177-2183. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14601087>.

337. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22226517>.

338. Kofoed SC, Muhic A, Baeksgaard L, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg 2012;101:26-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22414465>.

339. Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009;4:1264-1269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19668013>.

340. Kang J, Chang JY, Sun X, et al. Role of postoperative concurrent chemoradiotherapy for esophageal carcinoma: a meta-analysis of 2165 patients. J Cancer 2018;9:584-593. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29483964>.

341. Bedard EL, Inculet RI, Malthaner RA, et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001;91:2423-2430. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11413534>.

342. Rice TW, Adelstein DJ, Chidel MA, et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal

carcinoma. J Thorac Cardiovasc Surg 2003;126:1590-1596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14666038>.

343. Ford ER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78-86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24332238>.

344. Thuss-Patience PC, Kretschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21742485>.

345. Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 2017;11:CD004063. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29182797>.

346. Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer 2013;49:835-842. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23063354>.

347. Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600:727-730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34912120>.

348. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27-40. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34102137>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

349. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. *Lancet* 2021;398:759-771. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34454674>.

350. Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. *N Engl J Med* 2022;386:449-462. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35108470>.

351. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18349393>.

352. Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. *J Clin Oncol* 2016;34:2736-2742. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27382098>.

353. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22243774>.

354. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19549707>.

355. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation

Francophone de Cancerologie Digestive Group Study--FFCD 9803. *J Clin Oncol* 2004;22:4319-4328. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15514373>.

356. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19153121>.

357. Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. *Cancer Chemother Pharmacol* 2008;61:623-629. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17522863>.

358. Luo HY, Xu RH, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. *Chemotherapy* 2010;56:94-100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20357440>.

359. Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. *Ann Oncol* 2009;20:1529-1534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19474114>.

360. Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial. *J Clin Oncol* 2019;37:4006. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15\\_suppl.4006](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4006).

361. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. *Oncology (Williston Park)* 2004;18:22-25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15685830>.

362. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

Ann Oncol 2008;19:1450-1457. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18558665>.

363. Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. *Anticancer Drugs* 2009;20:165-173. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19125117>.

364. Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. *Ann Oncol* 2009;20:1242-1248. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19429872>.

365. Lustberg MB, Bekaii-Saab T, Young D, et al. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. *J Thorac Oncol* 2010;5:713-718. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20354452>.

366. Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2010;21:71-77. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19605504>.

367. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase iii study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. *J Clin Oncol* 2014;32:3520-3526. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25287828>.

368. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal

adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16110025>.

369. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991-4997. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17075117>.

370. Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. *Ann Oncol* 2015;26:149-156. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25416687>.

371. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874-3879. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26438119>.

372. Blum Murphy MA, Qiao W, Mewada N, et al. A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. *Am J Clin Oncol* 2018;41:321-325. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26908161>.

373. Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. *J Clin Oncol* 2005;23:4014. Available at:  
[http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16\\_suppl.4014](http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.4014).

374. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/11079171>.

375. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

oesophageal cancer. *Br J Cancer* 1998;78:511-514. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9716036>.

376. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12576922>.

377. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19763571>.

378. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12506170>.

379. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15319239>.

380. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17917090>.

381. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7912736>.

382. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol*

2007;18:898-902. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17351256>.

383. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014;383:31-39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24094768>.

384. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014;15:1224-1235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25240821>.

385. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. *N Engl J Med* 2020;382:2419-2430. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32469182>.

386. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019;20:1506-1517. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31582355>.

387. Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. *J Clin Oncol* 2019;37:2. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4\\_suppl.2](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.2).

388. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol* 2013;31:4438-4444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24190112>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

389. Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. *Cancer Chemother Pharmacol* 2013;71:481-488. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23192279>.

390. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. *J Clin Oncol* 2003;21:807-814. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12610178>.

391. Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. *Am J Clin Oncol* 2008;31:151-156. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18391599>.

392. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. *Ann Oncol* 2004;15:64-69. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14679122>.

393. Maugeri-Sacca M, Pizzuti L, Sergi D, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. *J Exp Clin Cancer Res* 2013;32:67. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24330513>.

394. U.S. Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma. 2019. Available at: <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm632032.htm>. Accessed March 6, 2020.

395. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*

2018;19:1437-1448. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30355453>.

396. Shitara K, Doi T, Hosaka H, et al. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): subgroup analysis from TAGS. *J Clin Oncol* 2019;37:4037. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15\\_suppl.4037](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4037).

397. Mansoor W, Arkenau H-T, ALSINA M, et al. Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): subgroup analysis from TAGS. *J Clin Oncol* 2019;37:4038. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15\\_suppl.4038](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4038).

398. Sakai D, Boku N, Kodera Y, et al. An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBERG trial). *J Clin Oncol* 2018;36:TPS4138. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15\\_suppl.TPS4138](https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS4138).

399. Klempner SJ, Maron SB, Chase L, et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. *Oncologist* 2019;24:475-482. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30470690>.

400. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol* 2020;38:1-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31682550>.

401. Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. *J Clin Oncol* 2021;39:2564-2564. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15\\_suppl.2564](https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2564).



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

402. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020;21:1353-1365. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32919526>.

403. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21:271-282. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31838007>.

404. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018;378:731-739. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29466156>.

405. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H. *J Clin Oncol* 2020;38:3895-3904. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32758030>.

406. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol* 2022;23:1261-1273. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36108661>.

407. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol* 2018;4:e180013. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29543932>.

408. Le DT, Uram JN, Wang H, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. *J Clin Oncol* 2016;34:195. Available at: [http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4\\_suppl.195](http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.195).

409. U.S. Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. 2019. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc>. Accessed July 14, 2020.

410. U.S. Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018. Available at: <https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions>. Accessed July 14, 2020.

411. Rivera F, Romero C, Jimenez-Fonseca P, et al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. *Cancer Chemother Pharmacol* 2019;83:1175-1181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30927036>.

412. Soularue E, Cohen R, Tournigand C, et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. *Bull Cancer* 2015;102:324-331. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25744576>.

413. Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). *J Clin Oncol* 2020;38:1919-1927. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32208960>.

414. U.S. Food and Drug Administration. FDA approves nivolumab for resected esophageal or GEJ cancer. 2021. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-resected-esophageal-or-gej-cancer>. Accessed November 8, 2021.

415. U.S. Food and Drug Administration. FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma. 2021. Available at:



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

<https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal>. Accessed November 4, 2021.

416. U.S. Food and Drug Administration. FDA approves nivolumab for esophageal squamous cell carcinoma. 2020. Available at: <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma>. Accessed July 14, 2020.

417. U.S. Food and Drug Administration. FDA approves pembrolizumab for esophageal or GEJ carcinoma. 2021. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma>. Accessed November 8, 2021.

418. U.S. Food and Drug Administration. FDA approves pembrolizumab for advanced esophageal squamous cell cancer. 2019. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer>. Accessed March 12, 2020.

419. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. *JAMA Oncol* 2018;5:546-550. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30570649>.

420. Kato K, Kojima T, Hochhauser D, et al. Pembrolizumab in previously treated metastatic esophageal cancer: longer term follow-up from the phase 2 KEYNOTE-180 Study. *J Clin Oncol* 2019;37:4032. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15\\_suppl.4032](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4032).

421. U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Available at: <https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm>. Accessed February 21, 2020.

422. U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. 2020. Available at: <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors>. Accessed January 19, 2021.

423. Tabernero J, Ohtsu A, Muro K, et al. Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. *Mol Cancer Ther* 2017;16:2215-2222. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28716815>.

424. Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019;20:420-435. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30718072>.

425. Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. *Mod Pathol* 2019;32:147-153. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30171197>.

426. Arnold A, Daum S, von Winterfeld M, et al. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. *Pathol Res Pract* 2019;215:152662. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31575452>.

427. Okamura R, Boichard A, Kato S, et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. *JCO Precis Oncol* 2018;2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30637364>.

428. Shinozaki-Ushiku A, Ishikawa S, Komura D, et al. The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion. *Gastric Cancer* 2020;23:944-947. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32189226>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

429. U.S. Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. 2021. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors>. Accessed August 30, 2021.
430. Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. *JAMA Oncology* 2020;6:1766-1772. Available at: <https://doi.org/10.1001/jamaoncol.2020.4515>.
431. U.S. Food and Drug Administration. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. 2022. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid-tumors>. Accessed January 23, 2023.
432. U.S. Food and Drug Administration. FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. 2022. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors>. Accessed January 23, 2023.
433. van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Radiofrequency ablation for the endoscopic eradication of esophageal squamous high grade intraepithelial neoplasia and mucosal squamous cell carcinoma. *Endoscopy* 2011;43:282-290. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21455869>.
434. Burmeister BH, Dickie G, Smithers BM, et al. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. *Arch Otolaryngol Head Neck Surg* 2000;126:205-208. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10680872>.
435. Meerten EV, Rij Cv, Tesselaar ME, et al. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study. *J Clin Oncol* 2010;28:e14508. Available at: [http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15\\_suppl.e14508](http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e14508).
436. Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. *J Thorac Oncol* 2013;8:1558-1562. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24389438>.
437. Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. *J Clin Oncol* 2013;31:4306-4310. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24145339>.
438. Dorth JA, Pura JA, Palta M, et al. Patterns of recurrence after trimodality therapy for esophageal cancer. *Cancer* 2014;120:2099-2105. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24711267>.
439. Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. *J Clin Oncol* 2014;32:3400-3405. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25225435>.
440. Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. *J Natl Compr Canc Netw* 2014;12:1139-1144. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25099446>.
441. Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). *Endoscopy* 2014;46:6-12. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24353120>.
442. Katada C, Muto M, Manabe T, et al. Local recurrence of squamous-cell carcinoma of the esophagus after EMR. *Gastrointest Endosc* 2005;61:219-225. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15729229>.
443. Haidry RJ, Butt MA, Dunn J, et al. Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes from United Kingdom



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

registry. *World J Gastroenterol* 2013;19:6011-6019. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24106401>.

444. Perry KA, Walker JP, Salazar M, et al. Endoscopic management of high-grade dysplasia and intramucosal carcinoma: experience in a large academic medical center. *Surg Endosc* 2014;28:777-782. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24122245>.

445. Yasuda K, Choi SE, Nishioka NS, et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. *Dig Dis Sci* 2014;59:1560-1566. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24395382>.

446. Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. *Clin Gastroenterol Hepatol* 2014;12:1840-1847. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24815329>.

447. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. *Evaluation of Chemotherapeutic Agents*. New York: Columbia University Press; 1949:199-205.

448. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649-655. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7165009>.

449. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. *J Clin Oncol* 1984;2:187-193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6699671>.

450. U.S. Food and Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA. 2018. Available at: <https://www.accessdata.fda.gov/scripts/drugshortages/>. Accessed January 8, 2020.

451. Reynolds J, Chamberland-Tremblay A, Herrington JD, et al. High-versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line

treatment of metastatic colorectal cancer. *J Oncol Pharm Pract* 2017;23:173-178. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26786027>.

452. Clarke S, Goldstein D, Mitchell P, et al. Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. *Clin Colorectal Cancer* 2007;6:578-582. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17681104>.

453. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. *Lancet* 2000;355:1588-1596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10821362>.

454. Blazeby JM, Williams MH, Brookes ST, et al. Quality of life measurement in patients with oesophageal cancer. *Gut* 1995;37:505-508. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7489936>.

455. Shin JH, Song HY, Kim JH, et al. Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. *J Vasc Interv Radiol* 2005;16:67-74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15640412>.

456. Didden P, Reijm AN, Eler NS, et al. Fully vs. partially covered self expandable metal stent for palliation of malignant esophageal strictures: a randomized trial (the COPAC study). *Endoscopy* 2018;50:961-971. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29895072>.

457. Persson J, Smedh U, Johnsson A, et al. Fully covered stents are similar to semi-covered stents with regard to migration in palliative treatment of malignant strictures of the esophagus and gastric cardia: results of a randomized controlled trial. *Surg Endosc* 2017;31:4025-4033. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28236016>.

458. Verschuur EM, Steyerberg EW, Kuipers EJ, Siersema PD. Effect of stent size on complications and recurrent dysphagia in patients with esophageal or gastric cardia cancer. *Gastrointest Endosc* 2007;65:592-601. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17383456>.



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

459. White RE, Chepkwony R, Mwachiro M, et al. Randomized trial of small-diameter versus large-diameter esophageal stents for palliation of malignant esophageal obstruction. *J Clin Gastroenterol* 2015;49:660-665. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25992812>.

460. Penniment MG, De Ieso PB, Harvey JA, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). *Lancet Gastroenterol Hepatol* 2018;3:114-124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29248399>.

461. Fan Y, Song HY, Kim JH, et al. Evaluation of the incidence of esophageal complications associated with balloon dilation and their management in patients with malignant esophageal strictures. *AJR Am J Roentgenol* 2012;198:213-218. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22194500>.

462. Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. *Lancet* 2004;364:1497-1504. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15500894>.

463. Sheibani S, Kim JJ, Chen B, et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. *Aliment Pharmacol Ther* 2013;38:144-150. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23710797>.

464. Jacobs M, Macefield RC, Elbers RG, et al. Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. *Qual Life Res* 2014;23:1097-1115. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24129668>.

465. Donohoe CL, McGillycuddy E, Reynolds JV. Long-term health-related quality of life for disease-free esophageal cancer patients. *World J Surg* 2011;35:1853-1860. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21553202>.

466. Wikman A, Johar A, Lagergren P. Presence of symptom clusters in surgically treated patients with esophageal cancer: implications for survival. *Cancer* 2014;120:286-293. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24555183>.

467. Anandavadivelan P, Wikman A, Johar A, Lagergren P. Impact of weight loss and eating difficulties on health-related quality of life up to 10 years after oesophagectomy for cancer. *Br J Surg* 2018;105:410-418. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29160918>.

468. Ginex P, Thom B, Jingeleski M, et al. Patterns of symptoms following surgery for esophageal cancer. *Oncol Nurs Forum* 2013;40:E101-107. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23615143>.

469. Deldycke A, Van Daele E, Ceelen W, et al. Functional outcome after Ivor Lewis esophagectomy for cancer. *J Surg Oncol* 2016;113:24-28. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26525826>.

470. Heneghan HM, Zaborowski A, Fanning M, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. *Ann Surg* 2015;262:803-808. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26583669>.

471. Lee HS, Kim MS, Lee JM, et al. Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer. *Ann Thorac Surg* 2005;80:443-447. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16039182>.

472. Schandl A, Lagergren J, Johar A, Lagergren P. Health-related quality of life 10 years after oesophageal cancer surgery. *Eur J Cancer* 2016;69:43-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27816831>.

473. Baker M, Halliday V, Williams RN, Bowrey DJ. A systematic review of the nutritional consequences of esophagectomy. *Clin Nutr* 2016;35:987-994. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26411750>.

474. D'Journo XB, Ouattara M, Loundou A, et al. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for



# NCCN Guidelines Version 4.2025

## Esophageal and Esophagogastric Junction Cancers

cancer. Dis Esophagus 2012;25:527-534. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/22121887>.

475. Ouattara M, D'Journo XB, Loundou A, et al. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. Eur J Cardiothorac Surg 2012;41:1088-1093. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/22334635>.

476. Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg 2009;96:1308-1314. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/19847871>.

477. Beukema JC, van Luijk P, Widder J, et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol 2015;114:85-90. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25554226>.

478. Frandsen J, Boothe D, Gaffney DK, et al. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol 2015;6:516-523. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26487946>.

479. Gharzai L, Verma V, Denniston KA, et al. Radiation therapy and cardiac death in long-term survivors of esophageal cancer: an analysis of the Surveillance, Epidemiology, and End Result database. PLoS One 2016;11:e0158916. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27428362>.

Discussion  
update in  
progress